ondansetron has been researched along with Nausea in 779 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Postoperative nausea and vomiting (PONV) is still a common perioperative complication and ondansetron has proved to be an effective antiemetic substance in its prevention." | 10.18 | [Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms]. ( Buhre, W; Kazmaier, S; Mühr, C; Neumann, P; Saur, P, 1996) |
| "Twenty patients receiving cisplatin (greater than or equal to 100 mg/m2) as initial chemotherapy were entered into this Phase II trial to test the effectiveness of oral ondansetron, a specific serotonin receptor (5-HT3) antagonist, in controlling delayed emesis." | 10.17 | Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. ( Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB, 1992) |
| "Ondansetron is a 5-HT3 receptor antagonist which is effective and well tolerated as an antiemetic for emesis induced by cancer chemotherapy and radiation therapy, and in the prevention and treatment of postoperative nausea and vomiting." | 10.17 | Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ( Baber, N; Frazer, NM; Palmer, JL; Pritchard, JF, 1992) |
| "We compared the efficacy of the granisetron transdermal system (GTS) with that of ondansetron for controlling chemotherapy-induced nausea and vomiting (CINV) in patients treated with highly emetogenic chemotherapy (HEC)." | 9.69 | Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial. ( Eom, YA; Jin, JY; Kang, JH; Kim, HK; Ko, YH; Park, SY; Sun, S; Woo, IS, 2023) |
| "5 mg IV with ondansetron 8 mg IV for the treatment of nausea and vomiting." | 9.69 | Droperidol versus ondansetron for nausea treatment within the emergency department. ( Clemensen, E; Lau, GT; Philpott, L, 2023) |
| "To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome." | 9.51 | Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. ( Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA, 2022) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 9.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| "To compare effectiveness of maropitant and ondansetron in preventing preoperative vomiting and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate." | 9.41 | Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate. ( Burke, JE; Hess, RS; Silverstein, DC, 2021) |
| " Interestingly, none of the patients aged under 7 years, receiving divided dosing ondansetron, presented nausea symptoms compared with those receiving single daily dosing (p-value ." | 9.41 | Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. ( Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C, 2021) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 9.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "To evaluate the efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for chemotherapy-induced nausea vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy (HEC)." | 9.34 | The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Angspatt, P; Chenaksara, P; Parinyanitikun, N; Poovorawan, N; Sakdejayont, S; Sriuranpong, V; Sukprakun, S; Tanasanvimon, S; Thawinwisan, W; Vimolchalao, V; Vinayanuwatikun, C; Wongchanapai, P, 2020) |
| "We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC)." | 9.34 | Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. ( Akewanlop, C; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Laocharoenkiat, A; Nimmannit, A; Soparattanapaisarn, N; Techawattanawanna, S; Theeratrakul, P, 2020) |
| " We decided to evaluate the efficacy of olanzapine with the real-life practice antiemetic drugs ondansetron and dexamethasone, in prevention of CINV resulting from doxorubicin plus cyclophosphamide regimen in early-stage breast cancer patients." | 9.30 | A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. ( Laohavinij, S; Maneechavakajorn, J; Maneenil, K; Nipondhkit, W; Payapwattanawong, S; Sa-Nguansai, S; Tienchaiananda, P, 2019) |
| "For adult ED patients with nausea, superiority was not demonstrated for droperidol or ondansetron over placebo." | 9.30 | Randomized Placebo-controlled Trial of Droperidol and Ondansetron for Adult Emergency Department Patients With Nausea. ( Blecher, G; Crow, S; Egerton-Warburton, D; Fahey, J; Graudins, A; Mee, MJ; Meek, R; Meyer, A; Pouryahya, P, 2019) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 9.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "Palonosetron is non-inferior and cost-effective compared to ondansetron for prevention of acute chemotherapy-induced vomiting (CIV) in children receiving moderate and high emetogenic chemotherapy." | 9.27 | A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy. ( Jain, S; Kapoor, G; Koneru, S; Vishwakarma, G, 2018) |
| "Subjects aged 6 months to 17 years scheduled to receive chemotherapeutic agents associated with at least moderate risk for emesis were randomly assigned to receive either aprepitant plus ondansetron (aprepitant regimen) or placebo plus ondansetron (control regimen); both could be administered with or without dexamethasone." | 9.27 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. ( DiCristina, C; Green, S; Kang, HJ; Loftus, S; Pong, A; Zwaan, CM, 2018) |
| "Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens." | 9.27 | Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018) |
| "Neurokinin-1 receptor antagonists, such as aprepitant are currently emerging as powerful prophylactic agents for chemotherapy-induced nausea and vomiting (CINV)." | 9.24 | Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy. ( Abbas, N; Abdel-Malek, R; Fawzy, R; Ismail, M; Safwat, E; Salem, DS; Shohdy, KS, 2017) |
| "The primary aim of this study was to compare the effectiveness of olanzapine, palonosetron and ondansetron infusion (standard of care) for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 9.24 | A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. ( Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M, 2017) |
| "This study evaluated the efficacy and safety of a 3-day aprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of non-anthracycline plus cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) based on government guidelines in Korean patients." | 9.24 | Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. ( Ahn, MJ; Cho, CH; Cho, EK; Jang, JS; Jung, H; Kim, DJ; Kim, JE; Kim, JW; Lee, KY; Lee, MA; Lim, MC; Min, KW; Sung, YL; Sym, SJ, 2017) |
| "Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy." | 9.22 | Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. ( Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016) |
| "Significantly more patients receiving rolapitant than control reported no emesis or interfering nausea (combined measure) in cycles 2 (p = 0." | 9.22 | Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. ( Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L, 2016) |
| "To evaluate the effect of prophylactic ondansetron on spinal anesthesia-induced hypotension and bradycardia among patients undergoing elective cesarean deliveries." | 9.22 | Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia-induced hypotension during elective cesarean delivery in Egypt. ( El Khouly, NI; Meligy, AM, 2016) |
| "The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC)." | 9.20 | Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. ( Wang, H; Wang, L; Wang, X; Zhang, H, 2015) |
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 9.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| " Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003)." | 9.19 | Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. ( Bateman, DN; Butcher, I; Cooper, JG; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, SC; Rodriguez, A; Sandilands, EA; Thanacoody, HK; Thomas, SH; Veiraiah, A; Vliegenthart, AD; Webb, DJ, 2014) |
| "Maternal hypotension and nausea were significantly lower in ondansetron-treated patients versus placebo (p = 0." | 9.19 | Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery. ( Shen, MK; Wang, M; Wang, Q; Yu, JJ; Yu, YY; Zhuo, L, 2014) |
| "We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting." | 9.19 | Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. ( Braitberg, G; Egerton-Warburton, D; Mee, MJ; Meek, R, 2014) |
| "Regardless of age, gender, or region, the aprepitant regimen provided better control for the no-vomiting and complete-response (no vomiting, no rescue therapy) endpoints." | 9.19 | Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. ( Rapoport, BL, 2014) |
| "Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy." | 9.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| "Patients were assessed for nausea and vomiting on their infusion day using the Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) at arrival, pre-ASCT infusion, pre-ondansetron administration, prior to the first bag, and after each bag of stem cells." | 9.17 | Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells. ( Eisenberg, S; Gooley, T; Holmberg, L; Linenberger, M; Wickline, M, 2013) |
| "Patients with colorectal cancer received either casopitant or placebo intravenously (IV) added to ondansetron 8 mg bid oral on study days 1 to 3 and one dose of dexamethasone 8 mg IV given prior to starting the oxaliplatin on day 1." | 9.16 | Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. ( Dube, P; Hesketh, PJ; Kopp, M; Lane, S; Levin, J; Makhson, A; Moiseyenko, V; Rosati, G; Russo, M; Wright, O, 2012) |
| "Breast cancer patients in a phase III double-blind, placebo-controlled trial were randomized to antiemetic regimens including ondansetron and dexamethasone, or aprepitant, ondansetron, and dexamethasone." | 9.15 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. ( Carides, AD; Street, JC; Warr, DG, 2011) |
| "Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours)." | 9.15 | Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. ( Beckford, E; Boice, JA; Carides, A; Chua, D; DeVandry, S; Dinis, J; Grunberg, S; Hardwick, JS; Herrstedt, J; Maru, A; Roila, F; Taylor, A, 2011) |
| "To compare the efficacy of acupressure wrist bands, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery." | 9.15 | Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery. ( Arbabi, S; Ebrahim Soltani, AR; Goudarzi, M; Mohammadinasab, A; Mohammadinasab, F; Mohammadinasab, H; Samimi, M, 2011) |
| "The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents." | 9.14 | Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ( Carides, AD; Chawla, S; Chua, V; Devandry, S; Evans, JK; Gore, L; Hemenway, M; Oxenius, B; Petrilli, A; Schissel, D; Taylor, A; Valentine, J, 2009) |
| "All doses of oral casopitant as a 3-day regimen (and likely as a 150-mg single oral dose) in combination with Ond/Dex provided significant improvement in the prevention of cisplatin-induced emesis." | 9.14 | Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. ( Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW, 2009) |
| "Aprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in breast cancer patients receiving an anthracycline and cyclophosphamide (AC)-based regimen." | 9.14 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. ( Boice, JA; Brown, C; Carides, A; Hardwick, JS; Jordan, K; Rapoport, BL; Schmoll, HJ; Taylor, A; Webb, T, 2010) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 9.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "This randomized, double-blind, dose-ranging, placebo-controlled, phase 2 trial evaluated the neurokinin-1 receptor antagonist casopitant mesylate in combination with ondansetron/dexamethasone (ond/dex) for the prevention of chemotherapy-induced nausea and vomiting (CINV) related to moderately emetogenic chemotherapy (MEC)." | 9.14 | Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera ( Albert, I; Arpornwirat, W; Bandekar, RR; Grunberg, SM; Hansen, VL; Levin, J, 2009) |
| "The authors compared 2 schedules of palonosetron versus ondansetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with AML receiving high-dose cytarabine." | 9.14 | Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. ( Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L, 2010) |
| "This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients." | 9.14 | A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. ( Chan, SL; Ho, WM; Hui, EK; Koh, J; Kwan, WH; Lam, KC; Lau, W; Lee, KK; Mo, FK; Mok, TS; Poon, AN; Suen, JJ; Yeo, W; Yeung, WK; Zee, B, 2009) |
| "Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0." | 9.13 | Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery. ( Diregpoke, S; Krobbuaban, B; Pitakpol, S, 2008) |
| "The authors sought to compare ondansetron and promethazine among emergency department (ED) patients with undifferentiated nausea." | 9.13 | Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. ( Braude, D; Crandall, C, 2008) |
| " This randomized, double-blind, double-dummy, multicenter study was designed to compare the efficacy and tolerance of metopimazine and ondansetron at preventing nausea and emesis in patients receiving chemotherapy." | 9.12 | A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. ( Bensaoula, O; Bethune-Volters, A; Chidiac, J; Delgado, A; Di Palma, M; Khamales, S, 2006) |
| "A prospective randomized study was performed to assess the value of some individual risk factors for postoperative nausea and vomiting (PONV), and to compare the efficacy of ondansetron, metoclopramide, dexamethason, and combinations of these antiemetics in preventing PONV in patients after laparoscopic cholecystectomy." | 9.12 | Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. ( Leksowski, K; Peryga, P; Szyca, R, 2006) |
| "This pivotal phase III trial evaluated the efficacy and safety of palonosetron in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC)." | 9.12 | A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Aapro, MS; Bertoli, LF; Grunberg, SM; Lordick, F; Macciocchi, A; Manikhas, GM; Morrica, B; Olivares, G; Suarez, T; Tjulandin, SA; Yunus, F, 2006) |
| "We compared the efficacy of inhaled isopropyl alcohol (IPA) with ondansetron for the control of postoperative nausea and vomiting (PONV) during a 24-hour period in 100 ASA class I-III women undergoing laparoscopic surgery." | 9.12 | A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home. ( Cotton, JW; Hood, RR; Pellegrini, JE; Rowell, LR, 2007) |
| "To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study." | 9.12 | Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. ( Baranowski, V; Barbato, LM; Carter, FJ; Jhangiani, H; Meiri, E; Vredenburgh, JJ; Yang, HM, 2007) |
| "This study in volunteers has shown that betamethasone does not prevent nausea and vomiting induced by oral intake of ipecacuanha syrup." | 9.11 | Betamethasone does not prevent nausea and vomiting induced by ipecacuanha. ( Axelsson, P; Thörn, SE; Wattwil, M, 2004) |
| "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide +/- doxorubicin or epirubicin." | 9.11 | Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. ( Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG, 2005) |
| "The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy." | 9.11 | Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. ( Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S, 2005) |
| " Overall nausea and vomiting were significantly lower in the ondansetron prophylaxis group than in the group without prophylaxis (52." | 9.11 | Postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy under spinal anaesthesia: a randomized study of ondansetron prophylaxis. ( Baublys, A; Ivaskevicius, J; Kontrimaviciute, E, 2005) |
| "To compare the efficacy and tolerability of associations of metopimazine and ondansetron with methylprednisolone for the prevention of delayed chemotherapy-induced nausea and emesis." | 9.11 | Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. ( Bloch, J; Delgado, A; Khayat, D; Meric, JB; Rixe, O, 2005) |
| "To study the enhancement by dexamethasone of the effect of ondansetron and tropiesetron against postoperative nausea and vomiting (PONV) in patients receiving patient-controlled analgesia (PCA) and observe the effect of dexamethasone on wound healing." | 9.10 | [Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia]. ( Liu, HF; Lu, ZH; Sheng, PT; Wang, C; Wang, LY; Xiong, LZ; Xu, N; Yang, XY, 2002) |
| "When it was added to a standard regimen of intravenous ondansetron and oral dexamethasone in the current study, aprepitant reduced chemotherapy-induced nausea and vomiting and was generally well tolerated, although increases in infection were noted that were assumed to be due to elevated dexamethasone levels as a result of the pharmacokinetic interaction." | 9.10 | Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. ( Carides, AD; Chawla, SP; Elmer, ME; Evans, JK; Gralla, RJ; Grunberg, SM; Hesketh, PJ; Horgan, KJ; Rittenberg, C; Schmidt, C; Taylor, A, 2003) |
| "In this study, the efficacy and safety of intravenous administration of droperidol followed by oral use of dimenhydrinate did not differ from that of intravenous followed by oral use of ondansetron in children undergoing strabismus surgery." | 9.10 | Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery. ( Bussières, JF; Caron, E; Jacob, JL; Lebel, D; Lortie, L; Mathews, S; Milot, J; Moride, Y, 2003) |
| "The results obtained showed that ondansetron was more effective in controlling nausea and vomiting than metoclopramide, either objectively (2." | 9.10 | Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. ( Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002) |
| "We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma." | 9.10 | [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate ( Fujimaki, K; Fukawa, H; Harano, H; Hashimoto, Y; Hattori, M; Kanamori, H; Kodama, F; Koharasawa, H; Mohri, H; Motomura, S; Sakai, R; Takemura, S; Tanabe, J; Tomita, N, 2002) |
| "We investigated the efficacy of combination of ondansetron hydrochloride injection and tablet against nausea and vomiting in 22 lung cancer patients (total number of chemotherapy courses: 23) receiving chemotherapy of single-dose carboplatin (CBDCA) at a dose of 302." | 9.09 | [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin]. ( Miyamoto, Y; Oomasa, M; Teramachi, M; Tomiyama, K; Yagi, K, 1999) |
| "This randomized, double-masked, placebo-controlled, multicenter trial was conducted in 9 countries to assess the safety and efficacy of 2 doses of intravenous ondansetron (8 and 16 mg) for the control of opioid-induced nausea and vomiting." | 9.09 | Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. ( Allegra, J; Ames, M; Creed, MR; Ducharme, J; Ferrer-Brechner, T; Foster, E; Grafstein, E; Larsen, LS; Montgomery, R; Noll, D; Ortenwall, P; Patel, V; Ramalanjaona, G; Schreck, D; Shurman, J; Sussman, G, 1999) |
| ") doses of ondansetron 8 mg, ondansetron 16 mg and metoclopramide 10 mg in the treatment of opioid-induced emesis." | 9.09 | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. ( Alahuta, S; Chung, F; Curtis, P; Duvaldestin, P; Jacka, M; Lane, R; Luttropp, HH; McQuade, B; Rocherieux, S; Roy, M; Spraggs, C, 1999) |
| "To assess the efficacy and safety of intravenous ondansetron (4 mg) for the prevention of nausea and vomiting after middle ear surgery under local anesthesia." | 9.09 | Efficacy of ondansetron for prevention of postoperative nausea and vomiting after outpatient ear surgery under local anesthesia. ( Ku, PK; Lo, P; Tong, MC; van Hasselt, CA, 2000) |
| " All the patients received ondansetron combined with dexamethasone for prophylaxis against emesis that might occur within 24 hours after the start of chemotherapy (acute emesis)." | 9.09 | Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. ( , 2000) |
| " Patients received an anti-nausea regimen of dexamethasone with ondansetron or granisetron." | 9.09 | The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. ( Baron, PL; Cole, DJ; Maize, JC; McClay, EF; McClay, ME; Metcalf, JS; Monroe, L; O'Brien, PH, 2000) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 9.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| "The efficacy and safety of granisetron and ondansetron for the prophylaxis of nausea and vomiting resulting from hyperfractionated total body irradiation (TBI) were assessed." | 9.09 | Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. ( Bushnell, W; Frankel, SR; Friedman, CJ; Raschko, J; Spitzer, TR, 2000) |
| ") ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy." | 9.09 | A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap ( Breatnach, F; Daly, SA; Haigh, C; Hung, IJ; Kowalczyk, J; Leal, C; McKenna, CJ; Mitchell, T; Ninane, J; Smelhaus, V; White, L; Zhestkova, N, 2000) |
| " dexamethasone had comparable antiemetic efficacy for the prevention of nausea in the first 24-hour period after initiation of chemotherapy compared with intravenous ondansetron plus i." | 9.09 | Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. ( Chen, PM; Chiou, TJ; Fan, FS; Liu, JH; Tzeng, WF; Wang, WS; Yen, CC, 2000) |
| "This prospective, randomized, placebo-controlled, double-blind study was designed to evaluate the efficacy of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting (PONV) after elective craniotomy in adult patients." | 9.09 | Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy. ( Bhatia, A; Dash, HH; Kathirvel, S; Prakash, A; Shenoy, S; Subramaniam, B, 2001) |
| "Twenty-six children (ages 18 mo to 15 y) receiving intrathecal chemotherapy with either methotrexate or the combination of methotrexate, hydrocortisone, and Ara-C for the prophylactic treatment of central nervous system leukemia were randomly assigned to receive an infusion of normal saline or ondansetron at one of two doses (0." | 9.09 | Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. ( Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D, 2001) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 9.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 9.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "Ondansetron and droperidol are both effective in the prevention of postoperative nausea and vomiting (PONV)." | 9.08 | Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery. ( Altrock, K; Diefenbach, C; Grond, S; Lehmann, KA; Lynch, J, 1995) |
| "The antiemetic effect of ondansetron (Supplied by Qi Lu Pharmaceutical Company) in cisplatin-induced nausea and vomiting was studied in a randomized cross-over trial in 167 patients." | 9.08 | [The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "To investigate the efficacy and safety of oral ondansetron in the control of cisplatin-induced delayed emesis in patients who do not require rescue antiemetic therapy for acute emesis." | 9.08 | Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. ( Anderson, N; Beck, TM; Caldwell, KC; Chang, AY; Garewal, H; Greenberg, B; Madajewicz, S; Navari, RM; Tchekmedyian, NS; Whaley, W, 1995) |
| "To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effective in the prevention of chemotherapy-induced emesis." | 9.08 | Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. ( Fitts, D; Friedman, C; Gandara, D; Hall, S; Hesketh, P; Mailliard, J; Navari, R; Ritter, H, 1995) |
| "This randomized, double-blind, multicentre, parallel-group study compared the efficacy and safety of an intravenous dose of ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV) with metoclopramide 10 mg and placebo in patients undergoing major gynaecological surgery." | 9.08 | [Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting]. ( Rust, M, 1995) |
| "We have compared the efficacy of ondansetron, metoclopramide, droperidol and placebo in the prevention of postoperative nausea and vomiting in 118 day stay patients undergoing laparoscopic gynaecological procedures." | 9.08 | Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. ( McKay, AC; Mirakhur, RK; Paxton, LD, 1995) |
| " Effective prophylaxis for postoperative nausea and vomiting can be achieved in adults with lower doses of ondansetron, a 5-hydroxytryptamine subtype 3 receptor antagonist, compared with chemotherapy-induced emesis." | 9.08 | The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery. ( Bras, PJ; Cieslak, GD; Pennant, JH; Watcha, MF, 1995) |
| "In a randomised, placebo-controlled trial we have compared the efficacy of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia after orthopaedic surgery." | 9.08 | Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia. ( Alexander, R; Jones, RM; Lovell, AT; Seingry, D, 1995) |
| "A single-institution, prospective, randomized, open controlled trial was carried out on head and neck cancer patients to compare granisetron (GRA), ondansetron (OND), and tropisetron (TRO) in the prevention of cisplatin-induced acute nausea and vomiting." | 9.08 | Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. ( Bianchi, A; Curreli, L; Ghiani, M; Macciò, A; Mantovani, G; Proto, E; Santona, MC, 1996) |
| "We performed a prospective, single arm, observational study examining the effectiveness of the 5HT3 receptor antagonist ondansetron in the management if nausea and vomiting associated with acetaminophen poisoning." | 9.08 | The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. ( Chen, R; Clark, RF; Harchelroad, F; Johnson, CL; Williams, SR, 1996) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 9.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| "The addition of bromazepam to ondansetron, and the extension of antiemetic prophylaxis to the day before and the day after chemotherapy improves the control of nausea and emesis compared to ondansetron monotherapy in patients with ovarian cancer." | 9.08 | Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. ( Conrad, A; Kuhn, W; Meden, H; Meissner, O, 1996) |
| "The aim of this study was to compare the efficacy and safety of ondansetron plus droperidol with each drug alone or placebo in the prevention of postoperative nausea and vomiting (PONV)." | 9.08 | Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting. ( Carrascosa, F; García-Pedrajas, F; Iribarren, MJ; Lopez, L; Pueyo, FJ; Saez, A, 1996) |
| " Patients received one of four regimens for the prevention of postoperative nausea and vomiting (PONV): ondansetron 4 mg (n = 25), dexamethasone 8 mg (n = 25), ondansetron with dexamethasone (4 mg and 8 mg, respectively, n = 25) or placebo (saline, n = 25) There were no differences in background factors or factors related to operation and anaesthesia, morphine consumption, pain or side effects between groups." | 9.08 | Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting. ( Busto, N; Carrascosa, F; López-Olaondo, L; Monedero, P; Pueyo, FJ; Sáez, A, 1996) |
| "The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dose > or = 50 mg/m2." | 9.08 | An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. ( Angelelli, B; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E, 1996) |
| "To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting." | 9.08 | Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P ( Anthony, L; Benedict, C; Gralla, R; Grote, T; Hahne, W; Hainsworth, J; Hesketh, P; Khojasteh, A; Kris, M; Navari, R; Tapazoglou, E, 1996) |
| "The efficacy of ondansetron 4 mg and 8 mg was compared with placebo in the reduction of postoperative nausea, retching and vomiting (PONV) after middle ear surgery during general anaesthesia, in 75 patients, in a double-blind and randomized study." | 9.08 | Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. ( Honkavaara, P, 1996) |
| "This study has compared the incidences of nausea, vomiting and headache after ondansetron 0." | 9.08 | Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy. ( van den Berg, AA, 1996) |
| "The new antiemetic ondansetron is effective for the prophylaxis and treatment of postoperative nausea and vomiting (PONV), but has been subject to limited comparative evaluation in surgical inpatients." | 9.08 | Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. ( Evans, SF; Paech, MJ; Pavy, TJ, 1995) |
| "In contrast to the broad experience concerning the therapeutic use of carboplatin, only limited data are available regarding the patterns of carboplatin-induced emesis, one of its most distressing side effects." | 9.08 | Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. ( Cramer-Giraud, U; du Bois, A; Fiola, M; Glaubitz, M; Thomssen, C; Vach, W, 1995) |
| "The efficacy of a preoperative 4-mg dose of ondansetron given intravenously in preventing postoperative nausea and vomiting after maxillofacial surgery was evaluated in a double-blind randomized study." | 9.08 | The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. ( Campbell, R; Chow, J; Rodrigo, C; Tong, A, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 9.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "The efficacy of ondansetron 4 mg was compared with metoclopramide 10 mg for the prevention of post-operative nausea and vomiting in patients after major gynaecological abdominal surgery." | 9.08 | Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. ( Chen, PP; Chui, PT; Gin, T, 1996) |
| "Propofol administered to induce and maintain anesthesia is more effective than ondansetron (with thiopental-isoflurane anesthesia) in preventing postoperative vomiting and is associated with fewer requests for rescue antiemetic and sedation in the early phase of recovery." | 9.08 | Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. ( Gan, TJ; Ginsberg, B; Glass, PS; Grant, AP, 1996) |
| "To determine (1) the efficacy and safety of ondansetron in the prevention of postoperative nausea and vomiting (PONV) in male outpatients; (2) prognostic factors for PONV in male outpatients; and (3) patients' perceptions of the debilitating effects of PONV in the ambulatory surgery setting." | 9.08 | Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group. ( Cox, F; Joslyn, AF; Khalil, SN; Kovac, AL; Pearman, MH; Prillaman, BA; Scuderi, PE, 1996) |
| "The purpose of this study was to investigate the efficacy and safety of oral ondansetron, given alone or in combination with dexamethasone in the control of cisplatin-induced delayed emesis." | 9.08 | A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. ( Depierre, A; Goedhals, L; McQuade, B; McRae, J; Olver, I; Paska, W; Seitz, JF; Stewart, DJ; Wilkinson, JR, 1996) |
| "The hypothesis that the addition of dexamethasone to the propofolondansetron combination would significantly reduce postoperative nausea and vomiting (PONV) was not confirmed." | 9.08 | Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery. ( Hamilton, DL; McKenzie, R; Riley, TJ; Tantisira, B, 1997) |
| "To assess the efficacy of 4 mg of intravenous ondansetron versus placebo for the prevention of postoperative nausea and vomiting (PONV) in cholecystectomy, a type of surgery that is highly emetic." | 9.08 | [Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy]. ( Cabrera, JC; Castaño, J; Castillo, J; Escolano, F; Matute, E; Santiveri, X, 1997) |
| "A double-blind, randomised, placebo-controlled trial was conducted to compare the efficacy of metoclopramide with the 5-HT3 antagonist, ondansetron, for the prevention of postoperative emesis in children undergoing elective strabismus surgery." | 9.08 | Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. ( Mandal, NG; Shende, D, 1997) |
| "To compare the efficacy of oral ondansetron with oral metoclopramide for the prevention of postoperative vomiting and nausea in children undergoing strabismus surgery." | 9.08 | [Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?]. ( Amraoui, A; Benaguida, M; el Harrar, N; Idali, B; Laouissi, F; Mjahed, K, 1996) |
| "To compare the efficacy in the treatment of post-operative nausea and/or vomiting (PONV), 75 patients undergoing gynaecological procedures under general anaesthesia using N2O/enflurane who suffered from PONV in the first hour after surgery were randomly allocated to three groups containing 25 patients each to receive either alizapride 100 mg, droperidol 1 mg or ondansetron 8 mg (i." | 9.08 | Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea. ( Bovill, JG; de Bont, LE; el-Mofty, M; Samhan, YM; Stienstra, R, 1997) |
| "The inhibitory effects of GG032X tablets, a new dosage form (fast dispersing tablet) of ondansetron, 5-HT2 receptor antagonist, on nausea and emesis induced by cisplatin (CDDP), were investigated along with safety and usefulness." | 9.08 | [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Ikeda, M; Nukariya, N; Ota, J; Suminaga, M; Taguchi, T, 1997) |
| "In a randomised, double-blind study, we have compared the incidence of postoperative nausea and vomitting in 124 patients undergoing major lower limb orthopaedic surgery following oral premedication with temazapam and ondansetron 8 mg, metoclopramide 10 mg or placebo." | 9.08 | Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. ( Alexander, R; Fennelly, M, 1997) |
| "The efficacy and safety of ondansetron 8 mg BID compared with 8 mg TID for 3 days in the prevention of nausea and vomiting in 402 patients on cyclophosphamide (> or = 500 mg/m2)-based chemotherapy were evaluated in a multicenter, randomized, double-blind, stratified study." | 9.08 | Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. ( Beck, TM; Chang, A; Griffin, D; Harvey, WH; Meshad, M; Navari, R; Wentz, A; York, M, 1997) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 9.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "To compare the efficacy of dolasetron and ondansetron in controlling nausea and vomiting in the first 24 hours; to evaluate the efficacy when dexamethasone is added to either drug in the first 24 hours; and to extend these comparisons over 7 days in patients receiving moderately emetogenic chemotherapy." | 9.08 | Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. ( Chin, C; Dempsey, E; Guevin, RM; Hainsworth, J; Hoskins, P; Krook, JE; Lofters, WS; Moquin, JP; Navari, R; Palmer, M; Pater, JL; Verma, S; Walde, D; Wilson, K; Zee, B, 1997) |
| "Intravenous dolasetron mesilate has shown efficacy in the prevention of postoperative nausea and vomiting (PONV) when administered as a single dose prior to emergence from anesthesia." | 9.08 | Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. ( Brown, R; Clergue, F; Feiss, P; Hahne, W; Korttila, K; Leeser, J; Nave, S; Olthoff, D; Payeur-Michel, C; Wessel, P, 1997) |
| "To compare the prophylactic administration of ondansetron with droperidol or placebo to determine its effectiveness in reducing postoperative nausea and vomiting after middle ear procedures." | 9.08 | Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures. ( Fluter, E; Jellish, WS; Leonetti, JP; Thalji, Z, 1997) |
| "To investigate the incidence of postoperative nausea and vomiting (PONV) depending on the administration time of ondansetron." | 9.08 | [Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients]. ( Kainzwaldner, A; Ploner, F, 1997) |
| "Patient functional status after administration of either granisetron or ondansetron to prevent acute chemotherapy-induced nausea and vomiting (CINV) was studied." | 9.08 | Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. ( Bernstein, G; Colgan, K; Dempsey, CL; Farley, PA; Kulis-Robitaille, C; Shillington, AA, 1997) |
| " After experiencing at least one nausea and/or one emetic episode in the 6 h after recovery from anaesthesia, patients received either ondansetron 4 mg i." | 9.08 | Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group. ( Clyti, N; Conseiller, C; Diemunsch, P; Mamet, JP, 1997) |
| "The proportion of patients with nausea was 48%, 50% and 67% in the ondansetron, droperidol and placebo groups, respectively; with a significant difference when both ondansetron (P=0." | 9.08 | Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial. ( Alahuhta, S; Koivuranta, M; Läärä, E; Ranta, P; Ravaska, P, 1997) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 9.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "Ondansetron 4 mg was compared with metoclopramide 10 mg for prevention of post-operative nausea and emesis in in-patients undergoing major gynaecological surgery in this double-blind, randomized, placebo-controlled, multicentre study." | 9.08 | International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. ( Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998) |
| " bolus dose of ondansetron 4 mg were evaluated in the prevention of postoperative nausea and vomiting (PONV), which remains one of the most unpleasant side effects experienced by patients postoperatively." | 9.08 | Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis. ( De Guchteneere, E; Hendrickx, P; Levarlet, M; Moens, P, 1997) |
| "To investigate the hypothesis that the combination of ondansetron and droperidol would be more effective than droperidol alone in reducing nausea and vomiting." | 9.08 | Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after total abdominal hysterectomy. ( Hamilton, DL; McKenzie, R; Riley, TJ; Trantisira, BR, 1998) |
| "This study compares the preoperative administration of ondansetron with that of droperidol or saline solution for the prevention of nausea and vomiting in otologic surgery patients." | 9.08 | Ondansetron versus droperidol or placebo to prevent nausea and vomiting after otologic surgery. ( Fluder, E; Jellish, WS; Leonetti, JP; Thalji, Z, 1998) |
| "A group of 48 patients with breast cancer were randomized in a double-blind fashion to receive either (1) granisetron as a 0." | 9.08 | Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. ( Bolwell, B; Boparai, N; Jones, E; Kalaycio, M; Mendez, Z; Overmoyer, B; Pohlman, B, 1998) |
| "To determine the dose-response relationship of ondansetron in preventing postoperative nausea and vomiting (PONV) in women undergoing elective surgery." | 9.08 | A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting. ( Chang, Y; Conant, JA; Connors, PM; Dershwitz, M; Rosow, CE, 1998) |
| "Ondansetron appeared to be superior to metoclopramide-diphenhydramine in the control of emesis induced by chemotherapy regimens containing cisplatin." | 9.08 | Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. ( Atay, AA; Köseoglu, V; Kürekçi, AE; Ozcan, O; Sarici, U; Sorici, U, 1998) |
| "We examined the efficacy of concurrent use of ondansetron hydrochloride and dexamethasone, and the effective dose of dexamethasone against nausea and vomiting in lung cancer patients receiving chemotherapy including single high dose cisplatin." | 9.08 | [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin]. ( Banba, J; Masaki, M; Tanimura, S; Tomoyasu, H, 1998) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 9.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following minor oral surgery was evaluated in a prospective randomized double-blind study." | 9.07 | Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study. ( Campbell, RC; Chow, J; Hui, E; Lueveswanij, S; Rodrigo, MR; Tong, CK, 1994) |
| "To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial." | 9.07 | Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. ( Cho, GY; Kim, SH; Kim, SW; Lee, CW; Lee, JS; Lee, KH; Suh, CW, 1994) |
| "Ondansetron in the prophylaxis of Cisplatin-induced emesis and nausea." | 9.07 | Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy. ( Chakrapee-Sirisuk, S; Cheirsilpa, A; Chindavijak, K; Lousoontornsiri, W; Ratanatharathorn, V; Sinlarat, P; Srimuninimit, V, 1994) |
| "Oral ondansetron is an effective therapy for the prevention of emesis induced by TBI." | 9.07 | Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. ( Bryson, JC; Cirenza, E; Dubois, A; Foelber, R; Kunka, RL; Plagge, PB; Spitzer, TR; Stout, C; Wallerstadt, M, 1994) |
| "The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients." | 9.07 | Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses ( Campora, E; Giudici, S; Merlini, L; Rosso, R; Rubagotti, A, 1994) |
| "25 mg droperidol in preventing postoperative vomiting." | 9.07 | [Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative study with droperidol]. ( Alon, E; Atanassoff, PG; Biro, P; Lenzlinger, PM, 1994) |
| "Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting (PONV), but it has not been proved to be superior to established antiemetics for prophylaxis or therapy." | 9.07 | [Ondansetron versus droperidol. Postoperative treatment against nausea and vomiting. Comparison of action, adverse effects and acceptance by gynecologic inpatients]. ( Heim, C; Listyo, R; Münzer, T, 1994) |
| "The purpose of this double-blind, randomized study was to compare the effectiveness of ondansetron plus saline versus ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting." | 9.07 | Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting. ( Abdelhady, H; Karambelkar, DJ; McKenzie, R; Riley, TJ; Tantisira, B, 1994) |
| "We studied the preventive effect on postoperative nausea and vomiting (PONV) of ondansetron, metoclopramide and placebo associated with epidural anaesthesia." | 9.07 | [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children]. ( Andreuccetti, T; Busoni, P; Calamandrei, M; Crescioli, M; Messeri, A; Sarti, A; Sestini, G, 1994) |
| "These data suggest that although both ondansetron and granisetron are very effective drugs for the control of acute emesis, their efficacy against delayed emesis is still not entirely satisfactory." | 9.07 | Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. ( Cannata, G; Cipolla, C; Curto, G; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A; Valenza, R, 1994) |
| "We have compared the incidence of postoperative nausea and vomiting up to 48 h after day-case gynaecological laparoscopy after oral premedication with ondansetron 4 mg, metoclopramide 10 mg or a placebo allocated randomly and assessed blindly." | 9.07 | Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. ( Cooper, GM; Field, JM; Malins, AF; Nesling, PM, 1994) |
| "In two placebo-controlled, double-blind, multicentre studies, the efficacy and safety of single oral doses of ondansetron 4 mg, 8 mg and 16 mg were evaluated for the prevention of postoperative nausea and vomiting in female inpatients." | 9.07 | Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups. ( Cohen, LA; Rust, M, 1994) |
| "One-hundred and forty-five chemotherapy patients receiving cisplatin- and non-cisplatin-containing regimens participated in an open evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and vomiting." | 9.07 | Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group. ( Batarda, M; Brandão, A; de Faria, L; de Matos, E; dos Reis, F; Fráguas, A; Ribeiro, I; Ribeiro, M; Ribiero, MM; Uva, S, 1993) |
| "We evaluated the efficacy and safety of oral ondansetron, a selective antagonist of 5-HT3 receptors, for the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy (> 500 mg/m2)." | 9.07 | Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. ( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 9.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "This study examines whether the schedule of ondansetron significantly influences its antiemetic efficacy in the first 24 hours after chemotherapy, whether the administration of oral ondansetron after 24 hours is effective in preventing delayed emesis, and whether the efficacy of ondansetron is preserved over multiple courses of moderately emetogenic chemotherapy." | 9.07 | Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of ( Hoskins, P; Kaizer, L; Latreille, J; Levy, M; Lofters, W; Palmer, M; Pater, J; Warr, D; Yau, J; Zee, B, 1994) |
| "This prospective, randomized, double-blind study assessed whether the addition of dexamethasone to ondansetron leads to improved control of chemotherapy--induced emesis, both in patients undergoing their first course of highly emetogenic chemotherapy and in chemotherapy-pretreated patients refractory to standard anti-emetics." | 9.07 | Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). ( Aapro, MS; Bacchi, M; Buser, K; Joss, RA; Kirchner, V; Neuenschwander, H; Orth, B; Thürlimann, B, 1994) |
| "We have compared the efficacy of ondansetron with droperidol and saline in the prevention of postoperative nausea and vomiting (PONV) in 120 ASA I and II patients undergoing hip and knee replacements and femoral resections." | 9.07 | Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. ( Collis, R; Gan, TJ; Hetreed, M, 1994) |
| "We studied the efficacy and safety of intravenous ondansetron 4 mg for the prevention of postoperative nausea and vomiting after minor gynaecological laparoscopic surgery in Oriental women." | 9.07 | Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery. ( Chen, PP; Critchley, LA; Gin, TA; Ray, AK; Rowbottom, YM; Suen, TK, 1994) |
| "The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, multicentre, international study." | 9.07 | A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. ( Abrahamsson, J; Briggs, L; Forrler, M; Hellstern, K; Helmers, JH; Moodley, J; Soni, J, 1993) |
| "Ondansetron is a serotonin antagonist that recently has been introduced as a preventive agent for chemotherapy-induced nausea and vomiting." | 9.07 | Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. ( Kilgore, JR; Navari, RM; Perrine, GM; Province, WS, 1993) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 9.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| "One hundred cancer patients receiving non-cisplatin containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron was compared with standard antiemetic treatments in the prophylaxis of nausea and emesis." | 9.07 | Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. ( Flander, MK; Heikkinen, MI; Jantunen, IT; Kataja, VV; Kuoppala, TA; Teerenhovi, L, 1993) |
| " Patients were stratified by gender and received, in a randomized, double-blind manner, 1, 4, or 8 mg ondansetron or placebo in response to nausea and/or vomiting postoperatively." | 9.07 | Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. ( Apfelbaum, J; Claybon, L; DuPen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1993) |
| "Data from the 544 women showed that all doses of intravenous ondansetron tested (1, 4, and 8 mg) were significantly more effective (62%, 76%, and 77%, respectively) than placebo (46%) in reducing the incidence of emesis following surgery until 24 h after recovery room entry." | 9.07 | Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. ( Angel, J; Duncalf, D; Gratz, I; Joslyn, A; Kovac, A; McKenzie, R; McLeskey, C; O'Connor, T; Tolpin, E, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 9.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following major gynaecological surgery was evaluated in this multicentre, double-blind study." | 9.07 | The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia. ( Conseiller, C; Dupeyron, JP; Gribomont, B; Hemmingsen, C; Kaplan, LA; Levarlet, M; Pedersen, FM; Schoeffler, P, 1993) |
| "The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized, double-blind, placebo-controlled, multi-centre studies." | 9.07 | Oral ondansetron in the prevention of postoperative nausea and vomiting. ( Helmers, JH, 1992) |
| "The efficacy of ondansetron, a selective 5-HT3 receptor antagonist, in preventing postoperative nausea and vomiting in surgical patients was studied." | 9.07 | Ondansetron is effective in decreasing postoperative nausea and vomiting. ( Dershwitz, M; Di Biase, PM; Joslyn, AF; Rosow, CE; Sanderson, PE, 1992) |
| "A total of 535 chemotherapy naive, hospitalised patients (263 male/272 female) scheduled to receive cisplatin (50-120 mg m-2)-containing regimens participated in a randomised, double-blind, parallel group study to evaluate the efficacy and safety of three intravenous dose schedules of ondansetron in the prophylaxis of acute nausea and emesis." | 9.07 | Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu ( Buser, K; Christmann, D; Kitchener, H; Paes, D; Porteder, H; Schmidt, M; Schuller, J; Sevelda, P; Seynaeve, C; Van Belle, S, 1992) |
| "In a placebo-controlled, double-blind study, we have compared the efficacy of ondansetron 16 mg, 8 mg and 1 mg administered 8-hourly for prevention of postoperative nausea and vomiting." | 9.07 | Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study. ( Haigh, CG; Kenny, GN; Leeser, J; Lip, H; Oates, JD; Onsrud, M; Rowbotham, DJ; Rust, M; Saur, P, 1992) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 9.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 9.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "The anti-emetic effect, safety and clinical usefulness of ondansetron for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin, was evaluated by a multi-institutional study in patients with various malignancies." | 9.07 | [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Following a single intravenous dose given pre-chemotherapy, the efficacy and tolerability of oral ondansetron treatment given twice daily was compared with the established three times daily oral supplementary regimen in the prophylaxis of nausea and vomiting induced by cyclophosphamide (greater than or equal to 500 mg/m2) in combination with doxorubicin (greater than or equal to 40 mg/m2) or epirubicin (greater than or equal to 40 mg/m2)." | 9.07 | Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group. ( Bleiberg, H; Campora, E; Cunningham, D; Dicato, MA; Kaasa, S; Liebhard, A; Upadhyaya, BK; Vindevoghel, A; Warnier, P, 1992) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 9.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| "Clinical usefulness of ondansetron as an antiemetic for the treatment of nausea and vomiting induced by anticancer drugs including cisplatin (> or = 50 mg/m2) was evaluated by a multi-institutional, double-blind comparative study with placebo with inpatients with various malignancies." | 9.07 | [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "The safety and efficacy of ondansetron were evaluated in the treatment of postoperative nausea and vomiting." | 9.07 | Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study. ( Apfelbaum, J; Clayborn, L; Du Pen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1992) |
| "This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis." | 9.07 | Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. ( Beck, TM; Gandara, DR; Hainsworth, JD; Hesketh, PJ; Kish, JA; Lester, EP; Madajewicz, S; Murphy, WK; Navari, RM; Pendergrass, K, 1992) |
| "The selective 5-hydroxytryptamine3 antagonist ondansetron has been shown to be effective in preventing nausea and vomiting associated with highly emetogenic cisplatin chemotherapy." | 9.07 | Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. ( Beck, TM, 1992) |
| "A multicentre, randomised, double-blind, cross-over trial was done to compare the efficacy and safety of a serotonin receptor antagonist--ondansetron--and dexamethasone in the prophylaxis of acute and delayed emesis and nausea induced by moderately emetogenic non-platinum-containing chemotherapy regimens." | 9.07 | Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. ( Carney, DN; Cassidy, J; Cunningham, D; Hill, AS; Hutcheon, AW; Jones, AL; Kaye, SB; Sikora, K; Soukop, M, 1991) |
| " In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy." | 9.07 | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. ( Gandara, D; Hainsworth, J; Harker, G; Harvey, W; Hesketh, P; Kasimis, B; Khojasteh, A; Monaghan, G; Oblon, D; Pendergrass, K, 1991) |
| "The effect of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting was investigated in a randomized, double-blind, placebo-controlled study of 84 patients undergoing gynecologic operation and receiving the same general anesthetic." | 9.07 | Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. ( Leeser, J; Lip, H, 1991) |
| "We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time." | 9.07 | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991) |
| "Ondansetron (OND) is a new 5-HT3 receptor antagonist that give complete protection from emesis/nausea in approximately 50% of cisplatin (CDDP)-treated patients." | 9.07 | Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. ( Amadori, D; Bella, MA; Cognetti, F; Cortesi, E; Donati, D; Favalli, G; Gramazio, V; Marangolo, M; Roila, F; Tonato, M, 1991) |
| " Patients who had suffered severe vomiting on carboplatin alone (23 patients with ovarian carcinoma) or in combination (two patients with testicular cancer) despite intensive antiemetic regimens were treated with ondansetron, given as 8 mg immediately prior to carboplatin followed by 8 mg orally, 8 hourly for 5 days." | 9.07 | Reduction of carboplatin induced emesis by ondansetron. ( Dickson, DS; Evans, BD; Harvey, VJ; Langley, GB; Mak, D; Mitchell, PL; Neave, LM, 1991) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 9.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "Dexamethasone makes a significant contribution to the efficacy of ondansetron in the control of acute platinum induced emesis." | 9.07 | Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? ( Allan, SG; Bruntsch, U; Coleman, RE; Cornbleet, MA; Gallmeier, WM; Leonard, RC; Nicolson, M; Smyth, JF; Upadhyaya, BK, 1991) |
| "We compared the efficacy and safety of ondansetron (GR 38032F), a selective antagonist of serotonin S3 receptors, with that of placebo in controlling the nausea and vomiting induced by cisplatin treatment in 28 patients with cancer." | 9.06 | Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffmann, IS, 1990) |
| "Ondansetron is a 5-hydroxytryptamine 3-receptor antagonist which has shown activity in the prevention of cytotoxic-induced emesis." | 9.06 | Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. ( Adams, M; Collis, CH; Lucraft, H; Priestman, S; Priestman, TJ; Roberts, JT; Upadhyaya, BK, 1990) |
| "To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer." | 9.06 | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. ( Azab, M; Bons, J; Brion, N; Droz, JP; Marty, M; Paes, D; Paule, B; Pouillart, P; Pujade-Lauraine, E; Scholl, S, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 9.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "The efficacy of ondansetron was compared with metoclopramide in the prophylaxis of nausea and vomiting induced by cyclophosphamide greater than or equal to 500 mg/m2 in combination with doxorubicin greater than or equal to 40 mg/m2 or epirubicin greater than or equal to 40 mg/m2." | 9.06 | A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. ( Carruthers, L; Dicato, MA; Huys, JV; Kaasa, S; Kvaløy, S; Ries, F; Royer, E, 1990) |
| "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated." | 9.06 | Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. ( Bernard, S; Finn, A; Gandara, D; Khojasteh, A; Lester, E; Sartiano, G; Tapazoglou, E, 1990) |
| " In this randomized, double-blind, placebo-controlled study, we evaluated the effect of serotonin S3 receptor blockade with ondansetron (GR 38032F) on the prevention of nausea and vomiting induced by cyclophosphamide-containing chemotherapy." | 9.06 | Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffman, IS, 1990) |
| "To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting." | 9.06 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. ( Allman, EL; Beranek, P; De Mulder, PH; Mols-Jevdevic, S; Seynaeve, C; van Liessum, PA; Vermorken, JB; Verweij, J, 1990) |
| "In an open, drug-oriented phase-II/III-study 24 patients were treated with the 5-HT3-antagonist Ondansetron as an antiemetic drug for chemotherapy-induced nausea and emesis." | 9.06 | [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. ( Berdel, WE; Ertl, A; Fink, U; Perker, M; Reichold, M; Serve, H, 1990) |
| " Ondansetron exhibited similar efficacy than granisetron and tropisetron, as well as greater efficacy than dolasetron for acute vomiting." | 8.93 | Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. ( Acúrcio, Fde A; Andrade, EI; Cherchiglia, ML; De Araújo, VE; Marra, LP; Reis, IA; Simino, GP, 2016) |
| "Ondansetron is a 5-HT₃ receptor antagonist commonly used as an antiemetic to prevent nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy or postoperatively." | 8.89 | Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. ( Doggrell, SA; Hancox, JC, 2013) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 8.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "Granisetron (Kytril, Roche) is a 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist indicated for the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin." | 8.82 | Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. ( Tan, M, 2003) |
| "Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor antagonists, control of chemotherapy-induced nausea and vomiting (CINV) with first-generation agents (ondansetron, dolasetron, and granisetron) is less than ideal." | 8.82 | Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ( Rubenstein, EB, 2004) |
| " The authors included all randomized controlled trials (RCTs) that had more than 25 patients per arm and compared ondansetron to granisetron for prophylaxis of acute (A) (< 24 hours) and delayed (D) (> 24 hours) nausea (N) and vomiting (V) induced by highly (H) or moderately (M) emetogenic chemotherapy." | 8.80 | Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. ( Caparroz, C; Castro, PC; del Giglio, A; Soares, HP, 2000) |
| "The clinical development of ondansetron for the prevention and treatment of postoperative nausea and vomiting has been progressing for 5 years, and continues as new directions of research are being addressed." | 8.79 | Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions. ( Joslyn, AF, 1994) |
| "Available clinical data on the use of oral ondansetron for the prevention of nausea and vomiting in patients undergoing cancer chemotherapy or surgery are reviewed." | 8.79 | Oral ondansetron for preventing nausea and vomiting. ( Cooke, CE; Mehra, IV, 1994) |
| "The efficacy and safety of the serotonin (5-HT3) receptor antagonists granisetron, ondansetron, and tropisetron in the control of acute and delayed emesis and emesis induced by repeat-cycle chemotherapy are summarized." | 8.79 | Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). ( Hickok, JT; Morrow, GR; Rosenthal, SN, 1995) |
| "To test the evidence for a dose-response with ondansetron for treatment of postoperative nausea and vomiting and to establish whether differences in efficacy between doses are of clinical relevance." | 8.79 | A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "The authors reviewed efficacy and safety data for ondansetron for preventing postoperative nausea and vomiting (PONV)." | 8.79 | Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "Ondansetron is a selective 5-HT3 receptor antagonist which has previously been reported in the Journal to be a promising new agent for use as prophylaxis against nausea and vomiting caused by chemotherapy and radiotherapy." | 8.78 | Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. ( Markham, A; Sorkin, EM, 1993) |
| "An international clinical trial programme has been established to assess the efficacy and safety of ondansetron in the prevention and treatment of postoperative nausea and vomiting." | 8.78 | The clinical development of ondansetron for use in the prevention and treatment of postoperative nausea and vomiting. ( Haigh, CG; Hellstern, K; Inall, FC; Isal, JP; Joslyn, AF; Kanarek, BK; Kaplan, LA; Povey, PM, 1992) |
| "Ondansetron hydrochloride dihydrate is a 5-hydroxytryptamine (5-HT3) antagonist that was recently approved by the Food and Drug Administration for the treatment of chemotherapy-induced emesis." | 8.78 | Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting. ( Burnette, PK; Perkins, J, 1992) |
| " Early clinical studies therefore examined ondansetron treatment to establish an optimal dosing schedule for acute emesis." | 8.77 | Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Marty, M, 1989) |
| "Ondansetron is a widely administered medication for nausea and vomiting of pregnancy." | 8.31 | Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes. ( Azab, AN; Betesh-Abay, B; Hadar, E; Masarwe, S; Peleg, N; Shvartsur, R, 2023) |
| "The objective of this study was to describe ondansetron drug utilization patterns during pregnancy to treat nausea and vomiting in pregnancy (NVP)." | 8.12 | Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice. ( Candore, G; Flynn, R; Kurz, X; Nordeng, H; Pinheiro, L; Quinten, C; Slattery, J, 2022) |
| "Monosodium glutamate induces behaviors thought to reflect headache and nausea in rats." | 8.12 | Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats. ( Benbow, T; Cairns, BE; Exposto, FG; Sheikhi, A; Svensson, P; Teja, F, 2022) |
| "Although there is no recommendation in France relating to the treatment of nausea and vomiting of pregnancy, there are some in other countries, where ondansetron, widely used, appears to be an effective second-line treatment option behind doxylamine/vitamin B6 association and metoclopramide." | 8.02 | [Nausea and vomiting in pregnancy: A place for ondansetron?] ( Coulm, B, 2021) |
| "Although NK1RA is generally recommended for cisplatin-containing regimen, our results suggest that ondansetron effectively controlled emesis in patients receiving ESHAP therapy which includes high-dose corticosteroid." | 8.02 | Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. ( Kamiya, T; Kato, J; Kikuchi, T; Koda, Y; Mizuno, K; Mori, T; Okayama, M; Sakurai, M; Tanigawa, T, 2021) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 8.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 8.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "The results provide preliminary evidence of the potential benefit of ondansetron in the treatment of nausea, which was present in all examined dogs." | 8.02 | The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome. ( Elliott, J; Foth, S; Kenward, H; Meller, S; Pelligand, L; Volk, HA, 2021) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 7.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| "Ondansetron is widely used in general practice for nausea and vomiting due to any cause." | 7.83 | Ondansetron-Induced Life Threatening Hypokalemia. ( Kutty, KK; Mathew, SK; Padmakumar, C; Pius, P; Ramya, I, 2016) |
| "The patient completed the remainder of the radiation treatment with no further emesis and minimal nausea, representing the first documented success of granisetron and aprepitant for RINV after failure on ondansetron." | 7.81 | Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report. ( Chow, E; DeAngelis, C; Hunyh, L; McDonald, R; Pasetka, M; Raman, S; Rowbottom, L, 2015) |
| "To evaluate the appearance of chemotherapy-induced nausea and vomiting, and to compare the antiemetic efficacy of the triple combination of palonosetron, aprepitant and dexamethasone with that of our old regimen using first-generation 5-hydroxytryptamine 3-receptor antagonists and dexamethasone during gemcitabine and cisplatin chemotherapy in patients with advanced urothelial cancer." | 7.81 | Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients. ( Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F, 2015) |
| "The current Tactical Combat Casualty Care (TCCC) Guidelines recommend parenteral promethazine as the single agent for the treatment of opioid-induced nausea and/or vomiting and give a secondary indication of "synergistic analgesic effect." | 7.81 | Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care. ( Burrell, E; Butler, FK; Gross, K; Onifer, DJ; Otten, EJ; Patton, R; Russell, RJ; Stockinger, Z, 2015) |
| "The effectiveness of cannabidiolic acid (CBDA) was compared with other potential treatments for anticipatory nausea (AN), using a rat model of contextually elicited conditioned gaping reactions." | 7.80 | A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. ( Bonner, N; Downey, R; Engeland, K; Jackson, M; Limebeer, CL; Morris, H; Navaratnam, R; Parker, LA; Rock, EM; Sticht, MA, 2014) |
| "To determine the minimally effective dose of cannabidiolic acid (CBDA) that effectively reduces lithium chloride (LiCl)-induced conditioned gaping reactions (nausea-induced behaviour) in rats and to determine if these low systemic doses of CBDA (5-0." | 7.79 | Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. ( Parker, LA; Rock, EM, 2013) |
| "The main objective of this study was to develop a microemulsion (ME) formulation for transdermal delivery of ondansetron for chemotherapy induced nausea and vomiting (CINV)." | 7.79 | Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting. ( Ahmad, FJ; Al Abood, RM; Talegaonkar, S; Tariq, M, 2013) |
| "The use of ondansetron in children with vomiting after a head injury has not been well studied." | 7.79 | The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED. ( Hirsh, DA; Khan, NS; Simon, HK; Sturm, JJ, 2013) |
| "The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea/vomiting (CINV) among lung cancer patients receiving multi-day chemotherapy and ondansetron- or palonosetron-initiated prophylactic antiemetic regimens in a community oncology setting." | 7.78 | Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. ( Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G, 2012) |
| "While I usually prescribe doxylamine-pyridoxine for morning sickness, some of my patients with severe nausea and vomiting of pregnancy (NVP) receive ondansetron in hospital." | 7.78 | Motherisk update. Is ondansetron safe for use during pregnancy? ( Koren, G, 2012) |
| "Nausea and vomiting have always been associated with anti-cancer agents in patients' minds because these effects were the main ones to occur during chemotherapy." | 7.78 | [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting]. ( Depierre, A, 1996) |
| "Methotrexate (MTX) is an effective treatment for Crohn disease (CD); however, its application may be limited by the occurrence of nausea." | 7.77 | Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. ( Barkey, J; Benchimol, EI; Boland, M; Kempinska, A; Mack, A; Mack, DR, 2011) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 7.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "The optimal dose of oral ondansetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) resulting from moderately emetogenic chemotherapy (MEC) is unknown." | 7.76 | The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. ( Della-Fiorentina, SA; Ng, WL, 2010) |
| "A 1-year-old girl with stage-IV neuroblastoma developed ondansetron hydrochloride anaphylaxis." | 7.76 | Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. ( Batu, ED; Büyükpamukçu, M; Civelek, E; Demir, HA; Saçkesen, C; Yalçın, B, 2010) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "Aprepitant is actually recommended in the prevention of nausea and vomiting induced by high emetic risk chemotherapy using cisplatin." | 7.75 | [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study]. ( Auger, A; Combes, JD; Favier, B; Galy, G; Labidi, SI; Latour, JF; Tissier, F, 2009) |
| "A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug." | 7.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| "Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects." | 7.74 | Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. ( Foley, KF; Kast, RE, 2007) |
| "Ondansetron is a commonly used medication in the treatment of nausea and vomiting arising from many etiologies, including chemotherapy." | 7.74 | Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL. ( Pinsk, M; Turner, SR, 2008) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 7.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| "Ondansetron (Zofran) is a drug used for the treatment of nausea and vomiting caused by cancer chemotherapy." | 7.72 | The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. ( Einarson, A; Kennedy, D; Koren, G; Maltepe, C; Navioz, Y; Tan, MP, 2004) |
| "To assess the effectiveness of ondansetron in relieving symptoms of nausea and vomiting which were refractory to metoclopramide and cyclizine, in a patient receiving iloprost infusions." | 7.71 | Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. ( Roome, C; Thompson, J, 2001) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 7.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The control of emesis for patients undergoing high-dose chemotherapy with APBSCT is fair with ondansetron." | 7.70 | Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours. ( Ang, PT; Leong, SS; Tao, M; Teo, CP, 1998) |
| "To determine the incidence of nausea and vomiting and the antiemetic effect of ondansetron hydrochloride (OND) in patients with hepatocellular carcinoma treated with arterial chemo-embolization, we studied 59 patients with hepatocellular carcinoma who were treated with transcatheter arterial embolization (TAE) or lipiodolized transcatheter arterial infusion (L-TAI)." | 7.70 | Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride. ( Abe, T; Hashimoto, Y; Kojima, A; Mori, M; Nagamine, T; Sohara, N; Takagi, H; Takahashi, H, 1999) |
| "The article reports a study comparing the cost-effectiveness of ondansetron tablets and prochlorperazine capsules in preventing nausea and vomiting after moderately emetogenic chemotherapy in an outpatient setting." | 7.70 | Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy. ( Kwong, WJ; Parasuraman, TV, 1999) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 7.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "Two young women with chronic nausea and vertigo caused by multiple sclerosis responded to the introduction and maintenance of the 5HT3 receptor antagonist, ondansetron." | 7.70 | Ondansetron in multiple sclerosis. ( Macleod, AD, 2000) |
| "To determine how many patients were deprived of treatment by being given placebo as comparator in trials of ondansetron for postoperative nausea and vomiting." | 7.69 | Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. ( Aspinall, RL; Goodman, NW, 1995) |
| "To measure the severity of nausea and vomiting in pediatric patients receiving intravenous or intrathecal chemotherapy for acute lymphoblastic leukemia and to evaluate the effectiveness of 2 intravenous doses of ondansetron for this condition." | 7.69 | Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. ( Chavez, CM; Duncan, MH; Holdsworth, MT; Leasure, MM; Raisch, DW, 1995) |
| "We investigated the prophylactic antiemetic effect of added low-dose infusion of propofol in patients exhibiting nausea and vomiting refractory to dexamethasone and serotonin antagonist during non-cisplatin chemotherapy for breast cancer." | 7.69 | Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. ( Borgeat, A; Forni, M; Suter, PM; Wilder-Smith, O, 1994) |
| "The efficacy and safety of prophylactic intravenous ondansetron on prevention of postoperative nausea and vomiting were investigated in 65 ASA grades I-III patients undergoing elective abdominal surgery and receiving general anesthesia." | 7.69 | [Ondansetron on postoperative nausea and vomiting]. ( Guo, XY; Luo, AL; Ye, TH, 1994) |
| "To describe the efficacy of ondansetron for the treatment of poisoning-associated vomiting in two patients following drug intoxication." | 7.69 | Ondansetron for treating nausea and vomiting in the poisoned patient. ( Marx, CM; Reed, MD, 1994) |
| "The incidences of nausea and vomiting were significantly lower in the patients premedicated with ondansetron." | 7.69 | [Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery]. ( Bejarano-López, C; Bustos-Molina, F; Cid-Calzada, J; Cortés-Uribe, A; García-Cruz, JJ; Soro-Domingo, M, 1996) |
| "Investigated the prevalence of anticipatory nausea and vomiting (ANV) among 59 pediatric cancer patients who had routinely received ondansetron (Zofran) antiemetic therapy and determined patient- and treatment-related factors associated with ANV." | 7.69 | Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. ( Barclay, DR; Bieberich, AA; Mulhern, RK; Smith, BF; Tyc, VL, 1997) |
| "The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer." | 7.68 | Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. ( Calabria, C; Casale, F; Di Tullio, M; Indolfi, P; Lampa, E; Lucarelli, C; Matera, MG; Rossi, F, 1993) |
| "While ondansetron is effective in the control of nausea and vomiting induced by high dose cisplatin, it has to be given in multiple doses and is very expensive." | 7.68 | [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting]. ( Zeng, WY, 1993) |
| "To assess the value of ondansetron in a patient with intractable nausea, abdominal pain and diarrhoea unrelated to cancer chemotherapy or radiotherapy." | 7.68 | Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron. ( Evans, JE, 1993) |
| "Ondansetron may be the preferred agent for controlling nausea and vomiting in patients with neurosurgical trauma." | 7.68 | Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports. ( Deppe, SA; Kleinerman, KB; Sargent, AI, 1993) |
| "The antiemetic activity of ondansetron (Zofran, Glaxo Pharmaceuticals, Research Triangle Park, NC) was evaluated in 25 patients with recurrent melanoma who were treated sequentially with dacarbazine (DTIC), vinblastine, and cisplatin." | 7.68 | Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. ( Hodges, C; Legha, SS; Ring, S, 1992) |
| " Ondansetron is an investigational serotonin antagonist that has documented effectiveness for cancer chemotherapy-induced emesis." | 7.68 | Ondansetron: a new entity in emesis control. ( Graves, T, 1990) |
| "The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide." | 7.67 | The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989) |
| "Patients on cancer chemotherapy, which has high occurrence of nausea and vomiting, were given either the low dose or the conventional dose of olanzapine for 3 days, in addition to some other antiemetic agents." | 7.01 | Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Dutta, P; M Navari, R; Mukhopadhyay, S, 2021) |
| "Palonosetron (PG) is a newer, safe, and effective long-acting 5-HT3 antagonist commonly used in adults, but data in children are limited." | 6.90 | Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. ( Boddu, D; Chaudhary, NK; John, RR; Mahasampath, G; Mathew, LG; Nesadeepam, N, 2019) |
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 6.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| " Aprepitant and ondansetron as dosed in this trial was not superior to standard ondansetron monotherapy." | 6.84 | Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). ( Ades, S; Ashikaga, T; Blackstock, W; Halyard, M; Heimann, R; Kumar, S; Wilson, K, 2017) |
| "Aprepitant is a P/neurokinin-1 receptor antagonist approved for the prevention of CINV in moderate emetic risk chemotherapy." | 6.80 | Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara ( Badar, T; Borthakur, G; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; Mattiuzzi, G; O'Brien, S; Poku, R; Wierda, W, 2015) |
| "Rolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist." | 6.80 | Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). ( Arora, S; Chua, D; Fein, LE; Poma, A; Rapoport, B; Wang, Y, 2015) |
| "Gabapentin is a low-cost strategy to improve complete control of CINV, specially delayed CINV control." | 6.77 | Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. ( Carrasco, MM; Cruz, FM; da Costa Miranda, M; da Cunha Vieira, M; de Afonseca, SO; de Iracema Gomes Cubero, D; de Souza Fêde, AB; del Giglio, A; Lera, AT; Lerner, T; Pinczowski, H; Schindler, F; Taranto, P, 2012) |
| "Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor." | 6.76 | Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. ( Cao, R; Dong, X; Huang, J; Liu, L, 2011) |
| "The meclizine group had lower VNRS scores in the PACU at 15 (P = ." | 6.73 | Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population. ( Benfield, DA; Forrester, CM; Kelly, JA; Matern, CE; Pellegrini, JE, 2007) |
| "as prophylaxis in breast cancer patients regimens was studied." | 6.71 | Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. ( Coop, AJ; Dempsey, CL; Eberhardt, DR; Farley, PA; O'Briant, S; Shillington, A, 2004) |
| "Nausea was assessed by means of a four-point ordinal scale at intervals over the 7 day period." | 6.70 | Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. ( Borms, M; Carides, AD; Cocquyt, V; De Smet, M; Decramer, ML; Eldridge, K; Gertz, BJ; O'Brien, M; Reinhardt, RR; Schellens, JH; Van Aelst, F; Van Belle, S; Verbeke, L, 2001) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 6.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "Sixty cancer patients took part in this randomized prospective study." | 6.69 | Granisetron and ondansetron for chemotherapy-related nausea and vomiting. ( Ben Dayan, D; Ben Zion, T; Cohen, AM; Kaufman, O; Mittelman, M; Zeidman, A, 1998) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 6.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "Ondansetron 24 mg q." | 6.69 | A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. ( Ames, M; Brogden, J; Cohen, G; Craig, J; Diaz, LB; Garcia Rodriguez, FM; Krasnow, S; Miranda, E; Needles, B; Spector, J, 1999) |
| "Ondansetron is an effective and well-tolerated antiemetic, which is used for the prevention of both chemotherapy and radiotherapy-induced emesis and nausea." | 6.69 | Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tab ( Coster, B; Feyer, P; Franzén, L; Goedhals, L; Graham, E; Haigh, C; LeBourgeois, JP; Marzecki, Z; McKenna, CJ; Mitchell, T; Souhami, L; Stewart, A; Tønnessen, F; Wilkinson, JR, 1999) |
| " The antiemetic efficacy of NK1 receptor antagonists against chemotherapy-induced emesis is, however, enhanced when combined with a 5-HT3 receptor antagonist." | 6.69 | Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. ( Clemes, SA; House, F; Palmer, JL; Reid, K; Somal, HS; Stott, JR; Troakes, C; Wright, RJ, 2000) |
| "Metoclopramide was ineffective." | 6.68 | The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. ( Clark, K; Cronin, MK; Darvish, AH; Desilva, PH; McDonald, SM, 1995) |
| "One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min." | 6.68 | [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. ( Fan, Y; Guo, N; Huang, X, 1995) |
| "Children who had solid tumors and who were receiving highly emetogenic chemotherapy, including cisplatin, carboplatin, cyclophosphamide, and ifosfamide, were randomized (1:1) in a double-blind fashion to receive either OND 0." | 6.68 | Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. ( Alvarez, O; Bedros, A; Call, SK; Convy, L; Cook, L; Freeman, A; Halverson, J; Kalbermatter, O; Mick, K; Volsch, J, 1995) |
| " In addition, ondansetron had a similar dose-response curve in both menstruating and nonmenstruating women." | 6.68 | The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron. ( Afshar, M; Allen, E; Buxbaum, J; Gratz, I; Joslyn, AF; Prilliman, B, 1996) |
| "001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters." | 6.68 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. ( Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA, 1996) |
| "Ondansetron is a serotonin (5HT) receptor antagonist at both peripheral and central 5-HT3 receptor sites with no known action on dopamine-mediated activity." | 6.68 | Droperidol/ondansetron combination controls nausea and vomiting after tubal banding. ( Hamilton, DL; McKenzie, R; Riley, TJ; Uy, NT, 1996) |
| "A group of 104 chemotherapy-naive ovarian cancer patients, scheduled for at least three cycles of combination chemotherapy including cisplatin (50 mg/m2), were randomly allocated to receive either dexamethasone or placebo in addition to ondansetron." | 6.68 | Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Lomberg, H; Peterson, C; Steineck, G, 1996) |
| "As ondansetron was clearly effective in patients receiving hemibody irradiation it seems it would be prudent to adopt it for use in such patients routinely." | 6.68 | Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. ( Kiltie, AE; Stewart, AL; Sykes, AJ, 1997) |
| "Nausea and emesis are significant side effects in patients undergoing stereotactic radiosurgery for brain lesions in the region of the chemoreceptor trigger zone (area postrema of the brain)." | 6.67 | The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone. ( Alexander, E; Bodis, S; Kooy, H; Loeffler, JS, 1994) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 6.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Ondansetron is a well tolerated, efficacious antiemetic which has a similar side effect profile to placebo." | 6.67 | Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting. ( Claybon, L, 1994) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 6.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "Oral ondansetron is a safe and effective antiemetic that is more efficacious than placebo for patients receiving cyclophosphamide-based chemotherapy." | 6.67 | Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. ( Beck, TM; Chang, A; Ciociola, AA; Galvin, D; Hart, NE; Harvey, WH; Jones, SE; Tchekmedyian, NS, 1993) |
| "Ondansetron was injected intravenously in a single dose of 4 mg, 8 mg or 12 mg, at 15 minutes before administration of cisplatin." | 6.67 | [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 6.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was well tolerated in the dose and schedule used." | 6.67 | The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. ( Bryson, JC; Finn, AL; Gandara, DR; Harvey, WH; Hesketh, PJ; Monaghan, GG; Perez, EA; Stokes, C, 1992) |
| "Ondansetron 4 mg was administered orally once daily for 3-5 consecutive days." | 6.67 | [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " Several clinical observations suggested that ondansetron may be effective when given in a single dose: (1) demonstration of efficacy over a wide dose range, (2) similar efficacy with dosing intervals of 2, 4, 6, and 8 hours, and (3) efficacy of single-dose regimens with high-dose metoclopramide and other 5-hydroxytryptamine3 antagonists." | 6.67 | Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. ( Hainsworth, JD; Hesketh, PJ, 1992) |
| "Ondansetron was an effective antiemetic in 78% (14/18) and placebo was effective in 28% (5/18) of the patients." | 6.67 | Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo. ( Afshar, M; Gratz, I; Larijani, GE; Minassian, S, 1991) |
| "Nausea and vomiting are two of the most distressing side effects of chemotherapy." | 6.44 | Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. ( Vrabel, M, 2007) |
| "Ondansetron is a serotonin receptor antagonist that is effective in preventing and treating PONV." | 6.39 | Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting. ( Charbonneau, J; Early, TE; Jenkins, P; McKnight, G, 1995) |
| "Ondansetron has marked activity against emesis associated with cisplatin and other highly emetogenic drugs." | 6.38 | Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting. ( Goldspiel, BR; Kohler, DR, 1991) |
| "Postoperative nausea and vomiting (PONV) is still a common perioperative complication and ondansetron has proved to be an effective antiemetic substance in its prevention." | 6.18 | [Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms]. ( Buhre, W; Kazmaier, S; Mühr, C; Neumann, P; Saur, P, 1996) |
| "A total of 1442 patients who had major gynaecological surgery were recruited into three multicentre studies using a standard general anaesthetic technique in order to assess the efficacy of various doses of orally administered ondansetron in the prevention of postoperative nausea and vomiting." | 6.17 | Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence. ( Dupeyron, JP; Durham, JM; Haigh, CG; Harmer, M; Kaplan, LA; Kenny, GN, 1993) |
| "Twenty patients receiving cisplatin (greater than or equal to 100 mg/m2) as initial chemotherapy were entered into this Phase II trial to test the effectiveness of oral ondansetron, a specific serotonin receptor (5-HT3) antagonist, in controlling delayed emesis." | 6.17 | Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. ( Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB, 1992) |
| "Ondansetron is a 5-HT3 receptor antagonist which is effective and well tolerated as an antiemetic for emesis induced by cancer chemotherapy and radiation therapy, and in the prevention and treatment of postoperative nausea and vomiting." | 6.17 | Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ( Baber, N; Frazer, NM; Palmer, JL; Pritchard, JF, 1992) |
| "The chemistry, pharmacokinetics, adverse effects, stability, compatibility, and dosage of ondansetron hydrochloride are described, and clinical studies of the use of ondansetron for the prophylaxis of nausea and vomiting induced by antineoplastic therapy are reviewed." | 6.16 | Ondansetron--the first of a new class of antiemetic agents. ( Chaffee, BJ; Tankanow, RM, 1991) |
| "We compared the efficacy of the granisetron transdermal system (GTS) with that of ondansetron for controlling chemotherapy-induced nausea and vomiting (CINV) in patients treated with highly emetogenic chemotherapy (HEC)." | 5.69 | Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial. ( Eom, YA; Jin, JY; Kang, JH; Kim, HK; Ko, YH; Park, SY; Sun, S; Woo, IS, 2023) |
| "5 mg IV with ondansetron 8 mg IV for the treatment of nausea and vomiting." | 5.69 | Droperidol versus ondansetron for nausea treatment within the emergency department. ( Clemensen, E; Lau, GT; Philpott, L, 2023) |
| "This study showed the effectiveness of the prescription of 5 mg ephedrine two minutes before changing from the lithotomy position to the supine in maintaining hemodynamic stability, reducing hypotension, bradycardia, nausea, and vomiting, and the amount of prescribed ephedrine, atropine, and ondansetron." | 5.69 | The Prophylaxis Effect of Ephedrine on Hemodynamic Variation in Patients Undergoing Percutaneous Nephrolithotomy Surgery with Spinal Anesthesia. ( Bahrami, A; Darvishzadehdaledari, S; Golabi, P; Hamoud Alshahrani, S; Kamalov, Z; Kazemi Haki, B; Nasiri, AA; Sajid Abdulabbas, H; Sane, S, 2023) |
| "When treating nausea in patients with chronic gastrointestinal syndromes, clinicians may consider trying higher performing treatments first, and forgoing lower performing treatments." | 5.56 | Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea. ( Clarke, JO; Fernandez-Becker, N; Garcia, M; Garcia, P; Grewal, D; Kamal, A; Nandwani, M; Neshatian, L; Nguyen, L; Okafor, P; Regalia, K; Sonu, I; Triadafilopoulos, G; Zikos, TA, 2020) |
| "Olanzapine significantly improved complete control of vomiting in the delayed phase." | 5.51 | Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial. ( Gupta, AK; Meena, JP; Moothedath, AW; Pandey, RM; Seth, R; Velpandian, T, 2022) |
| "To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome." | 5.51 | Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. ( Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA, 2022) |
| " The groups were analyzed and compared for frequency of vomiting, administered doses of on-demand antiemetic dimenhydrinate and adverse events during the acute (0-24 h after chemotherapy administration) and delayed (> 24 h-120 h) CINV phases." | 5.51 | Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. ( Binder, V; Blaeschke, F; Cabanillas Stanchi, KM; Döring, M; Feucht, J; Feuchtinger, T; von Have, M; Willier, S, 2019) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 5.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| "To compare effectiveness of maropitant and ondansetron in preventing preoperative vomiting and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate." | 5.41 | Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate. ( Burke, JE; Hess, RS; Silverstein, DC, 2021) |
| "To compare rates of complete response (no emesis, retching, or rescue antiemetics) in the late phase (days 4-7 post-chemotherapy) of cycle 1 between transdermal granisetron and oral ondansetron in cervical, endometrial, or vaginal cancer survivors undergoing chemoradiation at The University of Texas MD Anderson Cancer Center and LBJ Hospital in Houston, TX." | 5.41 | A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. ( Armbruster, SD; Coleman, RL; Eifel, PJ; Fellman, BM; Frumovitz, M; Jhingran, A; Klopp, AH; Ramondetta, LM, 2021) |
| " Interestingly, none of the patients aged under 7 years, receiving divided dosing ondansetron, presented nausea symptoms compared with those receiving single daily dosing (p-value ." | 5.41 | Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. ( Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C, 2021) |
| "Palonosetron was always administered as a single-day therapy while one- or multi-day ondansetron therapy was administered in 27% and 73% of cycles, respectively." | 5.37 | Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. ( Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC, 2011) |
| "A generalized tonic-clonic seizure occurred in each patient--12, 15, and 22 min after injection." | 5.35 | Ondansetron and seizures. ( Acharya, JN; Rai, A; Selhorst, JB; Singh, NN, 2009) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 5.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "To evaluate the efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for chemotherapy-induced nausea vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy (HEC)." | 5.34 | The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Angspatt, P; Chenaksara, P; Parinyanitikun, N; Poovorawan, N; Sakdejayont, S; Sriuranpong, V; Sukprakun, S; Tanasanvimon, S; Thawinwisan, W; Vimolchalao, V; Vinayanuwatikun, C; Wongchanapai, P, 2020) |
| "We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC)." | 5.34 | Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. ( Akewanlop, C; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Laocharoenkiat, A; Nimmannit, A; Soparattanapaisarn, N; Techawattanawanna, S; Theeratrakul, P, 2020) |
| " We decided to evaluate the efficacy of olanzapine with the real-life practice antiemetic drugs ondansetron and dexamethasone, in prevention of CINV resulting from doxorubicin plus cyclophosphamide regimen in early-stage breast cancer patients." | 5.30 | A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. ( Laohavinij, S; Maneechavakajorn, J; Maneenil, K; Nipondhkit, W; Payapwattanawong, S; Sa-Nguansai, S; Tienchaiananda, P, 2019) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 5.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "Ondansetron was administered as follows: 8 mg intravenously before the start of chemotherapy, followed by 8 mg orally three times daily for 10 days." | 5.29 | Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. ( Braken, JB; de Pauw, BE; Koopmans, PP; Raemaekers, JM, 1993) |
| "and metoclopramide 0." | 5.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Ondansetron is a cost effective and safe antiemetic in children receiving chemotherapy and total body irradiation, minimises weight loss on treatment and enables outpatient chemotherapy in some cases." | 5.28 | Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. ( Abbott, GD; Robinson, BA; Sullivan, MJ, 1992) |
| "During late 1991, a series of severe adverse events involving thrombocytopenia, renal insufficiency and thrombotic episodes was observed in patients receiving emetogenic chemotherapy." | 5.28 | Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. ( Childs, A; Coates, AS; Cox, K; Forsyth, C; Grygiel, JJ; Joshua, DE; McNeil, E, 1992) |
| "Ondansetron was also given to 16 patients receiving cisplatin chemotherapy." | 5.28 | Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. ( Allan, SG; Dickson, D; Evans, BD; Forgeson, GV; Harvey, VJ; Humm, G; Langley, G; Mak, D; Mitchell, PL; Neave, L, 1992) |
| "We compare aromatherapy with inhaled isopropyl alcohol versus oral ondansetron for treating nausea among emergency department (ED) patients not requiring immediate intravenous access." | 5.27 | Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial. ( April, MD; Davis, WT; Hunter, CJ; Ng, PC; Oliver, JJ; Ong, D; Simon, EM, 2018) |
| "Palonosetron is non-inferior and cost-effective compared to ondansetron for prevention of acute chemotherapy-induced vomiting (CIV) in children receiving moderate and high emetogenic chemotherapy." | 5.27 | A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy. ( Jain, S; Kapoor, G; Koneru, S; Vishwakarma, G, 2018) |
| " Complete response (CR; no vomiting and no rescue medication) rates in the acute, delayed, and overall phases (0-25, 25-120, and 0-120 h, respectively) were analyzed by chemotherapy type (carboplatin-based vs non-carboplatin-based), chemotherapy duration (single-day vs multiple-day), and baseline characteristics." | 5.27 | Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. ( Beckford-Brathwaite, E; Camacho, E; Green, SA; Jordan, K; Khanani, S; Noga, SJ; Pong, A; Rapoport, BL; Weinstein, C, 2018) |
| "Subjects aged 6 months to 17 years scheduled to receive chemotherapeutic agents associated with at least moderate risk for emesis were randomly assigned to receive either aprepitant plus ondansetron (aprepitant regimen) or placebo plus ondansetron (control regimen); both could be administered with or without dexamethasone." | 5.27 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. ( DiCristina, C; Green, S; Kang, HJ; Loftus, S; Pong, A; Zwaan, CM, 2018) |
| "Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens." | 5.27 | Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018) |
| "To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC)." | 5.24 | Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study. ( Basharova, E; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, A, 2017) |
| "Neurokinin-1 receptor antagonists, such as aprepitant are currently emerging as powerful prophylactic agents for chemotherapy-induced nausea and vomiting (CINV)." | 5.24 | Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy. ( Abbas, N; Abdel-Malek, R; Fawzy, R; Ismail, M; Safwat, E; Salem, DS; Shohdy, KS, 2017) |
| "Ginger (500 mg) twice daily was safe, but conferred no additional benefit in terms of reducing nausea severity in breast cancer patients receiving AC and ondansetron and dexamethasone for CINV prophylaxis." | 5.24 | Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. ( Akewanlop, C; Chantharasamee, J; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Soparattanapaisarn, N; Srimuninnimit, V; Techawathanawanna, S; Thamlikitkul, L, 2017) |
| "The primary aim of this study was to compare the effectiveness of olanzapine, palonosetron and ondansetron infusion (standard of care) for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients undergoing hematopoietic stem cell transplantation (HSCT)." | 5.24 | A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. ( Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M, 2017) |
| "This study evaluated the efficacy and safety of a 3-day aprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of non-anthracycline plus cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) based on government guidelines in Korean patients." | 5.24 | Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. ( Ahn, MJ; Cho, CH; Cho, EK; Jang, JS; Jung, H; Kim, DJ; Kim, JE; Kim, JW; Lee, KY; Lee, MA; Lim, MC; Min, KW; Sung, YL; Sym, SJ, 2017) |
| "Despite the addition of aprepitant, extended-duration dexamethasone and olanzapine, patients at high risk for CINV due to personal risk factors failed to achieve good nausea control." | 5.22 | Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. ( Bouganim, N; Clemons, M; Dranitsaris, G; Mazzarello, S; Smith, S; Vandermeer, L, 2016) |
| "Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy." | 5.22 | Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. ( Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016) |
| "Significantly more patients receiving rolapitant than control reported no emesis or interfering nausea (combined measure) in cycles 2 (p = 0." | 5.22 | Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. ( Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L, 2016) |
| "APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV)." | 5.22 | APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. ( Agajanian, R; Cooper, W; Dakhil, C; Gabrail, NY; Klepper, MJ; Mosier, MC; Payne, JY; Schnadig, ID; Schwartzberg, LS; Smith, RE; Taylor, C; Vacirca, JL; Wilks, ST, 2016) |
| "To evaluate the effect of prophylactic ondansetron on spinal anesthesia-induced hypotension and bradycardia among patients undergoing elective cesarean deliveries." | 5.22 | Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia-induced hypotension during elective cesarean delivery in Egypt. ( El Khouly, NI; Meligy, AM, 2016) |
| "To compare the efficacy between acupuncture and ondansetron in the prevention of delayed chemotherapy induced nausea and vomiting (CINV)." | 5.20 | Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. ( Akkayagorn, L; Manchana, T; Rithirangsriroj, K, 2015) |
| "The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC)." | 5.20 | Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. ( Wang, H; Wang, L; Wang, X; Zhang, H, 2015) |
| "Aprepitant, a neurokinin-1 receptor antagonist, in combination with 5 HT-3 antagonist and dexamethasone is recommended in adults receiving moderately and highly emetogenic chemotherapy to reduce chemotherapy-induced vomiting (CIV)." | 5.20 | Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. ( Bakhshi, S; Batra, A; Biswas, B; Dhawan, D; Paul, R; Sreenivas, V, 2015) |
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 5.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| " Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003)." | 5.19 | Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. ( Bateman, DN; Butcher, I; Cooper, JG; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, SC; Rodriguez, A; Sandilands, EA; Thanacoody, HK; Thomas, SH; Veiraiah, A; Vliegenthart, AD; Webb, DJ, 2014) |
| "Maternal hypotension and nausea were significantly lower in ondansetron-treated patients versus placebo (p = 0." | 5.19 | Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery. ( Shen, MK; Wang, M; Wang, Q; Yu, JJ; Yu, YY; Zhuo, L, 2014) |
| "We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting." | 5.19 | Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. ( Braitberg, G; Egerton-Warburton, D; Mee, MJ; Meek, R, 2014) |
| "Regardless of age, gender, or region, the aprepitant regimen provided better control for the no-vomiting and complete-response (no vomiting, no rescue therapy) endpoints." | 5.19 | Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. ( Rapoport, BL, 2014) |
| "Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy." | 5.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| "Patients were assessed for nausea and vomiting on their infusion day using the Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) at arrival, pre-ASCT infusion, pre-ondansetron administration, prior to the first bag, and after each bag of stem cells." | 5.17 | Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells. ( Eisenberg, S; Gooley, T; Holmberg, L; Linenberger, M; Wickline, M, 2013) |
| "To estimate whether the addition of metoclopramide or its combination with ondansetron to a prophylactic phenylephrine infusion provides improved intraoperative nausea and vomiting prophylaxis compared with phenylephrine infusion alone." | 5.17 | Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial. ( Allen, TK; George, RB; Habib, AS; Ituk, US; McKeen, DM; Megalla, SA; White, WD, 2013) |
| " The objective of this study was to establish the overall complete response (CR; no emesis or use of rescue medication 0-120 h after chemotherapy) with either ondansetron- or palonosetron-containing antiemetic regimens in patients receiving highly emetogenic chemotherapy (HEC)." | 5.17 | Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. ( Berger, MJ; Blazer, MA; Crawford, BS; Flynn, JM; Griffith, NL; Layman, RM; Lustberg, MB; Mrozek, E; Phillips, GS; Ramaswamy, B; Shapiro, CL; Wenzell, CM; Wesolowski, R, 2013) |
| "Patients with colorectal cancer received either casopitant or placebo intravenously (IV) added to ondansetron 8 mg bid oral on study days 1 to 3 and one dose of dexamethasone 8 mg IV given prior to starting the oxaliplatin on day 1." | 5.16 | Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. ( Dube, P; Hesketh, PJ; Kopp, M; Lane, S; Levin, J; Makhson, A; Moiseyenko, V; Rosati, G; Russo, M; Wright, O, 2012) |
| "For moderately emetogenic chemotherapy, palonosetron (PALO) is reported to provide complete control of chemotherapy-induced nausea and vomiting (CINV) in 69% of patients." | 5.16 | Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. ( Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L, 2012) |
| " Aprepitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting, is an inhibitor and inducer of CYP3A4." | 5.16 | Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. ( Bannerji, R; Kantesaria, B; Mita, M; Poon, J; Shapiro, GI; Small, K; Statkevich, P; Tzontcheva, A; Zhang, D; Zhu, Y, 2012) |
| "Breast cancer patients in a phase III double-blind, placebo-controlled trial were randomized to antiemetic regimens including ondansetron and dexamethasone, or aprepitant, ondansetron, and dexamethasone." | 5.15 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. ( Carides, AD; Street, JC; Warr, DG, 2011) |
| " For HEC, aprepitant reduced the risk of first emesis by 38-77% vs." | 5.15 | Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). ( Carides, AD; Hesketh, PJ; Street, JC; Warr, DG, 2011) |
| "The objective of the study was to assess whether ondansetron has superior nausea reduction compared with metoclopramide, promethazine, or saline placebo in emergency department (ED) adults." | 5.15 | A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. ( Barrett, TW; DiPersio, DM; Jack, M; Jenkins, CA; Lee, P; McCoin, NS; Singleton, LM; Slovis, CM; Storrow, AB; Zhou, C, 2011) |
| "Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours)." | 5.15 | Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. ( Beckford, E; Boice, JA; Carides, A; Chua, D; DeVandry, S; Dinis, J; Grunberg, S; Hardwick, JS; Herrstedt, J; Maru, A; Roila, F; Taylor, A, 2011) |
| "To compare the efficacy of acupressure wrist bands, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery." | 5.15 | Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery. ( Arbabi, S; Ebrahim Soltani, AR; Goudarzi, M; Mohammadinasab, A; Mohammadinasab, F; Mohammadinasab, H; Samimi, M, 2011) |
| "We performed a clinical study of a triple-drug combination to evaluate its efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM (BCNU [carmustine]+etoposide+ARA-C [cytarabine]+melphalan) before hematopoietic stem cell transplantation (HSCT) by comparison with a historical control group of patients treated with dexamethasone (dex) and ondansetron or palonosetron." | 5.15 | A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. ( Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A, 2011) |
| "The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents." | 5.14 | Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. ( Carides, AD; Chawla, S; Chua, V; Devandry, S; Evans, JK; Gore, L; Hemenway, M; Oxenius, B; Petrilli, A; Schissel, D; Taylor, A; Valentine, J, 2009) |
| "All doses of oral casopitant as a 3-day regimen (and likely as a 150-mg single oral dose) in combination with Ond/Dex provided significant improvement in the prevention of cisplatin-induced emesis." | 5.14 | Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. ( Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW, 2009) |
| "Aprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in breast cancer patients receiving an anthracycline and cyclophosphamide (AC)-based regimen." | 5.14 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. ( Boice, JA; Brown, C; Carides, A; Hardwick, JS; Jordan, K; Rapoport, BL; Schmoll, HJ; Taylor, A; Webb, T, 2010) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 5.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "This randomized, double-blind, dose-ranging, placebo-controlled, phase 2 trial evaluated the neurokinin-1 receptor antagonist casopitant mesylate in combination with ondansetron/dexamethasone (ond/dex) for the prevention of chemotherapy-induced nausea and vomiting (CINV) related to moderately emetogenic chemotherapy (MEC)." | 5.14 | Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera ( Albert, I; Arpornwirat, W; Bandekar, RR; Grunberg, SM; Hansen, VL; Levin, J, 2009) |
| "The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy." | 5.14 | Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. ( Blackburn, LM; Gridelli, C; Haiderali, AM; Lykopoulos, K; Russo, MW, 2010) |
| " The neurokinin-1 antagonist casopitant or its placebo was administered cyclically with ondansetron and dexamethasone in two randomized chemotherapy-induced nausea and vomiting clinical trials in nearly 3000 subjects." | 5.14 | The evaluation of drug rechallenge: the casopitant Phase III program. ( Abissi, CJ; Hunt, CM; Papay, JI; Rich, DS; Russo, MW, 2010) |
| "Palonosetron and ondansetron are two selective 5-hydroxytryptamine (5-HT3) receptor antagonists that have shown remarkable efficacy in controlling nausea and vomiting following administration of moderately emetic anticancer chemotherapy." | 5.14 | Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. ( Atri, R; Bhutani, G; Dhankar, R; Gupta, MC; Kaushal, J; Kaushal, V; Verma, S, 2010) |
| "The authors compared 2 schedules of palonosetron versus ondansetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with AML receiving high-dose cytarabine." | 5.14 | Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. ( Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L, 2010) |
| "This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients." | 5.14 | A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. ( Chan, SL; Ho, WM; Hui, EK; Koh, J; Kwan, WH; Lam, KC; Lau, W; Lee, KK; Mo, FK; Mok, TS; Poon, AN; Suen, JJ; Yeo, W; Yeung, WK; Zee, B, 2009) |
| "Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0." | 5.13 | Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery. ( Diregpoke, S; Krobbuaban, B; Pitakpol, S, 2008) |
| "The authors sought to compare ondansetron and promethazine among emergency department (ED) patients with undifferentiated nausea." | 5.13 | Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. ( Braude, D; Crandall, C, 2008) |
| "5 mg, nausea and vomiting were relieved at one hour in 74% and 68%, respectively, compared with 59% for intravenous ondansetron 4 mg." | 5.12 | No more than necessary: safety and efficacy of low-dose promethazine. ( Caldwell, JB; Moser, JD; Rhule, FJ, 2006) |
| " This randomized, double-blind, double-dummy, multicenter study was designed to compare the efficacy and tolerance of metopimazine and ondansetron at preventing nausea and emesis in patients receiving chemotherapy." | 5.12 | A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. ( Bensaoula, O; Bethune-Volters, A; Chidiac, J; Delgado, A; Di Palma, M; Khamales, S, 2006) |
| "A prospective randomized study was performed to assess the value of some individual risk factors for postoperative nausea and vomiting (PONV), and to compare the efficacy of ondansetron, metoclopramide, dexamethason, and combinations of these antiemetics in preventing PONV in patients after laparoscopic cholecystectomy." | 5.12 | Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. ( Leksowski, K; Peryga, P; Szyca, R, 2006) |
| "This pivotal phase III trial evaluated the efficacy and safety of palonosetron in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC)." | 5.12 | A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Aapro, MS; Bertoli, LF; Grunberg, SM; Lordick, F; Macciocchi, A; Manikhas, GM; Morrica, B; Olivares, G; Suarez, T; Tjulandin, SA; Yunus, F, 2006) |
| "To evaluate the effectiveness of prophylactic dexamethasone for the control of radiation induced emesis (RIE) when added to ondansetron during days 1 to 5 of fractionated radiotherapy." | 5.12 | 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). ( Ackerman, I; Brundage, M; Chabot, P; Ding, K; Fortin, A; Fyles, A; McKenzie, M; Nabid, A; Pater, J; Paul, N; Souhami, L; Whitehead, M; Wilke, D; Wilson, D; Wong, RK, 2006) |
| " Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss." | 5.12 | Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. ( Ai, B; Dong, M; Han, X; He, X; Huang, D; Liu, P; Shi, Y; Yang, S; Zhang, C; Zhou, S, 2007) |
| "We compared the efficacy of inhaled isopropyl alcohol (IPA) with ondansetron for the control of postoperative nausea and vomiting (PONV) during a 24-hour period in 100 ASA class I-III women undergoing laparoscopic surgery." | 5.12 | A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home. ( Cotton, JW; Hood, RR; Pellegrini, JE; Rowell, LR, 2007) |
| "To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study." | 5.12 | Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. ( Baranowski, V; Barbato, LM; Carter, FJ; Jhangiani, H; Meiri, E; Vredenburgh, JJ; Yang, HM, 2007) |
| "To evaluate the antiemetic effect of a single dose of ondansetron and dexamethasone as a prophylaxis for chemotherapy induced acute nausea and emesis and factors associated with the control of acute nausea and emesis." | 5.12 | Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. ( Manusirivithaya, S; Pradermdee, P; Sukwattana, P; Tangjitgamol, S; Thavaramara, T, 2006) |
| "This study in volunteers has shown that betamethasone does not prevent nausea and vomiting induced by oral intake of ipecacuanha syrup." | 5.11 | Betamethasone does not prevent nausea and vomiting induced by ipecacuanha. ( Axelsson, P; Thörn, SE; Wattwil, M, 2004) |
| "5-HT3 receptor antagonists, including granisetron and ondansetron, are widely used in the prophylactic treatment of chemotherapy-induced nausea and vomiting." | 5.11 | The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. ( Buyukavci, M; Ceviz, N; Olgun, H, 2005) |
| "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide +/- doxorubicin or epirubicin." | 5.11 | Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. ( Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG, 2005) |
| "The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy." | 5.11 | Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. ( Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S, 2005) |
| "The current analysis of > 1000 patients from 2 large randomized trials showed that in the subpopulation at increased risk of chemotherapy-induced nausea and vomiting due to concomitant emetogenic chemotherapy, the addition of aprepitant to standard antiemetics improved protection to an even greater extent than in the general study population." | 5.11 | Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize ( Carides, AD; de Wit, R; Evans, JK; Gralla, RJ; Guoguang-Ma, J; Herrstedt, J; Horgan, KJ; Ianus, J, 2005) |
| " Overall nausea and vomiting were significantly lower in the ondansetron prophylaxis group than in the group without prophylaxis (52." | 5.11 | Postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy under spinal anaesthesia: a randomized study of ondansetron prophylaxis. ( Baublys, A; Ivaskevicius, J; Kontrimaviciute, E, 2005) |
| "To compare the efficacy and tolerability of associations of metopimazine and ondansetron with methylprednisolone for the prevention of delayed chemotherapy-induced nausea and emesis." | 5.11 | Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. ( Bloch, J; Delgado, A; Khayat, D; Meric, JB; Rixe, O, 2005) |
| "To study the enhancement by dexamethasone of the effect of ondansetron and tropiesetron against postoperative nausea and vomiting (PONV) in patients receiving patient-controlled analgesia (PCA) and observe the effect of dexamethasone on wound healing." | 5.10 | [Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia]. ( Liu, HF; Lu, ZH; Sheng, PT; Wang, C; Wang, LY; Xiong, LZ; Xu, N; Yang, XY, 2002) |
| "When it was added to a standard regimen of intravenous ondansetron and oral dexamethasone in the current study, aprepitant reduced chemotherapy-induced nausea and vomiting and was generally well tolerated, although increases in infection were noted that were assumed to be due to elevated dexamethasone levels as a result of the pharmacokinetic interaction." | 5.10 | Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. ( Carides, AD; Chawla, SP; Elmer, ME; Evans, JK; Gralla, RJ; Grunberg, SM; Hesketh, PJ; Horgan, KJ; Rittenberg, C; Schmidt, C; Taylor, A, 2003) |
| "In this study, the efficacy and safety of intravenous administration of droperidol followed by oral use of dimenhydrinate did not differ from that of intravenous followed by oral use of ondansetron in children undergoing strabismus surgery." | 5.10 | Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery. ( Bussières, JF; Caron, E; Jacob, JL; Lebel, D; Lortie, L; Mathews, S; Milot, J; Moride, Y, 2003) |
| "To study if acupuncture, combined with ondansetron treatment, reduces nausea and vomiting associated with cyclophosphamide infusion in patients with rheumatic diseases." | 5.10 | Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases. ( Josefson, A; Kreuter, M, 2003) |
| " In the present study, the Functional Living Index-Emesis (FLIE), was used to assess patient-reported impact of chemotherapy-induced nausea and vomiting (CINV) after administration of a new NK-1 receptor antagonist (aprepitant)." | 5.10 | Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. ( Cai, B; Carides, AD; Chawla, SP; Elmer, M; Grunberg, SM; Horgan, K; Martin, AR; Pearson, JD; Schmidt, C, 2003) |
| "The results obtained showed that ondansetron was more effective in controlling nausea and vomiting than metoclopramide, either objectively (2." | 5.10 | Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. ( Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002) |
| "We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma." | 5.10 | [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate ( Fujimaki, K; Fukawa, H; Harano, H; Hashimoto, Y; Hattori, M; Kanamori, H; Kodama, F; Koharasawa, H; Mohri, H; Motomura, S; Sakai, R; Takemura, S; Tanabe, J; Tomita, N, 2002) |
| "Antiemetic treatment with tropisetron or ondansetron could be improved by adjustment for the CYP2D6 genotype; approximately 50 subjects would have to be genotyped to protect one patient from severe emesis." | 5.10 | Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. ( Bauer, S; Brockmöller, J; Kaiser, R; Papies, A; Possinger, K; Roots, I; Schelenz, C; Sezer, O; Tremblay, PB, 2002) |
| "The purpose of this study was to determine the role that serotonin (5-HT)3 receptors play in the prolactin and nausea responses to clomipramine challenge." | 5.09 | The effects of serotonin3 receptor blockade on the psychobiological response to intravenous clomipramine in healthy human subjects. ( Bebchuk, JM; Carson, SW; Ekstrom, RD; Golden, RN; Heine, AD; Leatherman, ME, 1999) |
| "We investigated the efficacy of combination of ondansetron hydrochloride injection and tablet against nausea and vomiting in 22 lung cancer patients (total number of chemotherapy courses: 23) receiving chemotherapy of single-dose carboplatin (CBDCA) at a dose of 302." | 5.09 | [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin]. ( Miyamoto, Y; Oomasa, M; Teramachi, M; Tomiyama, K; Yagi, K, 1999) |
| " If postoperative nausea or vomiting persisted after three sequences, intravenous ondansetron was administered as rescue therapy." | 5.09 | An alternative method to alleviate postoperative nausea and vomiting in children. ( Hofstadter, MB; Kain, ZN; Wang, SM, 1999) |
| "This randomized, double-masked, placebo-controlled, multicenter trial was conducted in 9 countries to assess the safety and efficacy of 2 doses of intravenous ondansetron (8 and 16 mg) for the control of opioid-induced nausea and vomiting." | 5.09 | Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. ( Allegra, J; Ames, M; Creed, MR; Ducharme, J; Ferrer-Brechner, T; Foster, E; Grafstein, E; Larsen, LS; Montgomery, R; Noll, D; Ortenwall, P; Patel, V; Ramalanjaona, G; Schreck, D; Shurman, J; Sussman, G, 1999) |
| "A double-blind randomized comparison (protocol S3AB4003, Glaxo Wellcome, Great Britain) carried out in a group of 52 children showed that the 5-HT3-receptor antagonist ondansetron (in syrup) effectively prevented vomiting, nausea and loss of appetite caused in combination chemotherapy with highly- or moderately emetogenic cytostatic drugs in 92." | 5.09 | [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors]. ( Gershanovich, ML; Kolygin, BA; Punanov, IuA; Safonova, SA, 1999) |
| ") doses of ondansetron 8 mg, ondansetron 16 mg and metoclopramide 10 mg in the treatment of opioid-induced emesis." | 5.09 | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. ( Alahuta, S; Chung, F; Curtis, P; Duvaldestin, P; Jacka, M; Lane, R; Luttropp, HH; McQuade, B; Rocherieux, S; Roy, M; Spraggs, C, 1999) |
| "We aimed to evaluate the antiemetic efficacy, safety, and clinical utility of prophylactic ondansetron administered at the end of the surgery for the prevention of postoperative nausea and vomiting (PONV) in a homogenous population of 54 women undergoing modified radical mastectomy (MRM)." | 5.09 | The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy. ( Kannan, TR; Kathirvel, S; Mohan, V; Sadhasivam, S; Saxena, A; Trikha, A, 1999) |
| "To assess the efficacy and safety of intravenous ondansetron (4 mg) for the prevention of nausea and vomiting after middle ear surgery under local anesthesia." | 5.09 | Efficacy of ondansetron for prevention of postoperative nausea and vomiting after outpatient ear surgery under local anesthesia. ( Ku, PK; Lo, P; Tong, MC; van Hasselt, CA, 2000) |
| "The efficacy of an intravenous 5-HT3 antagonist (granisetron) and four oral 5-HT3 antagonists (granisetron, ondansetron, tropisetron and ramosetron) on chemotherapy-induced emesis were investigated in 21 gynecologic cancer patients (63 courses)." | 5.09 | [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers]. ( Akutagawa, N; Ishioka, S; Ito, E; Kiya, T; Kudo, R; Sagae, S; Saito, T; Sugimura, M; Umemura, K, 2000) |
| " All the patients received ondansetron combined with dexamethasone for prophylaxis against emesis that might occur within 24 hours after the start of chemotherapy (acute emesis)." | 5.09 | Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. ( , 2000) |
| " Patients received an anti-nausea regimen of dexamethasone with ondansetron or granisetron." | 5.09 | The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. ( Baron, PL; Cole, DJ; Maize, JC; McClay, EF; McClay, ME; Metcalf, JS; Monroe, L; O'Brien, PH, 2000) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 5.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| ") ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy." | 5.09 | A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap ( Breatnach, F; Daly, SA; Haigh, C; Hung, IJ; Kowalczyk, J; Leal, C; McKenna, CJ; Mitchell, T; Ninane, J; Smelhaus, V; White, L; Zhestkova, N, 2000) |
| " dexamethasone had comparable antiemetic efficacy for the prevention of nausea in the first 24-hour period after initiation of chemotherapy compared with intravenous ondansetron plus i." | 5.09 | Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. ( Chen, PM; Chiou, TJ; Fan, FS; Liu, JH; Tzeng, WF; Wang, WS; Yen, CC, 2000) |
| "Oral granisetron 1 mg and ondansetron 16 mg plus dexamethasone are safe and effective in preventing nausea and vomiting related to emetogenic chemotherapy." | 5.09 | Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. ( Herrington, JD; Kwan, P; Lagow, E; Lagrone, L; Riggs, MW; Young, RR, 2000) |
| "This prospective, randomized, placebo-controlled, double-blind study was designed to evaluate the efficacy of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting (PONV) after elective craniotomy in adult patients." | 5.09 | Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy. ( Bhatia, A; Dash, HH; Kathirvel, S; Prakash, A; Shenoy, S; Subramaniam, B, 2001) |
| "Twenty-six children (ages 18 mo to 15 y) receiving intrathecal chemotherapy with either methotrexate or the combination of methotrexate, hydrocortisone, and Ara-C for the prophylactic treatment of central nervous system leukemia were randomly assigned to receive an infusion of normal saline or ondansetron at one of two doses (0." | 5.09 | Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. ( Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D, 2001) |
| " In a double-blind manner, the effects of ondansetron, droperidol, and placebo on the incidence of emesis, postanesthesia care unit stay, and hospital discharge time were evaluated in children undergoing dental surgery." | 5.08 | Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery. ( Davis, PJ; Hoffmann, P; Landsman, I; Maloney, K; McGowan, FX, 1995) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 5.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| "A single IV dose of either 8, 24, or 32 mg of ondansetron combined with a single 20-mg IV dose of dexamethasone resulted in good control of acute emesis across a wide spectrum of chemotherapy regimens." | 5.08 | Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. ( Beck, T; Cohen, JR; Griffen, D; Hainsworth, JD; Harker, WG; Hesketh, PJ; Kessler, JF; Kris, MG; Lester, E; Uhlenhopp, M, 1995) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 5.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "To compare ondansetron and domperidone for treatment of delayed nausea/vomiting (DN/V) following highly emetogenic chemotherapy, after attaining total suppression of emesis on the day of chemotherapy by mean of ondansetron (combined with dexamethasone in the case of cisplatin-treated patients)." | 5.08 | Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. ( Borm, JJ; Esseboom, EU; Rojer, RA; Statius van Eps, LW, 1995) |
| "Ondansetron and droperidol are both effective in the prevention of postoperative nausea and vomiting (PONV)." | 5.08 | Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery. ( Altrock, K; Diefenbach, C; Grond, S; Lehmann, KA; Lynch, J, 1995) |
| "Ondansetron has had a major impact on the prevention of emesis in patients receiving chemotherapy." | 5.08 | A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. ( Dranitsaris, G; Puodziunas, A; Warr, D, 1995) |
| "The antiemetic effect of ondansetron (Supplied by Qi Lu Pharmaceutical Company) in cisplatin-induced nausea and vomiting was studied in a randomized cross-over trial in 167 patients." | 5.08 | [The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "To investigate the efficacy and safety of oral ondansetron in the control of cisplatin-induced delayed emesis in patients who do not require rescue antiemetic therapy for acute emesis." | 5.08 | Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. ( Anderson, N; Beck, TM; Caldwell, KC; Chang, AY; Garewal, H; Greenberg, B; Madajewicz, S; Navari, RM; Tchekmedyian, NS; Whaley, W, 1995) |
| "To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effective in the prevention of chemotherapy-induced emesis." | 5.08 | Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. ( Fitts, D; Friedman, C; Gandara, D; Hall, S; Hesketh, P; Mailliard, J; Navari, R; Ritter, H, 1995) |
| "This randomized, double-blind, multicentre, parallel-group study compared the efficacy and safety of an intravenous dose of ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV) with metoclopramide 10 mg and placebo in patients undergoing major gynaecological surgery." | 5.08 | [Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting]. ( Rust, M, 1995) |
| "We have compared the efficacy of ondansetron, metoclopramide, droperidol and placebo in the prevention of postoperative nausea and vomiting in 118 day stay patients undergoing laparoscopic gynaecological procedures." | 5.08 | Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. ( McKay, AC; Mirakhur, RK; Paxton, LD, 1995) |
| " Effective prophylaxis for postoperative nausea and vomiting can be achieved in adults with lower doses of ondansetron, a 5-hydroxytryptamine subtype 3 receptor antagonist, compared with chemotherapy-induced emesis." | 5.08 | The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery. ( Bras, PJ; Cieslak, GD; Pennant, JH; Watcha, MF, 1995) |
| "In a randomised, placebo-controlled trial we have compared the efficacy of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia after orthopaedic surgery." | 5.08 | Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia. ( Alexander, R; Jones, RM; Lovell, AT; Seingry, D, 1995) |
| "A single-institution, prospective, randomized, open controlled trial was carried out on head and neck cancer patients to compare granisetron (GRA), ondansetron (OND), and tropisetron (TRO) in the prevention of cisplatin-induced acute nausea and vomiting." | 5.08 | Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. ( Bianchi, A; Curreli, L; Ghiani, M; Macciò, A; Mantovani, G; Proto, E; Santona, MC, 1996) |
| "We performed a prospective, single arm, observational study examining the effectiveness of the 5HT3 receptor antagonist ondansetron in the management if nausea and vomiting associated with acetaminophen poisoning." | 5.08 | The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. ( Chen, R; Clark, RF; Harchelroad, F; Johnson, CL; Williams, SR, 1996) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 5.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| "The addition of bromazepam to ondansetron, and the extension of antiemetic prophylaxis to the day before and the day after chemotherapy improves the control of nausea and emesis compared to ondansetron monotherapy in patients with ovarian cancer." | 5.08 | Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. ( Conrad, A; Kuhn, W; Meden, H; Meissner, O, 1996) |
| "The aim of this study was to compare the efficacy and safety of ondansetron plus droperidol with each drug alone or placebo in the prevention of postoperative nausea and vomiting (PONV)." | 5.08 | Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting. ( Carrascosa, F; García-Pedrajas, F; Iribarren, MJ; Lopez, L; Pueyo, FJ; Saez, A, 1996) |
| " Patients received one of four regimens for the prevention of postoperative nausea and vomiting (PONV): ondansetron 4 mg (n = 25), dexamethasone 8 mg (n = 25), ondansetron with dexamethasone (4 mg and 8 mg, respectively, n = 25) or placebo (saline, n = 25) There were no differences in background factors or factors related to operation and anaesthesia, morphine consumption, pain or side effects between groups." | 5.08 | Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting. ( Busto, N; Carrascosa, F; López-Olaondo, L; Monedero, P; Pueyo, FJ; Sáez, A, 1996) |
| "Two large randomized, double-blind, placebo-controlled studies with an appropriate study design have been conducted to fully evaluate the efficacy of ondansetron in the control of cisplatin-induced delayed emesis." | 5.08 | 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. ( Anderson, E; Freeman, A; Ossi, M, 1996) |
| "The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dose > or = 50 mg/m2." | 5.08 | An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. ( Angelelli, B; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E, 1996) |
| "To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting." | 5.08 | Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P ( Anthony, L; Benedict, C; Gralla, R; Grote, T; Hahne, W; Hainsworth, J; Hesketh, P; Khojasteh, A; Kris, M; Navari, R; Tapazoglou, E, 1996) |
| "The efficacy of ondansetron 4 mg and 8 mg was compared with placebo in the reduction of postoperative nausea, retching and vomiting (PONV) after middle ear surgery during general anaesthesia, in 75 patients, in a double-blind and randomized study." | 5.08 | Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. ( Honkavaara, P, 1996) |
| "This study has compared the incidences of nausea, vomiting and headache after ondansetron 0." | 5.08 | Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy. ( van den Berg, AA, 1996) |
| "The new antiemetic ondansetron is effective for the prophylaxis and treatment of postoperative nausea and vomiting (PONV), but has been subject to limited comparative evaluation in surgical inpatients." | 5.08 | Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. ( Evans, SF; Paech, MJ; Pavy, TJ, 1995) |
| "In contrast to the broad experience concerning the therapeutic use of carboplatin, only limited data are available regarding the patterns of carboplatin-induced emesis, one of its most distressing side effects." | 5.08 | Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. ( Cramer-Giraud, U; du Bois, A; Fiola, M; Glaubitz, M; Thomssen, C; Vach, W, 1995) |
| "The efficacy of a preoperative 4-mg dose of ondansetron given intravenously in preventing postoperative nausea and vomiting after maxillofacial surgery was evaluated in a double-blind randomized study." | 5.08 | The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. ( Campbell, R; Chow, J; Rodrigo, C; Tong, A, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 5.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "67% of patients given ondansetron had complete control of emesis compared with 45% of patients with placebo (P < 0." | 5.08 | A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. ( Franzén, L; Hagberg, H; Henriksson, R; Jakobsson, M; Lomberg, H; Nyman, J; Nyth, AL; Sorbe, B, 1996) |
| "The efficacy of ondansetron 4 mg was compared with metoclopramide 10 mg for the prevention of post-operative nausea and vomiting in patients after major gynaecological abdominal surgery." | 5.08 | Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. ( Chen, PP; Chui, PT; Gin, T, 1996) |
| "The efficacy of ondansetron and droperidol were evaluated for prophylactic treatment of nausea and vomiting in cesarean section patients under epidural anesthesia." | 5.08 | Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. ( Moore, CH; Pan, PH, 1996) |
| "This study determined the overall incidence of postoperative nausea and vomiting (PONV) in 38 patients undergoing laparoscopic gynaecological procedures who received a standardized propofol/isoflurane anaesthetic but no preoperative antiemetic." | 5.08 | A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy. ( Watts, SA, 1996) |
| "Propofol administered to induce and maintain anesthesia is more effective than ondansetron (with thiopental-isoflurane anesthesia) in preventing postoperative vomiting and is associated with fewer requests for rescue antiemetic and sedation in the early phase of recovery." | 5.08 | Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. ( Gan, TJ; Ginsberg, B; Glass, PS; Grant, AP, 1996) |
| "To determine (1) the efficacy and safety of ondansetron in the prevention of postoperative nausea and vomiting (PONV) in male outpatients; (2) prognostic factors for PONV in male outpatients; and (3) patients' perceptions of the debilitating effects of PONV in the ambulatory surgery setting." | 5.08 | Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group. ( Cox, F; Joslyn, AF; Khalil, SN; Kovac, AL; Pearman, MH; Prillaman, BA; Scuderi, PE, 1996) |
| "Efficiency of ondansetron, a selective 5-HT3 receptor antagonist, in prevention of postoperative nausea and vomiting in 40 ASA I-II patients who will undergo emergency intraabdominal operations is studied in a randomized double-blind and placebo controlled study." | 5.08 | Prophylactic administration of ondansetron in emergency intraabdominal operations. ( Aktürk, G; Albayrak, D; Kalaç, N; Lüleci, N; Ulusoy, HO, 1996) |
| "The purpose of this study was to investigate the efficacy and safety of oral ondansetron, given alone or in combination with dexamethasone in the control of cisplatin-induced delayed emesis." | 5.08 | A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. ( Depierre, A; Goedhals, L; McQuade, B; McRae, J; Olver, I; Paska, W; Seitz, JF; Stewart, DJ; Wilkinson, JR, 1996) |
| "A randomized, double-blind, placebo-controlled study was designed to compare the relative efficacy of prophylactic ondansetron, 4 mg intravenously (IV), when administered before induction of anesthesia or at the end of surgery to an outpatient population at high risk of developing postoperative nausea and vomiting (PONV)." | 5.08 | The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery. ( Klein, KW; Sun, R; White, PF, 1997) |
| "In a prospective, randomised, double-blind trial, we assessed the relative efficacy of prophylactic ondansetron and metoclopramide administration in the reduction of postoperative nausea and vomiting in 60 patients undergoing routine major neurosurgical procedures." | 5.08 | A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures. ( Barsoum, LZ; Jones, NC; Pugh, SC, 1996) |
| "The hypothesis that the addition of dexamethasone to the propofolondansetron combination would significantly reduce postoperative nausea and vomiting (PONV) was not confirmed." | 5.08 | Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery. ( Hamilton, DL; McKenzie, R; Riley, TJ; Tantisira, B, 1997) |
| "Efficiency of ondansetron, a selective 5- HT3 receptor antagonist, in prevention of postoperative nausea and vomiting in 40 ASA I-II patients to undergo emergency intraabdominal operations is studied in a randomized, double-blind and placebo controlled study." | 5.08 | Prophylactic administration of ondansetron in emergency intraabdominal operations. ( Aktürk, G; Albayrak, D; Kalaç, N; Lüleci, N; Ulusoy, HO, 1997) |
| "To assess the efficacy of 4 mg of intravenous ondansetron versus placebo for the prevention of postoperative nausea and vomiting (PONV) in cholecystectomy, a type of surgery that is highly emetic." | 5.08 | [Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy]. ( Cabrera, JC; Castaño, J; Castillo, J; Escolano, F; Matute, E; Santiveri, X, 1997) |
| "A double-blind, randomised, placebo-controlled trial was conducted to compare the efficacy of metoclopramide with the 5-HT3 antagonist, ondansetron, for the prevention of postoperative emesis in children undergoing elective strabismus surgery." | 5.08 | Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. ( Mandal, NG; Shende, D, 1997) |
| "To compare the efficacy of oral ondansetron with oral metoclopramide for the prevention of postoperative vomiting and nausea in children undergoing strabismus surgery." | 5.08 | [Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?]. ( Amraoui, A; Benaguida, M; el Harrar, N; Idali, B; Laouissi, F; Mjahed, K, 1996) |
| "To compare the efficacy in the treatment of post-operative nausea and/or vomiting (PONV), 75 patients undergoing gynaecological procedures under general anaesthesia using N2O/enflurane who suffered from PONV in the first hour after surgery were randomly allocated to three groups containing 25 patients each to receive either alizapride 100 mg, droperidol 1 mg or ondansetron 8 mg (i." | 5.08 | Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea. ( Bovill, JG; de Bont, LE; el-Mofty, M; Samhan, YM; Stienstra, R, 1997) |
| "The inhibitory effects of GG032X tablets, a new dosage form (fast dispersing tablet) of ondansetron, 5-HT2 receptor antagonist, on nausea and emesis induced by cisplatin (CDDP), were investigated along with safety and usefulness." | 5.08 | [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Ikeda, M; Nukariya, N; Ota, J; Suminaga, M; Taguchi, T, 1997) |
| "In a randomised, double-blind study, we have compared the incidence of postoperative nausea and vomitting in 124 patients undergoing major lower limb orthopaedic surgery following oral premedication with temazapam and ondansetron 8 mg, metoclopramide 10 mg or placebo." | 5.08 | Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. ( Alexander, R; Fennelly, M, 1997) |
| "The efficacy and safety of ondansetron 8 mg BID compared with 8 mg TID for 3 days in the prevention of nausea and vomiting in 402 patients on cyclophosphamide (> or = 500 mg/m2)-based chemotherapy were evaluated in a multicenter, randomized, double-blind, stratified study." | 5.08 | Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. ( Beck, TM; Chang, A; Griffin, D; Harvey, WH; Meshad, M; Navari, R; Wentz, A; York, M, 1997) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 5.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "To compare the efficacy of dolasetron and ondansetron in controlling nausea and vomiting in the first 24 hours; to evaluate the efficacy when dexamethasone is added to either drug in the first 24 hours; and to extend these comparisons over 7 days in patients receiving moderately emetogenic chemotherapy." | 5.08 | Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. ( Chin, C; Dempsey, E; Guevin, RM; Hainsworth, J; Hoskins, P; Krook, JE; Lofters, WS; Moquin, JP; Navari, R; Palmer, M; Pater, JL; Verma, S; Walde, D; Wilson, K; Zee, B, 1997) |
| "Intravenous dolasetron mesilate has shown efficacy in the prevention of postoperative nausea and vomiting (PONV) when administered as a single dose prior to emergence from anesthesia." | 5.08 | Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. ( Brown, R; Clergue, F; Feiss, P; Hahne, W; Korttila, K; Leeser, J; Nave, S; Olthoff, D; Payeur-Michel, C; Wessel, P, 1997) |
| "To compare the prophylactic administration of ondansetron with droperidol or placebo to determine its effectiveness in reducing postoperative nausea and vomiting after middle ear procedures." | 5.08 | Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures. ( Fluter, E; Jellish, WS; Leonetti, JP; Thalji, Z, 1997) |
| " The purpose of this study was to compare the efficacy of ondansetron, a highly selective 5-hydroxytryptamine subtype-3 receptor antagonist, with that of metoclopramide for the prevention of postoperative emesis in patients undergoing cataract surgery." | 5.08 | Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia. ( Ascaso, FJ; Ayala, I; Carbonell, P; Castro, FJ; Palomar, A, 1997) |
| "To investigate the incidence of postoperative nausea and vomiting (PONV) depending on the administration time of ondansetron." | 5.08 | [Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients]. ( Kainzwaldner, A; Ploner, F, 1997) |
| " Combination of corticosteroids with ondansetron enables greater control of emesis than that obtained with ondansetron alone, but some patients still experience symptoms." | 5.08 | The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. ( d'Allens, H; Depierre, A; Giovannini, M; Hédouin, M; Kaluzinski, L; Lebeau, B; Rivière, A; Votan, B, 1997) |
| "Patient functional status after administration of either granisetron or ondansetron to prevent acute chemotherapy-induced nausea and vomiting (CINV) was studied." | 5.08 | Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. ( Bernstein, G; Colgan, K; Dempsey, CL; Farley, PA; Kulis-Robitaille, C; Shillington, AA, 1997) |
| " After experiencing at least one nausea and/or one emetic episode in the 6 h after recovery from anaesthesia, patients received either ondansetron 4 mg i." | 5.08 | Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group. ( Clyti, N; Conseiller, C; Diemunsch, P; Mamet, JP, 1997) |
| "The proportion of patients with nausea was 48%, 50% and 67% in the ondansetron, droperidol and placebo groups, respectively; with a significant difference when both ondansetron (P=0." | 5.08 | Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial. ( Alahuhta, S; Koivuranta, M; Läärä, E; Ranta, P; Ravaska, P, 1997) |
| "To establish a dose-response relationship for ondansetron, and to evaluate any effects of oral premedication with metoclopramide in pediatric patients undergoing tonsillectomy and adenoidectomy and strabismus surgery." | 5.08 | Ondansetron dose response curve in high-risk pediatric patients. ( Kymer, PJ; Lawhorn, CD; Shirey, R; Stewart, FC; Stoner, JM; Volpe, P, 1997) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 5.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "Ondansetron 4 mg was compared with metoclopramide 10 mg for prevention of post-operative nausea and emesis in in-patients undergoing major gynaecological surgery in this double-blind, randomized, placebo-controlled, multicentre study." | 5.08 | International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. ( Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998) |
| " bolus dose of ondansetron 4 mg were evaluated in the prevention of postoperative nausea and vomiting (PONV), which remains one of the most unpleasant side effects experienced by patients postoperatively." | 5.08 | Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis. ( De Guchteneere, E; Hendrickx, P; Levarlet, M; Moens, P, 1997) |
| "To investigate the hypothesis that the combination of ondansetron and droperidol would be more effective than droperidol alone in reducing nausea and vomiting." | 5.08 | Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after total abdominal hysterectomy. ( Hamilton, DL; McKenzie, R; Riley, TJ; Trantisira, BR, 1998) |
| "05 mg kg(-1) +droperidol 20 microg kg(-1) was given as prophylaxis for postoperative pain and emesis, respectively." | 5.08 | Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy. ( Aasbø, V; Buanes, T; Grøgaard, B; Mjåland, O; Raeder, JC, 1998) |
| "More than 2000 patients at high risk of postoperative nausea and vomiting were given either placebo, ondansetron 4 mg, or droperidol 0." | 5.08 | A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. ( Creed, MR; Duncan, B; Fortney, JT; Gan, TJ; Glass, PS; Graczyk, S; Khalil, S; McKenzie, R; Melson, T; Moote, C; Parasuraman, TV; Parrillo, S; Wermeling, D; Wetchler, B, 1998) |
| "This study compares the preoperative administration of ondansetron with that of droperidol or saline solution for the prevention of nausea and vomiting in otologic surgery patients." | 5.08 | Ondansetron versus droperidol or placebo to prevent nausea and vomiting after otologic surgery. ( Fluder, E; Jellish, WS; Leonetti, JP; Thalji, Z, 1998) |
| "A double-blind randomized crossover trial was performed to compare the antiemetic efficacy of two 5-HT3 receptor antagonists, granisetron and ondansetron, in Chinese patients receiving adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) for breast cancer." | 5.08 | Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study. ( Chow, LW; Poon, RT, 1998) |
| "A group of 48 patients with breast cancer were randomized in a double-blind fashion to receive either (1) granisetron as a 0." | 5.08 | Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. ( Bolwell, B; Boparai, N; Jones, E; Kalaycio, M; Mendez, Z; Overmoyer, B; Pohlman, B, 1998) |
| "To determine the dose-response relationship of ondansetron in preventing postoperative nausea and vomiting (PONV) in women undergoing elective surgery." | 5.08 | A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting. ( Chang, Y; Conant, JA; Connors, PM; Dershwitz, M; Rosow, CE, 1998) |
| "To compare the prophylactic administration of ondansetron plus droperidol, droperidol plus metoclopramide, and perphenazine to determine effects on postoperative nausea, vomiting, and sedation after laparoscopic cholecystectomy." | 5.08 | Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide. ( Freiberger, D; Gosnell, JL; Steinbrook, RA, 1998) |
| "Ondansetron appeared to be superior to metoclopramide-diphenhydramine in the control of emesis induced by chemotherapy regimens containing cisplatin." | 5.08 | Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. ( Atay, AA; Köseoglu, V; Kürekçi, AE; Ozcan, O; Sarici, U; Sorici, U, 1998) |
| "We examined the efficacy of concurrent use of ondansetron hydrochloride and dexamethasone, and the effective dose of dexamethasone against nausea and vomiting in lung cancer patients receiving chemotherapy including single high dose cisplatin." | 5.08 | [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin]. ( Banba, J; Masaki, M; Tanimura, S; Tomoyasu, H, 1998) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 5.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following minor oral surgery was evaluated in a prospective randomized double-blind study." | 5.07 | Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study. ( Campbell, RC; Chow, J; Hui, E; Lueveswanij, S; Rodrigo, MR; Tong, CK, 1994) |
| "To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial." | 5.07 | Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. ( Cho, GY; Kim, SH; Kim, SW; Lee, CW; Lee, JS; Lee, KH; Suh, CW, 1994) |
| "Ondansetron in the prophylaxis of Cisplatin-induced emesis and nausea." | 5.07 | Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy. ( Chakrapee-Sirisuk, S; Cheirsilpa, A; Chindavijak, K; Lousoontornsiri, W; Ratanatharathorn, V; Sinlarat, P; Srimuninimit, V, 1994) |
| " Acetaminophen and meperidine were given for postoperative pain." | 5.07 | Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy. ( Furst, SR; Rodarte, A, 1994) |
| "Oral ondansetron is an effective therapy for the prevention of emesis induced by TBI." | 5.07 | Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. ( Bryson, JC; Cirenza, E; Dubois, A; Foelber, R; Kunka, RL; Plagge, PB; Spitzer, TR; Stout, C; Wallerstadt, M, 1994) |
| "The purpose of our study was to evaluate the effectiveness of alprazolam (APZ) as an adjuvant drug to ondansentron against cisplatin-induced emesis." | 5.07 | Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy. ( Bacoyiannis, C; Charalambidis, G; Karabelis, A; Kosmidis, P; Mylonakis, N; Pagou, M; Tsavaris, N, 1994) |
| "The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients." | 5.07 | Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses ( Campora, E; Giudici, S; Merlini, L; Rosso, R; Rubagotti, A, 1994) |
| "25 mg droperidol in preventing postoperative vomiting." | 5.07 | [Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative study with droperidol]. ( Alon, E; Atanassoff, PG; Biro, P; Lenzlinger, PM, 1994) |
| "Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting (PONV), but it has not been proved to be superior to established antiemetics for prophylaxis or therapy." | 5.07 | [Ondansetron versus droperidol. Postoperative treatment against nausea and vomiting. Comparison of action, adverse effects and acceptance by gynecologic inpatients]. ( Heim, C; Listyo, R; Münzer, T, 1994) |
| "The purpose of this double-blind, randomized study was to compare the effectiveness of ondansetron plus saline versus ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting." | 5.07 | Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting. ( Abdelhady, H; Karambelkar, DJ; McKenzie, R; Riley, TJ; Tantisira, B, 1994) |
| " dexamethasone and oral metoclopramide) for delayed emesis, while they had received either i." | 5.07 | Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research. ( , 1994) |
| "We studied the preventive effect on postoperative nausea and vomiting (PONV) of ondansetron, metoclopramide and placebo associated with epidural anaesthesia." | 5.07 | [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children]. ( Andreuccetti, T; Busoni, P; Calamandrei, M; Crescioli, M; Messeri, A; Sarti, A; Sestini, G, 1994) |
| "These data suggest that although both ondansetron and granisetron are very effective drugs for the control of acute emesis, their efficacy against delayed emesis is still not entirely satisfactory." | 5.07 | Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. ( Cannata, G; Cipolla, C; Curto, G; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A; Valenza, R, 1994) |
| "We have compared the incidence of postoperative nausea and vomiting up to 48 h after day-case gynaecological laparoscopy after oral premedication with ondansetron 4 mg, metoclopramide 10 mg or a placebo allocated randomly and assessed blindly." | 5.07 | Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. ( Cooper, GM; Field, JM; Malins, AF; Nesling, PM, 1994) |
| "In two placebo-controlled, double-blind, multicentre studies, the efficacy and safety of single oral doses of ondansetron 4 mg, 8 mg and 16 mg were evaluated for the prevention of postoperative nausea and vomiting in female inpatients." | 5.07 | Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups. ( Cohen, LA; Rust, M, 1994) |
| "One-hundred and forty-five chemotherapy patients receiving cisplatin- and non-cisplatin-containing regimens participated in an open evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and vomiting." | 5.07 | Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group. ( Batarda, M; Brandão, A; de Faria, L; de Matos, E; dos Reis, F; Fráguas, A; Ribeiro, I; Ribeiro, M; Ribiero, MM; Uva, S, 1993) |
| "We evaluated the efficacy and safety of oral ondansetron, a selective antagonist of 5-HT3 receptors, for the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy (> 500 mg/m2)." | 5.07 | Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. ( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 5.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "This study examines whether the schedule of ondansetron significantly influences its antiemetic efficacy in the first 24 hours after chemotherapy, whether the administration of oral ondansetron after 24 hours is effective in preventing delayed emesis, and whether the efficacy of ondansetron is preserved over multiple courses of moderately emetogenic chemotherapy." | 5.07 | Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of ( Hoskins, P; Kaizer, L; Latreille, J; Levy, M; Lofters, W; Palmer, M; Pater, J; Warr, D; Yau, J; Zee, B, 1994) |
| "This prospective, randomized, double-blind study assessed whether the addition of dexamethasone to ondansetron leads to improved control of chemotherapy--induced emesis, both in patients undergoing their first course of highly emetogenic chemotherapy and in chemotherapy-pretreated patients refractory to standard anti-emetics." | 5.07 | Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). ( Aapro, MS; Bacchi, M; Buser, K; Joss, RA; Kirchner, V; Neuenschwander, H; Orth, B; Thürlimann, B, 1994) |
| "We have compared the efficacy of ondansetron with droperidol and saline in the prevention of postoperative nausea and vomiting (PONV) in 120 ASA I and II patients undergoing hip and knee replacements and femoral resections." | 5.07 | Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. ( Collis, R; Gan, TJ; Hetreed, M, 1994) |
| "We studied the efficacy and safety of intravenous ondansetron 4 mg for the prevention of postoperative nausea and vomiting after minor gynaecological laparoscopic surgery in Oriental women." | 5.07 | Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery. ( Chen, PP; Critchley, LA; Gin, TA; Ray, AK; Rowbottom, YM; Suen, TK, 1994) |
| "The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, multicentre, international study." | 5.07 | A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. ( Abrahamsson, J; Briggs, L; Forrler, M; Hellstern, K; Helmers, JH; Moodley, J; Soni, J, 1993) |
| "Ondansetron is a serotonin antagonist that recently has been introduced as a preventive agent for chemotherapy-induced nausea and vomiting." | 5.07 | Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. ( Kilgore, JR; Navari, RM; Perrine, GM; Province, WS, 1993) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 5.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| "One hundred cancer patients receiving non-cisplatin containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron was compared with standard antiemetic treatments in the prophylaxis of nausea and emesis." | 5.07 | Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. ( Flander, MK; Heikkinen, MI; Jantunen, IT; Kataja, VV; Kuoppala, TA; Teerenhovi, L, 1993) |
| " Patients were stratified by gender and received, in a randomized, double-blind manner, 1, 4, or 8 mg ondansetron or placebo in response to nausea and/or vomiting postoperatively." | 5.07 | Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. ( Apfelbaum, J; Claybon, L; DuPen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1993) |
| "Data from the 544 women showed that all doses of intravenous ondansetron tested (1, 4, and 8 mg) were significantly more effective (62%, 76%, and 77%, respectively) than placebo (46%) in reducing the incidence of emesis following surgery until 24 h after recovery room entry." | 5.07 | Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. ( Angel, J; Duncalf, D; Gratz, I; Joslyn, A; Kovac, A; McKenzie, R; McLeskey, C; O'Connor, T; Tolpin, E, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following major gynaecological surgery was evaluated in this multicentre, double-blind study." | 5.07 | The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia. ( Conseiller, C; Dupeyron, JP; Gribomont, B; Hemmingsen, C; Kaplan, LA; Levarlet, M; Pedersen, FM; Schoeffler, P, 1993) |
| "The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized, double-blind, placebo-controlled, multi-centre studies." | 5.07 | Oral ondansetron in the prevention of postoperative nausea and vomiting. ( Helmers, JH, 1992) |
| "The efficacy of ondansetron, a selective 5-HT3 receptor antagonist, in preventing postoperative nausea and vomiting in surgical patients was studied." | 5.07 | Ondansetron is effective in decreasing postoperative nausea and vomiting. ( Dershwitz, M; Di Biase, PM; Joslyn, AF; Rosow, CE; Sanderson, PE, 1992) |
| "A total of 535 chemotherapy naive, hospitalised patients (263 male/272 female) scheduled to receive cisplatin (50-120 mg m-2)-containing regimens participated in a randomised, double-blind, parallel group study to evaluate the efficacy and safety of three intravenous dose schedules of ondansetron in the prophylaxis of acute nausea and emesis." | 5.07 | Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu ( Buser, K; Christmann, D; Kitchener, H; Paes, D; Porteder, H; Schmidt, M; Schuller, J; Sevelda, P; Seynaeve, C; Van Belle, S, 1992) |
| "In a placebo-controlled, double-blind study, we have compared the efficacy of ondansetron 16 mg, 8 mg and 1 mg administered 8-hourly for prevention of postoperative nausea and vomiting." | 5.07 | Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study. ( Haigh, CG; Kenny, GN; Leeser, J; Lip, H; Oates, JD; Onsrud, M; Rowbotham, DJ; Rust, M; Saur, P, 1992) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 5.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "Anti-emetic effects, safety and usefulness of Ondansetron given intravenously at 4 mg once daily for consecutive 3-5 days were investigated against nausea and emesis induced by non-platinum anticancer drugs." | 5.07 | [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 5.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "The anti-emetic effect, safety and clinical usefulness of ondansetron for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin, was evaluated by a multi-institutional study in patients with various malignancies." | 5.07 | [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Following a single intravenous dose given pre-chemotherapy, the efficacy and tolerability of oral ondansetron treatment given twice daily was compared with the established three times daily oral supplementary regimen in the prophylaxis of nausea and vomiting induced by cyclophosphamide (greater than or equal to 500 mg/m2) in combination with doxorubicin (greater than or equal to 40 mg/m2) or epirubicin (greater than or equal to 40 mg/m2)." | 5.07 | Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group. ( Bleiberg, H; Campora, E; Cunningham, D; Dicato, MA; Kaasa, S; Liebhard, A; Upadhyaya, BK; Vindevoghel, A; Warnier, P, 1992) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 5.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| "In order to make an objective evaluation of anti-emetic effect, safety and usefulness of ondansetron injection in nausea and vomiting associated with cancer chemotherapy, we carried out a double-blind placebo controlled comparative study in patients receiving high-single dose (50 mg/m2 or more) of cisplatin." | 5.07 | [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron, a selective 5-HT3 receptor antagonist, has already been reported to have a marked effect to alleviate or prevent nausea and vomiting associated with cancer chemotherapy, after its intravenous administration." | 5.07 | [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Clinical usefulness of ondansetron as an antiemetic for the treatment of nausea and vomiting induced by anticancer drugs including cisplatin (> or = 50 mg/m2) was evaluated by a multi-institutional, double-blind comparative study with placebo with inpatients with various malignancies." | 5.07 | [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "The efficacy and safety of prophylactic intravenous ondansetron in preventing postoperative nausea and vomiting was investigated in a randomized, stratified, double-blind, placebo-controlled, dose-comparison study of 580 ASA physical class I and II female outpatients undergoing gynaecological surgery and receiving general anaesthesia." | 5.07 | Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study. ( Angel, J; Duncalf, D; Fagraeus, I; Gratz, I; Joslyn, AF; Kovac, A; McKenzie, R; McLeskey, C; O'Connor, T, 1992) |
| "The safety and efficacy of ondansetron were evaluated in the treatment of postoperative nausea and vomiting." | 5.07 | Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study. ( Apfelbaum, J; Clayborn, L; Du Pen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1992) |
| "This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis." | 5.07 | Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. ( Beck, TM; Gandara, DR; Hainsworth, JD; Hesketh, PJ; Kish, JA; Lester, EP; Madajewicz, S; Murphy, WK; Navari, RM; Pendergrass, K, 1992) |
| "In a phase II study including 80 patients treated with highly emetic drugs such as cisplatin, carboplatin or cyclophosphamide > 600 mg/day) we confirmed the potential of ondansetron to prevent cancer chemotherapy- related acute nausea and vomiting." | 5.07 | The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index). ( Lelli, G; Martoni, A; Pannuti, F; Piana, E; Tanneberger, S, 1992) |
| "The selective 5-hydroxytryptamine3 antagonist ondansetron has been shown to be effective in preventing nausea and vomiting associated with highly emetogenic cisplatin chemotherapy." | 5.07 | Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. ( Beck, TM, 1992) |
| "A multicentre, randomised, double-blind, cross-over trial was done to compare the efficacy and safety of a serotonin receptor antagonist--ondansetron--and dexamethasone in the prophylaxis of acute and delayed emesis and nausea induced by moderately emetogenic non-platinum-containing chemotherapy regimens." | 5.07 | Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. ( Carney, DN; Cassidy, J; Cunningham, D; Hill, AS; Hutcheon, AW; Jones, AL; Kaye, SB; Sikora, K; Soukop, M, 1991) |
| "Ondansetron, a serotonin antagonist, is effective in controlling the emesis associated with cancer chemotherapy; however, emesis in patients receiving high-dose cisplatin is poorly controlled by ondansetron alone." | 5.07 | Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. ( Bagshawe, KD; Begent, RH; Howells, N; McQuade, B; Newlands, ES; Rustin, GJ; Smith, DB, 1991) |
| " In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy." | 5.07 | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. ( Gandara, D; Hainsworth, J; Harker, G; Harvey, W; Hesketh, P; Kasimis, B; Khojasteh, A; Monaghan, G; Oblon, D; Pendergrass, K, 1991) |
| "The effect of ondansetron, a 5-HT3 antagonist, in preventing postoperative nausea and vomiting was investigated in a randomized, double-blind, placebo-controlled study of 84 patients undergoing gynecologic operation and receiving the same general anesthetic." | 5.07 | Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. ( Leeser, J; Lip, H, 1991) |
| "We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time." | 5.07 | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991) |
| "Ondansetron (OND) is a new 5-HT3 receptor antagonist that give complete protection from emesis/nausea in approximately 50% of cisplatin (CDDP)-treated patients." | 5.07 | Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. ( Amadori, D; Bella, MA; Cognetti, F; Cortesi, E; Donati, D; Favalli, G; Gramazio, V; Marangolo, M; Roila, F; Tonato, M, 1991) |
| " Patients who had suffered severe vomiting on carboplatin alone (23 patients with ovarian carcinoma) or in combination (two patients with testicular cancer) despite intensive antiemetic regimens were treated with ondansetron, given as 8 mg immediately prior to carboplatin followed by 8 mg orally, 8 hourly for 5 days." | 5.07 | Reduction of carboplatin induced emesis by ondansetron. ( Dickson, DS; Evans, BD; Harvey, VJ; Langley, GB; Mak, D; Mitchell, PL; Neave, LM, 1991) |
| "The safety and efficacy of ondansetron were evaluated for the treatment of postoperative nausea and vomiting after laparoscopic surgical procedures." | 5.07 | Antiemetic efficacy of ondansetron after outpatient laparoscopy. ( Bodner, M; White, PF, 1991) |
| "Ondansetron as a single agent has been shown to be superior to metoclopramide in the control of acute nausea and vomiting induced by high-dose cisplatin, complete or major control (0-2 emetic episodes) being achieved in 65-75% of patients." | 5.07 | Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research. ( Tonato, M, 1991) |
| " dose prechemotherapy, was compared with the established three times a day oral supplement regimen for the prophylaxis of nausea and vomiting induced by cyclophosphamide (greater than or equal to 500 mg/m2) in combination with doxorubicin (greater than or equal to 40 mg/m2) or epirubicin (greater than or equal to 40 mg/m2)." | 5.07 | Oral treatment with ondansetron in an outpatient setting. ( Dicato, MA, 1991) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 5.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "Dexamethasone makes a significant contribution to the efficacy of ondansetron in the control of acute platinum induced emesis." | 5.07 | Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? ( Allan, SG; Bruntsch, U; Coleman, RE; Cornbleet, MA; Gallmeier, WM; Leonard, RC; Nicolson, M; Smyth, JF; Upadhyaya, BK, 1991) |
| "We compared the efficacy and safety of ondansetron (GR 38032F), a selective antagonist of serotonin S3 receptors, with that of placebo in controlling the nausea and vomiting induced by cisplatin treatment in 28 patients with cancer." | 5.06 | Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffmann, IS, 1990) |
| "Ondansetron is a 5-hydroxytryptamine 3-receptor antagonist which has shown activity in the prevention of cytotoxic-induced emesis." | 5.06 | Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. ( Adams, M; Collis, CH; Lucraft, H; Priestman, S; Priestman, TJ; Roberts, JT; Upadhyaya, BK, 1990) |
| "To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer." | 5.06 | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. ( Azab, M; Bons, J; Brion, N; Droz, JP; Marty, M; Paes, D; Paule, B; Pouillart, P; Pujade-Lauraine, E; Scholl, S, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 5.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated." | 5.06 | Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. ( Bernard, S; Finn, A; Gandara, D; Khojasteh, A; Lester, E; Sartiano, G; Tapazoglou, E, 1990) |
| " In this randomized, double-blind, placebo-controlled study, we evaluated the effect of serotonin S3 receptor blockade with ondansetron (GR 38032F) on the prevention of nausea and vomiting induced by cyclophosphamide-containing chemotherapy." | 5.06 | Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffman, IS, 1990) |
| "To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting." | 5.06 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. ( Allman, EL; Beranek, P; De Mulder, PH; Mols-Jevdevic, S; Seynaeve, C; van Liessum, PA; Vermorken, JB; Verweij, J, 1990) |
| "In an open, drug-oriented phase-II/III-study 24 patients were treated with the 5-HT3-antagonist Ondansetron as an antiemetic drug for chemotherapy-induced nausea and emesis." | 5.06 | [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. ( Berdel, WE; Ertl, A; Fink, U; Perker, M; Reichold, M; Serve, H, 1990) |
| "Well-designed investigations suggest that antagonists of the type 3 serotonin receptor, most frequently oral ondansetron, reduce the rate of vomiting, improve the tolerance of oral rehydration, and reduce the need for intravenous rehydration." | 4.98 | Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management. ( Agostoni, C; Bianchetti, MG; Canziani, BC; Fossali, EF; Lava, SAG; Milani, GP; Uestuener, P, 2018) |
| "Compatibility of ondansetron offers a broad number of options to be used to avoid nausea and vomiting symptoms in patients with other concomitant medication." | 4.95 | Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review. ( Estan-Cerezo, G; Jiménez-Pulido, I; Matoses Chirivella, C; Navarro-Ruiz, A; Rodríguez Lucena, FJ; Soriano-Irigaray, L, 2017) |
| " Ondansetron exhibited similar efficacy than granisetron and tropisetron, as well as greater efficacy than dolasetron for acute vomiting." | 4.93 | Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. ( Acúrcio, Fde A; Andrade, EI; Cherchiglia, ML; De Araújo, VE; Marra, LP; Reis, IA; Simino, GP, 2016) |
| "For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than placebo." | 4.93 | Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. ( Beyer, F; Bradley, J; Bryant, A; McParlin, C; Moloney, E; Muirhead, CR; Nelson-Piercy, C; Newbury-Birch, D; Norman, J; O'Donnell, A; Robson, SC; Shaw, C; Simpson, E; Swallow, B; Vale, L; Yates, L, 2016) |
| "Ondansetron is a 5-HT₃ receptor antagonist commonly used as an antiemetic to prevent nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy or postoperatively." | 4.89 | Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. ( Doggrell, SA; Hancox, JC, 2013) |
| " In postoperative nausea and vomiting (PONV), two randomized controlled trials found treatment with haloperidol comparable to ondansetron." | 4.89 | Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. ( Bennett, MI; Blenkinsopp, A; McLean, SL, 2013) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 4.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "Based on the safety and efficacy of ondansetron, it may be used as a first-line agent for relief of nausea or vomiting for most patient populations in the ED." | 4.86 | Antiemetic therapy for nausea and vomiting in the emergency department. ( Amini, R; Hays, DP; Patanwala, AE; Rosen, P, 2010) |
| "Ondansetron and granisetron appear to be equivalent drugs for the prevention of acute and delayed emesis following the use of highly emetogenic chemotherapy." | 4.86 | Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. ( Billio, A; Clarke, MJ; Morello, E, 2010) |
| "Granisetron (Kytril, Roche) is a 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist indicated for the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic chemotherapy, including high-dose cisplatin." | 4.82 | Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. ( Tan, M, 2003) |
| "Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor antagonists, control of chemotherapy-induced nausea and vomiting (CINV) with first-generation agents (ondansetron, dolasetron, and granisetron) is less than ideal." | 4.82 | Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ( Rubenstein, EB, 2004) |
| "Ondansetron has shown good efficacy in the prevention of acute nausea and vomiting in children receiving moderately or highly emetogenic chemotherapy and/or irradiation, particularly when combined with dexamethasone." | 4.81 | Ondansetron: a review of its use as an antiemetic in children. ( Bhana, N; Culy, CR; Plosker, GL, 2001) |
| "Ondansetron is a selective 5-hydroxytryptamine(3) (5-HT(3)) receptor antagonist that has been introduced to clinical practice as an antiemetic for cancer treatment-induced and anesthesia-related nausea and vomiting." | 4.81 | Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. ( Ponnudurai, R; Schaefer, R; Ye, JH, 2001) |
| " The authors included all randomized controlled trials (RCTs) that had more than 25 patients per arm and compared ondansetron to granisetron for prophylaxis of acute (A) (< 24 hours) and delayed (D) (> 24 hours) nausea (N) and vomiting (V) induced by highly (H) or moderately (M) emetogenic chemotherapy." | 4.80 | Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. ( Caparroz, C; Castro, PC; del Giglio, A; Soares, HP, 2000) |
| "Ondansetron is effective in the control of nausea and vomiting occurring 24-48 hours after highly emetogenic chemotherapy and after radiotherapy." | 4.79 | The clinical use of ondansetron. New South Wales Therapeutic Assessment Group. ( Currow, DC; Noble, PD; Stuart-Harris, RC, 1995) |
| "The clinical development of ondansetron for the prevention and treatment of postoperative nausea and vomiting has been progressing for 5 years, and continues as new directions of research are being addressed." | 4.79 | Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions. ( Joslyn, AF, 1994) |
| "Available clinical data on the use of oral ondansetron for the prevention of nausea and vomiting in patients undergoing cancer chemotherapy or surgery are reviewed." | 4.79 | Oral ondansetron for preventing nausea and vomiting. ( Cooke, CE; Mehra, IV, 1994) |
| "Ondansetron is a new selective serotonin-3-receptor antagonist which has proved to be effective in chemotherapy-induced nausea and vomiting." | 4.79 | [Ondansetron--a new anesthesia relevant antiemetic?]. ( Bach, A; Böhrer, H; Martin, E, 1994) |
| "The efficacy and safety of the serotonin (5-HT3) receptor antagonists granisetron, ondansetron, and tropisetron in the control of acute and delayed emesis and emesis induced by repeat-cycle chemotherapy are summarized." | 4.79 | Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). ( Hickok, JT; Morrow, GR; Rosenthal, SN, 1995) |
| "The use of ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well established in patients with nausea and vomiting associated with cancer chemotherapy, radiotherapy or anaesthesia and surgery." | 4.79 | Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. ( Markham, A; Wilde, MI, 1996) |
| "To test the evidence for a dose-response with ondansetron for treatment of postoperative nausea and vomiting and to establish whether differences in efficacy between doses are of clinical relevance." | 4.79 | A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "In the past few years important progress in the prevention of chemotherapy-induced nausea and vomiting has been made mainly thanks to the introduction of the 5-HT3 receptor antagonists in clinical practice (ondansetron, granisetron, tropisetron)." | 4.79 | [Recent improvements in antiemetic therapy]. ( Basurto, C; Ciccarese, G; Palladino, MA; Roila, F, 1997) |
| "The authors reviewed efficacy and safety data for ondansetron for preventing postoperative nausea and vomiting (PONV)." | 4.79 | Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "Ondansetron is a selective 5-HT3 receptor antagonist which has previously been reported in the Journal to be a promising new agent for use as prophylaxis against nausea and vomiting caused by chemotherapy and radiotherapy." | 4.78 | Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. ( Markham, A; Sorkin, EM, 1993) |
| "This paper described an outline of clinically applications of 5-HT3 receptor antagonists, mainly on ondansetron, which control nausea and vomiting associated with cancer chemotherapy." | 4.78 | [An outline of 5-HT3 receptor antagonists (2)--In clinical applications]. ( Ohta, J; Taguchi, T; Tsukagoshi, S, 1993) |
| "Ondansetron is more effective than high-dose metoclopramide in the prevention of acute nausea and vomiting due to highly emetogenic chemotherapy, and, unlike metoclopramide, is rarely associated with extrapyramidal effects." | 4.78 | Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. ( Milne, RJ; Plosker, GL, 1992) |
| " Ondansetron, currently the only serotonin antagonist with Food and Drug Administration approval for treatment of chemotherapy-induced emesis, demonstrates the efficacy and potential advantages of this class of antiemetics." | 4.78 | Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment. ( Graves, T, 1992) |
| "An international clinical trial programme has been established to assess the efficacy and safety of ondansetron in the prevention and treatment of postoperative nausea and vomiting." | 4.78 | The clinical development of ondansetron for use in the prevention and treatment of postoperative nausea and vomiting. ( Haigh, CG; Hellstern, K; Inall, FC; Isal, JP; Joslyn, AF; Kanarek, BK; Kaplan, LA; Povey, PM, 1992) |
| "Ondansetron hydrochloride dihydrate is a 5-hydroxytryptamine (5-HT3) antagonist that was recently approved by the Food and Drug Administration for the treatment of chemotherapy-induced emesis." | 4.78 | Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting. ( Burnette, PK; Perkins, J, 1992) |
| " Early clinical studies therefore examined ondansetron treatment to establish an optimal dosing schedule for acute emesis." | 4.77 | Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Marty, M, 1989) |
| "Ondansetron is a 5HT3 receptor antagonist, used to mitigate the effects of nausea and vomiting after chemotherapy or surgery." | 4.31 | Embryo-fetal safety evaluation of ondansetron in rats. ( Arena, AC; da Silva Moreira, S; de Matos Manoel, B; Jorge, BC; Perdão, CB; Reis, ACC; Stein, J, 2023) |
| "Ondansetron is a widely administered medication for nausea and vomiting of pregnancy." | 4.31 | Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes. ( Azab, AN; Betesh-Abay, B; Hadar, E; Masarwe, S; Peleg, N; Shvartsur, R, 2023) |
| " Ondansetron, which is widely used in treatment of nausea and vomiting symptoms in head injuries, was issued a safety warning from the U." | 4.31 | Ondansetron Safety Regarding Prolong QTc for Children with Head Trauma. ( Assaad, R; Pratt, RE; Qiao, H; Territo, HM; Wrotniak, BH, 2023) |
| "Ondansetron is a highly effective antiemetic for the treatment of nausea and vomiting." | 4.12 | A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women. ( Berger, H; Brodie, SM; Brown, J; Carleton, BC; Chaudhry, S; Drögemöller, BI; Groeneweg, GSS; Higginson, M; Israels, S; Ito, S; Jong, G'; Magee, LA; Miao, F; Rassekh, SR; Ross, CJD; Sanatani, S; Shaw, K; Staub, M; Trueman, J; West, N; Whyte, SD; Wright, GEB, 2022) |
| "The objective of this study was to describe ondansetron drug utilization patterns during pregnancy to treat nausea and vomiting in pregnancy (NVP)." | 4.12 | Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice. ( Candore, G; Flynn, R; Kurz, X; Nordeng, H; Pinheiro, L; Quinten, C; Slattery, J, 2022) |
| " Patients' demographics and postoperative pain, satisfaction, and nausea-vomiting scores and tramadol/ondansetron doses were evaluated." | 4.12 | Is Right Unilateral Transversus Abdominis Plane (TAP) Block Successful in Postoperative Analgesia in Laparoscopic Cholecystectomy? ( Akkaya, T; Ozciftci, S; Sahiner, IT; Sahiner, Y, 2022) |
| "Monosodium glutamate induces behaviors thought to reflect headache and nausea in rats." | 4.12 | Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats. ( Benbow, T; Cairns, BE; Exposto, FG; Sheikhi, A; Svensson, P; Teja, F, 2022) |
| "Rheumatoid arthritis, Methotrexate, Ondansetron, Nausea, Arthritis juvenile." | 4.12 | Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with Inflammatory Arthritis. ( Fida, S; Kakalia, S; Khan, HA; Kitchlew, R; Saif, S; Siddique, M, 2022) |
| "Although there is no recommendation in France relating to the treatment of nausea and vomiting of pregnancy, there are some in other countries, where ondansetron, widely used, appears to be an effective second-line treatment option behind doxylamine/vitamin B6 association and metoclopramide." | 4.02 | [Nausea and vomiting in pregnancy: A place for ondansetron?] ( Coulm, B, 2021) |
| "Although NK1RA is generally recommended for cisplatin-containing regimen, our results suggest that ondansetron effectively controlled emesis in patients receiving ESHAP therapy which includes high-dose corticosteroid." | 4.02 | Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. ( Kamiya, T; Kato, J; Kikuchi, T; Koda, Y; Mizuno, K; Mori, T; Okayama, M; Sakurai, M; Tanigawa, T, 2021) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 4.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 4.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "The results provide preliminary evidence of the potential benefit of ondansetron in the treatment of nausea, which was present in all examined dogs." | 4.02 | The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome. ( Elliott, J; Foth, S; Kenward, H; Meller, S; Pelligand, L; Volk, HA, 2021) |
| "In children presenting to the ED with an acute concussion, ondansetron use was associated with a higher risk of persistent post-concussion symptoms at 1 month." | 3.91 | Association between ondansetron use and symptom persistence in children with concussions: A 5P substudy. ( Beauchamp, MH; Boutis, K; Dubrovsky, AS; Freedman, SB; Gagnon, I; Gravel, J; Momoli, F; Tang, K; Zemek, R, 2019) |
| "Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM." | 3.91 | New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 3.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| "Evidence for the fetal safety of ondansetron, a 5-HT3 receptor antagonist that is commonly prescribed for nausea and vomiting during pregnancy, is limited and conflicting." | 3.88 | Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. ( Bateman, BT; Desai, RJ; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Straub, L; Zhu, Y, 2018) |
| "This study aimed to identify if prophylactic ondansetron administered with intravenous (IV) opioids prevents opioid-induced nausea or vomiting." | 3.85 | Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study. ( Culver, MA; Edwards, CJ; Jarrell, DH; Richards, EC, 2017) |
| "Background Two pivotal Phase III trials compared the efficacy of palonosetron, ondansetron and granisetron, combined with dexamethasone, for the prevention of nausea and vomiting following highly emetogenic chemotherapy." | 3.85 | Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients. ( Du, Q; Xu, XL; Yu, B; Zhai, Q; Zhu, B, 2017) |
| "Ondansetron is widely used in general practice for nausea and vomiting due to any cause." | 3.83 | Ondansetron-Induced Life Threatening Hypokalemia. ( Kutty, KK; Mathew, SK; Padmakumar, C; Pius, P; Ramya, I, 2016) |
| "The patient completed the remainder of the radiation treatment with no further emesis and minimal nausea, representing the first documented success of granisetron and aprepitant for RINV after failure on ondansetron." | 3.81 | Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report. ( Chow, E; DeAngelis, C; Hunyh, L; McDonald, R; Pasetka, M; Raman, S; Rowbottom, L, 2015) |
| "To evaluate the appearance of chemotherapy-induced nausea and vomiting, and to compare the antiemetic efficacy of the triple combination of palonosetron, aprepitant and dexamethasone with that of our old regimen using first-generation 5-hydroxytryptamine 3-receptor antagonists and dexamethasone during gemcitabine and cisplatin chemotherapy in patients with advanced urothelial cancer." | 3.81 | Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients. ( Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F, 2015) |
| "The current Tactical Combat Casualty Care (TCCC) Guidelines recommend parenteral promethazine as the single agent for the treatment of opioid-induced nausea and/or vomiting and give a secondary indication of "synergistic analgesic effect." | 3.81 | Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care. ( Burrell, E; Butler, FK; Gross, K; Onifer, DJ; Otten, EJ; Patton, R; Russell, RJ; Stockinger, Z, 2015) |
| "The effectiveness of cannabidiolic acid (CBDA) was compared with other potential treatments for anticipatory nausea (AN), using a rat model of contextually elicited conditioned gaping reactions." | 3.80 | A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. ( Bonner, N; Downey, R; Engeland, K; Jackson, M; Limebeer, CL; Morris, H; Navaratnam, R; Parker, LA; Rock, EM; Sticht, MA, 2014) |
| "To determine the minimally effective dose of cannabidiolic acid (CBDA) that effectively reduces lithium chloride (LiCl)-induced conditioned gaping reactions (nausea-induced behaviour) in rats and to determine if these low systemic doses of CBDA (5-0." | 3.79 | Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. ( Parker, LA; Rock, EM, 2013) |
| "Ondansetron, selective serotonin (5-HT3) receptor blocker, is used in treating chemotherapy induced nausea and vomiting in cancer patients." | 3.79 | Comparative pharmacokinetic studies of fast dissolving film and oral solution of ondansetron in rats. ( Chhalotiya, UK; Choudhary, DR; Kundawala, AJ; Patel, HV; Patel, VA, 2013) |
| "The main objective of this study was to develop a microemulsion (ME) formulation for transdermal delivery of ondansetron for chemotherapy induced nausea and vomiting (CINV)." | 3.79 | Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting. ( Ahmad, FJ; Al Abood, RM; Talegaonkar, S; Tariq, M, 2013) |
| "The use of ondansetron in children with vomiting after a head injury has not been well studied." | 3.79 | The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED. ( Hirsh, DA; Khan, NS; Simon, HK; Sturm, JJ, 2013) |
| "The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea/vomiting (CINV) among lung cancer patients receiving multi-day chemotherapy and ondansetron- or palonosetron-initiated prophylactic antiemetic regimens in a community oncology setting." | 3.78 | Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. ( Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G, 2012) |
| "While I usually prescribe doxylamine-pyridoxine for morning sickness, some of my patients with severe nausea and vomiting of pregnancy (NVP) receive ondansetron in hospital." | 3.78 | Motherisk update. Is ondansetron safe for use during pregnancy? ( Koren, G, 2012) |
| "Nausea and vomiting have always been associated with anti-cancer agents in patients' minds because these effects were the main ones to occur during chemotherapy." | 3.78 | [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting]. ( Depierre, A, 1996) |
| "We examined treatment outcomes in women with severe nausea and vomiting of pregnancy (NVP) receiving outpatient nursing support and either subcutaneous metoclopramide or subcutaneous ondansetron via a microinfusion pump." | 3.77 | Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. ( Desch, C; Fox, NS; Istwan, N; Klauser, CK; Palmer, B; Rebarber, A; Rhea, D; Saltzman, D, 2011) |
| "Methotrexate (MTX) is an effective treatment for Crohn disease (CD); however, its application may be limited by the occurrence of nausea." | 3.77 | Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. ( Barkey, J; Benchimol, EI; Boland, M; Kempinska, A; Mack, A; Mack, DR, 2011) |
| " Ondansetron 8 mg and dexamethasone 8 mg intravenously were the standard antiemetic therapy for prevention of acute chemotherapy-induced nausea and vomiting." | 3.77 | Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. ( Baak-Pablo, RF; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Mustofa, M; Nortier, JW; Perwitasari, DA; van der Straaten, RJ; Wessels, JA, 2011) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 3.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "The optimal dose of oral ondansetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) resulting from moderately emetogenic chemotherapy (MEC) is unknown." | 3.76 | The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. ( Della-Fiorentina, SA; Ng, WL, 2010) |
| "Until recently, ondansetron was approved for the prevention of nausea and vomiting only in patients older than 2 years." | 3.76 | Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. ( Adamson, PC; Barrett, JS; Coté, CJ; Croop, JM; Haberer, LJ; Hoke, JF; Johnson, BM; Mondick, JT; Russo, MW; Sale, ME, 2010) |
| "A 1-year-old girl with stage-IV neuroblastoma developed ondansetron hydrochloride anaphylaxis." | 3.76 | Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. ( Batu, ED; Büyükpamukçu, M; Civelek, E; Demir, HA; Saçkesen, C; Yalçın, B, 2010) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "The potential of the selective serotonin reuptake inhibitor (SSRI), fluoxetine (which produces nausea in the clinic), to produce conditioned gaping in rats and of the 5-HT(3) antagonists (ondansetron and palonosetron) and the 5-HT(1A) autoreceptor agonist (8-OH-DPAT) to reverse this effect were evaluated." | 3.75 | Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats. ( Limebeer, CL; Litt, DE; Parker, LA, 2009) |
| "Aprepitant is actually recommended in the prevention of nausea and vomiting induced by high emetic risk chemotherapy using cisplatin." | 3.75 | [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study]. ( Auger, A; Combes, JD; Favier, B; Galy, G; Labidi, SI; Latour, JF; Tissier, F, 2009) |
| "A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug." | 3.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| "Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects." | 3.74 | Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. ( Foley, KF; Kast, RE, 2007) |
| " Dolasetron ( n=157), granisetron ( n=81), and ondansetron ( n=131) achieved complete control of vomiting in 89." | 3.74 | Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? ( Awan, FT; Chaudhary, L; Hamadani, M; Khan, JK; Kojouri, K; Ozer, H; Tfayli, A, 2007) |
| "In highly emetogenic chemotherapy, the recommended dose of the serotonin-receptor antagonist ondansetron (5 mg/m(2) q8h) may be insufficient to prevent chemotherapy-induced nausea and vomiting." | 3.74 | Safety of ondansetron loading doses in children with cancer. ( Ammann, RA; Hasler, SB; Hirt, A; Leibundgut, KK; Ridolfi Luethy, A, 2008) |
| "Ondansetron is a commonly used medication in the treatment of nausea and vomiting arising from many etiologies, including chemotherapy." | 3.74 | Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL. ( Pinsk, M; Turner, SR, 2008) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 3.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| "Ondansetron (Zofran) is a drug used for the treatment of nausea and vomiting caused by cancer chemotherapy." | 3.72 | The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. ( Einarson, A; Kennedy, D; Koren, G; Maltepe, C; Navioz, Y; Tan, MP, 2004) |
| "To assess the effectiveness of ondansetron in relieving symptoms of nausea and vomiting which were refractory to metoclopramide and cyclizine, in a patient receiving iloprost infusions." | 3.71 | Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. ( Roome, C; Thompson, J, 2001) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 3.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "In the large majority of patients, serotonin-receptor antagonist antiemetic therapy, administered in combination with dexamethasone, is highly effective over multiple courses in preventing significant carboplatin-induced nausea and vomiting." | 3.71 | Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy. ( Kulp, B; Markman, M; Markman, MR; Peterson, G, 2002) |
| "The purpose of this study was to document the emetogenic potential of intrathecal chemotherapy (IC) in children and to evaluate the efficacy of ondansetron in reducing nausea and vomiting with this chemotherapy treatment." | 3.70 | Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. ( Chavez, CM; Holdsworth, MT; Raisch, DW; Winter, SS, 1998) |
| "The control of emesis for patients undergoing high-dose chemotherapy with APBSCT is fair with ondansetron." | 3.70 | Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours. ( Ang, PT; Leong, SS; Tao, M; Teo, CP, 1998) |
| "The effects of a NK1 antagonist, GR205171, and a 5-HT3 antagonist, ondansetron, in a novel model of post-anaesthesia-induced emesis in Suncus murinus is described." | 3.70 | Inhibition of anaesthetic-induced emesis by a NK1 or 5-HT3 receptor antagonist in the house musk shrew, Suncus murinus. ( Gardner, C; Perren, M, 1998) |
| "To determine the incidence of nausea and vomiting and the antiemetic effect of ondansetron hydrochloride (OND) in patients with hepatocellular carcinoma treated with arterial chemo-embolization, we studied 59 patients with hepatocellular carcinoma who were treated with transcatheter arterial embolization (TAE) or lipiodolized transcatheter arterial infusion (L-TAI)." | 3.70 | Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride. ( Abe, T; Hashimoto, Y; Kojima, A; Mori, M; Nagamine, T; Sohara, N; Takagi, H; Takahashi, H, 1999) |
| "We demonstrated that both eusatron and ondansetron effectively abolished the emesis normally induced by 2-Gy doses of either 60Co gamma or neutron:gamma, mixed-field irradiation, the latter with a neutron-to-total dose ratio (Dn/Dt) of 0." | 3.70 | 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation. ( King, GL; Rabin, BM; Weatherspoon, JK, 1999) |
| "The article reports a study comparing the cost-effectiveness of ondansetron tablets and prochlorperazine capsules in preventing nausea and vomiting after moderately emetogenic chemotherapy in an outpatient setting." | 3.70 | Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy. ( Kwong, WJ; Parasuraman, TV, 1999) |
| "To evaluate the effect of ondansetron availability on the costs of managing nausea and vomiting." | 3.70 | Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. ( Coyle, D; Dahrouge, S; Evans, WK; Stewart, DJ, 1999) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 3.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "Two young women with chronic nausea and vertigo caused by multiple sclerosis responded to the introduction and maintenance of the 5HT3 receptor antagonist, ondansetron." | 3.70 | Ondansetron in multiple sclerosis. ( Macleod, AD, 2000) |
| "To determine how many patients were deprived of treatment by being given placebo as comparator in trials of ondansetron for postoperative nausea and vomiting." | 3.69 | Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. ( Aspinall, RL; Goodman, NW, 1995) |
| "To measure the severity of nausea and vomiting in pediatric patients receiving intravenous or intrathecal chemotherapy for acute lymphoblastic leukemia and to evaluate the effectiveness of 2 intravenous doses of ondansetron for this condition." | 3.69 | Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. ( Chavez, CM; Duncan, MH; Holdsworth, MT; Leasure, MM; Raisch, DW, 1995) |
| "The efficacy and safety of ondansetron has led to the widespread use of this medication in the treatment of nausea and vomiting caused by cancer chemotherapy and radiation therapy." | 3.69 | Anaphylactoid reactions associated with ondansetron. ( Kossey, JL; Kwok, KK, 1994) |
| "We investigated the prophylactic antiemetic effect of added low-dose infusion of propofol in patients exhibiting nausea and vomiting refractory to dexamethasone and serotonin antagonist during non-cisplatin chemotherapy for breast cancer." | 3.69 | Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. ( Borgeat, A; Forni, M; Suter, PM; Wilder-Smith, O, 1994) |
| "The efficacy and safety of prophylactic intravenous ondansetron on prevention of postoperative nausea and vomiting were investigated in 65 ASA grades I-III patients undergoing elective abdominal surgery and receiving general anesthesia." | 3.69 | [Ondansetron on postoperative nausea and vomiting]. ( Guo, XY; Luo, AL; Ye, TH, 1994) |
| "To describe the efficacy of ondansetron for the treatment of poisoning-associated vomiting in two patients following drug intoxication." | 3.69 | Ondansetron for treating nausea and vomiting in the poisoned patient. ( Marx, CM; Reed, MD, 1994) |
| " Ondansetron use has improved the control of post-chemotherapy nausea, vomiting, and retching." | 3.69 | Nurses' perceptions of antiemetic effectiveness. ( Johnson, M; McDaniel, RW; Rhodes, VA; Simms, SG, 1995) |
| "The incidences of nausea and vomiting were significantly lower in the patients premedicated with ondansetron." | 3.69 | [Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery]. ( Bejarano-López, C; Bustos-Molina, F; Cid-Calzada, J; Cortés-Uribe, A; García-Cruz, JJ; Soro-Domingo, M, 1996) |
| "Prochlorperazine is a centrally acting dopamine receptor antagonist that is most commonly used for the treatment of nausea and vomiting." | 3.69 | Tardive dyskinesia as a result of long-term prochlorperazine use. ( Alberts, VA; Catalano, G; Poole, MA, 1996) |
| " Patients, who did not receive ondansetron (n = 37) showed a nausea and emesis rate of 73%." | 3.69 | [Acute tolerance in hyperfractionated accelerated whole-body irradiation]. ( Latz, D; Schraube, P; Wannenmacher, M, 1996) |
| "Investigated the prevalence of anticipatory nausea and vomiting (ANV) among 59 pediatric cancer patients who had routinely received ondansetron (Zofran) antiemetic therapy and determined patient- and treatment-related factors associated with ANV." | 3.69 | Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. ( Barclay, DR; Bieberich, AA; Mulhern, RK; Smith, BF; Tyc, VL, 1997) |
| "A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used." | 3.69 | Acute severe depression following peri-operative ondansetron. ( Blaine, EM, 1997) |
| "The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer." | 3.68 | Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. ( Calabria, C; Casale, F; Di Tullio, M; Indolfi, P; Lampa, E; Lucarelli, C; Matera, MG; Rossi, F, 1993) |
| "While ondansetron is effective in the control of nausea and vomiting induced by high dose cisplatin, it has to be given in multiple doses and is very expensive." | 3.68 | [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting]. ( Zeng, WY, 1993) |
| "To assess the value of ondansetron in a patient with intractable nausea, abdominal pain and diarrhoea unrelated to cancer chemotherapy or radiotherapy." | 3.68 | Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron. ( Evans, JE, 1993) |
| "Ondansetron may be the preferred agent for controlling nausea and vomiting in patients with neurosurgical trauma." | 3.68 | Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports. ( Deppe, SA; Kleinerman, KB; Sargent, AI, 1993) |
| "The study examined the budgetary implications of using 5-hydroxytryptamine3 receptor antagonists (5-HT3RA), granisetron or ondansetron, in the management of chemotherapy-induced emesis (CIE)." | 3.68 | The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. ( Bosanquet, N; Jones, AL; Lee, GJ, 1992) |
| " This study assessed the degree of postoperative pain and nausea when, during the operation, the trocar sites had been infiltrated with bupivacaine and antiemetics (ondansetron) had been administered." | 3.68 | Postoperative pain and nausea after laparoscopic cholecystectomy. ( Jensen, KE; Madsen, MR, 1992) |
| "The antiemetic activity of ondansetron (Zofran, Glaxo Pharmaceuticals, Research Triangle Park, NC) was evaluated in 25 patients with recurrent melanoma who were treated sequentially with dacarbazine (DTIC), vinblastine, and cisplatin." | 3.68 | Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. ( Hodges, C; Legha, SS; Ring, S, 1992) |
| "In summary, ondansetron has proved to be a highly effective anti-emetric and is superior to metoclopramide in the treatment of acute emesis." | 3.68 | Introduction: the clinical challenge. ( Schmoll, HJ, 1991) |
| " Ondansetron is an investigational serotonin antagonist that has documented effectiveness for cancer chemotherapy-induced emesis." | 3.68 | Ondansetron: a new entity in emesis control. ( Graves, T, 1990) |
| "The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide." | 3.67 | The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989) |
| "Nausea and vomiting is a common ED chief complaint." | 3.01 | Isopropyl alcohol inhalation for the treatment of nausea in adult emergency department patients: a systematic review and meta-analysis. ( Lee, SY; Tamale, JR, 2023) |
| "Patients on cancer chemotherapy, which has high occurrence of nausea and vomiting, were given either the low dose or the conventional dose of olanzapine for 3 days, in addition to some other antiemetic agents." | 3.01 | Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Dutta, P; M Navari, R; Mukhopadhyay, S, 2021) |
| "Palonosetron (PG) is a newer, safe, and effective long-acting 5-HT3 antagonist commonly used in adults, but data in children are limited." | 2.90 | Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. ( Boddu, D; Chaudhary, NK; John, RR; Mahasampath, G; Mathew, LG; Nesadeepam, N, 2019) |
| "The effect against nausea is of particular interest." | 2.87 | Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study. ( Christensen, TB; Daugaard, G; Fox, GM; Herrstedt, J; Holmskov, K; Molassiotis, A; Summers, Y; Taylor, PD, 2018) |
| " The overall incidence of adverse events was similar between the two treatment groups (p > ." | 2.84 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. ( Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017) |
| " Aprepitant and ondansetron as dosed in this trial was not superior to standard ondansetron monotherapy." | 2.84 | Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). ( Ades, S; Ashikaga, T; Blackstock, W; Halyard, M; Heimann, R; Kumar, S; Wilson, K, 2017) |
| "Aprepitant is a P/neurokinin-1 receptor antagonist approved for the prevention of CINV in moderate emetic risk chemotherapy." | 2.80 | Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara ( Badar, T; Borthakur, G; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; Mattiuzzi, G; O'Brien, S; Poku, R; Wierda, W, 2015) |
| "Rolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist." | 2.80 | Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). ( Arora, S; Chua, D; Fein, LE; Poma, A; Rapoport, B; Wang, Y, 2015) |
| "Gabapentin is a low-cost strategy to improve complete control of CINV, specially delayed CINV control." | 2.77 | Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. ( Carrasco, MM; Cruz, FM; da Costa Miranda, M; da Cunha Vieira, M; de Afonseca, SO; de Iracema Gomes Cubero, D; de Souza Fêde, AB; del Giglio, A; Lera, AT; Lerner, T; Pinczowski, H; Schindler, F; Taranto, P, 2012) |
| "Metoclopramide is a dopamine antagonist, which may enhance efficacy of ondansetron and dexamethasone." | 2.77 | Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. ( Akewanlop, C; Ithimakin, S; Keerativitayanan, N; Laocharoenkeat, A; Nimmannit, A; Runglodvatana, K; Soparattanapaisarn, N; Srimuninnimit, V, 2012) |
| "Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor." | 2.76 | Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. ( Cao, R; Dong, X; Huang, J; Liu, L, 2011) |
| "Pretreatment with ondansetron or metoclopramide does not reduce oral contrast solution ingestion time." | 2.74 | Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy. ( Bamber, D; Chohan, J; Garra, G; Singer, AJ; Thode, HC; Troxell, R, 2009) |
| "Nausea and vomiting are important symptoms observed in cancer patients." | 2.74 | Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. ( de Camargo, B; del Giglio, A; Lajolo, PP, 2009) |
| "Ondansetron exposure was equivalent in regimens B and C." | 2.74 | Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. ( Adams, L; Blum, R; Johnson, B; Lates, C; Lebowitz, P; Lu, E; Zhang, K, 2009) |
| "Seasickness is a common problem, causing a significant decrement in performance among naval crew." | 2.74 | Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. ( Asna, N; Bar, R; Hershkovitz, D; Kaminski, G; Shupak, A; Tal, D, 2009) |
| "The meclizine group had lower VNRS scores in the PACU at 15 (P = ." | 2.73 | Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population. ( Benfield, DA; Forrester, CM; Kelly, JA; Matern, CE; Pellegrini, JE, 2007) |
| "Eighty-five in-patients with cancer undergoing chemotherapy were randomly divided into 2 groups: Nasea group (group A, n = 43, Nasea, ramosetron hydrochloride was injected intravenously 30 minutes before chemotherapy) and ondansetron group (group B, n = 42, ondamsetron was injected intravenously 30 minutes before chemotherapy)." | 2.71 | [Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs]. ( Liu, DW; Liu, YY; Shan, XJ; Xie, XD; Zheng, ZD, 2003) |
| "as prophylaxis in breast cancer patients regimens was studied." | 2.71 | Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. ( Coop, AJ; Dempsey, CL; Eberhardt, DR; Farley, PA; O'Briant, S; Shillington, A, 2004) |
| "Patients with cancer (N = 216) treated with chemotherapeutic regimens composed of highly or moderately emetogenic agents were examined for their antiemetic responses to tropisetron, ondansetron, or granisetron." | 2.71 | Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. ( Abali, H; Aynacioglu, AS; Babaoglu, MO; Bayar, B; Bozkurt, A; Celik, I; Kerb, R, 2005) |
| "Ondansetron was administered as 8 mg bid, metopimazine as 30 mg qid, and prednisolone as 50 mg qd." | 2.70 | Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. ( Dombernowsky, P; Handberg, J; Herrstedt, J; Kjaer, M; Sigsgaard, T, 2001) |
| "Nausea was assessed by means of a four-point ordinal scale at intervals over the 7 day period." | 2.70 | Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. ( Borms, M; Carides, AD; Cocquyt, V; De Smet, M; Decramer, ML; Eldridge, K; Gertz, BJ; O'Brien, M; Reinhardt, RR; Schellens, JH; Van Aelst, F; Van Belle, S; Verbeke, L, 2001) |
| " Adverse reactions were observed in 2 cases (2 reports of headache) in the OND group and 5 cases (2 reports of hiccups, 2 headache, 2 diarrhea, one constipation, one hot facial flushes and one elevation of gamma-GTP) in the DEX group; however, since the symptoms were all mild, we did not consider there was any problem in safety." | 2.70 | [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin]. ( Eguchi, F; Furue, H; Ikeda, M; Taguchi, T; Tsukakoshi, S, 2001) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 2.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "The reduction in the frequency of posttreatment vomiting supports research findings of efficacy." | 2.69 | Progress in reducing anticipatory nausea and vomiting: a study of community practice. ( Burish, T; Flynn, PJ; Hynes, HE; Morrow, GR; Pierce, HI; Roscoe, JA, 1998) |
| "When ondansetron was given as a "split dose," its prophylactic antiemetic efficacy was not significantly different from that of the placebo group." | 2.69 | The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. ( Qi, J; Tang, J; Wang, B; Watcha, MF; Wender, RH; White, PF, 1998) |
| "Sixty cancer patients took part in this randomized prospective study." | 2.69 | Granisetron and ondansetron for chemotherapy-related nausea and vomiting. ( Ben Dayan, D; Ben Zion, T; Cohen, AM; Kaufman, O; Mittelman, M; Zeidman, A, 1998) |
| "Ondansetron 8 mg was added to dexamethasone and was administered i." | 2.69 | Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. ( , 1998) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 2.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "Ondansetron 24 mg q." | 2.69 | A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. ( Ames, M; Brogden, J; Cohen, G; Craig, J; Diaz, LB; Garcia Rodriguez, FM; Krasnow, S; Miranda, E; Needles, B; Spector, J, 1999) |
| "Ondansetron is an effective and well-tolerated antiemetic, which is used for the prevention of both chemotherapy and radiotherapy-induced emesis and nausea." | 2.69 | Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tab ( Coster, B; Feyer, P; Franzén, L; Goedhals, L; Graham, E; Haigh, C; LeBourgeois, JP; Marzecki, Z; McKenna, CJ; Mitchell, T; Souhami, L; Stewart, A; Tønnessen, F; Wilkinson, JR, 1999) |
| "Perceived nausea was evaluated using a nausea scoring system, and no differences were apparent between the granisetron and ondansetron groups; however, reported nausea was significantly higher in females (p<0." | 2.69 | A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. ( Burns, L; DeFor, TE; Larson, H; Orchard, PJ; Ramsay, NK; Rogosheske, J; Rydholm, N; Weisdorf, D, 1999) |
| " Serial plasma and pleural or ascitic fluid samples were collected during each dosing and analyzed by high-performance liquid chromatography for both the intact lactone form of topotecan and its ring-opened carboxylate form." | 2.69 | Topotecan lacks third space sequestration. ( de Jonge, MJ; Gelderblom, H; Loos, WJ; Sparreboom, A; Verweij, J, 2000) |
| " The antiemetic efficacy of NK1 receptor antagonists against chemotherapy-induced emesis is, however, enhanced when combined with a 5-HT3 receptor antagonist." | 2.69 | Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. ( Clemes, SA; House, F; Palmer, JL; Reid, K; Somal, HS; Stott, JR; Troakes, C; Wright, RJ, 2000) |
| "Forty-five malignant lymphoma patients (mean age 38 years, M:F 30:15), undergoing the highly emetogenic regimen BEAM prior to ASCT, were randomized to receive IV granisetron (G) 3 mg once a day, IV tropisetron (T) 5 mg once a day, or IV ondansetron (0) 8 mg twice daily, for six days." | 2.69 | Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. ( Klener, P; Procházka, B; Slabý, J; Trnený, M, 2000) |
| "Ondansetron appears to be a safe and efficacious antiemetic during conditioning for BMT." | 2.68 | Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. ( Agura, ED; Brown, MC; Donaldson, G; Schaffer, R; Shen, DD, 1995) |
| "Metoclopramide was ineffective." | 2.68 | The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. ( Clark, K; Cronin, MK; Darvish, AH; Desilva, PH; McDonald, SM, 1995) |
| "One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min." | 2.68 | [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. ( Fan, Y; Guo, N; Huang, X, 1995) |
| "Metoclopramide was given i." | 2.68 | Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance. ( Benou, N; Charalambidis, G; Ganas, N; Karabellis, A; Kosmidis, P; Mylonakis, N; Pagou, M; Tsavaris, N; Tsikalakis, D, 1995) |
| "Children who had solid tumors and who were receiving highly emetogenic chemotherapy, including cisplatin, carboplatin, cyclophosphamide, and ifosfamide, were randomized (1:1) in a double-blind fashion to receive either OND 0." | 2.68 | Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. ( Alvarez, O; Bedros, A; Call, SK; Convy, L; Cook, L; Freeman, A; Halverson, J; Kalbermatter, O; Mick, K; Volsch, J, 1995) |
| "Nausea was absent or mild in 79% of patients on day 1, 45% on day 2 and 41% on day 3." | 2.68 | A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. ( Barbounis, V; Efremidis, AP; Hatzichristou, H; Koumakis, G; Tsousis, S; Vassilomanolakis, M, 1995) |
| " In conclusion, ondansetron given prior to anaesthesia in a dosage of 4 mg did not prevent postoperative nausea and vomiting after laparoscopic cholecystectomy." | 2.68 | Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial. ( Koivuranta, MK; Läärä, E; Ryhänen, PT, 1996) |
| " In addition, ondansetron had a similar dose-response curve in both menstruating and nonmenstruating women." | 2.68 | The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron. ( Afshar, M; Allen, E; Buxbaum, J; Gratz, I; Joslyn, AF; Prilliman, B, 1996) |
| "Metoclopramide was ineffective." | 2.68 | Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. ( Attia, M; Channa, AB; el Bakry, AK; el Gammal, K; el Gammal, M; Elhattab, YS; Jaroudi, R; Khoshim, MH; Naguib, M; Saddique, A, 1996) |
| "We investigated how residual tumour burden after cytoreductive surgery was related to the occurrence of acute and delayed nausea and vomiting in 101 ovarian cancer patients receiving their first chemotherapy course." | 2.68 | Impact of tumour burden on chemotherapy-induced nausea and vomiting. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1996) |
| "Headache was frequent in the control (69%), i." | 2.68 | The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison. ( van den Berg, AA, 1996) |
| "001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters." | 2.68 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. ( Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA, 1996) |
| "Ondansetron is a serotonin (5HT) receptor antagonist at both peripheral and central 5-HT3 receptor sites with no known action on dopamine-mediated activity." | 2.68 | Droperidol/ondansetron combination controls nausea and vomiting after tubal banding. ( Hamilton, DL; McKenzie, R; Riley, TJ; Uy, NT, 1996) |
| "A group of 104 chemotherapy-naive ovarian cancer patients, scheduled for at least three cycles of combination chemotherapy including cisplatin (50 mg/m2), were randomly allocated to receive either dexamethasone or placebo in addition to ondansetron." | 2.68 | Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Lomberg, H; Peterson, C; Steineck, G, 1996) |
| "Nausea was measured at three intervals: at admission to the postanesthesia care unit (PACU), 1 h after admission to the PACU, and on Postoperative Day 1." | 2.68 | A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy. ( Alberts, MS; Sniadach, MS, 1997) |
| "As ondansetron was clearly effective in patients receiving hemibody irradiation it seems it would be prudent to adopt it for use in such patients routinely." | 2.68 | Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. ( Kiltie, AE; Stewart, AL; Sykes, AJ, 1997) |
| "Nausea and emesis are significant side effects in patients undergoing stereotactic radiosurgery for brain lesions in the region of the chemoreceptor trigger zone (area postrema of the brain)." | 2.67 | The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone. ( Alexander, E; Bodis, S; Kooy, H; Loeffler, JS, 1994) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 2.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Female patients with ovarian cancer are at high risk for emesis." | 2.67 | Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research. ( , 1994) |
| "Ondansetron or droperidol was given intravenously, 30 min prior to the first dose of IL-2 and then every 8 h for the duration of IL-2 treatment." | 2.67 | A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. ( Cole, DJ; Kim, H; Rosenberg, SA; Steinberg, SM; Weber, JS, 1994) |
| "Ondansetron is a well tolerated, efficacious antiemetic which has a similar side effect profile to placebo." | 2.67 | Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting. ( Claybon, L, 1994) |
| "ondansetron was superior to metoclopramide in preventing nausea and vomiting after general anaesthesia for day-case gynaecological laparoscopic surgery." | 2.67 | Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide. ( Norton, AC; Raphael, JH, 1993) |
| "Ondansetron was a very effective antiemetic in the first weeks of treatment but its efficacy waned later on." | 2.67 | Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. ( de Boer-Dennert, M; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1993) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 2.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "Oral ondansetron is a safe and effective antiemetic that is more efficacious than placebo for patients receiving cyclophosphamide-based chemotherapy." | 2.67 | Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. ( Beck, TM; Chang, A; Ciociola, AA; Galvin, D; Hart, NE; Harvey, WH; Jones, SE; Tchekmedyian, NS, 1993) |
| "Ondansetron use was concurrently monitored in adult inpatients for four months." | 2.67 | Multicenter evaluation of ondansetron use in hospitalized oncology patients. ( Emhart, GC; Jessen, LM; Long, KS; Patel, HS; Peters, MD; Reitz, JA, 1993) |
| "Ondansetron was injected intravenously in a single dose of 4 mg, 8 mg or 12 mg, at 15 minutes before administration of cisplatin." | 2.67 | [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 2.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was well tolerated in the dose and schedule used." | 2.67 | The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. ( Bryson, JC; Finn, AL; Gandara, DR; Harvey, WH; Hesketh, PJ; Monaghan, GG; Perez, EA; Stokes, C, 1992) |
| "Ondansetron 4 mg was administered orally once daily for 3-5 consecutive days." | 2.67 | [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron hydrochloride is a selective serotonin subtype 3 (5HT3) receptor antagonist that has been shown to be an effective antiemetic in patients receiving cisplatin chemotherapy." | 2.67 | Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. ( Einhorn, L; House, K; Nagy, C; Sledge, GW, 1992) |
| " Several clinical observations suggested that ondansetron may be effective when given in a single dose: (1) demonstration of efficacy over a wide dose range, (2) similar efficacy with dosing intervals of 2, 4, 6, and 8 hours, and (3) efficacy of single-dose regimens with high-dose metoclopramide and other 5-hydroxytryptamine3 antagonists." | 2.67 | Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. ( Hainsworth, JD; Hesketh, PJ, 1992) |
| "Ondansetron was an effective antiemetic in 78% (14/18) and placebo was effective in 28% (5/18) of the patients." | 2.67 | Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo. ( Afshar, M; Gratz, I; Larijani, GE; Minassian, S, 1991) |
| "Ondansetron was given as 4 mg oral +4 mg iv 30 minutes prior to carboplatin followed by 8 mg oral tds for 5 days." | 2.67 | A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group. ( Howells, N; Lambert, HE; McQuade, B; Rustin, GJ; Smith, DB, 1991) |
| "Bone cancer was the most incident (≥50%) neoplasm, followed by rhabdomyosarcoma and Hodgkin's lymphoma." | 2.55 | Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials. ( D'Athayde Rodrigues, F; Ferreira, MAP; Moreira, LB; Okumura, LM, 2017) |
| "Nausea and vomiting is a common and distressing presenting complaint in emergency departments (ED)." | 2.52 | Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. ( Egerton-Warburton, D; Furyk, JS; Meek, RA, 2015) |
| "The purpose of this article is to outline the risk of cardiac adverse events (AEs) from 5-HT3-RAs, with focus on the three most commonly used, ondansetron, granisetron and palonosetron." | 2.50 | 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. ( Brygger, L; Herrstedt, J, 2014) |
| "Nausea and vomiting are two of the most distressing side effects of chemotherapy." | 2.44 | Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. ( Vrabel, M, 2007) |
| "Ondansetron is a serotonin receptor antagonist that is effective in preventing and treating PONV." | 2.39 | Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting. ( Charbonneau, J; Early, TE; Jenkins, P; McKnight, G, 1995) |
| "Ondansetron is a highly potent and selective antagonist at 5-HT3 receptors." | 2.38 | Pharmacology of ondansetron. ( Naylor, RJ; Rudd, JA, 1992) |
| " In adult patients receiving single-day chemotherapy, the incidence of adverse events was 45% with IV ondansetron (n = 317) and 59% with metoclopramide (n = 279)." | 2.38 | Clinical safety of ondansetron. ( Bryson, JC, 1992) |
| "Ondansetron (GR 38032F) is a highly selective 5-HT3 receptor antagonist, one of a new class of compounds which may have several therapeutic applications." | 2.38 | Ondansetron. Therapeutic use as an antiemetic. ( Heel, RC; Milne, RJ, 1991) |
| "Ondansetron was effective in children receiving a wide variety of chemotherapy regimens." | 2.38 | The role of ondansetron in paediatric patients: a review of three studies. ( Stevens, RF, 1991) |
| "Ondansetron has marked activity against emesis associated with cisplatin and other highly emetogenic drugs." | 2.38 | Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting. ( Goldspiel, BR; Kohler, DR, 1991) |
| "Ondansetron is a specific antagonist of 5-HT3 serotonin receptors." | 2.38 | [Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ( Aubert, B; Bons, J; d'Allens, H; Pappo, M, 1991) |
| "Ondansetron failure was determined by review of the medical records and by patient-reported outcomes (PROs)." | 1.72 | Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population. ( Davenport, L; Dome, JS; Gai, J; Gross, AM; Hinds, PS; Jacobs, SS; Mowbray, C; Postell, E; van den Anker, JN, 2022) |
| "When treating nausea in patients with chronic gastrointestinal syndromes, clinicians may consider trying higher performing treatments first, and forgoing lower performing treatments." | 1.56 | Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea. ( Clarke, JO; Fernandez-Becker, N; Garcia, M; Garcia, P; Grewal, D; Kamal, A; Nandwani, M; Neshatian, L; Nguyen, L; Okafor, P; Regalia, K; Sonu, I; Triadafilopoulos, G; Zikos, TA, 2020) |
| " The groups were analyzed and compared for frequency of vomiting, administered doses of on-demand antiemetic dimenhydrinate and adverse events during the acute (0-24 h after chemotherapy administration) and delayed (> 24 h-120 h) CINV phases." | 1.51 | Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. ( Binder, V; Blaeschke, F; Cabanillas Stanchi, KM; Döring, M; Feucht, J; Feuchtinger, T; von Have, M; Willier, S, 2019) |
| "Snakebites are common in many regions of the United States." | 1.46 | White-Lipped Tree Viper (Cryptelytrops albolabris) Envenomation in an American Viper Keeper. ( Galdamez, LA; Greene, S; Tomasheski, R, 2017) |
| "Nausea is a common symptom in patients taken care of by the ambulance service." | 1.43 | Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study. ( Hjelte Judell, O; Lindström, V; Vicente, V; Westerlund, A, 2016) |
| "Nausea and vomiting are common, but prevalence of antiemetic use in ED patients is unknown." | 1.43 | Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective. ( Garra, G; Singer, AJ; Thode, HC, 2016) |
| "Pretreatment with ondansetron, a serotonin 5-HT3 receptor antagonist, which is used to treat nausea in patients in chemo- or radiation therapy, attenuated hypothermia by ~30%." | 1.40 | Thermoregulatory correlates of nausea in rats and musk shrews. ( Cerri, M; Corrigan, JJ; Del Vecchio, F; Dragic, AS; Kamphee, A; Nalivaiko, E; Ngampramuan, S; Romanovsky, AA; Rudd, JA, 2014) |
| "CYP2D6 drug-drug interactions appear to change effectiveness of commonly prescribed drugs in the ED." | 1.40 | The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. ( Campbell, J; Hamamura, D; Heard, KJ; Monte, AA; Vasiliou, V; Weinshilboum, RM, 2014) |
| "All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study." | 1.39 | Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013) |
| "Whereas nausea and emesis are burdensome side effects that lead to poor treatment compliance especially in chemotherapy, it is difficult to predict the emetic potential of agents in rats and mice because rodents do not vomit." | 1.38 | Enhanced gastric retention of solid resin beads as a marker for emetic potential of agents in rats. ( Ando, K; Takagi, K; Tsubone, H, 2012) |
| "Palonosetron was always administered as a single-day therapy while one- or multi-day ondansetron therapy was administered in 27% and 73% of cycles, respectively." | 1.37 | Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. ( Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC, 2011) |
| "A generalized tonic-clonic seizure occurred in each patient--12, 15, and 22 min after injection." | 1.35 | Ondansetron and seizures. ( Acharya, JN; Rai, A; Selhorst, JB; Singh, NN, 2009) |
| "Women with breast cancer without previous chemotherapy were eligible for this prospective study." | 1.35 | Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. ( Bani, MR; Beckmann, MW; Engel, J; Fasching, PA; Kollmannsberger, B; Kreis, H; Lausen, B; Lux, MP; Niesler, B; Strick, R; Strissel, PL; Weihbrecht, S, 2008) |
| "Morphine alone was associated with a significant increase in plasma AVP concentrations from baseline at 45, 60, and 90 min (P < 0." | 1.33 | Pretreatment with ondansetron blunts plasma vasopressin increases associated with morphine administration in ferrets. ( Wilkens, EP; Yates, BJ, 2005) |
| "Six children developed severe daily migraine-type headaches during cancer treatment." | 1.31 | Migraine-type headaches in children receiving chemotherapy and ondansetron. ( Khan, RB, 2002) |
| "To introduce a computerized data collection system used for an outcomes-based approach to antiemetic therapy in children, and to present data collected with this system in support of a new antiemetic dosing regimen." | 1.31 | Computerized system for outcomes-based antiemetic therapy in children. ( Adams, VR; Holdsworth, MT; Raisch, DW; Winter, SS; Wood, JG, 2000) |
| "Flushing was not affected." | 1.30 | Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. ( de Vries, EG; Kema, IP; Kleibeuker, JH; Leijsma, MK; Wymenga, AN, 1998) |
| " After a 4- to 5-day recovery, piglets were hydrated, then dosed with cisplatin (5." | 1.29 | The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. ( Blower, P; Grélot, L; Milano, S; Romain, D, 1995) |
| "It is the purpose of this article to discuss ondansetron hydrochloride (Zofran Glaxo, Research Triangle Park, NJ) and its mechanisms of action, indications for use, dosage and administration, side effects, and nursing implications." | 1.29 | Practical points in the use of ondansetron. ( Litwack, K, 1994) |
| " The dosage protocols with which it has usually been employed establish an i." | 1.29 | Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer. ( Cagnazzo, G; Marinaccio, M; Miniello, G; Pinto, V, 1993) |
| "Ondansetron was administered as follows: 8 mg intravenously before the start of chemotherapy, followed by 8 mg orally three times daily for 10 days." | 1.29 | Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. ( Braken, JB; de Pauw, BE; Koopmans, PP; Raemaekers, JM, 1993) |
| " Criteria for dosage and administration were met by 76% of the inpatient orders and 83% of the outpatient orders." | 1.29 | Ondansetron use in a major university teaching hospital. ( Chapman, SM; Pruemer, JM, 1993) |
| "The treatment of cancer patients has improved over the few past years." | 1.29 | [Future trends in chemotherapy and impact on the management of emesis]. ( Catimel, G; Droz, JP, 1995) |
| " Thus, controlling the adverse side effects associated with radiation therapy is critical to optimal patient care." | 1.29 | Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. ( Priestman, TJ, 1996) |
| "and metoclopramide 0." | 1.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Ondansetron is a cost effective and safe antiemetic in children receiving chemotherapy and total body irradiation, minimises weight loss on treatment and enables outpatient chemotherapy in some cases." | 1.28 | Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. ( Abbott, GD; Robinson, BA; Sullivan, MJ, 1992) |
| "During late 1991, a series of severe adverse events involving thrombocytopenia, renal insufficiency and thrombotic episodes was observed in patients receiving emetogenic chemotherapy." | 1.28 | Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. ( Childs, A; Coates, AS; Cox, K; Forsyth, C; Grygiel, JJ; Joshua, DE; McNeil, E, 1992) |
| "Ondansetron was also given to 16 patients receiving cisplatin chemotherapy." | 1.28 | Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. ( Allan, SG; Dickson, D; Evans, BD; Forgeson, GV; Harvey, VJ; Humm, G; Langley, G; Mak, D; Mitchell, PL; Neave, L, 1992) |
| "Ondansetron is a highly effective non-sedative antiemetic that justifies further assessment in combination with other antiemetics in patients receiving cytotoxic drugs associated with the production of severe nausea and vomiting." | 1.28 | Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan. ( Butcher, ME; Gore, ME; McElwain, TJ; Selby, PJ; Viner, CV; Wootton, CM; Zulian, GB, 1990) |
| "Ondansetron was well tolerated, with no significant drug-related adverse events." | 1.28 | [Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs]. ( Sampi, K; Taguchi, T, 1990) |
| "A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/m2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting." | 1.28 | GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Bons, J; Brion, N; Droz, JP; Marty, M; Paule, B; Pouillart, P, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (0.90) | 18.7374 |
| 1990's | 457 (58.66) | 18.2507 |
| 2000's | 126 (16.17) | 29.6817 |
| 2010's | 147 (18.87) | 24.3611 |
| 2020's | 42 (5.39) | 2.80 |
| Authors | Studies |
|---|---|
| Edwards, A | 1 |
| Teusink-Cross, A | 1 |
| Martin, LJ | 1 |
| Prows, CA | 1 |
| Mehta, PA | 1 |
| Ramsey, LB | 1 |
| Coulm, B | 1 |
| Robson, S | 1 |
| McParlin, C | 2 |
| Mossop, H | 1 |
| Lie, M | 1 |
| Fernandez-Garcia, C | 1 |
| Howel, D | 1 |
| Graham, R | 1 |
| Ternent, L | 1 |
| Steel, A | 1 |
| Goudie, N | 1 |
| Nadeem, A | 1 |
| Phillipson, J | 1 |
| Shehmar, M | 1 |
| Simpson, N | 1 |
| Tuffnell, D | 1 |
| Campbell, I | 1 |
| Williams, R | 1 |
| O'Hara, ME | 1 |
| McColl, E | 1 |
| Nelson-Piercy, C | 2 |
| Kamiya, T | 1 |
| Sakurai, M | 1 |
| Kikuchi, T | 1 |
| Okayama, M | 1 |
| Mizuno, K | 1 |
| Tanigawa, T | 1 |
| Koda, Y | 1 |
| Kato, J | 1 |
| Mori, T | 1 |
| Burke, JE | 1 |
| Hess, RS | 1 |
| Silverstein, DC | 1 |
| Jacobs, SS | 1 |
| Dome, JS | 1 |
| Gai, J | 1 |
| Gross, AM | 1 |
| Postell, E | 1 |
| Hinds, PS | 1 |
| Davenport, L | 1 |
| van den Anker, JN | 1 |
| Mowbray, C | 1 |
| Moothedath, AW | 1 |
| Meena, JP | 1 |
| Gupta, AK | 1 |
| Velpandian, T | 1 |
| Pandey, RM | 1 |
| Seth, R | 1 |
| Drögemöller, BI | 1 |
| Wright, GEB | 1 |
| Trueman, J | 1 |
| Shaw, K | 1 |
| Staub, M | 1 |
| Chaudhry, S | 1 |
| Miao, F | 1 |
| Higginson, M | 1 |
| Groeneweg, GSS | 1 |
| Brown, J | 1 |
| Magee, LA | 1 |
| Whyte, SD | 1 |
| West, N | 1 |
| Brodie, SM | 1 |
| Jong, G' | 1 |
| Israels, S | 1 |
| Berger, H | 1 |
| Ito, S | 1 |
| Rassekh, SR | 1 |
| Sanatani, S | 1 |
| Ross, CJD | 1 |
| Carleton, BC | 1 |
| Sun, S | 1 |
| Ko, YH | 2 |
| Jin, JY | 1 |
| Woo, IS | 1 |
| Park, SY | 1 |
| Eom, YA | 1 |
| Kang, JH | 2 |
| Kim, HK | 1 |
| Slattery, J | 1 |
| Quinten, C | 1 |
| Candore, G | 1 |
| Pinheiro, L | 1 |
| Flynn, R | 1 |
| Kurz, X | 1 |
| Nordeng, H | 1 |
| Ozciftci, S | 1 |
| Sahiner, Y | 1 |
| Sahiner, IT | 1 |
| Akkaya, T | 1 |
| Henze, L | 1 |
| Foth, S | 2 |
| Meller, S | 2 |
| Twele, F | 1 |
| Charalambous, M | 1 |
| Kenward, H | 2 |
| Elliott, J | 2 |
| Pelligand, L | 2 |
| Volk, HA | 2 |
| Na, S | 1 |
| Jung, DE | 1 |
| Hwang, E | 1 |
| Kim, T | 1 |
| Benbow, T | 1 |
| Teja, F | 1 |
| Sheikhi, A | 1 |
| Exposto, FG | 1 |
| Svensson, P | 1 |
| Cairns, BE | 1 |
| Saif, S | 1 |
| Kakalia, S | 1 |
| Kitchlew, R | 1 |
| Khan, HA | 1 |
| Fida, S | 1 |
| Siddique, M | 1 |
| Reis, ACC | 1 |
| Jorge, BC | 1 |
| da Silva Moreira, S | 1 |
| Stein, J | 1 |
| Perdão, CB | 1 |
| de Matos Manoel, B | 1 |
| Arena, AC | 1 |
| Philpott, L | 1 |
| Clemensen, E | 1 |
| Lau, GT | 1 |
| Sane, S | 1 |
| Nasiri, AA | 1 |
| Bahrami, A | 1 |
| Kamalov, Z | 1 |
| Hamoud Alshahrani, S | 1 |
| Sajid Abdulabbas, H | 1 |
| Darvishzadehdaledari, S | 1 |
| Golabi, P | 1 |
| Kazemi Haki, B | 1 |
| Masarwe, S | 1 |
| Shvartsur, R | 1 |
| Hadar, E | 1 |
| Betesh-Abay, B | 1 |
| Peleg, N | 1 |
| Azab, AN | 1 |
| Assaad, R | 1 |
| Pratt, RE | 1 |
| Wrotniak, BH | 1 |
| Qiao, H | 1 |
| Territo, HM | 1 |
| Lee, SY | 1 |
| Tamale, JR | 1 |
| Patel, MP | 2 |
| Woodring, S | 1 |
| Randazzo, DM | 1 |
| Friedman, HS | 1 |
| Desjardins, A | 1 |
| Healy, P | 1 |
| Herndon, JE | 2 |
| McSherry, F | 1 |
| Lipp, ES | 1 |
| Miller, E | 1 |
| Peters, KB | 1 |
| Affronti, ML | 2 |
| Tienchaiananda, P | 1 |
| Nipondhkit, W | 1 |
| Maneenil, K | 1 |
| Sa-Nguansai, S | 1 |
| Payapwattanawong, S | 1 |
| Laohavinij, S | 1 |
| Maneechavakajorn, J | 1 |
| Navari, RM | 5 |
| Huybrechts, KF | 2 |
| Hernandez-Diaz, S | 3 |
| Straub, L | 2 |
| Gray, KJ | 2 |
| Zhu, Y | 4 |
| Mogun, H | 2 |
| Bateman, BT | 2 |
| Willier, S | 1 |
| Cabanillas Stanchi, KM | 1 |
| von Have, M | 1 |
| Binder, V | 1 |
| Blaeschke, F | 1 |
| Feucht, J | 1 |
| Feuchtinger, T | 1 |
| Döring, M | 1 |
| Vimolchalao, V | 1 |
| Sakdejayont, S | 1 |
| Wongchanapai, P | 1 |
| Sukprakun, S | 1 |
| Angspatt, P | 1 |
| Thawinwisan, W | 1 |
| Chenaksara, P | 1 |
| Sriuranpong, V | 1 |
| Vinayanuwatikun, C | 1 |
| Parinyanitikun, N | 1 |
| Poovorawan, N | 1 |
| Tanasanvimon, S | 1 |
| Momper, JD | 1 |
| Heinrichs, MT | 1 |
| Krudys, K | 1 |
| Griebel, D | 1 |
| Kumar, S | 2 |
| Kim, I | 1 |
| Mehrotra, N | 1 |
| Mulberg, AE | 1 |
| Garimella, N | 1 |
| Nelson, R | 1 |
| Reaman, G | 1 |
| Sinha, V | 1 |
| Yao, L | 1 |
| Zineh, I | 1 |
| Burckart, G | 1 |
| Sachs, H | 1 |
| Mulugeta, Y | 1 |
| Yeo, W | 2 |
| Lau, TK | 1 |
| Li, L | 1 |
| Lai, KT | 1 |
| Pang, E | 1 |
| Cheung, M | 1 |
| Chan, VT | 1 |
| Wong, A | 1 |
| Soo, WM | 1 |
| Yeung, VT | 1 |
| Tse, T | 1 |
| Lam, DC | 1 |
| Yeung, EW | 1 |
| Ng, KP | 1 |
| Tang, NL | 1 |
| Tong, M | 1 |
| Suen, JJ | 2 |
| Mo, FK | 2 |
| Ithimakin, S | 3 |
| Theeratrakul, P | 1 |
| Laocharoenkiat, A | 1 |
| Nimmannit, A | 2 |
| Akewanlop, C | 3 |
| Soparattanapaisarn, N | 3 |
| Techawattanawanna, S | 1 |
| Korphaisarn, K | 2 |
| Danchaivijitr, P | 2 |
| Zikos, TA | 1 |
| Nguyen, L | 1 |
| Kamal, A | 1 |
| Fernandez-Becker, N | 1 |
| Regalia, K | 1 |
| Nandwani, M | 1 |
| Sonu, I | 1 |
| Garcia, M | 1 |
| Okafor, P | 1 |
| Neshatian, L | 1 |
| Grewal, D | 1 |
| Garcia, P | 1 |
| Triadafilopoulos, G | 1 |
| Clarke, JO | 1 |
| Armbruster, SD | 1 |
| Fellman, BM | 1 |
| Jhingran, A | 1 |
| Eifel, PJ | 1 |
| Klopp, AH | 1 |
| Coleman, RL | 1 |
| Ramondetta, LM | 1 |
| Frumovitz, M | 1 |
| Morio, K | 1 |
| Watanabe, J | 1 |
| Tsujimoto, Y | 1 |
| Ben-Yakov, M | 1 |
| Bhatt, M | 1 |
| Afzal, A | 1 |
| Khan, A | 2 |
| Farooqi, R | 1 |
| Khan, BT | 1 |
| Ara, I | 1 |
| Sakran, R | 1 |
| Shechtman, S | 2 |
| Arnon, J | 1 |
| Diav-Citrin, O | 2 |
| Damkier, P | 1 |
| Kaplan, YC | 1 |
| Cassina, M | 1 |
| Weber-Schoendorfer, C | 1 |
| Kamath, A | 1 |
| Rai, KM | 1 |
| Shreyas, R | 1 |
| Saxena, PUP | 1 |
| Banerjee, S | 2 |
| Ruktrirong, J | 1 |
| Traivaree, C | 1 |
| Monsereenusorn, C | 1 |
| Photia, A | 1 |
| Lertvivatpong, N | 1 |
| Rujkijyanont, P | 1 |
| Mukhopadhyay, S | 1 |
| Dutta, P | 1 |
| Bhattacharya, B | 1 |
| Biswas, S | 1 |
| M Navari, R | 1 |
| Goda, M | 1 |
| Kanda, M | 1 |
| Yoshioka, T | 1 |
| Yoshida, A | 1 |
| Murai, Y | 1 |
| Zamami, Y | 1 |
| Aizawa, F | 1 |
| Niimura, T | 1 |
| Hamano, H | 1 |
| Okada, N | 1 |
| Yagi, K | 2 |
| Chuma, M | 1 |
| Izawa-Ishizawa, Y | 1 |
| Ishizawa, K | 1 |
| De Puy, F | 1 |
| Kay, GN | 1 |
| Bernhardt, MB | 1 |
| Cerit, Z | 1 |
| Kovács, G | 2 |
| Wachtel, A | 1 |
| Basharova, E | 1 |
| Spinelli, T | 2 |
| Nicolas, P | 2 |
| Kabickova, E | 2 |
| Herrstedt, J | 10 |
| Summers, Y | 1 |
| Daugaard, G | 1 |
| Christensen, TB | 1 |
| Holmskov, K | 1 |
| Taylor, PD | 1 |
| Fox, GM | 1 |
| Molassiotis, A | 2 |
| Abdel-Malek, R | 1 |
| Abbas, N | 1 |
| Shohdy, KS | 1 |
| Ismail, M | 1 |
| Fawzy, R | 1 |
| Salem, DS | 1 |
| Safwat, E | 1 |
| Estan-Cerezo, G | 1 |
| Jiménez-Pulido, I | 1 |
| Rodríguez Lucena, FJ | 1 |
| Matoses Chirivella, C | 1 |
| Soriano-Irigaray, L | 1 |
| Navarro-Ruiz, A | 1 |
| Zhou, C | 2 |
| Bao, Z | 1 |
| Wang, X | 2 |
| Liu, Q | 1 |
| Tan, J | 1 |
| Wang, S | 1 |
| Liang, X | 1 |
| Li, CC | 1 |
| Zhang, J | 1 |
| Zhao, Z | 1 |
| Kong, XR | 1 |
| Deng, X | 1 |
| Peng, L | 1 |
| Yang, C | 1 |
| Canziani, BC | 1 |
| Uestuener, P | 1 |
| Fossali, EF | 1 |
| Lava, SAG | 1 |
| Bianchetti, MG | 1 |
| Agostoni, C | 1 |
| Milani, GP | 1 |
| Culver, MA | 1 |
| Richards, EC | 1 |
| Jarrell, DH | 1 |
| Edwards, CJ | 1 |
| Karabulut, B | 1 |
| Greene, S | 1 |
| Galdamez, LA | 1 |
| Tomasheski, R | 1 |
| April, MD | 1 |
| Oliver, JJ | 1 |
| Davis, WT | 1 |
| Ong, D | 1 |
| Simon, EM | 1 |
| Ng, PC | 1 |
| Hunter, CJ | 1 |
| Jain, S | 1 |
| Kapoor, G | 1 |
| Koneru, S | 1 |
| Vishwakarma, G | 1 |
| Rosenberg, K | 1 |
| Weinstein, C | 1 |
| Jordan, K | 3 |
| Green, SA | 1 |
| Camacho, E | 1 |
| Khanani, S | 1 |
| Beckford-Brathwaite, E | 1 |
| Pong, A | 2 |
| Noga, SJ | 1 |
| Rapoport, BL | 3 |
| Gravel, J | 1 |
| Boutis, K | 1 |
| Tang, K | 1 |
| Beauchamp, MH | 1 |
| Freedman, SB | 1 |
| Dubrovsky, AS | 1 |
| Gagnon, I | 1 |
| Momoli, F | 1 |
| Zemek, R | 1 |
| Kang, HJ | 1 |
| Loftus, S | 1 |
| DiCristina, C | 1 |
| Green, S | 1 |
| Zwaan, CM | 1 |
| Clemmons, AB | 1 |
| Orr, J | 1 |
| Andrick, B | 1 |
| Gandhi, A | 1 |
| Sportes, C | 1 |
| DeRemer, D | 1 |
| Steurer, J | 1 |
| LaPorte, J | 1 |
| Leone, K | 1 |
| Zhang, X | 1 |
| Holland, K | 1 |
| Morris, L | 1 |
| Bashey, A | 1 |
| Solh, M | 1 |
| Solomon, S | 1 |
| Lindblad, AJ | 1 |
| Ting, R | 1 |
| Harris, K | 1 |
| Wang, W | 1 |
| Lou, G | 1 |
| Zhang, Y | 2 |
| Carroll, C | 1 |
| Clinton, F | 1 |
| Smith, A | 1 |
| Fox, A | 1 |
| Capra, M | 1 |
| Pears, J | 1 |
| Owens, C | 1 |
| Osman, AAM | 1 |
| Elhassan, MMA | 1 |
| AbdElrahim, BHA | 1 |
| Ahmed, FHA | 1 |
| Yousif, JBH | 1 |
| Ahmed, MAM | 1 |
| Abdelhafeez, RHA | 1 |
| Ahmed, UMY | 1 |
| Meek, R | 3 |
| Mee, MJ | 2 |
| Egerton-Warburton, D | 3 |
| Graudins, A | 1 |
| Meyer, A | 1 |
| Pouryahya, P | 1 |
| Blecher, G | 1 |
| Fahey, J | 1 |
| Crow, S | 1 |
| Michopoulos, V | 1 |
| Maples-Keller, J | 1 |
| Roger, EI | 1 |
| Beaudoin, FL | 1 |
| Sumner, JA | 1 |
| Rothbaum, BO | 1 |
| Hudak, L | 1 |
| Gillespie, CF | 1 |
| Kronish, IM | 1 |
| McLean, SA | 1 |
| Ressler, KJ | 1 |
| Haas, DM | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Dalrymple, RA | 1 |
| Sampson, C | 1 |
| Dulal, S | 1 |
| Paudel, BD | 1 |
| Neupane, P | 1 |
| Shah, A | 1 |
| Acharya, B | 1 |
| Poudyal, BS | 1 |
| Shilpakar, R | 1 |
| Wood, LA | 1 |
| Chaudhary, NK | 1 |
| John, RR | 1 |
| Boddu, D | 1 |
| Mahasampath, G | 1 |
| Nesadeepam, N | 1 |
| Mathew, LG | 1 |
| McKenzie, E | 1 |
| Chan, D | 1 |
| Parsafar, S | 1 |
| Razvi, Y | 1 |
| McFarlane, T | 1 |
| Rico, V | 1 |
| Pasetka, M | 3 |
| DeAngelis, C | 4 |
| Chow, E | 4 |
| Bérard, A | 1 |
| Sheehy, O | 1 |
| Gorgui, J | 1 |
| Zhao, JP | 1 |
| Soares de Moura, C | 1 |
| Bernatsky, S | 1 |
| Rock, EM | 2 |
| Parker, LA | 7 |
| Doggrell, SA | 1 |
| Hancox, JC | 1 |
| Eisenberg, S | 1 |
| Wickline, M | 1 |
| Linenberger, M | 1 |
| Gooley, T | 1 |
| Holmberg, L | 1 |
| McLean, SL | 1 |
| Blenkinsopp, A | 1 |
| Bennett, MI | 1 |
| Habib, AS | 1 |
| George, RB | 1 |
| McKeen, DM | 1 |
| White, WD | 1 |
| Ituk, US | 1 |
| Megalla, SA | 1 |
| Allen, TK | 1 |
| Wenzell, CM | 1 |
| Berger, MJ | 1 |
| Blazer, MA | 1 |
| Crawford, BS | 1 |
| Griffith, NL | 1 |
| Wesolowski, R | 1 |
| Lustberg, MB | 1 |
| Phillips, GS | 1 |
| Ramaswamy, B | 1 |
| Mrozek, E | 1 |
| Flynn, JM | 1 |
| Shapiro, CL | 1 |
| Layman, RM | 1 |
| Choudhary, DR | 1 |
| Patel, VA | 1 |
| Chhalotiya, UK | 1 |
| Patel, HV | 1 |
| Kundawala, AJ | 1 |
| Kishi, T | 1 |
| Mukai, T | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Schwartzberg, L | 2 |
| Barbour, SY | 1 |
| Morrow, GR | 5 |
| Ballinari, G | 1 |
| Thorn, MD | 1 |
| Cox, D | 1 |
| Bateman, DN | 1 |
| Dear, JW | 1 |
| Thanacoody, HK | 1 |
| Thomas, SH | 1 |
| Eddleston, M | 1 |
| Sandilands, EA | 1 |
| Coyle, J | 1 |
| Cooper, JG | 1 |
| Rodriguez, A | 1 |
| Butcher, I | 1 |
| Lewis, SC | 1 |
| Vliegenthart, AD | 1 |
| Veiraiah, A | 1 |
| Webb, DJ | 1 |
| Gray, A | 1 |
| Billio, A | 2 |
| Morello, E | 2 |
| Clarke, MJ | 2 |
| Cotton, PJ | 1 |
| Noaman, SQ | 1 |
| Bodge, M | 1 |
| Shillingburg, A | 1 |
| Paul, S | 1 |
| Biondo, L | 1 |
| Wang, Q | 1 |
| Zhuo, L | 1 |
| Shen, MK | 1 |
| Yu, YY | 1 |
| Yu, JJ | 1 |
| Wang, M | 1 |
| Limebeer, CL | 4 |
| Navaratnam, R | 1 |
| Sticht, MA | 1 |
| Bonner, N | 1 |
| Engeland, K | 1 |
| Downey, R | 1 |
| Morris, H | 1 |
| Jackson, M | 1 |
| Ngampramuan, S | 1 |
| Cerri, M | 1 |
| Del Vecchio, F | 1 |
| Corrigan, JJ | 1 |
| Kamphee, A | 1 |
| Dragic, AS | 1 |
| Rudd, JA | 2 |
| Romanovsky, AA | 1 |
| Nalivaiko, E | 1 |
| Braitberg, G | 1 |
| He, H | 1 |
| Yin, JY | 1 |
| Xu, YJ | 1 |
| Li, X | 1 |
| Liu, ZG | 1 |
| Zhou, F | 1 |
| Zhai, M | 1 |
| Li, Y | 2 |
| Li, XP | 1 |
| Wang, Y | 2 |
| Zhou, HH | 1 |
| Liu, ZQ | 1 |
| Furyk, JS | 2 |
| McKenzie, S | 1 |
| Monte, AA | 1 |
| Heard, KJ | 1 |
| Campbell, J | 1 |
| Hamamura, D | 1 |
| Weinshilboum, RM | 1 |
| Vasiliou, V | 1 |
| Brygger, L | 1 |
| Oliveira, LG | 1 |
| Capp, SM | 1 |
| You, WB | 1 |
| Riffenburgh, RH | 1 |
| Carstairs, SD | 1 |
| Rithirangsriroj, K | 1 |
| Manchana, T | 1 |
| Akkayagorn, L | 1 |
| Gomollón, F | 1 |
| Rubio, S | 1 |
| Charro, M | 1 |
| García-López, S | 1 |
| Muñoz, F | 1 |
| Gisbert, JP | 1 |
| Domènech, E | 1 |
| Pitts, SR | 1 |
| Wang, L | 1 |
| Wang, H | 2 |
| Zhang, H | 2 |
| Badar, T | 1 |
| Cortes, J | 1 |
| Borthakur, G | 2 |
| O'Brien, S | 2 |
| Wierda, W | 1 |
| Garcia-Manero, G | 1 |
| Ferrajoli, A | 1 |
| Kadia, T | 1 |
| Poku, R | 1 |
| Kantarjian, H | 2 |
| Mattiuzzi, G | 1 |
| Rowbottom, L | 1 |
| McDonald, R | 1 |
| Hunyh, L | 1 |
| Raman, S | 1 |
| Bakhshi, S | 2 |
| Batra, A | 1 |
| Biswas, B | 1 |
| Dhawan, D | 1 |
| Paul, R | 1 |
| Sreenivas, V | 1 |
| Rapoport, B | 2 |
| Chua, D | 2 |
| Poma, A | 1 |
| Arora, S | 2 |
| Fein, LE | 1 |
| Jahn, F | 1 |
| Riesner, A | 1 |
| Jahn, P | 1 |
| Sieker, F | 1 |
| Vordermark, D | 1 |
| Kitamura, H | 1 |
| Takahashi, A | 1 |
| Hotta, H | 1 |
| Kato, R | 1 |
| Kunishima, Y | 1 |
| Takei, F | 1 |
| Horita, H | 1 |
| Masumori, N | 1 |
| Onifer, DJ | 1 |
| Butler, FK | 1 |
| Gross, K | 1 |
| Otten, EJ | 1 |
| Patton, R | 1 |
| Russell, RJ | 1 |
| Stockinger, Z | 1 |
| Burrell, E | 1 |
| Dranitsaris, G | 3 |
| Mazzarello, S | 2 |
| Smith, S | 2 |
| Vandermeer, L | 2 |
| Bouganim, N | 2 |
| Clemons, M | 2 |
| Meek, RA | 1 |
| Mills, JR | 1 |
| Greene, DN | 1 |
| Bainton, J | 1 |
| Lorey, TS | 1 |
| Baumann, NA | 1 |
| Kim, HJ | 2 |
| Shin, SW | 1 |
| Song, EK | 1 |
| Lee, NR | 1 |
| Kim, JS | 1 |
| Ahn, JS | 1 |
| Yun, HJ | 1 |
| Cho, YH | 1 |
| Park, KU | 1 |
| Kim, SY | 1 |
| Jang, JS | 2 |
| Kim, SW | 3 |
| Lee, HW | 1 |
| Lee, SR | 1 |
| Kim, YS | 1 |
| Lee, SN | 1 |
| Segal, R | 1 |
| Dent, S | 1 |
| Gertler, S | 1 |
| Song, X | 1 |
| Wheatley-Price, P | 1 |
| Okumura, LM | 2 |
| Wachtel, AE | 1 |
| Basharova, EV | 1 |
| Chiu, N | 1 |
| Chiu, L | 1 |
| Popovic, M | 1 |
| Lutz, S | 1 |
| Zhang, N | 1 |
| Marta, GN | 1 |
| Mendez, LC | 1 |
| Lechner, B | 1 |
| Pulenzas, N | 1 |
| Milakovic, M | 1 |
| Chow, R | 1 |
| Chasen, M | 1 |
| Powers, D | 1 |
| Navari, R | 6 |
| Schnadig, I | 1 |
| Schnadig, ID | 1 |
| Agajanian, R | 1 |
| Dakhil, C | 1 |
| Gabrail, NY | 1 |
| Smith, RE | 1 |
| Taylor, C | 1 |
| Wilks, ST | 1 |
| Schwartzberg, LS | 1 |
| Cooper, W | 1 |
| Mosier, MC | 1 |
| Payne, JY | 1 |
| Klepper, MJ | 1 |
| Vacirca, JL | 1 |
| Shi, Q | 1 |
| Li, W | 1 |
| Li, H | 1 |
| Le, Q | 1 |
| Liu, S | 1 |
| Zong, S | 1 |
| Zheng, L | 1 |
| Hou, F | 1 |
| Westerlund, A | 1 |
| Vicente, V | 1 |
| Hjelte Judell, O | 1 |
| Lindström, V | 1 |
| Simino, GP | 1 |
| Marra, LP | 1 |
| Andrade, EI | 1 |
| Acúrcio, Fde A | 1 |
| Reis, IA | 1 |
| De Araújo, VE | 1 |
| Cherchiglia, ML | 1 |
| Singer, AJ | 2 |
| Garra, G | 2 |
| Thode, HC | 2 |
| Suzuki, S | 1 |
| Karayama, M | 1 |
| Inui, N | 1 |
| Kuroishi, S | 1 |
| Fujisawa, T | 1 |
| Enomoto, N | 1 |
| Nakamura, Y | 1 |
| Yokomura, K | 1 |
| Toyoshima, M | 1 |
| Imokawa, S | 1 |
| Asada, K | 1 |
| Masuda, M | 1 |
| Yamada, T | 1 |
| Watanabe, H | 1 |
| Hayakawa, H | 2 |
| Suda, T | 1 |
| Du, Q | 1 |
| Zhai, Q | 1 |
| Zhu, B | 1 |
| Xu, XL | 1 |
| Yu, B | 1 |
| Wilbur, MB | 1 |
| Birrer, MJ | 1 |
| Spriggs, DR | 1 |
| Song, Z | 1 |
| Zhao, K | 1 |
| Zhang, M | 1 |
| Yang, F | 1 |
| El Khouly, NI | 1 |
| Meligy, AM | 1 |
| O'Donnell, A | 1 |
| Robson, SC | 1 |
| Beyer, F | 1 |
| Moloney, E | 1 |
| Bryant, A | 1 |
| Bradley, J | 1 |
| Muirhead, CR | 1 |
| Newbury-Birch, D | 1 |
| Norman, J | 1 |
| Shaw, C | 1 |
| Simpson, E | 1 |
| Swallow, B | 1 |
| Yates, L | 1 |
| Vale, L | 1 |
| Thamlikitkul, L | 1 |
| Srimuninnimit, V | 2 |
| Techawathanawanna, S | 1 |
| Chantharasamee, J | 1 |
| Mathew, SK | 1 |
| Kutty, KK | 1 |
| Ramya, I | 1 |
| Padmakumar, C | 1 |
| Pius, P | 1 |
| Nakagaki, M | 1 |
| Barras, M | 1 |
| Curley, C | 1 |
| Butler, JP | 1 |
| Kennedy, GA | 1 |
| Bourdon, F | 1 |
| Lecoeur, M | 1 |
| Leconte, L | 1 |
| Ultré, V | 1 |
| Kouach, M | 1 |
| Odou, P | 1 |
| Vaccher, C | 1 |
| Foulon, C | 1 |
| Kim, JE | 1 |
| Kim, JW | 1 |
| Sung, YL | 1 |
| Cho, CH | 1 |
| Lee, MA | 1 |
| Kim, DJ | 1 |
| Ahn, MJ | 2 |
| Lee, KY | 1 |
| Sym, SJ | 1 |
| Lim, MC | 1 |
| Jung, H | 1 |
| Cho, EK | 1 |
| Min, KW | 1 |
| D'Athayde Rodrigues, F | 1 |
| Ferreira, MAP | 1 |
| Moreira, LB | 1 |
| Ades, S | 1 |
| Halyard, M | 1 |
| Wilson, K | 3 |
| Ashikaga, T | 1 |
| Heimann, R | 1 |
| Blackstock, W | 1 |
| Bamber, D | 1 |
| Chohan, J | 1 |
| Troxell, R | 1 |
| Krobbuaban, B | 1 |
| Pitakpol, S | 1 |
| Diregpoke, S | 1 |
| Gore, L | 1 |
| Chawla, S | 2 |
| Petrilli, A | 1 |
| Hemenway, M | 1 |
| Schissel, D | 1 |
| Chua, V | 1 |
| Carides, AD | 8 |
| Taylor, A | 4 |
| Devandry, S | 2 |
| Valentine, J | 1 |
| Evans, JK | 4 |
| Oxenius, B | 1 |
| Kim, K | 1 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Tóth, J | 1 |
| Szántó, J | 1 |
| Litt, DE | 1 |
| Shapiro, R | 1 |
| Lajolo, PP | 2 |
| de Camargo, B | 1 |
| del Giglio, A | 4 |
| Johnson, B | 1 |
| Adams, L | 1 |
| Lu, E | 1 |
| Zhang, K | 1 |
| Lebowitz, P | 1 |
| Lates, C | 1 |
| Blum, R | 1 |
| Galy, G | 1 |
| Labidi, SI | 1 |
| Tissier, F | 1 |
| Combes, JD | 1 |
| Auger, A | 1 |
| Favier, B | 1 |
| Latour, JF | 1 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Du Bois, A | 2 |
| Singh, NN | 1 |
| Rai, A | 1 |
| Selhorst, JB | 1 |
| Acharya, JN | 1 |
| Roila, F | 9 |
| Rolski, J | 1 |
| Ramlau, R | 1 |
| Dediu, M | 1 |
| Russo, MW | 5 |
| Bandekar, RR | 2 |
| Grunberg, SM | 12 |
| Boice, JA | 2 |
| Brown, C | 1 |
| Hardwick, JS | 2 |
| Carides, A | 2 |
| Webb, T | 1 |
| Schmoll, HJ | 2 |
| Hershkovitz, D | 1 |
| Asna, N | 1 |
| Shupak, A | 1 |
| Kaminski, G | 1 |
| Bar, R | 1 |
| Tal, D | 1 |
| Ng, WL | 1 |
| Della-Fiorentina, SA | 1 |
| Mondick, JT | 1 |
| Johnson, BM | 1 |
| Haberer, LJ | 1 |
| Sale, ME | 1 |
| Adamson, PC | 1 |
| Coté, CJ | 1 |
| Croop, JM | 1 |
| Barrett, JS | 1 |
| Hoke, JF | 1 |
| Apornwirat, W | 1 |
| Shaharyar, A | 1 |
| Aziz, Z | 1 |
| Van Belle, S | 3 |
| Levin, J | 3 |
| Ranganathan, S | 1 |
| Guckert, M | 1 |
| Arpornwirat, W | 1 |
| Albert, I | 1 |
| Hansen, VL | 1 |
| Rzepecki, P | 2 |
| Pielichowski, W | 2 |
| Oborska, S | 2 |
| Barzal, J | 2 |
| Mlot, B | 2 |
| Gridelli, C | 2 |
| Haiderali, AM | 1 |
| Blackburn, LM | 1 |
| Lykopoulos, K | 1 |
| Patanwala, AE | 1 |
| Amini, R | 1 |
| Hays, DP | 1 |
| Rosen, P | 1 |
| Trepanier, L | 1 |
| Yeh, YC | 1 |
| McDonnell, A | 1 |
| Klinger, E | 1 |
| Fowler, B | 1 |
| Matta, L | 1 |
| Voit, D | 1 |
| Reddy, P | 1 |
| Warr, DG | 4 |
| Street, JC | 2 |
| Lee, JS | 3 |
| Costantino, M | 1 |
| McCullough, MF | 1 |
| Lee, JB | 1 |
| Jones, MM | 1 |
| Carter, EA | 1 |
| Spies, JB | 1 |
| Brearley, SG | 1 |
| Stamataki, Z | 1 |
| Dong, X | 1 |
| Huang, J | 2 |
| Cao, R | 1 |
| Liu, L | 1 |
| Hesketh, PJ | 13 |
| Barrett, TW | 1 |
| DiPersio, DM | 1 |
| Jenkins, CA | 1 |
| Jack, M | 1 |
| McCoin, NS | 1 |
| Storrow, AB | 1 |
| Singleton, LM | 1 |
| Lee, P | 1 |
| Slovis, CM | 1 |
| Pillai, AK | 1 |
| Sharma, KK | 1 |
| Gupta, YK | 1 |
| Demir, HA | 1 |
| Batu, ED | 1 |
| Yalçın, B | 1 |
| Civelek, E | 1 |
| Saçkesen, C | 1 |
| Büyükpamukçu, M | 1 |
| Hunt, CM | 1 |
| Papay, JI | 1 |
| Rich, DS | 1 |
| Abissi, CJ | 1 |
| Kaushal, J | 1 |
| Gupta, MC | 1 |
| Kaushal, V | 1 |
| Bhutani, G | 1 |
| Dhankar, R | 1 |
| Atri, R | 1 |
| Verma, S | 3 |
| Mattiuzzi, GN | 1 |
| Cortes, JE | 1 |
| Blamble, DA | 1 |
| Bekele, BN | 1 |
| Xiao, L | 1 |
| Cabanillas, M | 1 |
| Grunberg, S | 1 |
| Maru, A | 1 |
| Dinis, J | 1 |
| Beckford, E | 1 |
| Cruz, FM | 1 |
| de Iracema Gomes Cubero, D | 1 |
| Taranto, P | 1 |
| Lerner, T | 1 |
| Lera, AT | 1 |
| da Costa Miranda, M | 1 |
| da Cunha Vieira, M | 1 |
| de Souza Fêde, AB | 1 |
| Schindler, F | 1 |
| Carrasco, MM | 1 |
| de Afonseca, SO | 1 |
| Pinczowski, H | 1 |
| Runglodvatana, K | 1 |
| Keerativitayanan, N | 1 |
| Laocharoenkeat, A | 1 |
| Benner, JP | 1 |
| Ferguson, JD | 1 |
| Judkins, AE | 1 |
| O'Connor, RE | 1 |
| Brady, WJ | 1 |
| Klauser, CK | 1 |
| Fox, NS | 1 |
| Istwan, N | 1 |
| Rhea, D | 1 |
| Rebarber, A | 1 |
| Desch, C | 1 |
| Palmer, B | 1 |
| Saltzman, D | 1 |
| Kempinska, A | 1 |
| Benchimol, EI | 1 |
| Mack, A | 1 |
| Barkey, J | 1 |
| Boland, M | 1 |
| Mack, DR | 1 |
| Ebrahim Soltani, AR | 1 |
| Mohammadinasab, H | 1 |
| Goudarzi, M | 1 |
| Arbabi, S | 1 |
| Mohammadinasab, A | 1 |
| Mohammadinasab, F | 1 |
| Samimi, M | 1 |
| Feinberg, B | 1 |
| Gilmore, J | 1 |
| Haislip, S | 1 |
| Jackson, J | 1 |
| Jain, G | 1 |
| Balu, S | 1 |
| Buchner, D | 1 |
| Wright, O | 1 |
| Rosati, G | 1 |
| Russo, M | 1 |
| Lane, S | 1 |
| Moiseyenko, V | 1 |
| Dube, P | 1 |
| Kopp, M | 1 |
| Makhson, A | 1 |
| Perwitasari, DA | 1 |
| Wessels, JA | 1 |
| van der Straaten, RJ | 1 |
| Baak-Pablo, RF | 1 |
| Mustofa, M | 1 |
| Hakimi, M | 1 |
| Nortier, JW | 1 |
| Gelderblom, H | 2 |
| Guchelaar, HJ | 1 |
| Almeida, JF | 1 |
| Ferreira, P | 1 |
| Lopes, A | 1 |
| Gil, MH | 1 |
| Dennis, K | 1 |
| Nguyen, J | 1 |
| Presutti, R | 1 |
| Tsao, M | 1 |
| Danjoux, C | 1 |
| Barnes, E | 1 |
| Sahgal, A | 1 |
| Holden, L | 1 |
| Jon, F | 1 |
| Wong, S | 1 |
| Hayashi, T | 1 |
| Ikesue, H | 1 |
| Esaki, T | 1 |
| Fukazawa, M | 1 |
| Abe, M | 1 |
| Ohno, S | 1 |
| Tomizawa, T | 1 |
| Oishi, R | 1 |
| Gawronski, K | 1 |
| Wasko-Grabowska, A | 1 |
| Tuerke, KJ | 2 |
| Winters, BD | 1 |
| Siddique, R | 1 |
| Hafiz, MG | 1 |
| Rokeya, B | 1 |
| Jamal, CY | 1 |
| Islam, A | 1 |
| Anderka, M | 1 |
| Mitchell, AA | 1 |
| Louik, C | 1 |
| Werler, MM | 1 |
| Rasmussen, SA | 1 |
| Gupta, V | 1 |
| Bala, M | 1 |
| Prasad, J | 1 |
| Singh, S | 1 |
| Gupta, M | 1 |
| Reichmann, JP | 1 |
| Kirkbride, MS | 1 |
| Ando, K | 1 |
| Takagi, K | 1 |
| Tsubone, H | 1 |
| Al Abood, RM | 1 |
| Talegaonkar, S | 1 |
| Tariq, M | 1 |
| Ahmad, FJ | 1 |
| Blazer, M | 1 |
| Phillips, G | 1 |
| Reardon, J | 1 |
| Efries, D | 1 |
| Smith, Y | 1 |
| Weatherby, L | 1 |
| Juergens, K | 1 |
| Rose, J | 1 |
| Griffith, N | 1 |
| Bekaii-Saab, T | 1 |
| Cooper, D | 1 |
| Selvan, D | 1 |
| Jagannathan, V | 1 |
| Sturm, JJ | 1 |
| Simon, HK | 1 |
| Khan, NS | 1 |
| Hirsh, DA | 1 |
| Fletcher, PJ | 1 |
| Zhang, D | 1 |
| Mita, M | 1 |
| Shapiro, GI | 1 |
| Poon, J | 1 |
| Small, K | 1 |
| Tzontcheva, A | 1 |
| Kantesaria, B | 1 |
| Bannerji, R | 1 |
| Statkevich, P | 1 |
| Koren, G | 2 |
| Gomez, DR | 1 |
| Liao, KP | 1 |
| Giordano, S | 1 |
| Nguyen, H | 1 |
| Smith, BD | 1 |
| Elting, LS | 2 |
| Oddby-Muhrbeck, E | 1 |
| Öbrink, E | 1 |
| Eksborg, S | 1 |
| Rotstein, S | 1 |
| Lönnqvist, PA | 1 |
| Markman, M | 4 |
| Wang, C | 1 |
| Xu, N | 1 |
| Xiong, LZ | 1 |
| Liu, HF | 1 |
| Yang, XY | 1 |
| Lu, ZH | 1 |
| Sheng, PT | 1 |
| Wang, LY | 1 |
| Zhang, P | 2 |
| Feng, F | 1 |
| He, Y | 1 |
| Zhou, M | 1 |
| Cheng, G | 1 |
| Chen, Y | 1 |
| Liaw, CC | 3 |
| Chang, HK | 3 |
| Liau, CT | 2 |
| Huang, JS | 3 |
| Lin, YC | 2 |
| Chen, JS | 1 |
| Khan, RB | 1 |
| Chawla, SP | 3 |
| Gralla, RJ | 8 |
| Rittenberg, C | 1 |
| Elmer, ME | 2 |
| Schmidt, C | 2 |
| Horgan, KJ | 4 |
| Caron, E | 1 |
| Bussières, JF | 1 |
| Lebel, D | 1 |
| Mathews, S | 1 |
| Milot, J | 1 |
| Jacob, JL | 1 |
| Moride, Y | 1 |
| Lortie, L | 1 |
| Josefson, A | 1 |
| Kreuter, M | 1 |
| Martin, AR | 1 |
| Pearson, JD | 1 |
| Horgan, K | 1 |
| Elmer, M | 1 |
| Cai, B | 1 |
| Quinla, JD | 1 |
| Hill, DA | 1 |
| Xie, XD | 1 |
| Zheng, ZD | 1 |
| Liu, DW | 1 |
| Liu, YY | 1 |
| Shan, XJ | 1 |
| Tan, M | 1 |
| Gralla, R | 2 |
| Lichinitser, M | 1 |
| Van Der Vegt, S | 1 |
| Sleeboom, H | 1 |
| Mezger, J | 1 |
| Peschel, C | 1 |
| Tonini, G | 1 |
| Labianca, R | 1 |
| Macciocchi, A | 2 |
| Aapro, M | 3 |
| de Wit, R | 3 |
| Ianus, J | 2 |
| Beck, K | 1 |
| Reines, S | 1 |
| Gershanovich, ML | 2 |
| Beresneva, IA | 1 |
| Makhnova, EV | 1 |
| Dempsey, CL | 2 |
| Coop, AJ | 1 |
| Shillington, A | 1 |
| Farley, PA | 2 |
| Eberhardt, DR | 1 |
| O'Briant, S | 1 |
| Einarson, A | 1 |
| Maltepe, C | 1 |
| Navioz, Y | 1 |
| Kennedy, D | 1 |
| Tan, MP | 1 |
| Goldsmith, B | 1 |
| Walsh, T | 1 |
| Morris, AK | 1 |
| Holle, LM | 1 |
| Callander, N | 1 |
| Bradshaw, P | 1 |
| Valley, AW | 1 |
| Clark, G | 1 |
| Freytes, CO | 1 |
| Axelsson, P | 1 |
| Thörn, SE | 1 |
| Wattwil, M | 1 |
| Dua, N | 1 |
| Bhatnagar, S | 1 |
| Mishra, S | 1 |
| Singhal, AK | 1 |
| Buyukavci, M | 1 |
| Olgun, H | 1 |
| Ceviz, N | 1 |
| Muss, HB | 1 |
| Eisenberg, PD | 1 |
| Raftopoulos, H | 1 |
| Gabriel, M | 1 |
| Rodgers, A | 1 |
| Bohidar, N | 1 |
| Klinger, G | 1 |
| Hustad, CM | 1 |
| Skobieranda, F | 1 |
| Lindley, C | 1 |
| Goodin, S | 1 |
| McCune, J | 1 |
| Kane, M | 1 |
| Amamoo, MA | 1 |
| Shord, S | 1 |
| Pham, T | 1 |
| Yowell, S | 1 |
| Laliberte, K | 1 |
| Schell, M | 1 |
| Bernard, S | 2 |
| Socinski, MA | 1 |
| Guoguang-Ma, J | 1 |
| Kontrimaviciute, E | 1 |
| Baublys, A | 1 |
| Ivaskevicius, J | 1 |
| Nathan, PC | 1 |
| Tomlinson, G | 1 |
| Dupuis, LL | 1 |
| Greenberg, ML | 1 |
| Ota, S | 1 |
| Bartels, U | 1 |
| Feldman, BM | 1 |
| Rubenstein, EB | 2 |
| Wilkens, EP | 1 |
| Yates, BJ | 1 |
| Kwiatkowska, M | 1 |
| Mechoulam, R | 1 |
| Bloch, J | 1 |
| Rixe, O | 1 |
| Meric, JB | 1 |
| Delgado, A | 2 |
| Khayat, D | 3 |
| Rabaeus, M | 1 |
| Pinarli, FG | 1 |
| Elli, M | 1 |
| Dagdemir, A | 1 |
| Baysal, K | 1 |
| Acar, S | 1 |
| Babaoglu, MO | 1 |
| Bayar, B | 1 |
| Aynacioglu, AS | 1 |
| Kerb, R | 1 |
| Abali, H | 1 |
| Celik, I | 1 |
| Bozkurt, A | 1 |
| Moser, JD | 1 |
| Caldwell, JB | 1 |
| Rhule, FJ | 1 |
| Khamales, S | 1 |
| Bethune-Volters, A | 1 |
| Chidiac, J | 1 |
| Bensaoula, O | 1 |
| Di Palma, M | 1 |
| Hall, G | 1 |
| Leksowski, K | 1 |
| Peryga, P | 1 |
| Szyca, R | 1 |
| Aapro, MS | 6 |
| Manikhas, GM | 1 |
| Olivares, G | 1 |
| Suarez, T | 1 |
| Tjulandin, SA | 1 |
| Bertoli, LF | 1 |
| Yunus, F | 1 |
| Morrica, B | 1 |
| Lordick, F | 2 |
| Wong, RK | 1 |
| Paul, N | 1 |
| Ding, K | 1 |
| Whitehead, M | 1 |
| Brundage, M | 1 |
| Fyles, A | 1 |
| Wilke, D | 1 |
| Nabid, A | 1 |
| Fortin, A | 1 |
| Wilson, D | 1 |
| McKenzie, M | 1 |
| Ackerman, I | 1 |
| Souhami, L | 2 |
| Chabot, P | 1 |
| Pater, J | 2 |
| Hamadani, M | 2 |
| Awab, A | 1 |
| Chaudhary, L | 2 |
| Tfayli, A | 2 |
| Ehlken, B | 1 |
| Ihbe-Heffinger, A | 1 |
| Berger, K | 1 |
| Krobot, KJ | 1 |
| Pellissier, J | 1 |
| Davies, G | 1 |
| Deuson, R | 1 |
| Malik, NM | 1 |
| Liu, YL | 1 |
| Cole, N | 1 |
| Sanger, GJ | 1 |
| Andrews, PL | 1 |
| Shi, Y | 1 |
| He, X | 1 |
| Yang, S | 1 |
| Ai, B | 1 |
| Zhang, C | 1 |
| Huang, D | 1 |
| Dong, M | 1 |
| Liu, P | 1 |
| Zhou, S | 1 |
| Han, X | 1 |
| McNulty, R | 1 |
| Cotton, JW | 1 |
| Rowell, LR | 1 |
| Hood, RR | 1 |
| Pellegrini, JE | 2 |
| Forrester, CM | 1 |
| Benfield, DA | 1 |
| Matern, CE | 1 |
| Kelly, JA | 1 |
| Guigui, N | 1 |
| Luyt, CE | 1 |
| Vincent, F | 1 |
| Takenaka, M | 1 |
| Okamoto, Y | 1 |
| Ikeda, K | 2 |
| Hashimoto, R | 1 |
| Ueda, T | 1 |
| Kurokawa, N | 1 |
| Takagi, T | 1 |
| Uejima, E | 1 |
| Meiri, E | 1 |
| Jhangiani, H | 1 |
| Vredenburgh, JJ | 1 |
| Barbato, LM | 1 |
| Carter, FJ | 1 |
| Yang, HM | 1 |
| Baranowski, V | 1 |
| Hernández García, D | 1 |
| Lara Vila, I | 1 |
| Caba Barrientos, F | 1 |
| Ramos Curado, P | 1 |
| Núñez García, A | 1 |
| Echevarría Moreno, M | 1 |
| Kast, RE | 1 |
| Foley, KF | 1 |
| Pradermdee, P | 1 |
| Manusirivithaya, S | 1 |
| Tangjitgamol, S | 1 |
| Thavaramara, T | 1 |
| Sukwattana, P | 1 |
| Wilkes, G | 1 |
| Awan, FT | 1 |
| Khan, JK | 1 |
| Kojouri, K | 1 |
| Ozer, H | 1 |
| Hasler, SB | 1 |
| Hirt, A | 1 |
| Ridolfi Luethy, A | 1 |
| Leibundgut, KK | 1 |
| Ammann, RA | 1 |
| Dizdar, V | 1 |
| Gilja, OH | 1 |
| Hausken, T | 1 |
| Vrabel, M | 1 |
| Turner, SR | 1 |
| Pinsk, M | 1 |
| Rizzo, R | 1 |
| Marino, S | 1 |
| Gulisano, M | 1 |
| Robertson, MM | 1 |
| Shelke, AR | 1 |
| Roscoe, JA | 2 |
| Colman, LK | 1 |
| Banerjee, TK | 1 |
| Kirshner, JJ | 1 |
| Braude, D | 1 |
| Crandall, C | 1 |
| Ho, WM | 1 |
| Chan, SL | 1 |
| Lau, W | 1 |
| Koh, J | 1 |
| Yeung, WK | 1 |
| Kwan, WH | 1 |
| Lee, KK | 1 |
| Mok, TS | 1 |
| Poon, AN | 1 |
| Lam, KC | 1 |
| Hui, EK | 1 |
| Zee, B | 4 |
| Fasching, PA | 1 |
| Kollmannsberger, B | 1 |
| Strissel, PL | 1 |
| Niesler, B | 1 |
| Engel, J | 1 |
| Kreis, H | 1 |
| Lux, MP | 1 |
| Weihbrecht, S | 1 |
| Lausen, B | 1 |
| Bani, MR | 1 |
| Beckmann, MW | 1 |
| Strick, R | 1 |
| Campbell, RC | 2 |
| Rodrigo, MR | 2 |
| Davis, PJ | 1 |
| McGowan, FX | 1 |
| Landsman, I | 1 |
| Maloney, K | 1 |
| Hoffmann, P | 1 |
| Campora, E | 3 |
| Chiara, S | 1 |
| Aschele, C | 1 |
| Dick, GS | 1 |
| Meller, ST | 2 |
| Pinkerton, CR | 2 |
| Cole, RM | 1 |
| Robinson, F | 1 |
| Harvey, L | 1 |
| Trethowan, K | 1 |
| Murdoch, V | 1 |
| Parasuraman, TV | 4 |
| Osterhaus, JT | 1 |
| Aspinall, RL | 1 |
| Goodman, NW | 1 |
| Agura, ED | 1 |
| Brown, MC | 1 |
| Schaffer, R | 1 |
| Donaldson, G | 1 |
| Shen, DD | 1 |
| Desilva, PH | 1 |
| Darvish, AH | 1 |
| McDonald, SM | 1 |
| Cronin, MK | 1 |
| Clark, K | 1 |
| Walton, SC | 1 |
| Koenig, TJ | 1 |
| Chow, J | 2 |
| Tong, CK | 1 |
| Hui, E | 1 |
| Lueveswanij, S | 1 |
| Beck, T | 1 |
| Uhlenhopp, M | 1 |
| Kris, MG | 6 |
| Hainsworth, JD | 3 |
| Harker, WG | 1 |
| Cohen, JR | 1 |
| Lester, E | 2 |
| Kessler, JF | 1 |
| Griffen, D | 1 |
| Milano, S | 1 |
| Blower, P | 1 |
| Romain, D | 1 |
| Grélot, L | 1 |
| Framarino dei Malatesta, M | 1 |
| Veneziano, M | 1 |
| Fiorelli, C | 1 |
| Bandiera, AF | 1 |
| Yacoub, M | 1 |
| Toccaceli Blasi, MR | 1 |
| Marzetti, L | 1 |
| Esseboom, EU | 1 |
| Rojer, RA | 1 |
| Borm, JJ | 1 |
| Statius van Eps, LW | 1 |
| Grond, S | 1 |
| Lynch, J | 1 |
| Diefenbach, C | 1 |
| Altrock, K | 1 |
| Lehmann, KA | 1 |
| Noble, A | 1 |
| Bremer, K | 1 |
| Goedhals, L | 3 |
| Cupissol, D | 1 |
| Dilly, SG | 1 |
| Warr, D | 3 |
| Puodziunas, A | 1 |
| Huang, X | 1 |
| Guo, N | 1 |
| Fan, Y | 1 |
| Zhou, J | 3 |
| Zeng, W | 1 |
| Madajewicz, S | 2 |
| Anderson, N | 1 |
| Tchekmedyian, NS | 2 |
| Whaley, W | 1 |
| Garewal, H | 1 |
| Beck, TM | 5 |
| Chang, AY | 1 |
| Greenberg, B | 1 |
| Caldwell, KC | 1 |
| Markham, A | 2 |
| Sorkin, EM | 1 |
| Matera, MG | 1 |
| Di Tullio, M | 1 |
| Lucarelli, C | 1 |
| Casale, F | 1 |
| Calabria, C | 1 |
| Lampa, E | 1 |
| Indolfi, P | 1 |
| Rossi, F | 1 |
| Lee, CW | 1 |
| Suh, CW | 1 |
| Lee, KH | 2 |
| Cho, GY | 1 |
| Kim, SH | 2 |
| Lévy, E | 1 |
| Paillarse, JM | 3 |
| Votan, B | 4 |
| Gin, T | 3 |
| Holdsworth, MT | 3 |
| Raisch, DW | 3 |
| Duncan, MH | 1 |
| Chavez, CM | 2 |
| Leasure, MM | 1 |
| Gelman, S | 1 |
| Khalil, S | 2 |
| Tsavaris, N | 4 |
| Charalambidis, G | 2 |
| Ganas, N | 1 |
| Pagou, M | 2 |
| Karabellis, A | 1 |
| Mylonakis, N | 3 |
| Benou, N | 1 |
| Tsikalakis, D | 1 |
| Kosmidis, P | 3 |
| Andrews, PA | 1 |
| Quan, V | 1 |
| Ogg, CS | 1 |
| Gandara, D | 3 |
| Hesketh, P | 4 |
| Hall, S | 1 |
| Mailliard, J | 1 |
| Ritter, H | 1 |
| Friedman, C | 3 |
| Fitts, D | 1 |
| Hebbar, M | 1 |
| Hecquet, B | 3 |
| Vanlemmens, L | 1 |
| Lecomte, S | 1 |
| Pion, JM | 2 |
| Adenis, A | 2 |
| Bonneterre, J | 7 |
| Marty, M | 5 |
| Kleisbauer, JP | 1 |
| Fournel, P | 1 |
| Vergnenegre, A | 1 |
| Carles, P | 1 |
| Loria-Kanza, Y | 1 |
| Simonetta, C | 1 |
| de Bruijn, KM | 1 |
| Alvarez, O | 1 |
| Freeman, A | 2 |
| Bedros, A | 1 |
| Call, SK | 1 |
| Volsch, J | 1 |
| Kalbermatter, O | 1 |
| Halverson, J | 1 |
| Convy, L | 1 |
| Cook, L | 1 |
| Mick, K | 1 |
| Favier, M | 1 |
| de Cazanove, F | 1 |
| Bressolle, F | 1 |
| Bons, F | 1 |
| Coste, E | 1 |
| Galtier, M | 1 |
| Priestley, GS | 1 |
| Seavell, CR | 1 |
| Rust, M | 4 |
| Oren, DA | 1 |
| Paxton, LD | 1 |
| McKay, AC | 1 |
| Mirakhur, RK | 1 |
| Litwack, K | 1 |
| Kossey, JL | 1 |
| Kwok, KK | 1 |
| Borgeat, A | 1 |
| Wilder-Smith, O | 1 |
| Forni, M | 1 |
| Suter, PM | 1 |
| Seliuzhitskiĭ, IV | 1 |
| Eliseev, SN | 1 |
| Ivanov, AI | 1 |
| Watcha, MF | 3 |
| Bras, PJ | 1 |
| Cieslak, GD | 1 |
| Pennant, JH | 1 |
| Forster, ER | 1 |
| Palmer, JL | 3 |
| Guo, XY | 1 |
| Ye, TH | 1 |
| Luo, AL | 1 |
| Cheirsilpa, A | 1 |
| Ratanatharathorn, V | 1 |
| Sinlarat, P | 1 |
| Chindavijak, K | 1 |
| Lousoontornsiri, W | 1 |
| Chakrapee-Sirisuk, S | 1 |
| Srimuninimit, V | 1 |
| Lim, AK | 1 |
| Haron, MR | 1 |
| Yap, TM | 1 |
| Currow, DC | 1 |
| Noble, PD | 1 |
| Stuart-Harris, RC | 1 |
| de Boer, M | 1 |
| Stoter, G | 2 |
| Verweij, J | 5 |
| Chevalier-Evain, V | 1 |
| Joslyn, AF | 6 |
| Bodis, S | 1 |
| Alexander, E | 1 |
| Kooy, H | 1 |
| Loeffler, JS | 1 |
| Fisher, DM | 2 |
| Furst, SR | 2 |
| Rodarte, A | 1 |
| Ummenhofer, W | 1 |
| Frei, FJ | 1 |
| Urwyler, A | 1 |
| Kern, C | 1 |
| Drewe, J | 1 |
| Spitzer, TR | 2 |
| Bryson, JC | 3 |
| Cirenza, E | 1 |
| Foelber, R | 1 |
| Wallerstadt, M | 1 |
| Stout, C | 1 |
| Kunka, RL | 1 |
| Plagge, PB | 2 |
| Dubois, A | 1 |
| Czeglédi, F | 1 |
| Baki, M | 1 |
| Karabelis, A | 1 |
| Bacoyiannis, C | 2 |
| Giudici, S | 1 |
| Merlini, L | 1 |
| Rubagotti, A | 1 |
| Rosso, R | 1 |
| Alon, E | 2 |
| Biro, P | 2 |
| Lenzlinger, PM | 1 |
| Atanassoff, PG | 1 |
| Heim, C | 1 |
| Münzer, T | 1 |
| Listyo, R | 1 |
| Khalil, SN | 2 |
| Kataria, B | 1 |
| Pearson, K | 1 |
| Conahan, T | 1 |
| Kallar, S | 1 |
| Zahl, K | 1 |
| Gillies, B | 1 |
| Campbell, C | 1 |
| Brahen, N | 1 |
| Gilmour, I | 1 |
| McKenzie, R | 7 |
| Tantisira, B | 2 |
| Karambelkar, DJ | 1 |
| Riley, TJ | 4 |
| Abdelhady, H | 1 |
| Chevallier, B | 2 |
| Pisters, KM | 2 |
| Hinkley, L | 1 |
| Cooke, CE | 1 |
| Mehra, IV | 1 |
| Lewis, MA | 1 |
| Fishman, DA | 1 |
| Tonato, M | 4 |
| Del Favero, A | 4 |
| Ballatori, E | 3 |
| Wilson, BA | 1 |
| Calamandrei, M | 1 |
| Andreuccetti, T | 1 |
| Crescioli, M | 1 |
| Messeri, A | 1 |
| Sarti, A | 1 |
| Sestini, G | 1 |
| Busoni, P | 1 |
| Kim, H | 1 |
| Rosenberg, SA | 1 |
| Steinberg, SM | 1 |
| Cole, DJ | 2 |
| Weber, JS | 1 |
| Gebbia, V | 2 |
| Cannata, G | 2 |
| Testa, A | 2 |
| Curto, G | 1 |
| Valenza, R | 1 |
| Cipolla, C | 1 |
| Latteri, MA | 1 |
| Gebbia, N | 2 |
| Katsikas, M | 1 |
| Lioni, A | 1 |
| Zbrozek, AS | 2 |
| Cantor, SB | 1 |
| Cardenas, MP | 1 |
| Hill, DP | 1 |
| Minton, N | 1 |
| Swift, R | 1 |
| Lawlor, C | 1 |
| Mant, T | 1 |
| Henry, J | 1 |
| Malins, AF | 1 |
| Field, JM | 1 |
| Nesling, PM | 1 |
| Cooper, GM | 1 |
| Claussen, DW | 1 |
| Pearman, MH | 2 |
| Cohen, LA | 3 |
| Claybon, L | 3 |
| Zoubek, A | 1 |
| Kronberger, M | 1 |
| Puschmann, A | 1 |
| Gadner, H | 1 |
| Ribiero, MM | 1 |
| de Faria, L | 1 |
| dos Reis, F | 1 |
| Fráguas, A | 1 |
| de Matos, E | 1 |
| Uva, S | 1 |
| Ribeiro, I | 1 |
| Brandão, A | 1 |
| Ribeiro, M | 1 |
| Batarda, M | 1 |
| Marschner, N | 2 |
| Cubeddu, LX | 4 |
| Pendergrass, K | 3 |
| Ryan, T | 1 |
| York, M | 2 |
| Burton, G | 1 |
| Meshad, M | 2 |
| Galvin, D | 2 |
| Ciociola, AA | 2 |
| Suh, C | 1 |
| Choi, SS | 1 |
| Böhrer, H | 1 |
| Bach, A | 1 |
| Martin, E | 1 |
| Kaizer, L | 1 |
| Hoskins, P | 3 |
| Latreille, J | 2 |
| Lofters, W | 1 |
| Yau, J | 1 |
| Palmer, M | 3 |
| Levy, M | 1 |
| Joss, RA | 2 |
| Bacchi, M | 1 |
| Buser, K | 2 |
| Kirchner, V | 1 |
| Neuenschwander, H | 1 |
| Orth, B | 1 |
| Thürlimann, B | 1 |
| Reed, MD | 1 |
| Marx, CM | 1 |
| Gan, TJ | 4 |
| Collis, R | 1 |
| Hetreed, M | 1 |
| Suen, TK | 1 |
| Gin, TA | 1 |
| Chen, PP | 2 |
| Rowbottom, YM | 1 |
| Critchley, LA | 1 |
| Ray, AK | 1 |
| Sargent, AI | 2 |
| Deppe, SA | 2 |
| Chan, FA | 1 |
| Zeng, WY | 2 |
| Hindle, AT | 1 |
| Fox, SM | 1 |
| Einhorn, LH | 1 |
| Cox, E | 1 |
| Powell, N | 1 |
| Abdy, A | 1 |
| Hindle, A | 1 |
| Tsukagoshi, S | 12 |
| Ohta, J | 11 |
| Taguchi, T | 14 |
| Haigh, CG | 3 |
| Kaplan, LA | 3 |
| Durham, JM | 1 |
| Dupeyron, JP | 2 |
| Harmer, M | 1 |
| Kenny, GN | 4 |
| Raphael, JH | 1 |
| Norton, AC | 1 |
| Helmers, JH | 2 |
| Briggs, L | 1 |
| Abrahamsson, J | 1 |
| Soni, J | 1 |
| Moodley, J | 1 |
| Forrler, M | 1 |
| Hellstern, K | 2 |
| Priestman, TJ | 3 |
| Roberts, JT | 4 |
| Upadhyaya, BK | 4 |
| Province, WS | 1 |
| Perrine, GM | 1 |
| Kilgore, JR | 1 |
| Lane, M | 1 |
| Lester, EP | 3 |
| Sridhar, KS | 1 |
| Mortimer, J | 1 |
| Murphy, W | 1 |
| Sanderson, PE | 3 |
| Evans, JE | 1 |
| Philpot, CR | 1 |
| Pinto, V | 1 |
| Marinaccio, M | 1 |
| Miniello, G | 1 |
| Cagnazzo, G | 1 |
| Kleinerman, KB | 1 |
| Sage, TA | 1 |
| Jones, WN | 1 |
| Clark, RF | 2 |
| Buser, KS | 1 |
| Piquet, D | 1 |
| Cavalli, F | 1 |
| Haefliger, JM | 1 |
| Jungi, WF | 1 |
| Bauer, J | 1 |
| Obrist, R | 1 |
| Brunner, KW | 1 |
| Norum, J | 1 |
| Jantunen, IT | 1 |
| Flander, MK | 1 |
| Heikkinen, MI | 1 |
| Kuoppala, TA | 1 |
| Teerenhovi, L | 1 |
| Kataja, VV | 1 |
| DiStasio, SA | 1 |
| Delahunt, JW | 1 |
| Burgess, C | 1 |
| Bott, V | 1 |
| Planting, AS | 1 |
| van der Burg, ME | 1 |
| de Boer-Dennert, M | 1 |
| Mahaney, FX | 1 |
| Clark, RA | 2 |
| Tyson, LB | 2 |
| Hahne, WF | 1 |
| Scuderi, P | 2 |
| Wetchler, B | 3 |
| Sung, YF | 2 |
| Mingus, M | 2 |
| DuPen, S | 1 |
| Leslie, J | 2 |
| Talke, P | 2 |
| Apfelbaum, J | 2 |
| Sharifi-Azad, S | 2 |
| Kovac, A | 2 |
| O'Connor, T | 2 |
| Duncalf, D | 2 |
| Angel, J | 2 |
| Gratz, I | 4 |
| Tolpin, E | 1 |
| McLeskey, C | 2 |
| Joslyn, A | 1 |
| Hewitt, M | 2 |
| McQuade, B | 6 |
| Stevens, R | 1 |
| Braken, JB | 1 |
| Raemaekers, JM | 1 |
| Koopmans, PP | 1 |
| de Pauw, BE | 2 |
| Incoronato, P | 1 |
| Airoma, G | 1 |
| Pepe, R | 1 |
| Arpinelli, F | 1 |
| Bianco, AR | 1 |
| Jones, SE | 1 |
| Harvey, WH | 3 |
| Chang, A | 2 |
| Hart, NE | 1 |
| Citron, ML | 1 |
| Woodward, M | 1 |
| Gora, ML | 1 |
| Sigsgaard, T | 3 |
| Boesgaard, M | 1 |
| Jensen, TP | 1 |
| Dombernowsky, P | 4 |
| Levitt, M | 1 |
| Yelle, L | 1 |
| Rayner, HL | 1 |
| Lofters, WS | 3 |
| Perrault, DJ | 1 |
| Wilson, KS | 1 |
| Potvin, M | 1 |
| Warner, E | 1 |
| Maisano, R | 1 |
| Toscano, G | 1 |
| Adamo, V | 1 |
| Altavilla, G | 1 |
| Caristi, N | 1 |
| Chiofalo, G | 1 |
| Gnani, A | 1 |
| Scimone, A | 1 |
| Conseiller, C | 2 |
| Levarlet, M | 2 |
| Hemmingsen, C | 1 |
| Schoeffler, P | 1 |
| Pedersen, FM | 1 |
| Gribomont, B | 1 |
| Chapman, SM | 1 |
| Pruemer, JM | 1 |
| Marsden, SC | 1 |
| Peters, MD | 1 |
| Long, KS | 1 |
| Patel, HS | 1 |
| Reitz, JA | 1 |
| Jessen, LM | 1 |
| Emhart, GC | 1 |
| Barbounis, V | 1 |
| Koumakis, G | 1 |
| Vassilomanolakis, M | 1 |
| Hatzichristou, H | 1 |
| Tsousis, S | 1 |
| Efremidis, AP | 1 |
| Berard, CM | 1 |
| Mahoney, CD | 1 |
| Rhodes, VA | 1 |
| McDaniel, RW | 1 |
| Simms, SG | 1 |
| Johnson, M | 1 |
| Alexander, R | 2 |
| Lovell, AT | 1 |
| Seingry, D | 1 |
| Jones, RM | 1 |
| Palmer, JB | 1 |
| Gibbs, TG | 1 |
| Taylor, CM | 1 |
| Mantovani, G | 1 |
| Macciò, A | 1 |
| Bianchi, A | 1 |
| Curreli, L | 1 |
| Ghiani, M | 1 |
| Proto, E | 1 |
| Santona, MC | 1 |
| Chen, R | 1 |
| Williams, SR | 1 |
| Johnson, CL | 1 |
| Harchelroad, F | 1 |
| Eriksson, H | 1 |
| Korttila, K | 2 |
| Hickok, JT | 2 |
| Rosenthal, SN | 1 |
| Fedele, P | 1 |
| Spina, M | 1 |
| Valentini, M | 1 |
| Collini, D | 1 |
| Lucia, C | 1 |
| Manicone, M | 1 |
| Tirelli, U | 1 |
| Early, TE | 1 |
| Charbonneau, J | 1 |
| McKnight, G | 1 |
| Jenkins, P | 1 |
| Thavaraj, V | 1 |
| Arya, LS | 1 |
| Jørgensen, M | 1 |
| Victor, MA | 1 |
| Depierre, A | 3 |
| Meden, H | 1 |
| Meissner, O | 1 |
| Conrad, A | 1 |
| Kuhn, W | 1 |
| Pueyo, FJ | 2 |
| Carrascosa, F | 2 |
| Lopez, L | 1 |
| Iribarren, MJ | 1 |
| García-Pedrajas, F | 1 |
| Saez, A | 2 |
| Macario, A | 1 |
| Ronquillo, RB | 1 |
| Brose, WG | 1 |
| Gaeta, RR | 1 |
| Koivuranta, MK | 1 |
| Läärä, E | 2 |
| Ryhänen, PT | 1 |
| Harousseau, JL | 2 |
| López-Olaondo, L | 1 |
| Monedero, P | 1 |
| Busto, N | 1 |
| Ossi, M | 1 |
| Anderson, E | 1 |
| Tang, J | 2 |
| White, PF | 4 |
| Sullivan, LJ | 1 |
| Soriano, SG | 1 |
| McDermott, JS | 1 |
| Adelson, PD | 1 |
| Rockoff, MA | 1 |
| Martoni, A | 2 |
| Angelelli, B | 1 |
| Guaraldi, M | 1 |
| Strocchi, E | 1 |
| Pannuti, F | 2 |
| Grote, T | 1 |
| Hainsworth, J | 5 |
| Kris, M | 1 |
| Anthony, L | 1 |
| Khojasteh, A | 4 |
| Tapazoglou, E | 3 |
| Benedict, C | 1 |
| Hahne, W | 2 |
| Pereira, J | 1 |
| Bruera, E | 1 |
| Tezcan, C | 1 |
| Ates, Y | 1 |
| Dönmez, A | 1 |
| Ozatamer, O | 1 |
| Thwaites, R | 1 |
| Paska, W | 2 |
| Catimel, G | 1 |
| Droz, JP | 3 |
| Güller, R | 1 |
| Reichlin, B | 1 |
| Jost, G | 1 |
| Perevodchikova, NI | 1 |
| Volkova, MA | 1 |
| Gorbunova, VA | 1 |
| Manziuk, LV | 1 |
| Marenich, AF | 1 |
| Smirnova, NB | 1 |
| Honkavaara, P | 1 |
| Allen, E | 1 |
| Afshar, M | 2 |
| Buxbaum, J | 1 |
| Prilliman, B | 1 |
| van den Berg, AA | 3 |
| Paech, MJ | 1 |
| Pavy, TJ | 1 |
| Evans, SF | 1 |
| Wrench, IJ | 1 |
| Ward, JE | 1 |
| Walder, AD | 1 |
| Hobbs, GJ | 1 |
| Bustos-Molina, F | 1 |
| García-Cruz, JJ | 1 |
| Cid-Calzada, J | 1 |
| Soro-Domingo, M | 1 |
| Bejarano-López, C | 1 |
| Cortés-Uribe, A | 1 |
| Naguib, M | 1 |
| el Bakry, AK | 1 |
| Khoshim, MH | 1 |
| Channa, AB | 1 |
| el Gammal, M | 1 |
| el Gammal, K | 1 |
| Elhattab, YS | 1 |
| Attia, M | 1 |
| Jaroudi, R | 1 |
| Saddique, A | 1 |
| Mathews, HG | 1 |
| Tancil, CG | 1 |
| Vach, W | 1 |
| Cramer-Giraud, U | 1 |
| Thomssen, C | 1 |
| Glaubitz, M | 1 |
| Fiola, M | 1 |
| Lekprasert, V | 1 |
| Meesangnil, S | 1 |
| Pausawasdi, S | 1 |
| Pongravee, V | 1 |
| Hursti, TJ | 2 |
| Avall-Lundqvist, E | 2 |
| Börjeson, S | 2 |
| Fredrikson, M | 2 |
| Fürst, CJ | 2 |
| Steineck, G | 2 |
| Peterson, C | 2 |
| Rodrigo, C | 1 |
| Campbell, R | 1 |
| Tong, A | 1 |
| Alberts, VA | 1 |
| Catalano, G | 1 |
| Poole, MA | 1 |
| Bosnjak, SM | 1 |
| Neskovic-Konstantinovic, ZB | 1 |
| Jovanovic-Micic, DJ | 1 |
| Mitrovic, LB | 1 |
| Radulovic, SS | 1 |
| Franzén, L | 2 |
| Nyman, J | 1 |
| Hagberg, H | 1 |
| Jakobsson, M | 1 |
| Sorbe, B | 1 |
| Nyth, AL | 1 |
| Lomberg, H | 2 |
| Henriksson, R | 1 |
| Davies, PR | 1 |
| Warwick, P | 1 |
| O'Connor, M | 1 |
| Chui, PT | 1 |
| Pan, PH | 1 |
| Moore, CH | 1 |
| Steinbrook, RA | 2 |
| Freiberger, D | 2 |
| Gosnell, JL | 2 |
| Brooks, DC | 1 |
| Morimoto, Y | 1 |
| Nakamura, M | 1 |
| Tamura, T | 1 |
| Kunii, T | 1 |
| Shimizu, K | 1 |
| Miyauchi, Y | 1 |
| Watts, SA | 1 |
| Fauser, AA | 1 |
| Duclos, B | 1 |
| Chemaissani, A | 1 |
| Cognetti, F | 2 |
| Diaz-Rubio, E | 1 |
| Cortes-Funes, H | 1 |
| Conte, PF | 1 |
| Dressler, H | 1 |
| Ginsberg, B | 1 |
| Grant, AP | 1 |
| Glass, PS | 2 |
| Polati, E | 2 |
| Finco, G | 2 |
| Bartoloni, A | 1 |
| Gottin, L | 2 |
| Pinaroli, AM | 2 |
| Zanoni, L | 1 |
| Mazzetti, C | 1 |
| Fontanive, P | 1 |
| Tremont-Lukats, IW | 1 |
| Teixeira, GM | 1 |
| Uy, NT | 1 |
| Hamilton, DL | 3 |
| Kovac, AL | 1 |
| Scuderi, PE | 1 |
| Prillaman, BA | 1 |
| Cox, F | 1 |
| Brock, P | 1 |
| Brichard, B | 1 |
| Rechnitzer, C | 1 |
| Langeveld, NE | 1 |
| Lanning, M | 1 |
| Söderhäll, S | 1 |
| Laurent, C | 1 |
| Latz, D | 1 |
| Schraube, P | 1 |
| Wannenmacher, M | 1 |
| Ulusoy, HO | 2 |
| Aktürk, G | 2 |
| Lüleci, N | 2 |
| Kalaç, N | 2 |
| Albayrak, D | 2 |
| Olver, I | 1 |
| Seitz, JF | 1 |
| Stewart, DJ | 2 |
| McRae, J | 1 |
| Wilkinson, JR | 2 |
| García del Valle, S | 1 |
| González, A | 1 |
| Vidal, M | 1 |
| Tyc, VL | 1 |
| Mulhern, RK | 1 |
| Barclay, DR | 1 |
| Smith, BF | 1 |
| Bieberich, AA | 1 |
| Sun, R | 1 |
| Klein, KW | 1 |
| Pugh, SC | 1 |
| Jones, NC | 1 |
| Barsoum, LZ | 1 |
| Morton, NS | 1 |
| Camu, F | 2 |
| Dorman, T | 1 |
| Knudsen, KE | 2 |
| Kvalsvik, O | 1 |
| Nellgard, P | 1 |
| Saint-Maurice, CP | 1 |
| Wilhelm, W | 1 |
| Saur, P | 2 |
| Mühr, C | 1 |
| Kazmaier, S | 1 |
| Neumann, P | 1 |
| Buhre, W | 1 |
| Mansfield, M | 1 |
| Russell, D | 2 |
| Kinsella, J | 1 |
| Rung, GW | 1 |
| Hord, A | 1 |
| Patel, C | 1 |
| Kallgren, M | 1 |
| Koppel, J | 1 |
| Benedetti, C | 1 |
| Creed, M | 1 |
| Asgharian, A | 1 |
| Bryson, J | 1 |
| Bliss, A | 1 |
| Lewis, IH | 1 |
| Kobayashi, F | 1 |
| Yamanouchi, T | 1 |
| Shimizu, T | 1 |
| Sato, H | 1 |
| Adachi, I | 1 |
| Sakamoto, T | 1 |
| Fujimaki, M | 1 |
| Horikoshi, I | 1 |
| Pitkänen, MT | 1 |
| Numminen, MK | 1 |
| Tuominen, MK | 1 |
| Rosenberg, PH | 1 |
| Pater, JL | 2 |
| Dempsey, E | 2 |
| Walde, D | 2 |
| Moquin, JP | 2 |
| Guevin, RM | 2 |
| Krook, JE | 2 |
| Chin, C | 2 |
| Tavorath, R | 1 |
| Wilde, MI | 1 |
| Tramèr, MR | 4 |
| Moore, RA | 4 |
| Reynolds, DJ | 4 |
| McQuay, HJ | 4 |
| Cabrera, JC | 1 |
| Matute, E | 1 |
| Escolano, F | 1 |
| Castillo, J | 1 |
| Santiveri, X | 1 |
| Castaño, J | 1 |
| Lawhorn, S | 1 |
| Lawhorn, CD | 2 |
| Davison, C | 1 |
| Gabriel, CM | 1 |
| Minor, JR | 1 |
| Vogel, S | 1 |
| Piscitelli, SC | 1 |
| Shende, D | 1 |
| Mandal, NG | 1 |
| Mjahed, K | 1 |
| el Harrar, N | 1 |
| Idali, B | 1 |
| Laouissi, F | 1 |
| Benaguida, M | 1 |
| Amraoui, A | 1 |
| Benline, TA | 1 |
| French, J | 1 |
| Handberg, J | 2 |
| Schousboe, BM | 2 |
| Hansen, M | 1 |
| Stienstra, R | 1 |
| Samhan, YM | 1 |
| el-Mofty, M | 1 |
| de Bont, LE | 1 |
| Bovill, JG | 1 |
| Arango, HA | 1 |
| Kalter, CS | 1 |
| Decesare, SL | 1 |
| Fiorica, JV | 1 |
| Lyman, GH | 1 |
| Spellacy, WN | 1 |
| Ariyoshi, Y | 11 |
| Nukariya, N | 3 |
| Akasaka, Y | 11 |
| Suminaga, M | 9 |
| Ota, J | 1 |
| Ikeda, M | 13 |
| Palladino, MA | 1 |
| Ciccarese, G | 1 |
| Basurto, C | 1 |
| Fennelly, M | 1 |
| Griffin, D | 1 |
| Wentz, A | 1 |
| Verlato, G | 1 |
| Mosaner, W | 1 |
| Grosso, S | 1 |
| Ischia, S | 1 |
| Clergue, F | 1 |
| Leeser, J | 3 |
| Feiss, P | 3 |
| Olthoff, D | 1 |
| Payeur-Michel, C | 1 |
| Wessel, P | 1 |
| Nave, S | 1 |
| Brown, R | 1 |
| Cieślińska, A | 1 |
| Pajak, K | 1 |
| Ziemba, AB | 1 |
| Filipczyk-Cisarz, E | 1 |
| Gajewska, A | 1 |
| Jellish, WS | 2 |
| Thalji, Z | 2 |
| Fluter, E | 1 |
| Leonetti, JP | 2 |
| Cunningham, RS | 1 |
| Ascaso, FJ | 1 |
| Ayala, I | 1 |
| Carbonell, P | 1 |
| Castro, FJ | 1 |
| Palomar, A | 1 |
| Saphir, A | 1 |
| Ploner, F | 1 |
| Kainzwaldner, A | 1 |
| Khoo, VS | 1 |
| Rainford, K | 1 |
| Horwich, A | 1 |
| Dearnaley, DP | 1 |
| Sniadach, MS | 1 |
| Alberts, MS | 1 |
| Blaine, EM | 1 |
| Coiffier, B | 1 |
| Misset, JL | 1 |
| Koivuranta, M | 2 |
| Jokela, R | 1 |
| Kiviluoma, K | 1 |
| Alahuhta, S | 2 |
| Lebeau, B | 1 |
| Giovannini, M | 2 |
| Rivière, A | 1 |
| Kaluzinski, L | 1 |
| Hédouin, M | 2 |
| d'Allens, H | 2 |
| Shillington, AA | 1 |
| Kulis-Robitaille, C | 1 |
| Colgan, K | 1 |
| Bernstein, G | 1 |
| Hoshino, K | 1 |
| Ono, K | 1 |
| Kimura, O | 1 |
| Kawaguchi, H | 1 |
| Fukui, H | 1 |
| Diemunsch, P | 1 |
| Clyti, N | 1 |
| Mamet, JP | 1 |
| Park, JO | 1 |
| Rha, SY | 1 |
| Yoo, NC | 1 |
| Kim, JH | 1 |
| Roh, JK | 1 |
| Min, JS | 1 |
| Kim, BS | 1 |
| Chung, HC | 1 |
| Moyle, JT | 1 |
| Sykes, AJ | 1 |
| Kiltie, AE | 1 |
| Stewart, AL | 1 |
| Fumoleau, P | 1 |
| Rolland, F | 1 |
| Ranta, P | 1 |
| Ravaska, P | 1 |
| Kymer, PJ | 1 |
| Stewart, FC | 1 |
| Stoner, JM | 1 |
| Shirey, R | 1 |
| Volpe, P | 1 |
| Hynes, HE | 1 |
| Flynn, PJ | 1 |
| Pierce, HI | 1 |
| Burish, T | 1 |
| Wang, B | 1 |
| Qi, J | 1 |
| Wender, RH | 1 |
| Monagle, J | 1 |
| Barnes, R | 1 |
| Goodchild, C | 1 |
| Perez, EA | 4 |
| Sandbach, J | 1 |
| Reeves, J | 1 |
| Bushnell, W | 3 |
| Nolte, MJ | 1 |
| Berkery, R | 1 |
| Pizzo, B | 1 |
| Baltzer, L | 1 |
| Grossano, D | 1 |
| Lucarelli, CD | 1 |
| Shinohara, H | 1 |
| Yonekawa, H | 1 |
| Machimura, T | 1 |
| Furukawa, T | 1 |
| Nishihori, H | 1 |
| Kurihara, N | 1 |
| Urakami, H | 1 |
| Nemoto, Y | 1 |
| Yano, K | 1 |
| Matsui, H | 1 |
| Fujisawa, S | 1 |
| Morris, RW | 1 |
| Aune, H | 1 |
| Hanson, A | 1 |
| Hasselstrøm, L | 1 |
| Maltby, JR | 1 |
| Rocke, DA | 1 |
| Rozenberg, B | 1 |
| Moens, P | 1 |
| Hendrickx, P | 1 |
| De Guchteneere, E | 1 |
| Trantisira, BR | 1 |
| Raeder, JC | 1 |
| Mjåland, O | 1 |
| Aasbø, V | 1 |
| Grøgaard, B | 1 |
| Buanes, T | 1 |
| Fortney, JT | 1 |
| Graczyk, S | 1 |
| Melson, T | 1 |
| Parrillo, S | 1 |
| Moote, C | 1 |
| Wermeling, D | 1 |
| Duncan, B | 1 |
| Creed, MR | 2 |
| Winter, SS | 2 |
| Popovic, W | 1 |
| Strupp, J | 1 |
| Noy, J | 1 |
| Einhorn, L | 2 |
| Ettinger, D | 1 |
| Martin, C | 1 |
| Roman, V | 1 |
| Agay, D | 1 |
| Fatôme, M | 1 |
| Chan, MT | 1 |
| Harper, CM | 1 |
| Barker, JP | 1 |
| Fluder, E | 1 |
| Poon, RT | 1 |
| Chow, LW | 1 |
| Kalaycio, M | 1 |
| Mendez, Z | 1 |
| Pohlman, B | 1 |
| Overmoyer, B | 1 |
| Boparai, N | 1 |
| Jones, E | 1 |
| Bolwell, B | 1 |
| Blanco, R | 1 |
| González-Gay, MA | 1 |
| García-Porrúa, C | 1 |
| Ibañez, D | 1 |
| García-Pais, MJ | 1 |
| Sánchez-Andrade, A | 1 |
| Vázquez-Caruncho, M | 1 |
| Rovsing, ML | 1 |
| Borgbjerg, FM | 1 |
| Dershwitz, M | 2 |
| Conant, JA | 1 |
| Chang, Y | 1 |
| Rosow, CE | 2 |
| Connors, PM | 1 |
| Zeidman, A | 1 |
| Ben Dayan, D | 1 |
| Ben Zion, T | 1 |
| Kaufman, O | 1 |
| Cohen, AM | 1 |
| Mittelman, M | 1 |
| Huc, P | 1 |
| Block, S | 1 |
| Carlier, D | 1 |
| Darloy, F | 1 |
| Bonneterre, ME | 1 |
| Bleuse, JP | 1 |
| Fournier, C | 1 |
| Arndt, GA | 1 |
| Mercadante, S | 1 |
| Sapio, M | 1 |
| Serretta, R | 1 |
| Köseoglu, V | 1 |
| Kürekçi, AE | 1 |
| Sarici, U | 1 |
| Atay, AA | 1 |
| Ozcan, O | 1 |
| Sorici, U | 1 |
| Wymenga, AN | 1 |
| de Vries, EG | 1 |
| Leijsma, MK | 1 |
| Kema, IP | 1 |
| Kleibeuker, JH | 1 |
| Tanimura, S | 1 |
| Banba, J | 1 |
| Tomoyasu, H | 1 |
| Masaki, M | 1 |
| Leong, SS | 1 |
| Teo, CP | 1 |
| Tao, M | 1 |
| Ang, PT | 1 |
| Gardner, C | 1 |
| Perren, M | 1 |
| Leatherman, ME | 1 |
| Bebchuk, JM | 1 |
| Ekstrom, RD | 1 |
| Heine, AD | 1 |
| Carson, SW | 1 |
| Golden, RN | 1 |
| Miyamoto, Y | 1 |
| Teramachi, M | 1 |
| Oomasa, M | 1 |
| Tomiyama, K | 1 |
| Stoner, NS | 1 |
| Bacić, A | 1 |
| Rumboldt, Z | 2 |
| Gluncić, I | 1 |
| Buklijas, J | 1 |
| Sohara, N | 1 |
| Takagi, H | 1 |
| Abe, T | 1 |
| Hashimoto, Y | 2 |
| Kojima, A | 1 |
| Takahashi, H | 1 |
| Nagamine, T | 1 |
| Mori, M | 1 |
| Carpenter, CE | 2 |
| Weitzel, LC | 1 |
| Johnson, NE | 2 |
| Nash, DB | 2 |
| Sistek, CJ | 1 |
| Berto, P | 1 |
| De Angelis, V | 1 |
| Neri, C | 1 |
| Olivieri, A | 1 |
| Plosker, GL | 2 |
| Milne, RJ | 2 |
| Rough, SS | 1 |
| Carro, GW | 1 |
| Mabro, M | 1 |
| Granisétron, PK | 1 |
| Lubarsky, DA | 1 |
| King, GL | 1 |
| Rabin, BM | 1 |
| Weatherspoon, JK | 1 |
| Kwong, WJ | 1 |
| Wang, SM | 1 |
| Hofstadter, MB | 1 |
| Kain, ZN | 1 |
| Dahrouge, S | 1 |
| Coyle, D | 1 |
| Evans, WK | 1 |
| Sussman, G | 1 |
| Shurman, J | 1 |
| Larsen, LS | 1 |
| Ferrer-Brechner, T | 1 |
| Noll, D | 1 |
| Allegra, J | 1 |
| Montgomery, R | 1 |
| Schreck, D | 1 |
| Grafstein, E | 1 |
| Ramalanjaona, G | 1 |
| Patel, V | 1 |
| Ducharme, J | 1 |
| Ortenwall, P | 1 |
| Foster, E | 1 |
| Ames, M | 2 |
| Needles, B | 1 |
| Miranda, E | 1 |
| Garcia Rodriguez, FM | 1 |
| Diaz, LB | 1 |
| Spector, J | 1 |
| Craig, J | 1 |
| Cohen, G | 1 |
| Krasnow, S | 1 |
| Brogden, J | 1 |
| Safonova, SA | 1 |
| Punanov, IuA | 1 |
| Kolygin, BA | 1 |
| Tiemeier, T | 1 |
| Solberg, LA | 1 |
| Miyashita, M | 1 |
| Onda, M | 1 |
| Bando, K | 1 |
| Hagiwara, N | 1 |
| Tsuchiya, Y | 1 |
| Yoshiyuki, T | 1 |
| Kiyama, T | 1 |
| Saito, T | 2 |
| Sasajima, K | 1 |
| Yamashita, K | 1 |
| Chung, F | 1 |
| Lane, R | 1 |
| Spraggs, C | 1 |
| Jacka, M | 1 |
| Luttropp, HH | 1 |
| Alahuta, S | 1 |
| Rocherieux, S | 1 |
| Roy, M | 1 |
| Duvaldestin, P | 1 |
| Curtis, P | 2 |
| Sadhasivam, S | 1 |
| Saxena, A | 1 |
| Kathirvel, S | 2 |
| Kannan, TR | 1 |
| Trikha, A | 1 |
| Mohan, V | 1 |
| DuBeshter, B | 1 |
| Lipshultz, SE | 1 |
| LeBourgeois, JP | 1 |
| McKenna, CJ | 2 |
| Coster, B | 1 |
| Feyer, P | 1 |
| Marzecki, Z | 1 |
| Stewart, A | 1 |
| Tønnessen, F | 1 |
| Haigh, C | 2 |
| Mitchell, T | 2 |
| Graham, E | 1 |
| Orchard, PJ | 1 |
| Rogosheske, J | 1 |
| Burns, L | 1 |
| Rydholm, N | 1 |
| Larson, H | 1 |
| DeFor, TE | 1 |
| Ramsay, NK | 1 |
| Weisdorf, D | 1 |
| Lachaine, J | 1 |
| Laurier, C | 1 |
| Langleben, A | 1 |
| Vaillant, L | 1 |
| Ku, PK | 1 |
| Tong, MC | 1 |
| Lo, P | 1 |
| van Hasselt, CA | 1 |
| Sasaki, K | 1 |
| Yanagida, T | 1 |
| Ohya, M | 1 |
| Ishikawa, H | 1 |
| Oge, A | 1 |
| Alkiş, N | 1 |
| Oge, O | 1 |
| Kartum, A | 1 |
| Loos, WJ | 1 |
| de Jonge, MJ | 1 |
| Sparreboom, A | 1 |
| Ishioka, S | 1 |
| Sagae, S | 1 |
| Kiya, T | 1 |
| Sugimura, M | 1 |
| Akutagawa, N | 1 |
| Umemura, K | 1 |
| Ito, E | 1 |
| Kudo, R | 1 |
| McClay, EF | 1 |
| McClay, ME | 1 |
| Monroe, L | 1 |
| Baron, PL | 1 |
| O'Brien, PH | 1 |
| Metcalf, JS | 1 |
| Maize, JC | 1 |
| Reid, K | 1 |
| Wright, RJ | 1 |
| Clemes, SA | 1 |
| Troakes, C | 1 |
| Somal, HS | 1 |
| House, F | 1 |
| Stott, JR | 1 |
| Zittoun, R | 1 |
| Ouvry, J | 1 |
| Friedman, CJ | 1 |
| Frankel, SR | 1 |
| Raschko, J | 1 |
| Xu, B | 2 |
| Zhou, A | 2 |
| Wang, Z | 1 |
| Zhou, L | 1 |
| Barrajon, E | 1 |
| de las Peñas, R | 1 |
| Coupland, NJ | 1 |
| Bailey, JE | 1 |
| Potokar, JP | 1 |
| Nutt, DJ | 1 |
| Wang, CH | 2 |
| Kao, CY | 1 |
| White, L | 1 |
| Daly, SA | 1 |
| Zhestkova, N | 1 |
| Leal, C | 1 |
| Breatnach, F | 1 |
| Smelhaus, V | 1 |
| Hung, IJ | 1 |
| Kowalczyk, J | 1 |
| Ninane, J | 1 |
| Harmon, D | 1 |
| O'Brien, B | 1 |
| Adams, VR | 1 |
| Wood, JG | 1 |
| Macleod, AD | 1 |
| Chiou, TJ | 1 |
| Tzeng, WF | 1 |
| Wang, WS | 1 |
| Yen, CC | 1 |
| Fan, FS | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| Herrington, JD | 1 |
| Kwan, P | 1 |
| Young, RR | 1 |
| Lagow, E | 1 |
| Lagrone, L | 1 |
| Riggs, MW | 1 |
| Slabý, J | 1 |
| Trnený, M | 1 |
| Procházka, B | 1 |
| Klener, P | 1 |
| Lacerda, JF | 1 |
| Martins, C | 1 |
| Carmo, JA | 1 |
| Lourenço, MF | 1 |
| Araújo Pereira, ME | 1 |
| Rodrigues, A | 1 |
| Juncal, C | 1 |
| Lacerda, JM | 1 |
| Soares, HP | 1 |
| Caparroz, C | 1 |
| Castro, PC | 1 |
| Kjaer, M | 1 |
| Cocquyt, V | 1 |
| Reinhardt, RR | 1 |
| Decramer, ML | 1 |
| O'Brien, M | 1 |
| Schellens, JH | 1 |
| Borms, M | 1 |
| Verbeke, L | 1 |
| Van Aelst, F | 1 |
| De Smet, M | 1 |
| Eldridge, K | 1 |
| Gertz, BJ | 1 |
| Kosmas, CH | 1 |
| Vadiaka, M | 1 |
| Kontos, A | 1 |
| Katsorida, M | 1 |
| Dimitrakopoulos, A | 1 |
| Zerai, A | 1 |
| Koufos, CH | 1 |
| Lara, DR | 1 |
| Busnello, ED | 1 |
| Souza, DO | 1 |
| Dash, HH | 1 |
| Bhatia, A | 1 |
| Subramaniam, B | 1 |
| Prakash, A | 1 |
| Shenoy, S | 1 |
| Culy, CR | 1 |
| Bhana, N | 1 |
| Roome, C | 1 |
| Thompson, J | 1 |
| Ye, JH | 1 |
| Ponnudurai, R | 1 |
| Schaefer, R | 1 |
| Yeh, KY | 1 |
| Eguchi, F | 1 |
| Furue, H | 11 |
| Tsukakoshi, S | 1 |
| Fox-Geiman, MP | 1 |
| Fisher, SG | 1 |
| Kiley, K | 1 |
| Fletcher-Gonzalez, D | 1 |
| Porter, N | 1 |
| Stiff, P | 1 |
| Nishida, T | 1 |
| Yakushiji, M | 1 |
| Ohizumi, K | 1 |
| Noda, S | 1 |
| Rikimaru, T | 1 |
| Matsuoka, K | 1 |
| Watters, J | 1 |
| Riley, M | 1 |
| Pedley, I | 1 |
| Whitehead, A | 1 |
| Overend, M | 1 |
| Goss, I | 1 |
| Allgar, V | 1 |
| Ljutić, D | 1 |
| Perković, D | 1 |
| Bagatin, J | 1 |
| Hozo, I | 1 |
| Pivac, N | 1 |
| Keefe, DL | 1 |
| Kodama, F | 1 |
| Mohri, H | 1 |
| Motomura, S | 1 |
| Fukawa, H | 1 |
| Tanabe, J | 1 |
| Koharasawa, H | 1 |
| Kanamori, H | 1 |
| Harano, H | 1 |
| Sakai, R | 1 |
| Tomita, N | 1 |
| Fujimaki, K | 1 |
| Takemura, S | 1 |
| Hattori, M | 1 |
| Parker, RI | 1 |
| Prakash, D | 1 |
| Mahan, RA | 1 |
| Giugliano, DM | 1 |
| Atlas, MP | 1 |
| Hardy, J | 1 |
| Daly, S | 1 |
| Albertsson, M | 1 |
| Chimontsi-Kypriou, V | 1 |
| Stathopoulos, P | 1 |
| Ishida, T | 1 |
| Kusaba, T | 1 |
| Markman, MR | 1 |
| Peterson, G | 1 |
| Kulp, B | 1 |
| Kaiser, R | 1 |
| Sezer, O | 1 |
| Papies, A | 1 |
| Bauer, S | 1 |
| Schelenz, C | 1 |
| Tremblay, PB | 1 |
| Possinger, K | 1 |
| Roots, I | 1 |
| Brockmöller, J | 1 |
| Parr, MD | 1 |
| McIntyre, WJ | 1 |
| Henderson, LM | 1 |
| MacDonald, JS | 1 |
| Chandler, MH | 1 |
| Dilly, S | 1 |
| Jones, AL | 2 |
| Lee, GJ | 1 |
| Bosanquet, N | 1 |
| Madsen, MR | 1 |
| Jensen, KE | 1 |
| Rosenthal, SA | 1 |
| Marquez, CM | 1 |
| Hourigan, HP | 1 |
| Ryu, JK | 1 |
| Nicholson, S | 1 |
| Evans, C | 1 |
| Mansi, J | 1 |
| Mulvenna, PM | 1 |
| Regnard, CF | 1 |
| Kaye, SB | 2 |
| Diehl, V | 1 |
| Di Biase, PM | 1 |
| Seynaeve, C | 3 |
| Schuller, J | 1 |
| Porteder, H | 1 |
| Sevelda, P | 1 |
| Christmann, D | 2 |
| Schmidt, M | 1 |
| Kitchener, H | 1 |
| Paes, D | 3 |
| Oates, JD | 1 |
| Rowbotham, DJ | 1 |
| Lip, H | 2 |
| Onsrud, M | 1 |
| Ota, K | 10 |
| Niitani, H | 10 |
| Gandara, DR | 4 |
| Monaghan, GG | 1 |
| Stokes, C | 1 |
| Finn, AL | 3 |
| Bleiberg, H | 2 |
| Graves, T | 2 |
| Legha, SS | 1 |
| Hodges, C | 1 |
| Ring, S | 1 |
| Dicato, MA | 3 |
| Kaasa, S | 3 |
| Warnier, P | 1 |
| Vindevoghel, A | 1 |
| Cunningham, D | 4 |
| Liebhard, A | 1 |
| Sledge, GW | 1 |
| Nagy, C | 1 |
| House, K | 1 |
| Baber, N | 1 |
| Frazer, NM | 1 |
| Pritchard, JF | 2 |
| Lauwers, MH | 1 |
| Verbessem, D | 1 |
| Naylor, RJ | 1 |
| Isal, JP | 1 |
| Inall, FC | 1 |
| Kanarek, BK | 1 |
| Povey, PM | 1 |
| Fagraeus, I | 1 |
| Du Pen, S | 1 |
| Clayborn, L | 1 |
| Sullivan, MJ | 1 |
| Abbott, GD | 1 |
| Robinson, BA | 1 |
| Wells, CD | 1 |
| Coates, AS | 1 |
| Childs, A | 1 |
| Cox, K | 1 |
| Forsyth, C | 1 |
| Joshua, DE | 1 |
| McNeil, E | 1 |
| Grygiel, JJ | 1 |
| Castle, WM | 1 |
| Cunningham, K | 1 |
| Kanarek, BB | 1 |
| Kish, JA | 1 |
| Murphy, WK | 2 |
| Tobias, JD | 1 |
| Bouly, A | 1 |
| Nathan, N | 1 |
| Tanneberger, S | 1 |
| Lelli, G | 1 |
| Piana, E | 1 |
| Berry, WR | 1 |
| House, KW | 1 |
| Lee, JT | 1 |
| Meshad, MW | 1 |
| Grapski, R | 1 |
| Scarantino, CW | 1 |
| Ornitz, RD | 1 |
| Hoffman, LG | 1 |
| Anderson, RF | 1 |
| Tiley, C | 1 |
| Powles, R | 1 |
| Catalano, J | 1 |
| Treleaven, J | 1 |
| Eshelby, J | 1 |
| Hewetson, M | 1 |
| Tait, D | 1 |
| Sands, R | 1 |
| Marsh, M | 1 |
| Gill, A | 1 |
| Dundee, JW | 3 |
| McMillan, CM | 2 |
| Mitchell, PL | 2 |
| Evans, BD | 2 |
| Allan, SG | 2 |
| Forgeson, GV | 1 |
| Mak, D | 2 |
| Neave, L | 1 |
| Humm, G | 1 |
| Langley, G | 1 |
| Dickson, D | 1 |
| Harvey, VJ | 2 |
| Yang, J | 1 |
| Wright, PM | 1 |
| Burnette, PK | 1 |
| Perkins, J | 1 |
| Vohra, S | 1 |
| Juricic, J | 1 |
| Egan, AP | 1 |
| Taggart, JR | 1 |
| Bender, CM | 1 |
| Hill, AS | 1 |
| Soukop, M | 1 |
| Hutcheon, AW | 1 |
| Cassidy, J | 1 |
| Sikora, K | 1 |
| Carney, DN | 1 |
| Figg, WD | 1 |
| Hoffmann, IS | 1 |
| Fuenmayor, NT | 2 |
| Lucraft, H | 1 |
| Collis, CH | 1 |
| Adams, M | 1 |
| Priestman, S | 1 |
| Heel, RC | 1 |
| Smith, DB | 3 |
| Newlands, ES | 2 |
| Rustin, GJ | 3 |
| Begent, RH | 2 |
| Howells, N | 2 |
| Bagshawe, KD | 2 |
| Harvey, W | 1 |
| Kasimis, B | 1 |
| Oblon, D | 1 |
| Monaghan, G | 1 |
| Harker, G | 1 |
| Ersbøll, J | 1 |
| Fraschini, G | 1 |
| Ciociola, A | 1 |
| Esparza, L | 1 |
| Templeton, D | 1 |
| Holmes, FA | 1 |
| Walters, RS | 1 |
| Hortobagyi, GN | 1 |
| Chaffee, BJ | 1 |
| Tankanow, RM | 1 |
| Cortesi, E | 1 |
| Favalli, G | 1 |
| Marangolo, M | 1 |
| Amadori, D | 1 |
| Bella, MA | 1 |
| Gramazio, V | 1 |
| Donati, D | 1 |
| Neave, LM | 1 |
| Langley, GB | 1 |
| Dickson, DS | 1 |
| Sagar, SM | 1 |
| Bayliss, MA | 1 |
| Chong, SL | 1 |
| Retsas, S | 1 |
| Kapur, PA | 1 |
| Larijani, GE | 1 |
| Minassian, S | 1 |
| Bodner, M | 1 |
| Stevens, RF | 1 |
| Kohler, DR | 1 |
| Goldspiel, BR | 1 |
| Betcher, DL | 1 |
| Burnham, N | 1 |
| McMillan, C | 1 |
| Abram, WP | 1 |
| Marschner, NW | 1 |
| Adler, M | 1 |
| Nagel, GA | 1 |
| Fenzl, E | 1 |
| Upadhyaya, B | 1 |
| Smyth, JF | 1 |
| Coleman, RE | 1 |
| Nicolson, M | 1 |
| Gallmeier, WM | 1 |
| Leonard, RC | 1 |
| Cornbleet, MA | 1 |
| Bruntsch, U | 1 |
| Aubert, B | 1 |
| Bons, J | 4 |
| Pappo, M | 1 |
| Lambert, HE | 1 |
| Pouillart, P | 2 |
| Scholl, S | 1 |
| Azab, M | 1 |
| Brion, N | 2 |
| Pujade-Lauraine, E | 2 |
| Paule, B | 2 |
| Spruyt, OW | 1 |
| Mellor, B | 1 |
| Viner, CV | 1 |
| Selby, PJ | 1 |
| Zulian, GB | 1 |
| Gore, ME | 1 |
| Butcher, ME | 2 |
| Wootton, CM | 1 |
| McElwain, TJ | 2 |
| Sampi, K | 1 |
| Metz, R | 1 |
| Fargeot, P | 1 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Kvaløy, S | 1 |
| Ries, F | 1 |
| Huys, JV | 1 |
| Royer, E | 1 |
| Carruthers, L | 1 |
| van Liessum, PA | 2 |
| de Mulder, PH | 3 |
| Lane-Allman, E | 1 |
| Beex, LV | 2 |
| Williams, D | 1 |
| Wootton, C | 1 |
| Sartiano, G | 1 |
| Finn, A | 1 |
| Hoffman, IS | 1 |
| Groshen, S | 1 |
| Robinson, DC | 1 |
| Stevenson, LL | 2 |
| Hait, WN | 1 |
| Vermorken, JB | 1 |
| Mols-Jevdevic, S | 1 |
| Allman, EL | 1 |
| Beranek, P | 1 |
| Nielsen, OH | 1 |
| Hvid-Jacobsen, K | 1 |
| Lund, P | 1 |
| Langholz, E | 1 |
| Serve, H | 1 |
| Perker, M | 1 |
| Ertl, A | 1 |
| Reichold, M | 1 |
| Fink, U | 1 |
| Berdel, WE | 1 |
| Kidgell, AE | 1 |
| Brown, GW | 1 |
| Sartiano, GP | 1 |
| White, DR | 1 |
| Werner, K | 1 |
| Chubb, JM | 1 |
| Green, JA | 1 |
| Watkin, SW | 1 |
| Hammond, P | 1 |
| Griggs, J | 1 |
| Challoner, T | 3 |
| Russell, CA | 1 |
| McDermed, JE | 1 |
| Hawthorn, J | 1 |
| Pople, A | 1 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Coombes, RC | 1 |
| de Haan, LD | 1 |
| Debruyne, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Isopropyl Alcohol Inhalation as Anti-emetic Therapy in the Emergency Department[NCT04464915] | 0 participants (Actual) | Interventional | 2020-07-31 | Withdrawn (stopped due to Given the COVID-19 pandemic, there has been a temporary suspension of study activities, therefore the study has not yet been initiated.) | |||
| Inhaled Isopropyl Alcohol Versus Placebo to Manage Nausea at Electronic Dance Music Festivals[NCT04307550] | 70 participants (Anticipated) | Interventional | 2021-07-12 | Recruiting | |||
| Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial[NCT02760069] | Phase 4 | 122 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention [NCT01594749] | Phase 3 | 1,015 participants (Actual) | Interventional | 2012-09-24 | Completed | ||
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Ped[NCT01362530] | Phase 3 | 307 participants (Actual) | Interventional | 2011-09-13 | Completed | ||
| Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant[NCT04535141] | Phase 3 | 91 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Re[NCT02635984] | Phase 3 | 108 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay[NCT02956616] | Phase 2 | 118 participants (Actual) | Interventional | 2017-09-01 | Completed | ||
| The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section[NCT01216410] | 306 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| A Randomised Trial to Assess the Effectiveness of Pre-treatment With Ondansetron at Reducing Nausea and Vomiting in Patients Treated With Either the Conventional Regimen or a Modified Regimen of Acetylcysteine for Paracetamol Poisoning[NCT01050270] | Phase 4 | 222 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Does Prophylactic Ondansetron Reduce Norepinephrine Consumption in Patients Undergoing Caesarean Section With Spinal Anesthesia?[NCT02928601] | Phase 4 | 108 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial[NCT04252521] | 150 participants (Actual) | Interventional | 2019-07-03 | Completed | |||
| A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetoge[NCT00337727] | Phase 3 | 848 participants (Actual) | Interventional | 2007-01-01 | Completed | ||
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.[NCT03606369] | Phase 2/Phase 3 | 560 participants (Anticipated) | Interventional | 2015-11-05 | Recruiting | ||
| Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy[NCT01668069] | 36 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Effect of Ketamine Versus Sevoflurane On The Right Ventricular Pressure During Congenital Pulmonary Stenosis Balloon Dilatation[NCT05582213] | 40 participants (Actual) | Interventional | 2022-10-01 | Completed | |||
| Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)[NCT03125811] | Early Phase 1 | 121 participants (Actual) | Interventional | 2017-07-17 | Completed | ||
| A Randomized, Phase IV Trial of Individualized Care Versus Standard Care, in the Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. The EPIC Study[NCT01913990] | Phase 4 | 323 participants (Anticipated) | Interventional | 2011-09-30 | Active, not recruiting | ||
| A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC o[NCT01442376] | Phase 3 | 502 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexameth[NCT02106494] | Phase 3 | 942 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Evaluation of the Impact of the HLNatural, Inc. Immune Support Product in Reducing the Length of Cold Symptoms in Adults Suffering From the Common Cold[NCT04103099] | 200 participants (Actual) | Interventional | 2019-10-16 | Completed | |||
| A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC R[NCT01636947] | Phase 4 | 494 participants (Actual) | Interventional | 2012-12-12 | Completed | ||
| Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen[NCT00970905] | Phase 2 | 52 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated W[NCT00080444] | Phase 3 | 50 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients[NCT01757210] | 20 participants (Actual) | Observational | 2012-09-30 | Completed | |||
| Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron When Administered in Healthy Adult Subjects[NCT00437229] | Phase 1 | 37 participants (Actual) | Interventional | 2007-02-19 | Completed | ||
| A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron a[NCT00366834] | Phase 3 | 1,840 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for [NCT00104403] | Phase 2 | 722 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Randomized, Double Blind, and Placebo-Controlled Trial Comparing Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult Emergency Department.[NCT00655642] | 171 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Conditional analysis showed observed differences were significantly less than power calculations) | |||
| A Study to Evaluate the Anti-Emetic Effect of Ginger Powder Vs Placebo as an Add-on Therapy in Children and Adolescents Receiving Chemotherapy : A Randomized Controlled Trial[NCT00940368] | Phase 3 | 60 participants (Anticipated) | Interventional | 2009-06-30 | Recruiting | ||
| Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving Carboplatin[NCT03237611] | Phase 2 | 15 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Expired IRB approval on 2/11/21) | ||
| Phase 2B Double Blind Placebo Controlled Crossover Study Evaluating the Efficacy of IV Fosaprepitant for Chemo Induced N/V With High Dose Interleukin 2 for Metastatic Melanoma and Metastatic Renal Cell Carcinoma[NCT01874119] | Phase 2 | 13 participants (Actual) | Interventional | 2013-09-30 | Terminated (stopped due to Enrollment issues) | ||
| A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Indu[NCT00619359] | Phase 3 | 2,322 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase III Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer Receiving 5-day Cisplatin C[NCT05244577] | Phase 3 | 75 participants (Anticipated) | Interventional | 2022-01-18 | Recruiting | ||
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer[NCT04669132] | Phase 2 | 50 participants (Actual) | Interventional | 2020-12-17 | Completed | ||
| Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study[NCT01052844] | Phase 3 | 80 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Oxaliplatin Induced Nausea and Vomiting.[NCT00601172] | Phase 3 | 710 participants (Actual) | Interventional | 2008-03-10 | Completed | ||
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies[NCT00871910] | Phase 1 | 81 participants (Actual) | Interventional | 2006-10-11 | Completed | ||
| Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial[NCT00869310] | Phase 3 | 303 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to we terminated the study before enrolling 303/560 due to a slow accrual) | ||
| Observational Study of Delayed Nausea and Vomiting Following Administration of Carboplatin Containing Regimens for Treatment of Cancer[NCT00696280] | 106 participants (Actual) | Observational | 2006-11-30 | Completed | |||
| Is the Application of Scopolamine Patch With or Without Intra-operative Acupressure Point P6 Stimulation More Effective Than Intra-operative Acupressure Point P6 Stimulation Alone?[NCT02960113] | Phase 4 | 240 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Studying the Effectiveness of Triple Therapy With Palonosetron, Dexamethasone and Promethazine for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia[NCT02635828] | Phase 4 | 40 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study[NCT00869973] | Phase 3 | 580 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to We terminated the study after enrolling 580/900 patients due to a slow accrual) | ||
| IRB-HSR# 14583: Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients[NCT01414777] | Phase 2/Phase 3 | 68 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With [NCT00092196] | Phase 3 | 820 participants (Actual) | Interventional | 2002-12-01 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Che[NCT00092183] | Phase 4 | 866 participants (Actual) | Interventional | 2002-10-10 | Completed | ||
| A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis[NCT00016380] | Phase 3 | 211 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Inhalation Intervention for Nausea in the Emergency Department[NCT02092441] | 80 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| A Randomized Controlled Trial of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department[NCT00429832] | Phase 4 | 120 participants | Interventional | 2003-10-31 | Completed | ||
| A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.[NCT02130622] | Phase 2 | 3 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Lack of recruitment) | ||
| Preoperative Pregabalin to Prevent Postoperative Nausea & Vomiting in Laparoscopic Surgery.[NCT05529004] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| A Phase III, Randomized, Open-label, Active-controlled, Two-arm, Parallel-design, Interventional Clinical Trial Evaluating the Efficacy and Safety of Ondansetron 8 mg IV/ IM Injection Compared to Metoclopramide 10 mg in the Management of Nausea and Vomiti[NCT05876585] | Phase 3 | 126 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| Optimizing Anesthesia Antiemetic Measures Versus Combination With Dexamethasone or Ondansetron in the Prevention of Postoperative Nausea and Vomiting.[NCT00825071] | Phase 4 | 180 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection[NCT03134612] | Phase 2 | 104 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Effect of Intravenous Granisetron on Incidence and Severity of Intrathecal Morphine Induced Pruritus in Elective Cesarean Section[NCT03483870] | Phase 2 | 80 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| A Prospective Evaluation of an Anesthesia Protocol to Reduce Post-operative and Post-discharge Nausea and Vomiting in a High Risk Orthognathic Surgery Population[NCT01592708] | 233 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Randomized Single-Blind Study of Nometex as an Adjunct to Standard Anti-emetics in Ovarian and Advanced Endometrial and Cervical Cancer Patients Who Receive Moderately to Highly Emetogenic Chemotherapy[NCT01980160] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to Did not receive IRB approval from our institution therefore the study was closed.) | |||
| Antagonism Research Between Antiemetics Agents (Droperidol, Dexametasone, Ondansetron) and Acetaminophen in Thyroidectomy's Post-operative Analgesia.[NCT01679093] | Phase 3 | 66 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Effect of Postoperative Trendelenburg Position on Shoulder Pain After Gynecological Laparoscopic Procedures.[NCT04129385] | 108 participants (Actual) | Interventional | 2016-03-01 | Completed | |||
| The Effect of Hot Application on Shoulder Pain and Analgesic Use After Laparoscopic Upper Abdominal Surgery[NCT05334797] | 60 participants (Anticipated) | Interventional | 2022-04-12 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea. (NCT02760069)
Timeframe: 30 minutes post intervention
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled ISO + Oral Ondansetron | 23 |
| Inhaled ISO + Oral Placebo | 19 |
| Inhaled Placebo + Oral Ondansetron | 42 |
Whether patient required rescue anti-emetics (binary variable). Measured using nurse drug administration record. (NCT02760069)
Timeframe: Study duration (up to 5 hours post intervention)
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled ISO + Oral Ondansetron | 11 |
| Inhaled ISO + Oral Placebo | 10 |
| Inhaled Placebo + Oral Ondansetron | 18 |
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 0 to 120 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 77.1 |
| Control Regimen | 66.9 |
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 0 to 24 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 93.2 |
| Control Regimen | 91.0 |
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 25 to 120 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 78.9 |
| Control Regimen | 68.5 |
The percentages of participants with infusion-site thrombophlebitis are presented. Thrombophlebitis was defined as a condition affecting a superficial vein used for an IV infusion, associated with red color, hardness upon palpation, and the presence of a tender cord and possible fever. (NCT01594749)
Timeframe: Day 1 through Day 17, inclusive
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 0.6 |
| Control Regimen | 0.0 |
No Vomiting was defined as no emetic (vomiting) episodes, including no vomiting and no retching or dry heaves (attempts to vomit that are not productive of stomach contents), regardless of use of rescue medication. (NCT01594749)
Timeframe: 0 to 120 hours after initiation of MEC
| Intervention | Percentage of participants (Number) |
|---|---|
| Fosaprepitant Regimen | 82.7 |
| Control Regimen | 72.9 |
The percentages of participants with severe infusion-site reactions, including severe site pain, or severe site redness (erythema) or severe site hardness (induration) are presented. (NCT01594749)
Timeframe: Day 1 through Day 17, inclusive
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 0.0 |
| Control Regimen | 0.0 |
Acute phase was defined as 0 to 24 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the acute phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 24 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 66.4 |
| Control Regimen | 52.0 |
Delayed Phase was defined as 25-120 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the delayed phase of Cycle 1. (NCT01362530)
Timeframe: 25 to 120 hours after the start of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 50.7 |
| Control Regimen | 26.0 |
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the overall phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 120 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 40.1 |
| Control Regimen | 20.0 |
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. No vomiting was defined as no emesis or retching or dry heaves in the overall phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 120 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 46.7 |
| Control Regimen | 21.3 |
"The total number of rescue medications needed for breakthrough chemotherapy-induced nausea and vomiting were calculated, starting from the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for CINV prophylaxis." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).
| Intervention | number of rescue medication (Mean) |
|---|---|
| Usual Care | 0.47 |
| Olanzapine | 1.17 |
"The total number of rescue medications needed acute was calculated, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for chemotherapy-induced nausea and vomiting (CINV) prophylaxis." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)
| Intervention | number of rescue medication (Mean) |
|---|---|
| Usual Care | 0.08 |
| Olanzapin | 0.10 |
"Starting with the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions. Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely in the first 24 hours following receipt of chemotherapy." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration (Up to day 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 44 | 1 |
| Usual Care | 43 | 3 |
The frequency of somnolence was determined as the number of patients who experienced somnolence based on Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). The number of subjects has somnolence during the study period was counted. (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| subjects have somnolence | subjects do not have somnolence | |
| Olanzapine | 1 | 42 |
| Usual Care | 0 | 46 |
The number of emesis episodes in acute phase was defined as the number of subjects with no emesis, 1 emesis, and 2 or more emesis. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| No emesis episodes | 1 emesis episode | 2 or more emesis episodes | |
| Olanzapine | 36 | 6 | 3 |
| Usual Care | 32 | 9 | 5 |
: The number of subjects who did not experience emesis, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy. Met endpoint = 0 emesis. (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 45 | 0 |
| Usual Care | 45 | 1 |
"Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions, starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~The number of subjects who experienced never or rarely nausea were considered as met the endpoint while those who experienced occasionally, frequently or almost constantly were considered as not met the endpoint." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2-12).
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 27 | 18 |
| Usual Care | 19 | 27 |
"To determine the number of subjects achieving minimal nausea was defined as the frequency of participants responded to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea question In the last 24 hours, how often did you have nausea? as rarely or less Starting with the first dose of chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~PRO-CTCAE of nausea scale includes categories: Never, Rarely, Occasionally, Frequently, Almost constantly To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely and the score reported for the Pro-CTCAE question for nausea severity cannot exceed mild" (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Yes | No | |
| Olanzapine | 25 | 20 |
| Usual Care | 15 | 31 |
Prolongation of corrected QTc interval graded as defined in Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Corrected QTc was calculated using Fredericia's Formula. Corrected QT interval (QTc) = QT interval / (60/Heart rate)^0.33. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2- 12).
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | None | |
| Baseline Olanzapine | 4 | 0 | 0 | 0 | 0 | 41 |
| Baseline Usual Care | 3 | 0 | 0 | 0 | 0 | 43 |
| Olanzapine Post-chemo Day 1 | 3 | 0 | 0 | 0 | 0 | 42 |
| Olanzapine- End of Study | 3 | 0 | 1 | 0 | 0 | 41 |
| Usual Care End of Study | 3 | 0 | 1 | 0 | 0 | 42 |
| Usual Care Post-chemo Day 1 | 2 | 0 | 0 | 0 | 0 | 44 |
"The severity of nausea in the delayed phase was defined as the response of the subject to the PRO- CTCAE nausea question.~Starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy (PRO-CTCAE) Scale: Never, Rarely, Occasionally, Frequently, Almost constantly~o meet the endpoint, the subject could not have answered a score as higher than mild in the period of time starting 24 hours after the last dose of chemotherapy and continuing until the 5th day following receipt of chemotherapy ." (NCT04535141)
Timeframe: Day 2-12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Met endpoint | Did not meet endpoint | |
| Olanzapine | 31 | 24 |
| Usual Care | 23 | 23 |
Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (< 25 mm on a 100 mm visual analog scale [VAS]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy. (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 13 |
| Triplet Therapy Plus Olanzapine | 28 |
Reported as acute [chemotherapy days]. All assessment with all VAS < 25 mm on days of chemotherapy (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 33 |
| Triplet Therapy Plus Olanzapine | 39 |
Reported for delayed [5 days after chemotherapy administration] All assessment with all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 16 |
| Triplet Therapy Plus Olanzapine | 34 |
(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases [chemotherapy days plus 5 days after] (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 6 |
| Triplet Therapy Plus Olanzapine | 13 |
Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in acute phase (days of chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 31 |
| Triplet Therapy Plus Olanzapine | 39 |
Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in delayed phase (5 days after chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 15 |
| Triplet Therapy Plus Olanzapine | 31 |
No nausea (all VAS <5 mm) in overall assessment period (days of chemotherapy plus five days after) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 6 |
| Triplet Therapy Plus Olanzapine | 18 |
Reported for overall phases [chemotherapy days plus 5 days after] where all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Triplet Therapy Plus Placebo | 14 |
| Triplet Therapy Plus Olanzapine | 30 |
Number of patients discharged on postoperative Day #2 (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Enhanced Recovery | 5 |
| Routine Perioperative Care | 2 |
Postoperative Length of Hospital Stay in Hours from time of surgery (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Hours (Median) |
|---|---|
| Enhanced Recovery | 73.58 |
| Routine Perioperative Care | 75.50 |
The amount of postoperative pain medication required for each patient in Morphine Milligram Equivalents (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Morphine Milligram Equivalents (Mean) |
|---|---|
| Enhanced Recovery | 117.16 |
| Routine Perioperative Care | 119.38 |
All patients will be queried regarding whether breastfeeding was initiated after cesarean birth and how soon after birth (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Breastfeeding | Bottlefeeding | Both Breastfeeding and Bottlefeeding | |
| Enhanced Recovery | 39 | 4 | 15 |
| Routine Perioperative Care | 29 | 2 | 29 |
Comparison of intraoperative nausea and vomiting between the 3 groups. (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants (Number) |
|---|---|
| Combination Group | 23 |
| Metoclopramide | 31 |
| Phenylephrine Infusion | 49 |
The number of patients with systolic blood pressure decrease to less than 20 % of baseline intraoperatively (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants with SBP< 20 % baseline (Number) |
|---|---|
| Combination Group | 16 |
| Metoclopramide | 19 |
| Phenylephrine Infusion | 16 |
(NCT01216410)
Timeframe: 0-24 hrs
| Intervention | participants (Number) |
|---|---|
| Combination Group | 95 |
| Metoclopramide | 93 |
| Phenylephrine Infusion | 97 |
1=very satisfied, 2=somewhat satisfied, 3= neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5= very dissatisfied. Number of very satisfied subjects posted. (NCT01216410)
Timeframe: 24 h
| Intervention | participants (Number) |
|---|---|
| Combination Group | 94 |
| Metoclopramide | 85 |
| Phenylephrine Infusion | 87 |
(NCT01216410)
Timeframe: 0-2h, 2-6h, 6-24h
| Intervention | participants (Number) | ||
|---|---|---|---|
| 0-2 hrs PONV | 2-6 hrs PONV | 6-24 hrs PONV | |
| Combination Group | 20 | 28 | 22 |
| Metoclopramide | 33 | 35 | 26 |
| Phenylephrine Infusion | 39 | 41 | 22 |
The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1. (NCT00337727)
Timeframe: Overall phase (0-120 hours post initiation of MEC) in Cycle 1
| Intervention | Participants (Number) |
|---|---|
| Aprepitant Regimen | 292 |
| Standard Regimen | 229 |
"The number of patients who reported No Vomiting in the overall phase in Cycle~1" (NCT00337727)
Timeframe: Overall phase (0-120 hours post initiation of MEC) in Cycle 1.
| Intervention | Participants (Number) |
|---|---|
| Aprepitant Regimen | 324 |
| Standard Regimen | 252 |
Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from >24 to 120 hours (delayed phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. (NCT01442376)
Timeframe: from >24 to 120 hours (delayed phase) after T0
| Intervention | percentage of patients (Number) |
|---|---|
| Palonosetron 10 mcg/kg | 28.9 |
| Palonosetron 20 mcg/kg | 38.8 |
| Ondansetron | 28.4 |
Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. Time 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy. (NCT01442376)
Timeframe: 0 to 24 hours after T0
| Intervention | percentage of patients (Number) |
|---|---|
| Palonosetron 10 mcg/kg | 54.2 |
| Palonosetron 20 mcg/kg | 59.4 |
| Ondansetron | 58.6 |
To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the delayed phase (24 to 120 hours) of CINV. (NCT02106494)
Timeframe: 24 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 60.7 |
| Ondansetron + Fosaprepitant + Dexamethasone | 53.1 |
Percentage of Participants with no emesis and no rescue medication in patients receiving HEC in the delayed phase (24 to 120 hours) of CINV. (NCT02106494)
Timeframe: 24 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 64.7 |
| Ondansetron + Fosaprepitant + Dexamethasone | 56.6 |
To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 54.7 |
| Ondansetron + Fosaprepitant + Dexamethasone | 49.6 |
To determine the effect of APF530 on complete response rates in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 58.4 |
| Ondansetron + Fosaprepitant + Dexamethasone | 52.9 |
To determine the effect of APF530 on the rate of no emetic episodes (vomiting or retching) in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| APF530 + Fosaprepitant + Dexamethasone | 82.2 |
| Ondansetron + Fosaprepitant + Dexamethasone | 79.2 |
The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Number of Emetic Events (Number) |
|---|---|
| Aprepitant Regimen | 54 |
| Control Regimen | 68 |
"The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, No Impact on daily life was defined as an average item score of >6 on the 7-point scale; a total score >108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC." (NCT01636947)
Timeframe: Day 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 76.8 |
| Control Regimen | 73.8 |
"Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: How much nausea have you had over the last 24 hours? The left end of the scale (0 mm) was labeled no nausea, and the right end of the scale (100 mm) is labeled nausea as bad as it could be. In this study, No Significant Nausea was defined as a VAS nausea rating <25 mm." (NCT01636947)
Timeframe: Days 1 to Day 5
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 76.4 |
| Control Regimen | 72.4 |
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event. (NCT01636947)
Timeframe: Day 1 through Day 29 (Up to 28 days after first dose of study drug)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 56.2 |
| Control Regimen | 53.2 |
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC). (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 77.2 |
| Control Regimen | 72.0 |
The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1 to Day 5
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Overall Stage | Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 84.8 | 98.7 | 84.8 |
| Control Regimen | 87.7 | 99.2 | 88.5 |
A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Overall Stage | Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 73.4 | 95.8 | 74.3 |
| Control Regimen | 70.4 | 97.9 | 71.2 |
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1, Day 2 to Day 5
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 95.8 | 78.5 |
| Control Regimen | 98.8 | 72.4 |
"Participants independently rated their nausea severity on separate scales at the baseline and 30-minute evaluations to prevent the baseline VAS score from influencing the 30-minute mark. The VAS had the words Least Severe on the left and Most Severe on the right. The possible values range from 0 to 100mm with 0 at the Least Severe extreme and 100 at the Most Severe extreme. Investigators instructed the participant to draw a single vertical line through the point on the 100mm scale that corresponded to their nausea severity at the times of measurement (Baseline and 30 minutes)." (NCT00655642)
Timeframe: Baseline and 30 minute assessments
| Intervention | millimeter (Median) |
|---|---|
| Ondansetron | -22.0 |
| Metoclopramide | -30.0 |
| Promethazine | -29.0 |
| Placebo | -16.0 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during the overall phase of the first carboplatin-based chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: 24 hours following the first cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 11 | 10 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during the overall phase of the first carboplatin-based chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: From 24 to 120 hours following the first cycle of chemotherapy, approximately 5 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 9 | 9 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during overall phase of the second chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: 24 hours following the second cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 3 | 3 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during overall phase of the second chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: From 24 to 120 hours following the second cycle of chemotherapy, approximately 5 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 3 | 3 |
No vomiting from the initiation of through 48 hours following the final dose of HD IL-2 (NCT01874119)
Timeframe: From the initiation of through 48 hours following the final dose of Interleukin-2
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosaprepitant | 1 |
| Placebo | 0 |
The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 25 to 120 hours following initiation of cisplatin chemotherapy. (NCT00619359)
Timeframe: Delayed phase (25 to 120 hours following initiation of cisplatin).
| Intervention | Participants (Number) |
|---|---|
| Fosaprepitant | 822 |
| Aprepitant | 841 |
The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 120 hours following initiation of cisplatin chemotherapy. (NCT00619359)
Timeframe: Overall (in the 120 hours following initiation of cisplatin chemotherapy).
| Intervention | Participants (Number) |
|---|---|
| Fosaprepitant | 795 |
| Aprepitant | 820 |
The number of patients who reported No Vomiting in the 120 hours following initiation of cisplatin chemotherapy. (NCT00619359)
Timeframe: Overall (the 120 hours following initiation of cisplatin chemotherapy)
| Intervention | Participants (Number) |
|---|---|
| Fosaprepitant | 806 |
| Aprepitant | 844 |
The CR was defined as no emetic episodes and no nausea episodes from day 1 to day 5 (0-120h) (NCT01052844)
Timeframe: 5 days
| Intervention | participants (Number) |
|---|---|
| Control Group | 17 |
| Gabapentin | 26 |
Complete response during delayed-onset phase was defined as the absence of any episode of nausea or vomiting and no use of rescue medication when occurring during the period from days 2 through 5 after chemotherapy (NCT01052844)
Timeframe: 6 days
| Intervention | participants (Number) |
|---|---|
| Control Group | 21 |
| Gabapentin | 29 |
Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. Percentage of participants who achieved a complete response in the acute phase of Cycle 1 are presented. (NCT00601172)
Timeframe: 0 to 24 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 96 |
| Casopitant 90 mg | 97 |
Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. Percentage of participants who achieved a complete response in the delayed phase of Cycle 1 are presented. (NCT00601172)
Timeframe: 24 to 120 hours (delayed phase) in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 85 |
| Casopitant 90 mg | 86 |
Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. The overall phase began at the start of the administration of the oxaliplatin infusion. Percentage of participants who achieved a complete response in the overall phase (0-120 hours) are presented. (NCT00601172)
Timeframe: 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 85 |
| Casopitant 90 mg | 86 |
Complete response was defined as no vomiting, no retching and no use of anti-emetic rescue medication. Participants who vomited or retched or received rescue medication in the acute phase (0- 24 hours) following administration of oxaliplatin were also considered as complete response failures in the subsequent delayed (24-120 hour) time period, irrespective of actual response in the delayed phase. However, participants who vomited or retched or received rescue medication in the delayed (24-120 hours) phase were not considered as failures in the acute (0-24 hours) phase. The overall phase began at the start of the administration of the oxaliplatin infusion. Percentage of participants who achieved a complete response in the overall phase of Cycle 2 are presented. (NCT00601172)
Timeframe: 0 to 120 hours in the second cycle of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 84 |
| Casopitant 90 mg | 90 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the eCRF. Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. CL for casopitant is presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Liter/hour (Geometric Mean) |
|---|---|
| Casopitant 90 mg | 10.457 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the eCRF. Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. Vdss for casopitant is presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Liter (Geometric Mean) |
|---|---|
| Casopitant 90 mg | 126.776 |
Time to first rescue medication was defined as the length of time from initiation of oxaliplatin till the first reported use of a rescue medication. Participants withdrawing prematurely during the 120 hour assessment period without having received a rescue medication were assumed to have done so and the time of rescue medication was set to 0 hours. The first quartile for time to use of anti-emetic rescue medication was evaluated when 25th percentile of participants of MITT population reported use of anti-emetic rescue medication. Similarly, median and 75th percentile of participants of MITT population was planned to be reported. If, less than 25th percentile of participants reported use of anti-emetic rescue medication at the end of the 120 hour time period, then the observation was censored for the purpose of this analysis and in such case the data was planned to be reported as not evaluable (NA). (NCT00601172)
Timeframe: 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Hours (Median) |
|---|---|
| Placebo | NA |
| Casopitant 90 mg | NA |
Time to first emetic event was defined as the length of time from initiation of oxaliplatin until the time of first emetic event. Participants withdrawing prematurely from the study without having experienced an emetic event were assumed to have done so and the time of emetic event was set to 0 hours. The first quartile for time to emetic event was evaluated when 25th percentile of participants of MITT population reported emetic event. Similarly, median and 75th percentile of participants of MITT population was planned to be reported. If, less than 25th percentile of participants reported emetic event at the end of the 120 hour time period, then the observation was censored for the purpose of this analysis and in such case the data was planned to be reported as not evaluable (NA). (NCT00601172)
Timeframe: 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Hours (Median) |
|---|---|
| Placebo | NA |
| Casopitant 90 mg | NA |
Vital signs assessment included DBP and SBP. SBP and DBP were recorded at Screening, on Day 1 of each cycle immediately before start of the investigational product infusion, at the completion of the infusion, and immediately after the end of the oxaliplatin infusion, then again at each end of cycle visit. Mean SBP and DBP are presented. (NCT00601172)
Timeframe: Up to End of Cycle for 6 cycles, an average of 24 days per cycle
| Intervention | Millimeters of mercury (mmHg) (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DBP: Cycle 1, post-oxaliplatin | DBP: Cycle 1, End of cycle | DBP: Cycle 2, post-oxaliplatin | DBP: Cycle 2, End of cycle | DBP: Cycle 3, post-oxaliplatin | DBP: Cycle 3, End of cycle | DBP: Cycle 4, post-oxaliplatin | DBP: Cycle 4, End of cycle | DBP: Cycle 5, post-oxaliplatin | DBP: Cycle 5, End of cycle | DBP: Cycle 6, post-oxaliplatin | DBP: Cycle 6, End of cycle | SBP: Cycle 1, post-oxaliplatin | SBP: Cycle 1, End of cycle | SBP: Cycle 2, post-oxaliplatin | SBP: Cycle 2, End of cycle | SBP: Cycle 3, post-oxaliplatin | SBP: Cycle 3, End of cycle | SBP: Cycle 4, post-oxaliplatin | SBP: Cycle 4, End of cycle | SBP: Cycle 5, post-oxaliplatin | SBP: Cycle 5, End of cycle | SBP: Cycle 6, post-oxaliplatin | SBP: Cycle 6, End of cycle | |
| Casopitant 90 mg | 76.5 | 76.5 | 76.8 | 77.1 | 76.6 | 77.2 | 76.9 | 76.4 | 77.7 | 77.7 | 77.6 | 77.5 | 126.8 | 126.7 | 129.3 | 127.8 | 128.7 | 127.7 | 129.0 | 128.3 | 129.7 | 128.8 | 131.5 | 129.1 |
| Placebo | 77.2 | 76.9 | 77.7 | 76.8 | 78.0 | 77.3 | 78.2 | 76.8 | 77.4 | 77.1 | 77.9 | 77.9 | 130.6 | 128.7 | 130.1 | 128.9 | 131.0 | 128.8 | 131.8 | 128.0 | 131.3 | 128.6 | 132.2 | 129.7 |
Vital sign included heart rate which was recorded at Screening, on Day 1 of each cycle immediately before start of the investigational product infusion, at the completion of the infusion, and immediately after the end of the oxaliplatin infusion, then again at each end of cycle visit. Mean heart rate is presented. (NCT00601172)
Timeframe: Up to End of Cycle for 6 cycles, an average of 24 days per cycle
| Intervention | Beats/minute (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, post-oxaliplatin | Cycle 1, End of cycle | Cycle 2, post-oxaliplatin | Cycle 2, End of cycle | Cycle 3, post-oxaliplatin | Cycle 3, End of cycle | Cycle 4, post-oxaliplatin | Cycle 4, End of cycle | Cycle 5, post-oxaliplatin | Cycle 5, End of cycle | Cycle 6, post-oxaliplatin | Cycle 6, End of cycle | |
| Casopitant 90 mg | 73.7 | 75.3 | 73.7 | 74.7 | 72.2 | 75.4 | 72.2 | 74.7 | 72.9 | 75.0 | 73.4 | 75.6 |
| Placebo | 73.1 | 75.1 | 73.0 | 74.8 | 73.2 | 74.9 | 72.6 | 75.0 | 72.8 | 74.7 | 73.5 | 74.7 |
VAS was used to assess severity of nausea. The participants rated the severity of nausea by marking a line on a 100 millimeter (mm) (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no nausea and extreme right that is 100 mm indicated nausea as bad as it can be. This scale has no subscales. The participant perception of their symptoms was measured using the VAS. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Scores on a Scale (Mean) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 16.0 | 5.3 | 15.3 |
| Placebo | 13.5 | 4.3 | 13.0 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly or birth defect. Any SAEs assessed as related to study participation (e.g. study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK product was recorded from the time a participant consents to participate in the study up to and including any follow-up contact. (NCT00601172)
Timeframe: Up to 35 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AE | SAE | |
| Casopitant 90 mg | 171 | 26 |
| Placebo | 176 | 23 |
Grade shifts from Baseline were assessed as shift from any Grade to Grade 3 or Grade 4 in any cycle. Toxicities were graded according to the NCI-CTCAE, version 3.0. Grade refers to the severity of the toxicity. The NCI-CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on the following general guideline: Grade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE and Grade 5: Death related to AE. It was assessed on Baseline (Day 1), during Day 6-10 and end of cycle. Clinical chemistry parameters assessed were alanine amino transferase (ALT), aspartate amino transferase (AST), chloride, glucose, potassium, sodium and total bilirubin. Data has been presented for the number of participants with chemistry toxicity grade shifts from Baseline to toxicity grade 3 and 4 for all cycles in a consolidated format. (NCT00601172)
Timeframe: Up to Day 24
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT: All cycles, Grade 0 to 3 | ALT: All cycles, Grade 2 to 3 | AST: All cycles, Grade 0 to 3 | High chloride: All cycles, Grade 1 to 3 | Low chloride: All cycles, Grade 0 to 3 | Hyperglycemia: Al cycles, Grade 0 to 3 | Hyperglycemia: All cycles, Grade 1 to 3 | Hyperglycemia: All cycles, Grade 2 to 3 | Hyperglycemia: All cycles, Grade 3 to 3 | Hypoglycemia: All cycles, Grade 0 to 4 | Hyperkalemia: All cycles, Grade 2 to 3 | Hyperkalemia: All cycles, Grade 4 to 3 | Hyperkalemia: All cycles, Grade 0 to 3 | Hyperkalemia: All cycles, Grade 0 to 4 | Hypokalemia: All cycles, Grade 0 to 3 | Hyponatremia: All cycles, Grade 1 to 3 | Total Bilirubin: All cycles, Grade 0 to 3 | Total Bilirubin: All cycles, Grade 0 to 4 | |
| Casopitant 90 mg | 2 | 0 | 1 | 0 | 1 | 3 | 2 | 5 | 3 | 1 | 0 | 0 | 2 | 2 | 8 | 8 | 1 | 0 |
| Placebo | 1 | 1 | 0 | 2 | 0 | 1 | 1 | 9 | 3 | 1 | 1 | 1 | 0 | 0 | 6 | 6 | 1 | 1 |
Grade shifts from Baseline were assessed as shift from any Grade to Grade 3 or Grade 4 in any cycle. Toxicities were graded according to the National Cancer Institute common toxicity criteria for adverse events (NCI-CTCAE), version 3.0. Grade refers to the severity of the toxicity. The NCI-CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on the following general guideline: Grade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE and Grade 5: Death related to AE. It was assessed on Baseline (Day 1), during Day 6-10 and end of cycle. Hematology parameters assessed were hematocrit, hemoglobin, platelet count, total neutrophils and white blood cell count. Data has been presented for the number of participants with hematology toxicity grade shifts from Baseline to toxicity grade 3 and 4 for all cycles in a consolidated format. (NCT00601172)
Timeframe: Baseline (Day 1) to Day 24
| Intervention | Participants (Count of Participants) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hematocrit: All cycles, Grade 2 to Grade 3 | Hemoglobin: All cycles, Grade 1 to Grade 3 | Hemoglobin: All cycles, Grade 2 to Grade 3 | Hemoglobin: All cycles, Grade 3 to Grade 3 | Platelet count: All cycles, Grade 0 to 3 | Total Neutrophils: All cycles, Grade 0 to 3 | Total Neutrophils: All cycles, Grade 1 to 3 | Total Neutrophils: All cycles, Grade 2 to 3 | White Blood Cell count: All cycles, Grade 0 to 3 | White Blood Cell count: All cycles, Grade 1 to 3 | White Blood Cell count: All cycles, Grade 2 to 3 | |
| Casopitant 90 mg | 1 | 0 | 1 | 2 | 1 | 37 | 1 | 0 | 5 | 1 | 2 |
| Placebo | 0 | 2 | 3 | 0 | 1 | 24 | 0 | 1 | 10 | 0 | 1 |
Complete protection was defined as no vomiting/retching, no use of rescue medication and no significant nausea. Percentage of participants who achieved complete protection or complete responders with no significant nausea are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 74 | 93 | 74 |
| Placebo | 75 | 93 | 75 |
Total control was defined as no vomiting/retching, no use of rescue medication and no nausea. Percentage of participants who achieved total control or complete responders with no nausea are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 54 | 83 | 54 |
| Placebo | 61 | 88 | 61 |
Anti-emetic rescue medication was defined as medication that was administered specifically for the treatment of nausea and/or emesis during Days 1-6 of each cycle. The choice of rescue anti-emetic medication was left to the discretion of the investigator. Participants who required antiemetic rescue medication(s) during the 120-hour assessment period were considered treatment failures for that cycle. Percentage of participants who received rescue medication are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 8 | 1 | 8 |
| Placebo | 9 | 2 | 9 |
VAS was used to assess severity of nausea. The participants rated the severity of nausea by marking a line on a 100 mm (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no nausea and extreme right that is 100 mm indicated nausea as bad as it can be. This scale has no subscales. The participant perception of their symptoms was measured using the VAS. Percentage of participants who reported nausea, defined as a maximum score of >= 5 mm on the VAS are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 45 | 15 | 45 |
| Placebo | 37 | 12 | 37 |
VAS was used to assess severity of nausea. The participants rated the severity of nausea by marking a line on a 100 mm (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no nausea and extreme right that is 100 mm indicated nausea as bad as it can be. This scale has no subscales. The participant perception of their symptoms was measured using the VAS. Percentage of participants who reported significant nausea, defined as a maximum score >= 25 mm on the VAS are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 21 | 5 | 21 |
| Placebo | 19 | 4 | 19 |
Vomiting was defined as the forceful expulsion of gastrointestinal contents through the mouth or nose. Retching was defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit, that is not productive of gastrointestinal contents (also known as dry heaves). If a participant took rescue medication but there was no evidence of vomiting or retching, then the participant was considered as not having vomited. Percentage of participants who vomited and/or retched during the first 120 hours of the first cycle of chemotherapy are presented. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 0-120 hours | 0-24 hours | 24-120 hours | |
| Casopitant 90 mg | 10 | 2 | 10 |
| Placebo | 11 | 3 | 11 |
FLIE questionnaire specifically addresses the impact of nausea and vomiting on daily activities (physical, social and emotional function, ability to enjoy meals). It consists of 18 items with questions divided into two domains: Nausea (questions 1-9) and Vomiting (questions 10-18). Each item is scored on a VAS with 7 hatch marks. The scale is anchored at 1 (Not at all) and 7 (A great deal). For questions 1,2,4,5,7,8-10,12-14,16 and 17 the final score was calculated by subtracting the initial score from 100 for questions 3,6,11,15 and 18 the final score was the one provided in the dataset. The score for the nausea domain: ([sum of nausea item scores] ÷ [Number of items answered] x 9) and for vomiting domain: ([sum of vomiting item scores] ÷ [Number of items answered] x 9). The total score was the sum of the nausea and vomiting domain scores. Higher scores indicate less impairment on daily life as a result of nausea or vomiting. (NCT00601172)
Timeframe: 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Nausea impact | Vomiting impact | |
| Casopitant 90 mg | 23.7 | 11.5 |
| Placebo | 21.3 | 12.5 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the electronic case report form (eCRF). Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. AUC(0-∞), AUC(0-t), AUC(0-24) for casopitant and metabolites GSK525060, GSK517142 and GSK631832 are presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Hour*nanogram/milliliter (hr*ng/mL) (Geometric Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Casopitant: AUC(0-24) | Casopitant: AUC(0-inf) | Casopitant: AUC(0-t) | GSK525060: AUC(0-24) | GSK525060: AUC(0-t) | GSK517142: AUC(0-24) | GSK517142: AUC(0-t) | GSK631832: AUC(0-24) | GSK631832: AUC(0-t) | |
| Casopitant 90 mg | 6913.626 | 8607.049 | 7688.562 | 2247.290 | 2796.734 | 49.964 | 40.997 | 165.550 | 231.018 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the electronic case report form (eCRF). Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. (Cmax) for casopitant and metabolites GSK525060, GSK517142 and GSK631832 are presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Nanogram/milliliter (ng/mL) (Geometric Mean) | |||
|---|---|---|---|---|
| Casopitant | GSK525060 | GSK517142 | GSK631832 | |
| Casopitant 90 mg | 2078.776 | 143.038 | 3.426 | 9.853 |
Blood samples were obtained during Cycle 1 at the following times relative to the investigational product administration: pre-dose, end of infusion, 0.5, 1, 3, 5, 8, 12, 16, and 24 hours after the end of infusion. A final PK sample was collected between 30 and 48 hours after the investigational product infusion had completed. The actual time each sample was collected was captured to the nearest minute in the eCRF. Following unblinding, only those participants who had been randomized to receive casopitant were included in the PK analyses. Tmax and t1/2 for casopitant and metabolites GSK525060, GSK517142 and GSK631832 are presented. (NCT00601172)
Timeframe: Pre-dose, end of infusion and 0.5, 1, 3, 5, 8, 12, 16, 24 hours after the end of infusion
| Intervention | Hour (Median) | ||||
|---|---|---|---|---|---|
| Casopitant: Tmax | Casopitant: t1/2 | GSK525060: Tmax | GSK517142: Tmax | GSK631832: Tmax | |
| Casopitant 90 mg | 0.520 | 12.347 | 3.580 | 1.500 | 5.500 |
Participants were asked to rate the level of nausea he/she experienced over the previous (24 hours for a period of 120 hours following the administration of MEC), by placing a vertical mark on a VAS. The severity of nausea and was calculated by using a 0 - 100 VAS where 0 = No Nausea and 100 = Nausea as bad as it can be. The categorical scale assessed the participants severity of his/her nausea using the following: mild: Queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit/throw up (but not vomiting), that has significant negative effect on the daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others) and severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities. Higher scores indicated worst outcome. (NCT00601172)
Timeframe: 0 to 24 hours, 24 to 120 hours and 0 to 120 hours in the first cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0-120 hours72379989 | 0-120 hours72379990 | 0-24 hours72379989 | 0-24 hours72379990 | 24-120 hours72379990 | 24-120 hours72379989 | |||||||||||||||||||
| Mild | Moderate | Severe | None | |||||||||||||||||||||
| Placebo | 218 | |||||||||||||||||||||||
| Placebo | 73 | |||||||||||||||||||||||
| Casopitant 90 mg | 97 | |||||||||||||||||||||||
| Placebo | 49 | |||||||||||||||||||||||
| Casopitant 90 mg | 54 | |||||||||||||||||||||||
| Placebo | 12 | |||||||||||||||||||||||
| Casopitant 90 mg | 12 | |||||||||||||||||||||||
| Placebo | 313 | |||||||||||||||||||||||
| Casopitant 90 mg | 299 | |||||||||||||||||||||||
| Placebo | 23 | |||||||||||||||||||||||
| Casopitant 90 mg | 40 | |||||||||||||||||||||||
| Placebo | 13 | |||||||||||||||||||||||
| Casopitant 90 mg | 15 | |||||||||||||||||||||||
| Placebo | 3 | |||||||||||||||||||||||
| Casopitant 90 mg | 1 | |||||||||||||||||||||||
| Casopitant 90 mg | 192 | |||||||||||||||||||||||
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after eversion of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After eversion of the uterus until replacement of the uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 1.28 |
| Acupressure Point P6 | 1.09 |
| Scopolamine Patch + Acupressure Point P6 | 1.40 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after replacement of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After replacement of the uterus and to the next 15 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.19 |
| Acupressure Point P6 | 2.19 |
| Scopolamine Patch + Acupressure Point P6 | 2.51 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after the administration of the regional anesthesia medications. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: From administration of anaesthesia until eversion of uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.71 |
| Acupressure Point P6 | 2.57 |
| Scopolamine Patch + Acupressure Point P6 | 2.84 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) upon arrival to the post-operative recovery room. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: 15 minutes after replacement of the uterus to arrival at post-anaesthesia care unit
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 0.18 |
| Acupressure Point P6 | 0.25 |
| Scopolamine Patch + Acupressure Point P6 | 0.23 |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02960113)
Timeframe: Throughout the entire surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 40 |
| Acupressure Point P6 | 39 |
| Scopolamine Patch + Acupressure Point P6 | 46 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 24 |
| Acupressure Point P6 | 25 |
| Scopolamine Patch + Acupressure Point P6 | 31 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After eversion of to replacement of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 8 |
| Acupressure Point P6 | 6 |
| Scopolamine Patch + Acupressure Point P6 | 9 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After replacement of the uterus and for next 15 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 10 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 12 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After the administration of the regional anesthesia medications until eversion of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 20 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 20 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: From 15 minutes after replacement of the uterus until arrival at the post-anaesthesia care unit
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 1 |
| Acupressure Point P6 | 1 |
| Scopolamine Patch + Acupressure Point P6 | 4 |
Patients are asked their nausea and vomiting treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Patients are also asked their overall satisfaction with the procedure (0 = Not Satisfied, 10 = Extremely Satisfied). (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 9.29 |
| Acupressure Point P6 | 8.96 |
| Scopolamine Patch + Acupressure Point P6 | 9.59 |
The incidence of significant QTc prolongation was measured by comparing baseline EKG, 24 hours and 120 hours after surgery (NCT02635828)
Timeframe: 24 and 120 hours/discharge after end of surgery
| Intervention | participants (Number) |
|---|---|
| Triple Therapy PONV Prohylaxis | 0 |
The incidence of PONV (NCT02635828)
Timeframe: 24 hours after end of surgery
| Intervention | participants (Number) |
|---|---|
| Triple Therapy PONV Prohylaxis | 12 |
"Primary outcome is nausea and vomiting measured on a scale from 0 (no nausea) to 10 (worst nausea imaginable) Verbal Numerical Response Scale (VNRS) at 10 minutes post intervention." (NCT02092441)
Timeframe: 10 minutes post intervention
| Intervention | VNRS (Median) |
|---|---|
| Alcohol Prep Pad Group | 3 |
| Normal Saline Prep Pad | 6 |
"Patient satisfaction of smelling prep pad to alleviate nausea on a scale from 1 (completely unsatisfied) to 5 (completely satisfied)" (NCT02092441)
Timeframe: 10 minutes post intervention
| Intervention | 5 point Likert Scale (Median) |
|---|---|
| Alcohol Prep Pad Group | 4 |
| Normal Saline Prep Pad | 2 |
"Scale ranges from 0 (no pain) to 10 (worst pain imaginable)" (NCT02092441)
Timeframe: 10 minutes post intervention
| Intervention | VNRS (Median) |
|---|---|
| Alcohol Prep Pad Group | 6 |
| Normal Saline Prep Pad | 6 |
Anesthesia start time determined from anesthesia portion of the medical record. Time at which discharge order was placed will serve as time of discharge. (NCT01592708)
Timeframe: Anesthesia start time to placement of hospital discharge order - average 26 - 28 hours
| Intervention | hours (Median) |
|---|---|
| Intervention Cohort | 26.4 |
| Comparison Cohort | 28.2 |
To be assessed based on patient diary completed daily for 1 week following discharge to home from the hospital (NCT01592708)
Timeframe: 1 week from discharge from hospital
| Intervention | percentage of subjects with PDN (Number) |
|---|---|
| Intervention Cohort | 72 |
| Comparison Cohort | 60 |
(NCT01592708)
Timeframe: 1 week post discharge
| Intervention | percentage of subjects with PDV (Number) |
|---|---|
| Intervention Cohort | 22 |
| Comparison Cohort | 29 |
End of surgery time determined by anesthesia portion of the medical record. PONV to be assessed by review of surgeons' and nurses' notes in the medical record as well as through review of patient diaries. Vomiting constitutes a safety issue and, as such, associated adverse events will be noted. (NCT01592708)
Timeframe: End of surgery to discharge from hospital
| Intervention | percentage of subjects with PON (Number) |
|---|---|
| Intervention Cohort | 24 |
| Comparison Cohort | 70 |
(NCT01592708)
Timeframe: End of surgery to discharge from hospital
| Intervention | percentage of subjects with POV (Number) |
|---|---|
| Intervention Cohort | 11 |
| Comparison Cohort | 28 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
96 reviews available for ondansetron and Nausea
| Article | Year |
|---|---|
Isopropyl alcohol inhalation for the treatment of nausea in adult emergency department patients: a systematic review and meta-analysis.
Topics: 2-Propanol; Adult; Emergency Service, Hospital; Humans; Nausea; Ondansetron; Vomiting | 2023 |
Isopropyl alcohol inhalation for the treatment of nausea in adult emergency department patients: a systematic review and meta-analysis.
Topics: 2-Propanol; Adult; Emergency Service, Hospital; Humans; Nausea; Ondansetron; Vomiting | 2023 |
Isopropyl alcohol inhalation for the treatment of nausea in adult emergency department patients: a systematic review and meta-analysis.
Topics: 2-Propanol; Adult; Emergency Service, Hospital; Humans; Nausea; Ondansetron; Vomiting | 2023 |
Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review.
Topics: Antiemetics; Drug Combinations; Drug Stability; Humans; Infusions, Parenteral; Nausea; Ondansetron; | 2017 |
Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review.
Topics: Antiemetics; Drug Combinations; Drug Stability; Humans; Infusions, Parenteral; Nausea; Ondansetron; | 2017 |
Chemical stability of ondansetron hydrochloride with other drugs in admixtures via parenteral; a review.
Topics: Antiemetics; Drug Combinations; Drug Stability; Humans; Infusions, Parenteral; Nausea; Ondansetron; | 2017 |
Efficacy of ondansetron for spinal anesthesia during cesarean section: a meta-analysis of randomized trials.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Local; Antiemetics; Bradycardia; Cesarean Section; Female; H | 2018 |
Efficacy of ondansetron for spinal anesthesia during cesarean section: a meta-analysis of randomized trials.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Local; Antiemetics; Bradycardia; Cesarean Section; Female; H | 2018 |
Efficacy of ondansetron for spinal anesthesia during cesarean section: a meta-analysis of randomized trials.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Local; Antiemetics; Bradycardia; Cesarean Section; Female; H | 2018 |
Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management.
Topics: Acute Disease; Antiemetics; Combined Modality Therapy; Fluid Therapy; Gastroenteritis; Humans; Nause | 2018 |
Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management.
Topics: Acute Disease; Antiemetics; Combined Modality Therapy; Fluid Therapy; Gastroenteritis; Humans; Nause | 2018 |
Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management.
Topics: Acute Disease; Antiemetics; Combined Modality Therapy; Fluid Therapy; Gastroenteritis; Humans; Nause | 2018 |
Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
Topics: Adult; Ambulatory Care Facilities; Antiemetics; Humans; Medical Oncology; Middle Aged; Nausea; Neopl | 2019 |
Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
Topics: Adult; Ambulatory Care Facilities; Antiemetics; Humans; Medical Oncology; Middle Aged; Nausea; Neopl | 2019 |
Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
Topics: Adult; Ambulatory Care Facilities; Antiemetics; Humans; Medical Oncology; Middle Aged; Nausea; Neopl | 2019 |
Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Humans; Nausea; Ondansetron; Randomized Co | 2013 |
Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Humans; Nausea; Ondansetron; Randomized Co | 2013 |
Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Humans; Nausea; Ondansetron; Randomized Co | 2013 |
Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts.
Topics: Antiemetics; Antineoplastic Agents; Haloperidol; Humans; Nausea; Ondansetron; Palliative Care; Posto | 2013 |
Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts.
Topics: Antiemetics; Antineoplastic Agents; Haloperidol; Humans; Nausea; Ondansetron; Palliative Care; Posto | 2013 |
Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts.
Topics: Antiemetics; Antineoplastic Agents; Haloperidol; Humans; Nausea; Ondansetron; Palliative Care; Posto | 2013 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinucl | 2013 |
WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinucl | 2013 |
WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinucl | 2013 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinoline | 2014 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinoline | 2014 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinoline | 2014 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Latest advances in the management of radiation-induced pain flare, nausea and vomiting.
Topics: Antiemetics; Bone Neoplasms; Dexamethasone; Humans; Methylprednisolone; Musculoskeletal Pain; Nausea | 2016 |
Latest advances in the management of radiation-induced pain flare, nausea and vomiting.
Topics: Antiemetics; Bone Neoplasms; Dexamethasone; Humans; Methylprednisolone; Musculoskeletal Pain; Nausea | 2016 |
Latest advances in the management of radiation-induced pain flare, nausea and vomiting.
Topics: Antiemetics; Bone Neoplasms; Dexamethasone; Humans; Methylprednisolone; Musculoskeletal Pain; Nausea | 2016 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2016 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2016 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2016 |
Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Nausea; Neoplasms; Ondansetron; Quality of Life; Randomi | 2016 |
Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Nausea; Neoplasms; Ondansetron; Quality of Life; Randomi | 2016 |
Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Nausea; Neoplasms; Ondansetron; Quality of Life; Randomi | 2016 |
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans | 2016 |
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans | 2016 |
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans | 2016 |
Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Dexamethasone; | 2017 |
Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Dexamethasone; | 2017 |
Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Dexamethasone; | 2017 |
[Prophylaxis of chemotherapy-induced vomiting and nausea].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Aprepitant; Granisetron; Humans; Morpho | 2008 |
[Prophylaxis of chemotherapy-induced vomiting and nausea].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Aprepitant; Granisetron; Humans; Morpho | 2008 |
[Prophylaxis of chemotherapy-induced vomiting and nausea].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Aprepitant; Granisetron; Humans; Morpho | 2008 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Huma | 2009 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Huma | 2009 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Huma | 2009 |
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Dexamethasone; Dose-Response Relations | 1998 |
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Dexamethasone; Dose-Response Relations | 1998 |
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Dexamethasone; Dose-Response Relations | 1998 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinucl | 2010 |
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinucl | 2010 |
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinucl | 2010 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indol | 2010 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indol | 2010 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indol | 2010 |
Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy.
Topics: Antiemetics; Evidence-Based Medicine; Female; Humans; Infusions, Subcutaneous; Metoclopramide; Nause | 2012 |
Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy.
Topics: Antiemetics; Evidence-Based Medicine; Female; Humans; Infusions, Subcutaneous; Metoclopramide; Nause | 2012 |
Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy.
Topics: Antiemetics; Evidence-Based Medicine; Female; Humans; Infusions, Subcutaneous; Metoclopramide; Nause | 2012 |
Progress in preventing chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Granisetron; Humans; Indoles; Nausea; Neurotransm | 2002 |
Progress in preventing chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Granisetron; Humans; Indoles; Nausea; Neurotransm | 2002 |
Progress in preventing chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Granisetron; Humans; Indoles; Nausea; Neurotransm | 2002 |
Nausea and vomiting of pregnancy.
Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru | 2003 |
Nausea and vomiting of pregnancy.
Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru | 2003 |
Nausea and vomiting of pregnancy.
Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru | 2003 |
Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Granisetron; Humans; Indoles; Nausea; | 2003 |
Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Granisetron; Humans; Indoles; Nausea; | 2003 |
Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Granisetron; Humans; Indoles; Nausea; | 2003 |
First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Topics: Age Factors; Aged; Antiemetics; Drug Resistance; Granisetron; Humans; Nausea; Neoplasms; Ondansetron | 2004 |
First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Topics: Age Factors; Aged; Antiemetics; Drug Resistance; Granisetron; Humans; Nausea; Neoplasms; Ondansetron | 2004 |
First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Topics: Age Factors; Aged; Antiemetics; Drug Resistance; Granisetron; Humans; Nausea; Neoplasms; Ondansetron | 2004 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome | 2004 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome | 2004 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome | 2004 |
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Clinical Trials, | 2007 |
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Clinical Trials, | 2007 |
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Clinical Trials, | 2007 |
Coronary spasm after injection of ondansetron: case report and review of the literature.
Topics: Acute Coronary Syndrome; Coronary Vasospasm; Cyclophosphamide; Electrocardiography; Female; Follow-U | 2008 |
Coronary spasm after injection of ondansetron: case report and review of the literature.
Topics: Acute Coronary Syndrome; Coronary Vasospasm; Cyclophosphamide; Electrocardiography; Female; Follow-U | 2008 |
Coronary spasm after injection of ondansetron: case report and review of the literature.
Topics: Acute Coronary Syndrome; Coronary Vasospasm; Cyclophosphamide; Electrocardiography; Female; Follow-U | 2008 |
Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Evidence-Based Medicine; Granisetron; | 2007 |
Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Evidence-Based Medicine; Granisetron; | 2007 |
Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Evidence-Based Medicine; Granisetron; | 2007 |
Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Humans; Nausea; Ond | 1993 |
Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Humans; Nausea; Ond | 1993 |
Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Humans; Nausea; Ond | 1993 |
[Efficacy of ondansetron in radiation-induced nausea and vomiting: review of the literature].
Topics: Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1994 |
[Efficacy of ondansetron in radiation-induced nausea and vomiting: review of the literature].
Topics: Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1994 |
[Efficacy of ondansetron in radiation-induced nausea and vomiting: review of the literature].
Topics: Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1994 |
Recent advances in the understanding and management of postoperative nausea and vomiting.
Topics: Antiemetics; Child; Female; Humans; Male; Nausea; Ondansetron; Postoperative Complications; Serotoni | 1994 |
Recent advances in the understanding and management of postoperative nausea and vomiting.
Topics: Antiemetics; Child; Female; Humans; Male; Nausea; Ondansetron; Postoperative Complications; Serotoni | 1994 |
Recent advances in the understanding and management of postoperative nausea and vomiting.
Topics: Antiemetics; Child; Female; Humans; Male; Nausea; Ondansetron; Postoperative Complications; Serotoni | 1994 |
The clinical use of ondansetron. New South Wales Therapeutic Assessment Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; D | 1995 |
The clinical use of ondansetron. New South Wales Therapeutic Assessment Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; D | 1995 |
The clinical use of ondansetron. New South Wales Therapeutic Assessment Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; D | 1995 |
Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions.
Topics: Adult; Aged; Analgesics, Opioid; Child; Drug Administration Schedule; Female; Humans; Nausea; Ondans | 1994 |
Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions.
Topics: Adult; Aged; Analgesics, Opioid; Child; Drug Administration Schedule; Female; Humans; Nausea; Ondans | 1994 |
Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions.
Topics: Adult; Aged; Analgesics, Opioid; Child; Drug Administration Schedule; Female; Humans; Nausea; Ondans | 1994 |
Delayed emesis following anticancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Dexamethasone; Huma | 1994 |
Delayed emesis following anticancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Dexamethasone; Huma | 1994 |
Delayed emesis following anticancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Dexamethasone; Huma | 1994 |
Oral ondansetron for preventing nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Humans; Nausea; Ondansetron; Vomiting | 1994 |
Oral ondansetron for preventing nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Humans; Nausea; Ondansetron; Vomiting | 1994 |
Oral ondansetron for preventing nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Humans; Nausea; Ondansetron; Vomiting | 1994 |
Antiemetics in cancer chemotherapy: historical perspective and current state of the art.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Nausea; Neoplasms; Ondansetron | 1994 |
Antiemetics in cancer chemotherapy: historical perspective and current state of the art.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Nausea; Neoplasms; Ondansetron | 1994 |
Antiemetics in cancer chemotherapy: historical perspective and current state of the art.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Nausea; Neoplasms; Ondansetron | 1994 |
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Metoclopramide; Nausea; Ondan | 1994 |
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Metoclopramide; Nausea; Ondan | 1994 |
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Metoclopramide; Nausea; Ondan | 1994 |
Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Ev | 1993 |
Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Ev | 1993 |
Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Ev | 1993 |
Ondansetron in the treatment of nausea and vomiting. Introduction.
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Evaluation; Drug Therapy, Combinatio | 1993 |
Ondansetron in the treatment of nausea and vomiting. Introduction.
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Evaluation; Drug Therapy, Combinatio | 1993 |
Ondansetron in the treatment of nausea and vomiting. Introduction.
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Evaluation; Drug Therapy, Combinatio | 1993 |
[Ondansetron--a new anesthesia relevant antiemetic?].
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
[Ondansetron--a new anesthesia relevant antiemetic?].
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
[Ondansetron--a new anesthesia relevant antiemetic?].
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Child; Cisplatin; Clinical Trials, Phase I as To | 1994 |
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Child; Cisplatin; Clinical Trials, Phase I as To | 1994 |
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Child; Cisplatin; Clinical Trials, Phase I as To | 1994 |
[An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Topics: Antineoplastic Agents; Granisetron; Humans; Metoclopramide; Nausea; Ondansetron; Serotonin Antagonis | 1993 |
[An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Topics: Antineoplastic Agents; Granisetron; Humans; Metoclopramide; Nausea; Ondansetron; Serotonin Antagonis | 1993 |
[An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Topics: Antineoplastic Agents; Granisetron; Humans; Metoclopramide; Nausea; Ondansetron; Serotonin Antagonis | 1993 |
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1993 |
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1993 |
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1993 |
Review of experience with ondansetron and granisetron.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin A | 1993 |
Review of experience with ondansetron and granisetron.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin A | 1993 |
Review of experience with ondansetron and granisetron.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin A | 1993 |
Ondansetron for postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1993 |
Ondansetron for postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1993 |
Ondansetron for postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1993 |
Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indoles; Nausea; Ondansetron; Serotonin Ant | 1995 |
Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indoles; Nausea; Ondansetron; Serotonin Ant | 1995 |
Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indoles; Nausea; Ondansetron; Serotonin Ant | 1995 |
Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1995 |
Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1995 |
Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1995 |
Ondansetron.
Topics: Administration, Oral; Adult; Antiemetics; Child; Child, Preschool; Clinical Trials as Topic; Drug-Re | 1995 |
Ondansetron.
Topics: Administration, Oral; Adult; Antiemetics; Child; Child, Preschool; Clinical Trials as Topic; Drug-Re | 1995 |
Ondansetron.
Topics: Administration, Oral; Adult; Antiemetics; Child; Child, Preschool; Clinical Trials as Topic; Drug-Re | 1995 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 1996 |
[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 1996 |
[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 1996 |
[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Topics: Antiemetics; Clinical Trials as Topic; Dose-Response Relationship, Drug; Granisetron; Humans; Indole | 1996 |
[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Topics: Antiemetics; Clinical Trials as Topic; Dose-Response Relationship, Drug; Granisetron; Humans; Indole | 1996 |
[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Topics: Antiemetics; Clinical Trials as Topic; Dose-Response Relationship, Drug; Granisetron; Humans; Indole | 1996 |
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
Topics: Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
Topics: Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
Topics: Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
[A new antiemetic ramosetron hydrochloride].
Topics: Animals; Antiemetics; Antineoplastic Agents; Benzimidazoles; Granisetron; Guinea Pigs; Humans; Male; | 1997 |
[A new antiemetic ramosetron hydrochloride].
Topics: Animals; Antiemetics; Antineoplastic Agents; Benzimidazoles; Granisetron; Guinea Pigs; Humans; Male; | 1997 |
[A new antiemetic ramosetron hydrochloride].
Topics: Animals; Antiemetics; Antineoplastic Agents; Benzimidazoles; Granisetron; Guinea Pigs; Humans; Male; | 1997 |
Drug treatment of chemotherapy-induced delayed emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1996 |
Drug treatment of chemotherapy-induced delayed emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1996 |
Drug treatment of chemotherapy-induced delayed emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1996 |
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
Topics: Animals; Antiemetics; Brain; Colonic Diseases, Functional; Digestive System; Drug Interactions; Drug | 1996 |
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
Topics: Animals; Antiemetics; Brain; Colonic Diseases, Functional; Digestive System; Drug Interactions; Drug | 1996 |
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
Topics: Animals; Antiemetics; Brain; Colonic Diseases, Functional; Digestive System; Drug Interactions; Drug | 1996 |
A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting.
Topics: Antiemetics; Dose-Response Relationship, Drug; Humans; Nausea; Ondansetron; Postoperative Complicati | 1997 |
A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting.
Topics: Antiemetics; Dose-Response Relationship, Drug; Humans; Nausea; Ondansetron; Postoperative Complicati | 1997 |
A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting.
Topics: Antiemetics; Dose-Response Relationship, Drug; Humans; Nausea; Ondansetron; Postoperative Complicati | 1997 |
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Filgrastim; Gra | 1994 |
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Filgrastim; Gra | 1994 |
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Filgrastim; Gra | 1994 |
[Recent improvements in antiemetic therapy].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron | 1997 |
[Recent improvements in antiemetic therapy].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron | 1997 |
[Recent improvements in antiemetic therapy].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron | 1997 |
5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Nausea; Ondansetron; Serotonin Antagonists; | 1997 |
5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Nausea; Ondansetron; Serotonin Antagonists; | 1997 |
5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Nausea; Ondansetron; Serotonin Antagonists; | 1997 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
[Serotonin antagonists in the treatment of postoperative nausea and vomiting].
Topics: Adult; Antiemetics; Child; Humans; Nausea; Ondansetron; Postoperative Complications; Serotonin Antag | 1998 |
[Serotonin antagonists in the treatment of postoperative nausea and vomiting].
Topics: Adult; Antiemetics; Child; Humans; Nausea; Ondansetron; Postoperative Complications; Serotonin Antag | 1998 |
[Serotonin antagonists in the treatment of postoperative nausea and vomiting].
Topics: Adult; Antiemetics; Child; Humans; Nausea; Ondansetron; Postoperative Complications; Serotonin Antag | 1998 |
When placebo controlled trials are essential and equivalence trials are inadequate.
Topics: Antiemetics; Control Groups; Controlled Clinical Trials as Topic; Data Interpretation, Statistical; | 1998 |
When placebo controlled trials are essential and equivalence trials are inadequate.
Topics: Antiemetics; Control Groups; Controlled Clinical Trials as Topic; Data Interpretation, Statistical; | 1998 |
When placebo controlled trials are essential and equivalence trials are inadequate.
Topics: Antiemetics; Control Groups; Controlled Clinical Trials as Topic; Data Interpretation, Statistical; | 1998 |
Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review.
Topics: Antiemetics; Granisetron; Humans; Nausea; Ondansetron; Radiotherapy; Randomized Controlled Trials as | 1998 |
Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review.
Topics: Antiemetics; Granisetron; Humans; Nausea; Ondansetron; Radiotherapy; Randomized Controlled Trials as | 1998 |
Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review.
Topics: Antiemetics; Granisetron; Humans; Nausea; Ondansetron; Radiotherapy; Randomized Controlled Trials as | 1998 |
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Topics: Costs and Cost Analysis; Drug Therapy; Drug Tolerance; Economics, Pharmaceutical; Forecasting; Formu | 1992 |
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Topics: Costs and Cost Analysis; Drug Therapy; Drug Tolerance; Economics, Pharmaceutical; Forecasting; Formu | 1992 |
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Topics: Costs and Cost Analysis; Drug Therapy; Drug Tolerance; Economics, Pharmaceutical; Forecasting; Formu | 1992 |
Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review.
Topics: Administration, Oral; Adrenal Cortex Hormones; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 1999 |
Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review.
Topics: Administration, Oral; Adrenal Cortex Hormones; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 1999 |
Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review.
Topics: Administration, Oral; Adrenal Cortex Hormones; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 1999 |
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
Topics: Antiemetics; Antineoplastic Agents; Cross-Over Studies; Granisetron; Humans; Nausea; Neoplasms; Onda | 2000 |
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
Topics: Antiemetics; Antineoplastic Agents; Cross-Over Studies; Granisetron; Humans; Nausea; Neoplasms; Onda | 2000 |
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
Topics: Antiemetics; Antineoplastic Agents; Cross-Over Studies; Granisetron; Humans; Nausea; Neoplasms; Onda | 2000 |
Ondansetron: a review of its use as an antiemetic in children.
Topics: Adolescent; Antiemetics; Child; Clinical Trials as Topic; Dexamethasone; Drug-Related Side Effects a | 2001 |
Ondansetron: a review of its use as an antiemetic in children.
Topics: Adolescent; Antiemetics; Child; Clinical Trials as Topic; Dexamethasone; Drug-Related Side Effects a | 2001 |
Ondansetron: a review of its use as an antiemetic in children.
Topics: Adolescent; Antiemetics; Child; Clinical Trials as Topic; Dexamethasone; Drug-Related Side Effects a | 2001 |
Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.
Topics: Animals; Colonic Diseases, Functional; Humans; Ion Channels; Nausea; Ondansetron; Receptors, Seroton | 2001 |
Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.
Topics: Animals; Colonic Diseases, Functional; Humans; Ion Channels; Nausea; Ondansetron; Receptors, Seroton | 2001 |
Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.
Topics: Animals; Colonic Diseases, Functional; Humans; Ion Channels; Nausea; Ondansetron; Receptors, Seroton | 2001 |
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Electrocardiog | 2002 |
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Electrocardiog | 2002 |
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Electrocardiog | 2002 |
Are granisetron and ondansetron equivalent in the clinic?
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Granisetron; Humans; Imidazoles; Indazoles; Nausea; O | 1992 |
Are granisetron and ondansetron equivalent in the clinic?
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Granisetron; Humans; Imidazoles; Indazoles; Nausea; O | 1992 |
Are granisetron and ondansetron equivalent in the clinic?
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Granisetron; Humans; Imidazoles; Indazoles; Nausea; O | 1992 |
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Topics: Administration, Oral; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Femal | 1992 |
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Topics: Administration, Oral; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Femal | 1992 |
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Topics: Administration, Oral; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Femal | 1992 |
Antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Humans; Imi | 1992 |
Antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Humans; Imi | 1992 |
Antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Humans; Imi | 1992 |
Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
Topics: Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
Topics: Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
Topics: Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Advances in the control of chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1992 |
Advances in the control of chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1992 |
Advances in the control of chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1992 |
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Incidence and aetiology of postoperative nausea and vomiting.
Topics: Humans; Incidence; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Incidence and aetiology of postoperative nausea and vomiting.
Topics: Humans; Incidence; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Incidence and aetiology of postoperative nausea and vomiting.
Topics: Humans; Incidence; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Pharmacology of ondansetron.
Topics: Animals; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Pharmacology of ondansetron.
Topics: Animals; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Pharmacology of ondansetron.
Topics: Animals; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
The clinical development of ondansetron for use in the prevention and treatment of postoperative nausea and vomiting.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
The clinical development of ondansetron for use in the prevention and treatment of postoperative nausea and vomiting.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
The clinical development of ondansetron for use in the prevention and treatment of postoperative nausea and vomiting.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
[Prevention of postoperative nausea and vomiting by ondansetron].
Topics: Administration, Oral; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Nause | 1992 |
[Prevention of postoperative nausea and vomiting by ondansetron].
Topics: Administration, Oral; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Nause | 1992 |
[Prevention of postoperative nausea and vomiting by ondansetron].
Topics: Administration, Oral; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Nause | 1992 |
Mechanisms by which cancer chemotherapeutic drugs induce emesis.
Topics: Animals; Antineoplastic Agents; Chemoreceptor Cells; Humans; Models, Biological; Nausea; Ondansetron | 1992 |
Mechanisms by which cancer chemotherapeutic drugs induce emesis.
Topics: Animals; Antineoplastic Agents; Chemoreceptor Cells; Humans; Models, Biological; Nausea; Ondansetron | 1992 |
Mechanisms by which cancer chemotherapeutic drugs induce emesis.
Topics: Animals; Antineoplastic Agents; Chemoreceptor Cells; Humans; Models, Biological; Nausea; Ondansetron | 1992 |
Clinical safety of ondansetron.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Vomiting | 1992 |
Clinical safety of ondansetron.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Vomiting | 1992 |
Clinical safety of ondansetron.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Vomiting | 1992 |
Radiation-induced emesis: effects of ondansetron.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1992 |
Radiation-induced emesis: effects of ondansetron.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1992 |
Radiation-induced emesis: effects of ondansetron.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1992 |
5-HT3 antagonists in postoperative nausea and vomiting.
Topics: Aged; Anesthesia, General; Humans; Male; Metoclopramide; Nausea; Ondansetron; Postoperative Complica | 1992 |
5-HT3 antagonists in postoperative nausea and vomiting.
Topics: Aged; Anesthesia, General; Humans; Male; Metoclopramide; Nausea; Ondansetron; Postoperative Complica | 1992 |
5-HT3 antagonists in postoperative nausea and vomiting.
Topics: Aged; Anesthesia, General; Humans; Male; Metoclopramide; Nausea; Ondansetron; Postoperative Complica | 1992 |
Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Imidazoles; Nausea; | 1992 |
Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Imidazoles; Nausea; | 1992 |
Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Imidazoles; Nausea; | 1992 |
Ondansetron. Therapeutic use as an antiemetic.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Metoclopramide; Nausea; Ondansetron; Radiati | 1991 |
Ondansetron. Therapeutic use as an antiemetic.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Metoclopramide; Nausea; Ondansetron; Radiati | 1991 |
Ondansetron. Therapeutic use as an antiemetic.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Metoclopramide; Nausea; Ondansetron; Radiati | 1991 |
Ondansetron--the first of a new class of antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Multicenter Studies as Topic; Nausea; Ondans | 1991 |
Ondansetron--the first of a new class of antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Multicenter Studies as Topic; Nausea; Ondans | 1991 |
Ondansetron--the first of a new class of antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Multicenter Studies as Topic; Nausea; Ondans | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
The role of ondansetron in paediatric patients: a review of three studies.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Imidazoles; Nausea; | 1991 |
The role of ondansetron in paediatric patients: a review of three studies.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Imidazoles; Nausea; | 1991 |
The role of ondansetron in paediatric patients: a review of three studies.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Imidazoles; Nausea; | 1991 |
Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomi | 1991 |
Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomi | 1991 |
Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomi | 1991 |
[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Rec | 1991 |
[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Rec | 1991 |
[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Rec | 1991 |
Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Granisetron; Headache; Human | 1990 |
Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Granisetron; Headache; Human | 1990 |
Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Granisetron; Headache; Human | 1990 |
Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; N | 1989 |
Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; N | 1989 |
Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; N | 1989 |
418 trials available for ondansetron and Nausea
| Article | Year |
|---|---|
Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Topics: Antiemetics; Cost-Benefit Analysis; Female; Humans; Metoclopramide; Nausea; Ondansetron; Pregnancy; | 2021 |
Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Topics: Antiemetics; Cost-Benefit Analysis; Female; Humans; Metoclopramide; Nausea; Ondansetron; Pregnancy; | 2021 |
Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Topics: Antiemetics; Cost-Benefit Analysis; Female; Humans; Metoclopramide; Nausea; Ondansetron; Pregnancy; | 2021 |
Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.
Topics: Acepromazine; Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Glycopyrrolate; Hydromor | 2021 |
Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.
Topics: Acepromazine; Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Glycopyrrolate; Hydromor | 2021 |
Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.
Topics: Acepromazine; Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Glycopyrrolate; Hydromor | 2021 |
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Double-Blind Method; Humans; Nausea; Neopl | 2022 |
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Double-Blind Method; Humans; Nausea; Neopl | 2022 |
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Double-Blind Method; Humans; Nausea; Neopl | 2022 |
Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Granisetron; Humans; Nausea; Ondansetron; Q | 2023 |
Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Granisetron; Humans; Nausea; Ondansetron; Q | 2023 |
Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Granisetron; Humans; Nausea; Ondansetron; Q | 2023 |
Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.
Topics: Animals; Antiemetics; Arginine Vasopressin; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Met | 2022 |
Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.
Topics: Animals; Antiemetics; Arginine Vasopressin; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Met | 2022 |
Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.
Topics: Animals; Antiemetics; Arginine Vasopressin; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Met | 2022 |
Droperidol versus ondansetron for nausea treatment within the emergency department.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Emergency Service, Hospital; Humans; Nausea; On | 2023 |
Droperidol versus ondansetron for nausea treatment within the emergency department.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Emergency Service, Hospital; Humans; Nausea; On | 2023 |
Droperidol versus ondansetron for nausea treatment within the emergency department.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Emergency Service, Hospital; Humans; Nausea; On | 2023 |
The Prophylaxis Effect of Ephedrine on Hemodynamic Variation in Patients Undergoing Percutaneous Nephrolithotomy Surgery with Spinal Anesthesia.
Topics: Anesthesia, Spinal; Atropine; Bradycardia; Ephedrine; Hemodynamics; Humans; Hypotension; Nausea; Nep | 2023 |
The Prophylaxis Effect of Ephedrine on Hemodynamic Variation in Patients Undergoing Percutaneous Nephrolithotomy Surgery with Spinal Anesthesia.
Topics: Anesthesia, Spinal; Atropine; Bradycardia; Ephedrine; Hemodynamics; Humans; Hypotension; Nausea; Nep | 2023 |
The Prophylaxis Effect of Ephedrine on Hemodynamic Variation in Patients Undergoing Percutaneous Nephrolithotomy Surgery with Spinal Anesthesia.
Topics: Anesthesia, Spinal; Atropine; Bradycardia; Ephedrine; Hemodynamics; Humans; Hypotension; Nausea; Nep | 2023 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 2019 |
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 2019 |
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 2019 |
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Female; Humans; | 2020 |
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Female; Humans; | 2020 |
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Female; Humans; | 2020 |
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2020 |
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2020 |
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2020 |
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemopreventio | 2020 |
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemopreventio | 2020 |
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemopreventio | 2020 |
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Agents; Cancer Survivors; Endometrial | 2021 |
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Agents; Cancer Survivors; Endometrial | 2021 |
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Agents; Cancer Survivors; Endometrial | 2021 |
Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 2021 |
Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 2021 |
Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 2021 |
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Topics: Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relations | 2021 |
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Topics: Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relations | 2021 |
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Topics: Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relations | 2021 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, New | 2017 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, New | 2017 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, New | 2017 |
Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Amisulpride; Antiemetics; Cisplatin; Dopamine Antagonists; Female; Humans; Male; Middle | 2018 |
Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Amisulpride; Antiemetics; Cisplatin; Dopamine Antagonists; Female; Humans; Male; Middle | 2018 |
Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Amisulpride; Antiemetics; Cisplatin; Dopamine Antagonists; Female; Humans; Male; Middle | 2018 |
Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemoprevention; Cis | 2017 |
Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemoprevention; Cis | 2017 |
Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemoprevention; Cis | 2017 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans | 2018 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans | 2018 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Antiemetics; Aromatherapy; Doub | 2018 |
A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Nausea; | 2018 |
A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Nausea; | 2018 |
A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Nausea; | 2018 |
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophospham | 2018 |
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophospham | 2018 |
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophospham | 2018 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group.
Topics: Adolescent; Age Factors; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Do | 2018 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group.
Topics: Adolescent; Age Factors; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Do | 2018 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group.
Topics: Adolescent; Age Factors; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Do | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe | 2018 |
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Emergency Service, Hospital; Fe | 2018 |
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Emergency Service, Hospital; Fe | 2018 |
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Emergency Service, Hospital; Fe | 2018 |
A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Ce | 2019 |
A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Ce | 2019 |
A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Ce | 2019 |
Randomized Placebo-controlled Trial of Droperidol and Ondansetron for Adult Emergency Department Patients With Nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Australia; Double-Blind Method; Droperidol; | 2019 |
Randomized Placebo-controlled Trial of Droperidol and Ondansetron for Adult Emergency Department Patients With Nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Australia; Double-Blind Method; Droperidol; | 2019 |
Randomized Placebo-controlled Trial of Droperidol and Ondansetron for Adult Emergency Department Patients With Nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Australia; Double-Blind Method; Droperidol; | 2019 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo | 2019 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo | 2019 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo | 2019 |
Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Nause | 2019 |
Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Nause | 2019 |
Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Nause | 2019 |
Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells.
Topics: Antiemetics; Blood Transfusion, Autologous; Cohort Studies; Cryoprotective Agents; Dimethyl Sulfoxid | 2013 |
Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells.
Topics: Antiemetics; Blood Transfusion, Autologous; Cohort Studies; Cryoprotective Agents; Dimethyl Sulfoxid | 2013 |
Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells.
Topics: Antiemetics; Blood Transfusion, Autologous; Cohort Studies; Cryoprotective Agents; Dimethyl Sulfoxid | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2013 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2013 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2013 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoqu | 2014 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoqu | 2014 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoqu | 2014 |
Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial.
Topics: Acetaminophen; Acetylcysteine; Adult; Aged; Alanine Transaminase; Antiemetics; Double-Blind Method; | 2014 |
Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial.
Topics: Acetaminophen; Acetylcysteine; Adult; Aged; Alanine Transaminase; Antiemetics; Double-Blind Method; | 2014 |
Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial.
Topics: Acetaminophen; Acetylcysteine; Adult; Aged; Alanine Transaminase; Antiemetics; Double-Blind Method; | 2014 |
Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Body Weight; Ch | 2014 |
Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Body Weight; Ch | 2014 |
Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Body Weight; Ch | 2014 |
Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anti-Anxiety Agents; Blood Pressure; Carbon Diox | 2014 |
Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anti-Anxiety Agents; Blood Pressure; Carbon Diox | 2014 |
Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anti-Anxiety Agents; Blood Pressure; Carbon Diox | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepit | 2014 |
Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepit | 2014 |
Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepit | 2014 |
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Adult; Antiemetics; Double-Blind Method; Doxylamine; Drug Therapy, Combination; Female; Follow-Up St | 2014 |
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Adult; Antiemetics; Double-Blind Method; Doxylamine; Drug Therapy, Combination; Female; Follow-Up St | 2014 |
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Adult; Antiemetics; Double-Blind Method; Doxylamine; Drug Therapy, Combination; Female; Follow-Up St | 2014 |
Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients.
Topics: Acupuncture Therapy; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross | 2015 |
Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients.
Topics: Acupuncture Therapy; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross | 2015 |
Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients.
Topics: Acupuncture Therapy; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross | 2015 |
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Carcinoma, Non-Small-Cell Lung; Dr | 2015 |
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Carcinoma, Non-Small-Cell Lung; Dr | 2015 |
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Carcinoma, Non-Small-Cell Lung; Dr | 2015 |
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cytarabine; Dose-Response R | 2015 |
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cytarabine; Dose-Response R | 2015 |
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cytarabine; Dose-Response R | 2015 |
Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Anti-Inflammatory Agents; Antiemetics; Aprepitant; Child; C | 2015 |
Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Anti-Inflammatory Agents; Antiemetics; Aprepitant; Child; C | 2015 |
Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Anti-Inflammatory Agents; Antiemetics; Aprepitant; Child; C | 2015 |
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method | 2015 |
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method | 2015 |
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method | 2015 |
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Th | 2015 |
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Th | 2015 |
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Th | 2015 |
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female | 2016 |
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female | 2016 |
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female | 2016 |
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzimidazoles; Dexam | 2015 |
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzimidazoles; Dexam | 2015 |
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzimidazoles; Dexam | 2015 |
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiaze | 2016 |
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiaze | 2016 |
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiaze | 2016 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose- | 2016 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose- | 2016 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose- | 2016 |
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 2016 |
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 2016 |
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 2016 |
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2016 |
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2016 |
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carbopl | 2016 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carbopl | 2016 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carbopl | 2016 |
Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug | 2017 |
Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug | 2017 |
Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug | 2017 |
Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia-induced hypotension during elective cesarean delivery in Egypt.
Topics: Administration, Intravenous; Adult; Anesthesia, Spinal; Blood Pressure; Bradycardia; Cesarean Sectio | 2016 |
Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia-induced hypotension during elective cesarean delivery in Egypt.
Topics: Administration, Intravenous; Adult; Anesthesia, Spinal; Blood Pressure; Bradycardia; Cesarean Sectio | 2016 |
Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia-induced hypotension during elective cesarean delivery in Egypt.
Topics: Administration, Intravenous; Adult; Anesthesia, Spinal; Blood Pressure; Bradycardia; Cesarean Sectio | 2016 |
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Ov | 2017 |
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Ov | 2017 |
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Ov | 2017 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepine | 2017 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepine | 2017 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepine | 2017 |
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2017 |
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2017 |
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2017 |
Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
Topics: Abdomen; Aged; Antiemetics; Aprepitant; Dose Fractionation, Radiation; Female; Humans; Male; Middle | 2017 |
Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
Topics: Abdomen; Aged; Antiemetics; Aprepitant; Dose Fractionation, Radiation; Female; Humans; Male; Middle | 2017 |
Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
Topics: Abdomen; Aged; Antiemetics; Aprepitant; Dose Fractionation, Radiation; Female; Humans; Male; Middle | 2017 |
Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy.
Topics: Administration, Oral; Adult; Analysis of Variance; Antiemetics; Chi-Square Distribution; Contrast Me | 2009 |
Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy.
Topics: Administration, Oral; Adult; Analysis of Variance; Antiemetics; Chi-Square Distribution; Contrast Me | 2009 |
Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy.
Topics: Administration, Oral; Adult; Analysis of Variance; Antiemetics; Chi-Square Distribution; Contrast Me | 2009 |
Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Meto | 2008 |
Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Meto | 2008 |
Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Meto | 2008 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind | 2009 |
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost Savings; Dexamethasone; | 2009 |
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost Savings; Dexamethasone; | 2009 |
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost Savings; Dexamethasone; | 2009 |
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Topics: Adolescent; Adult; Antiemetics; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects | 2009 |
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Topics: Adolescent; Adult; Antiemetics; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects | 2009 |
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Topics: Adolescent; Adult; Antiemetics; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects | 2009 |
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 2009 |
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 2009 |
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 2009 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Dru | 2010 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Dru | 2010 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Dru | 2010 |
Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea.
Topics: Adolescent; Adult; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Israel; Male; | 2009 |
Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea.
Topics: Adolescent; Adult; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Israel; Male; | 2009 |
Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea.
Topics: Adolescent; Adult; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Israel; Male; | 2009 |
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2009 |
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2009 |
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2009 |
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antin | 2010 |
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antin | 2010 |
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antin | 2010 |
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Breast Ne | 2011 |
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Breast Ne | 2011 |
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Breast Ne | 2011 |
Transdermal scopolamine patch with odansetron for the control of nausea after uterine artery embolization compared with odansetron alone: results of a randomized placebo-controlled trial.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Delayed-Action Preparations; Drug Combinations; | 2010 |
Transdermal scopolamine patch with odansetron for the control of nausea after uterine artery embolization compared with odansetron alone: results of a randomized placebo-controlled trial.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Delayed-Action Preparations; Drug Combinations; | 2010 |
Transdermal scopolamine patch with odansetron for the control of nausea after uterine artery embolization compared with odansetron alone: results of a randomized placebo-controlled trial.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Delayed-Action Preparations; Drug Combinations; | 2010 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Iso | 2011 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Iso | 2011 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Iso | 2011 |
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2011 |
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2011 |
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2011 |
Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2011 |
Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2011 |
The evaluation of drug rechallenge: the casopitant Phase III program.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, | 2010 |
The evaluation of drug rechallenge: the casopitant Phase III program.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, | 2010 |
The evaluation of drug rechallenge: the casopitant Phase III program.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, | 2010 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Th | 2010 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Th | 2010 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Th | 2010 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administr | 2010 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administr | 2010 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administr | 2010 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2011 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.
Topics: Amines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanecarboxylic Acids; De | 2012 |
Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Doub | 2012 |
Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Doub | 2012 |
Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Doub | 2012 |
Ondansetron as an effective antiemetic in the rural, out-of-hospital setting.
Topics: Antiemetics; Emergency Medical Services; Female; Humans; Male; Nausea; Ondansetron; Rural Health Ser | 2011 |
Ondansetron as an effective antiemetic in the rural, out-of-hospital setting.
Topics: Antiemetics; Emergency Medical Services; Female; Humans; Male; Nausea; Ondansetron; Rural Health Ser | 2011 |
Ondansetron as an effective antiemetic in the rural, out-of-hospital setting.
Topics: Antiemetics; Emergency Medical Services; Female; Humans; Male; Nausea; Ondansetron; Rural Health Ser | 2011 |
Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery.
Topics: Acupressure; Adolescent; Adult; Antiemetics; Child; Combined Modality Therapy; Double-Blind Method; | 2011 |
Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery.
Topics: Acupressure; Adolescent; Adult; Antiemetics; Child; Combined Modality Therapy; Double-Blind Method; | 2011 |
Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery.
Topics: Acupressure; Adolescent; Adult; Antiemetics; Child; Combined Modality Therapy; Double-Blind Method; | 2011 |
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neop | 2012 |
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neop | 2012 |
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neop | 2012 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Topics: Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Double-Blind Method; Female; Granisetro | 2011 |
Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Topics: Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Double-Blind Method; Female; Granisetro | 2011 |
Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Topics: Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Double-Blind Method; Female; Granisetro | 2011 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidi | 2012 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidi | 2012 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidi | 2012 |
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Aprepit | 2012 |
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Aprepit | 2012 |
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Aprepit | 2012 |
[Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia].
Topics: Analgesia, Patient-Controlled; Anti-Inflammatory Agents; Antiemetics; Dexamethasone; Drug Synergism; | 2002 |
[Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia].
Topics: Analgesia, Patient-Controlled; Anti-Inflammatory Agents; Antiemetics; Dexamethasone; Drug Synergism; | 2002 |
[Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia].
Topics: Analgesia, Patient-Controlled; Anti-Inflammatory Agents; Antiemetics; Dexamethasone; Drug Synergism; | 2002 |
[Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Digestive System; Doxorubici | 2002 |
[Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Digestive System; Doxorubici | 2002 |
[Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Digestive System; Doxorubici | 2002 |
Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2003 |
Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2003 |
Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2003 |
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Doub | 2003 |
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Doub | 2003 |
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Doub | 2003 |
Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dimenhydrinate; Double-Blind Method; Dro | 2003 |
Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dimenhydrinate; Double-Blind Method; Dro | 2003 |
Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery.
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Dimenhydrinate; Double-Blind Method; Dro | 2003 |
Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases.
Topics: Acupuncture Therapy; Adult; Aged; Antiemetics; Antirheumatic Agents; Combined Modality Therapy; Cycl | 2003 |
Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases.
Topics: Acupuncture Therapy; Adult; Aged; Antiemetics; Antirheumatic Agents; Combined Modality Therapy; Cycl | 2003 |
Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases.
Topics: Acupuncture Therapy; Adult; Aged; Antiemetics; Antirheumatic Agents; Combined Modality Therapy; Cycl | 2003 |
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplati | 2003 |
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplati | 2003 |
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplati | 2003 |
[Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzimidazoles; Female; Gastrointestinal | 2003 |
[Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzimidazoles; Female; Gastrointestinal | 2003 |
[Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzimidazoles; Female; Gastrointestinal | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Int | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cancer Care Facilities; Cohort Studies; | 2004 |
Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cancer Care Facilities; Cohort Studies; | 2004 |
Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cancer Care Facilities; Cohort Studies; | 2004 |
Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
Topics: Antiemetics; Double-Blind Method; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Huma | 2004 |
Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
Topics: Antiemetics; Double-Blind Method; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Huma | 2004 |
Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
Topics: Antiemetics; Double-Blind Method; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Huma | 2004 |
Betamethasone does not prevent nausea and vomiting induced by ipecacuanha.
Topics: Adolescent; Adult; Antiemetics; Betamethasone; Cross-Over Studies; Double-Blind Method; Emetics; Fem | 2004 |
Betamethasone does not prevent nausea and vomiting induced by ipecacuanha.
Topics: Adolescent; Adult; Antiemetics; Betamethasone; Cross-Over Studies; Double-Blind Method; Emetics; Fem | 2004 |
Betamethasone does not prevent nausea and vomiting induced by ipecacuanha.
Topics: Adolescent; Adult; Antiemetics; Betamethasone; Cross-Over Studies; Double-Blind Method; Emetics; Fem | 2004 |
Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy.
Topics: Adult; Aged; Analysis of Variance; Anesthesia, General; Breast Neoplasms; Chi-Square Distribution; D | 2004 |
Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy.
Topics: Adult; Aged; Analysis of Variance; Anesthesia, General; Breast Neoplasms; Chi-Square Distribution; D | 2004 |
Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy.
Topics: Adult; Aged; Analysis of Variance; Anesthesia, General; Breast Neoplasms; Chi-Square Distribution; D | 2004 |
The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Adolescent; Antiemetics; Antimetabolites, Antineoplastic; Child; Child, Preschool; Electrocardiograp | 2005 |
The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Adolescent; Antiemetics; Antimetabolites, Antineoplastic; Child; Child, Preschool; Electrocardiograp | 2005 |
The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Adolescent; Antiemetics; Antimetabolites, Antineoplastic; Child; Child, Preschool; Electrocardiograp | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize
Topics: Adrenal Cortex Hormones; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize
Topics: Adrenal Cortex Hormones; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize
Topics: Adrenal Cortex Hormones; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy under spinal anaesthesia: a randomized study of ondansetron prophylaxis.
Topics: Analgesia, Patient-Controlled; Anesthesia, Spinal; Antiemetics; Female; Hemodynamics; Humans; Hyster | 2005 |
Postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy under spinal anaesthesia: a randomized study of ondansetron prophylaxis.
Topics: Analgesia, Patient-Controlled; Anesthesia, Spinal; Antiemetics; Female; Hemodynamics; Humans; Hyster | 2005 |
Postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy under spinal anaesthesia: a randomized study of ondansetron prophylaxis.
Topics: Analgesia, Patient-Controlled; Anesthesia, Spinal; Antiemetics; Female; Hemodynamics; Humans; Hyster | 2005 |
A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
Topics: Antiemetics; Antineoplastic Agents; Bayes Theorem; Brain Neoplasms; Child; Child, Preschool; Cisplat | 2006 |
A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
Topics: Antiemetics; Antineoplastic Agents; Bayes Theorem; Brain Neoplasms; Child; Child, Preschool; Cisplat | 2006 |
A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
Topics: Antiemetics; Antineoplastic Agents; Bayes Theorem; Brain Neoplasms; Child; Child, Preschool; Cisplat | 2006 |
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Drug Therapy, Combination; Fema | 2005 |
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Drug Therapy, Combination; Fema | 2005 |
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Drug Therapy, Combination; Fema | 2005 |
Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 2006 |
Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 2006 |
Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 2006 |
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporter | 2005 |
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporter | 2005 |
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporter | 2005 |
No more than necessary: safety and efficacy of low-dose promethazine.
Topics: Antiemetics; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Middle | 2006 |
No more than necessary: safety and efficacy of low-dose promethazine.
Topics: Antiemetics; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Middle | 2006 |
No more than necessary: safety and efficacy of low-dose promethazine.
Topics: Antiemetics; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Middle | 2006 |
A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.
Topics: Administration, Sublingual; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blin | 2006 |
A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.
Topics: Administration, Sublingual; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blin | 2006 |
A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.
Topics: Administration, Sublingual; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blin | 2006 |
Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Dexamethasone; Drug Therapy, Combination; F | 2006 |
Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Dexamethasone; Drug Therapy, Combination; F | 2006 |
Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Dexamethasone; Drug Therapy, Combination; F | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Hu | 2006 |
5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
Topics: Antiemetics; Canada; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 2006 |
5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
Topics: Antiemetics; Canada; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 2006 |
5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
Topics: Antiemetics; Canada; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 2006 |
Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 2007 |
Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 2007 |
Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 2007 |
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benz | 2007 |
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benz | 2007 |
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benz | 2007 |
A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home.
Topics: 2-Propanol; Adult; Antiemetics; Female; Humans; Laparoscopy; Nausea; Ondansetron; Postoperative Comp | 2007 |
A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home.
Topics: 2-Propanol; Adult; Antiemetics; Female; Humans; Laparoscopy; Nausea; Ondansetron; Postoperative Comp | 2007 |
A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home.
Topics: 2-Propanol; Adult; Antiemetics; Female; Humans; Laparoscopy; Nausea; Ondansetron; Postoperative Comp | 2007 |
Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population.
Topics: Adult; Drug Therapy, Combination; Elective Surgical Procedures; Female; Humans; Male; Meclizine; Mid | 2007 |
Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population.
Topics: Adult; Drug Therapy, Combination; Elective Surgical Procedures; Female; Humans; Male; Meclizine; Mid | 2007 |
Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population.
Topics: Adult; Drug Therapy, Combination; Elective Surgical Procedures; Female; Humans; Male; Meclizine; Mid | 2007 |
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Dose-Respon | 2007 |
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Dose-Respon | 2007 |
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Dose-Respon | 2007 |
[Cost-effectiveness analysis of patient-controlled analgesia compared to continuous elastomeric pump infusion of tramadol and metamizole].
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Analgesics, Opioid | 2007 |
[Cost-effectiveness analysis of patient-controlled analgesia compared to continuous elastomeric pump infusion of tramadol and metamizole].
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Analgesics, Opioid | 2007 |
[Cost-effectiveness analysis of patient-controlled analgesia compared to continuous elastomeric pump infusion of tramadol and metamizole].
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Analgesics, Opioid | 2007 |
Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Cis | 2006 |
Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Cis | 2006 |
Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Cis | 2006 |
Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Dyspepsia; Female; Gastric Emptying; Giardiasis; Human | 2007 |
Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Dyspepsia; Female; Gastric Emptying; Giardiasis; Human | 2007 |
Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Dyspepsia; Female; Gastric Emptying; Giardiasis; Human | 2007 |
Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community clinical oncology program study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Attitude to Health; Community Health Services; Fema | 2008 |
Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community clinical oncology program study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Attitude to Health; Community Health Services; Fema | 2008 |
Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community clinical oncology program study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Attitude to Health; Community Health Services; Fema | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Follow-Up Studies; Hum | 2008 |
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Carcinoma, Ductal, Br | 2009 |
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Carcinoma, Ductal, Br | 2009 |
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Carcinoma, Ductal, Br | 2009 |
Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperido | 1995 |
Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperido | 1995 |
Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperido | 1995 |
Ondansetron for the control of dacarbazine-induced emesis.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dacarbazine; Humans; Middle Aged; Nausea; Ondansetron; Vom | 1995 |
Ondansetron for the control of dacarbazine-induced emesis.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dacarbazine; Humans; Middle Aged; Nausea; Ondansetron; Vom | 1995 |
Ondansetron for the control of dacarbazine-induced emesis.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dacarbazine; Humans; Middle Aged; Nausea; Ondansetron; Vom | 1995 |
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child | 1995 |
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child | 1995 |
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child | 1995 |
Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant.
Topics: Aged; Aged, 80 and over; Antiemetics; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; | 1995 |
Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant.
Topics: Aged; Aged, 80 and over; Antiemetics; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; | 1995 |
Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant.
Topics: Aged; Aged, 80 and over; Antiemetics; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; | 1995 |
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Akathisia, Drug-Induced; Consciousness; Double-Blind Method; Droperidol; Female; Humans; Hypotension | 1995 |
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Akathisia, Drug-Induced; Consciousness; Double-Blind Method; Droperidol; Female; Humans; Hypotension | 1995 |
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Akathisia, Drug-Induced; Consciousness; Double-Blind Method; Droperidol; Female; Humans; Hypotension | 1995 |
Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study.
Topics: Adolescent; Adult; Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthesia, Intravenous; Bloo | 1994 |
Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study.
Topics: Adolescent; Adult; Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthesia, Intravenous; Bloo | 1994 |
Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study.
Topics: Adolescent; Adult; Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthesia, Intravenous; Bloo | 1994 |
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1995 |
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1995 |
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1995 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Prophylaxis of delayed nausea and vomiting after cancer chemotherapy.
Topics: Adult; Aged; Chi-Square Distribution; Cisplatin; Domperidone; Double-Blind Method; Female; Humans; M | 1995 |
Prophylaxis of delayed nausea and vomiting after cancer chemotherapy.
Topics: Adult; Aged; Chi-Square Distribution; Cisplatin; Domperidone; Double-Blind Method; Female; Humans; M | 1995 |
Prophylaxis of delayed nausea and vomiting after cancer chemotherapy.
Topics: Adult; Aged; Chi-Square Distribution; Cisplatin; Domperidone; Double-Blind Method; Female; Humans; M | 1995 |
Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery.
Topics: Adult; Anesthesia; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; Isoflurane; M | 1995 |
Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery.
Topics: Adult; Anesthesia; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; Isoflurane; M | 1995 |
Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery.
Topics: Adult; Anesthesia; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; Isoflurane; M | 1995 |
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Female; Granise | 1994 |
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Female; Granise | 1994 |
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Female; Granise | 1994 |
A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost Control; Drug Costs; Dru | 1995 |
A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost Control; Drug Costs; Dru | 1995 |
A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost Control; Drug Costs; Dru | 1995 |
[Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)].
Topics: Adult; Female; Humans; Leukemia, Myeloid, Acute; Male; Nausea; Ondansetron; Precursor Cell Lymphobla | 1995 |
[Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)].
Topics: Adult; Female; Humans; Leukemia, Myeloid, Acute; Male; Nausea; Ondansetron; Precursor Cell Lymphobla | 1995 |
[Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)].
Topics: Adult; Female; Humans; Leukemia, Myeloid, Acute; Male; Nausea; Ondansetron; Precursor Cell Lymphobla | 1995 |
[The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Child; China; Cisplatin; Cross-Over Studies; Female; Humans; Male; Middle A | 1995 |
[The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Child; China; Cisplatin; Cross-Over Studies; Female; Humans; Male; Middle A | 1995 |
[The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Child; China; Cisplatin; Cross-Over Studies; Female; Humans; Male; Middle A | 1995 |
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Female; Humans | 1995 |
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Female; Humans | 1995 |
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Female; Humans | 1995 |
Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Eating; Female; Humans; Male | 1994 |
Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Eating; Female; Humans; Male | 1994 |
Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Eating; Female; Humans; Male | 1994 |
Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance.
Topics: Adult; Aged; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Middle Aged | 1995 |
Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance.
Topics: Adult; Aged; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Middle Aged | 1995 |
Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance.
Topics: Adult; Aged; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Middle Aged | 1995 |
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Bl | 1995 |
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Bl | 1995 |
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Bl | 1995 |
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
Topics: Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neo | 1995 |
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
Topics: Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neo | 1995 |
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
Topics: Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neo | 1995 |
Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cr | 1995 |
Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cr | 1995 |
Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cr | 1995 |
[Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting].
Topics: Adult; Double-Blind Method; Female; Genital Diseases, Female; Humans; Injections, Intravenous; Metoc | 1995 |
[Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting].
Topics: Adult; Double-Blind Method; Female; Genital Diseases, Female; Humans; Injections, Intravenous; Metoc | 1995 |
[Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting].
Topics: Adult; Double-Blind Method; Female; Genital Diseases, Female; Humans; Injections, Intravenous; Metoc | 1995 |
Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Droperidol; Female; | 1995 |
Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Droperidol; Female; | 1995 |
Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Droperidol; Female; | 1995 |
The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Anesthesia, General; Child; Child, Preschool; Dose-Response Relation | 1995 |
The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Anesthesia, General; Child; Child, Preschool; Dose-Response Relation | 1995 |
The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Anesthesia, General; Child; Child, Preschool; Dose-Response Relation | 1995 |
Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1994 |
Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1994 |
Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1994 |
Ondansetron against metoclopramide/dexamethasone--a comparative study.
Topics: Adult; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Mi | 1994 |
Ondansetron against metoclopramide/dexamethasone--a comparative study.
Topics: Adult; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Mi | 1994 |
Ondansetron against metoclopramide/dexamethasone--a comparative study.
Topics: Adult; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Mi | 1994 |
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Cross-Over Studies; Drug Resistance; Female; Humans; Indoles; M | 1995 |
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Cross-Over Studies; Drug Resistance; Female; Humans; Indoles; M | 1995 |
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Cross-Over Studies; Drug Resistance; Female; Humans; Indoles; M | 1995 |
The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone.
Topics: Adult; Aged; Cerebral Ventricles; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Pilot Proj | 1994 |
The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone.
Topics: Adult; Aged; Cerebral Ventricles; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Pilot Proj | 1994 |
The prevention of radiosurgery-induced nausea and vomiting by ondansetron: evidence of a direct effect on the central nervous system chemoreceptor trigger zone.
Topics: Adult; Aged; Cerebral Ventricles; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Pilot Proj | 1994 |
Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy.
Topics: Acetaminophen; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Female; Humans | 1994 |
Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy.
Topics: Acetaminophen; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Female; Humans | 1994 |
Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy.
Topics: Acetaminophen; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Female; Humans | 1994 |
Effects of ondansetron in the prevention of postoperative nausea and vomiting in children.
Topics: Anesthesia, General; Anesthesia, Inhalation; Child; Child, Preschool; Dose-Response Relationship, Dr | 1994 |
Effects of ondansetron in the prevention of postoperative nausea and vomiting in children.
Topics: Anesthesia, General; Anesthesia, Inhalation; Child; Child, Preschool; Dose-Response Relationship, Dr | 1994 |
Effects of ondansetron in the prevention of postoperative nausea and vomiting in children.
Topics: Anesthesia, General; Anesthesia, Inhalation; Child; Child, Preschool; Dose-Response Relationship, Dr | 1994 |
Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation.
Topics: Administration, Oral; Adult; Biological Availability; Double-Blind Method; Female; Half-Life; Humans | 1994 |
Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation.
Topics: Administration, Oral; Adult; Biological Availability; Double-Blind Method; Female; Half-Life; Humans | 1994 |
Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation.
Topics: Administration, Oral; Adult; Biological Availability; Double-Blind Method; Female; Half-Life; Humans | 1994 |
[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1994 |
[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1994 |
[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1994 |
Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adult; Aged; Alprazolam; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 1994 |
Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adult; Aged; Alprazolam; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 1994 |
Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adult; Aged; Alprazolam; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 1994 |
Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1994 |
Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1994 |
Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1994 |
[Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative study with droperidol].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; | 1994 |
[Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative study with droperidol].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; | 1994 |
[Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative study with droperidol].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; | 1994 |
[Ondansetron versus droperidol. Postoperative treatment against nausea and vomiting. Comparison of action, adverse effects and acceptance by gynecologic inpatients].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; | 1994 |
[Ondansetron versus droperidol. Postoperative treatment against nausea and vomiting. Comparison of action, adverse effects and acceptance by gynecologic inpatients].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; | 1994 |
[Ondansetron versus droperidol. Postoperative treatment against nausea and vomiting. Comparison of action, adverse effects and acceptance by gynecologic inpatients].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Droperidol; Female; Genitalia, Female; Humans; | 1994 |
Ondansetron prevents postoperative nausea and vomiting in women outpatients.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Middle Aged; Nausea; Ondansetron; Outp | 1994 |
Ondansetron prevents postoperative nausea and vomiting in women outpatients.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Middle Aged; Nausea; Ondansetron; Outp | 1994 |
Ondansetron prevents postoperative nausea and vomiting in women outpatients.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Middle Aged; Nausea; Ondansetron; Outp | 1994 |
Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 1994 |
Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 1994 |
Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 1994 |
Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.
Topics: Acute Disease; Adult; Antiemetics; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female | 1994 |
Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.
Topics: Acute Disease; Adult; Antiemetics; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female | 1994 |
Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.
Topics: Acute Disease; Adult; Antiemetics; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female | 1994 |
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Topics: Acute Disease; Chi-Square Distribution; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Com | 1994 |
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Topics: Acute Disease; Chi-Square Distribution; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Com | 1994 |
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Topics: Acute Disease; Chi-Square Distribution; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Com | 1994 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
[Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children].
Topics: Anesthesia, Epidural; Child; Child, Preschool; Female; Humans; Male; Metoclopramide; Nausea; Ondanse | 1994 |
[Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children].
Topics: Anesthesia, Epidural; Child; Child, Preschool; Female; Humans; Male; Metoclopramide; Nausea; Ondanse | 1994 |
[Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children].
Topics: Anesthesia, Epidural; Child; Child, Preschool; Female; Humans; Male; Metoclopramide; Nausea; Ondanse | 1994 |
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Topics: Adult; Aged; Carcinoma, Renal Cell; Droperidol; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin | 1994 |
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Topics: Adult; Aged; Carcinoma, Renal Cell; Droperidol; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin | 1994 |
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Topics: Adult; Aged; Carcinoma, Renal Cell; Droperidol; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin | 1994 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; | 1994 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; | 1994 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; | 1994 |
Comparison of ondansentron versus ondansentron plus methylprednisolone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Co | 1994 |
Comparison of ondansentron versus ondansentron plus methylprednisolone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Co | 1994 |
Comparison of ondansentron versus ondansentron plus methylprednisolone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Co | 1994 |
Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ipecac; Male; Naus | 1993 |
Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ipecac; Male; Naus | 1993 |
Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ipecac; Male; Naus | 1993 |
Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Female; Gynecology; Humans; | 1994 |
Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Female; Gynecology; Humans; | 1994 |
Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Female; Gynecology; Humans; | 1994 |
Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Dose-Response Relationship, Drug; Double-Bl | 1994 |
Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Dose-Response Relationship, Drug; Double-Bl | 1994 |
Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Dose-Response Relationship, Drug; Double-Bl | 1994 |
Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind | 1994 |
Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind | 1994 |
Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind | 1994 |
Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Human | 1994 |
Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Human | 1994 |
Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Human | 1994 |
Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Nausea; Neopla | 1993 |
Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Nausea; Neopla | 1993 |
Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Nausea; Neopla | 1993 |
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1994 |
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1994 |
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1994 |
A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1994 |
A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1994 |
A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1994 |
Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Female; Hum | 1994 |
Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Female; Hum | 1994 |
Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Female; Hum | 1994 |
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Double-Blind | 1994 |
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Double-Blind | 1994 |
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Double-Blind | 1994 |
Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Epidural; Anesthesia, General; Double-Blind | 1994 |
Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Epidural; Anesthesia, General; Double-Blind | 1994 |
Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Epidural; Anesthesia, General; Double-Blind | 1994 |
Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery.
Topics: Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Double-Blind Method; Female; Follow-Up Studi | 1994 |
Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery.
Topics: Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Double-Blind Method; Female; Follow-Up Studi | 1994 |
Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery.
Topics: Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Double-Blind Method; Female; Follow-Up Studi | 1994 |
Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
Topics: Chlorpromazine; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; H | 1993 |
Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
Topics: Chlorpromazine; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; H | 1993 |
Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
Topics: Chlorpromazine; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; H | 1993 |
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1993 |
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1993 |
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 1993 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Female; | 1993 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Female; | 1993 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Female; | 1993 |
A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Bradycardia; Constipation; Double-Blind Method; Female | 1993 |
A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Bradycardia; Constipation; Double-Blind Method; Female | 1993 |
A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Bradycardia; Constipation; Double-Blind Method; Female | 1993 |
A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Neop | 1993 |
A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Neop | 1993 |
A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Neop | 1993 |
Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Drug A | 1993 |
Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Drug A | 1993 |
Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Drug A | 1993 |
Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Double-B | 1993 |
Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Double-B | 1993 |
Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Double-B | 1993 |
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1993 |
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1993 |
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1993 |
Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1993 |
Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1993 |
Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1993 |
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
Topics: Adult; Aged; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; | 1993 |
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
Topics: Adult; Aged; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; | 1993 |
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
Topics: Adult; Aged; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; | 1993 |
Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
Topics: Adult; Aged; Cisplatin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Ondansetr | 1993 |
Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
Topics: Adult; Aged; Cisplatin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Ondansetr | 1993 |
Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
Topics: Adult; Aged; Cisplatin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Ondansetr | 1993 |
Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron.
Topics: Adult; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Male; Nausea; Ondansetro | 1993 |
Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron.
Topics: Adult; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Male; Nausea; Ondansetro | 1993 |
Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron.
Topics: Adult; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Male; Nausea; Ondansetro | 1993 |
Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Laparoscopy; Middl | 1993 |
Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Laparoscopy; Middl | 1993 |
Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Laparoscopy; Middl | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cyclophosphamide; Double-Blind Method; Female; | 1993 |
Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cyclophosphamide; Double-Blind Method; Female; | 1993 |
Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cyclophosphamide; Double-Blind Method; Female; | 1993 |
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Hum | 1993 |
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Hum | 1993 |
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Hum | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Belgium; Double-Blind Method; Drug Administration Sche | 1993 |
The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Belgium; Double-Blind Method; Drug Administration Sche | 1993 |
The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Belgium; Double-Blind Method; Drug Administration Sche | 1993 |
Multicenter evaluation of ondansetron use in hospitalized oncology patients.
Topics: Aged; Antineoplastic Agents; Drug Utilization; Female; Hospitalization; Humans; Male; Middle Aged; N | 1993 |
Multicenter evaluation of ondansetron use in hospitalized oncology patients.
Topics: Aged; Antineoplastic Agents; Drug Utilization; Female; Hospitalization; Humans; Male; Middle Aged; N | 1993 |
Multicenter evaluation of ondansetron use in hospitalized oncology patients.
Topics: Aged; Antineoplastic Agents; Drug Utilization; Female; Hospitalization; Humans; Male; Middle Aged; N | 1993 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female | 1995 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female | 1995 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female | 1995 |
Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Antiemetics; Droperidol; | 1995 |
Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Antiemetics; Droperidol; | 1995 |
Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Antiemetics; Droperidol; | 1995 |
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Gr | 1996 |
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Gr | 1996 |
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Gr | 1996 |
The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antiemetics; Humans; Injections, I | 1996 |
The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antiemetics; Humans; Injections, I | 1996 |
The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antiemetics; Humans; Injections, I | 1996 |
Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Analgesics; Anesthesia Recovery Period; Anestheti | 1996 |
Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Analgesics; Anesthesia Recovery Period; Anestheti | 1996 |
Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Analgesics; Anesthesia Recovery Period; Anestheti | 1996 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Granisetron; Humans; Lymphoma, AIDS-Related; Lympho | 1995 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Granisetron; Humans; Lymphoma, AIDS-Related; Lympho | 1995 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Granisetron; Humans; Lymphoma, AIDS-Related; Lympho | 1995 |
Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemot | 1996 |
Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemot | 1996 |
Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemot | 1996 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bromazepam; Cisplatin; Cyclophosphamide | 1996 |
Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bromazepam; Cisplatin; Cyclophosphamide | 1996 |
Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bromazepam; Cisplatin; Cyclophosphamide | 1996 |
Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Droperidol; Drug Therapy, Combination; Fe | 1996 |
Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Droperidol; Drug Therapy, Combination; Fe | 1996 |
Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Droperidol; Drug Therapy, Combination; Fe | 1996 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Dr | 1996 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Dr | 1996 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Dr | 1996 |
Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; | 1996 |
Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; | 1996 |
Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; | 1996 |
5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures.
Topics: Activities of Daily Living; Adult; Ambulatory Surgical Procedures; Antiemetics; Anxiety; Conscious S | 1996 |
A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures.
Topics: Activities of Daily Living; Adult; Ambulatory Surgical Procedures; Antiemetics; Anxiety; Conscious S | 1996 |
A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures.
Topics: Activities of Daily Living; Adult; Ambulatory Surgical Procedures; Antiemetics; Anxiety; Conscious S | 1996 |
Effects of ondansetron on emesis in the first 24 hours after craniotomy in children.
Topics: Adolescent; Antiemetics; Brain; Cerebellum; Child; Child, Preschool; Craniotomy; Double-Blind Method | 1996 |
Effects of ondansetron on emesis in the first 24 hours after craniotomy in children.
Topics: Adolescent; Antiemetics; Brain; Cerebellum; Child; Child, Preschool; Craniotomy; Double-Blind Method | 1996 |
Effects of ondansetron on emesis in the first 24 hours after craniotomy in children.
Topics: Adolescent; Antiemetics; Brain; Cerebellum; Child; Child, Preschool; Craniotomy; Double-Blind Method | 1996 |
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Femal | 1996 |
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Femal | 1996 |
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Femal | 1996 |
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles | 1996 |
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles | 1996 |
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles | 1996 |
Propofol induction is more effective than ondansetron in prophylaxis of postoperative nausea, but not vomiting.
Topics: Anesthesia; Double-Blind Method; Humans; Nausea; Ondansetron; Propofol; Prospective Studies; Vomitin | 1996 |
Propofol induction is more effective than ondansetron in prophylaxis of postoperative nausea, but not vomiting.
Topics: Anesthesia; Double-Blind Method; Humans; Nausea; Ondansetron; Propofol; Prospective Studies; Vomitin | 1996 |
Propofol induction is more effective than ondansetron in prophylaxis of postoperative nausea, but not vomiting.
Topics: Anesthesia; Double-Blind Method; Humans; Nausea; Ondansetron; Propofol; Prospective Studies; Vomitin | 1996 |
Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1995 |
Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1995 |
Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1995 |
[Colonic preparation with sodium phosphate. Prospective, randomized, placebo-controlled double blind study with various antiemetics].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cathartics; Cisapride | 1996 |
[Colonic preparation with sodium phosphate. Prospective, randomized, placebo-controlled double blind study with various antiemetics].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cathartics; Cisapride | 1996 |
[Colonic preparation with sodium phosphate. Prospective, randomized, placebo-controlled double blind study with various antiemetics].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cathartics; Cisapride | 1996 |
Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Ear, Middle; Female; Human | 1996 |
Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Ear, Middle; Female; Human | 1996 |
Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Ear, Middle; Female; Human | 1996 |
The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Female; Humans; Menstrual Cycle; Multicenter S | 1996 |
The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Female; Humans; Menstrual Cycle; Multicenter S | 1996 |
The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Female; Humans; Menstrual Cycle; Multicenter S | 1996 |
Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy.
Topics: Adenoidectomy; Adolescent; Adult; Aged; Antiemetics; Child; Child, Preschool; Double-Blind Method; F | 1996 |
Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy.
Topics: Adenoidectomy; Adolescent; Adult; Aged; Antiemetics; Child; Child, Preschool; Double-Blind Method; F | 1996 |
Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy.
Topics: Adenoidectomy; Adolescent; Adult; Aged; Antiemetics; Child; Child, Preschool; Double-Blind Method; F | 1996 |
Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol.
Topics: Abdomen; Antiemetics; Droperidol; Female; Humans; Injections, Intravenous; Intraoperative Period; Mi | 1995 |
Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol.
Topics: Abdomen; Antiemetics; Droperidol; Female; Humans; Injections, Intravenous; Intraoperative Period; Mi | 1995 |
Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol.
Topics: Abdomen; Antiemetics; Droperidol; Female; Humans; Injections, Intravenous; Intraoperative Period; Mi | 1995 |
The prevention of postoperative nausea and vomiting using a combination of ondansetron and droperidol.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Droperidol; Drug Therapy, Combination; Female; Hu | 1996 |
The prevention of postoperative nausea and vomiting using a combination of ondansetron and droperidol.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Droperidol; Drug Therapy, Combination; Female; Hu | 1996 |
The prevention of postoperative nausea and vomiting using a combination of ondansetron and droperidol.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Droperidol; Drug Therapy, Combination; Female; Hu | 1996 |
Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Granisetron; H | 1996 |
Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Granisetron; H | 1996 |
Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Granisetron; H | 1996 |
Pattern of carboplatin-induced emesis. The German Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Clinical Protocols; Cyclop | 1995 |
Pattern of carboplatin-induced emesis. The German Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Clinical Protocols; Cyclop | 1995 |
Pattern of carboplatin-induced emesis. The German Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Clinical Protocols; Cyclop | 1995 |
Efficacy of prophylactic ondansetron in Thai patients undergoing gastrointestinal tract surgery.
Topics: Adolescent; Adult; Aged; Antiemetics; Child; Double-Blind Method; Female; Gastrointestinal Diseases; | 1996 |
Efficacy of prophylactic ondansetron in Thai patients undergoing gastrointestinal tract surgery.
Topics: Adolescent; Adult; Aged; Antiemetics; Child; Double-Blind Method; Female; Gastrointestinal Diseases; | 1996 |
Efficacy of prophylactic ondansetron in Thai patients undergoing gastrointestinal tract surgery.
Topics: Adolescent; Adult; Aged; Antiemetics; Child; Double-Blind Method; Female; Gastrointestinal Diseases; | 1996 |
Impact of tumour burden on chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; C | 1996 |
Impact of tumour burden on chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; C | 1996 |
Impact of tumour burden on chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; C | 1996 |
The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery.
Topics: Adult; Aged; Anesthesia, Dental; Anesthesia, General; Antiemetics; Chi-Square Distribution; Cleft Pa | 1996 |
The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery.
Topics: Adult; Aged; Anesthesia, Dental; Anesthesia, General; Antiemetics; Chi-Square Distribution; Cleft Pa | 1996 |
The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery.
Topics: Adult; Aged; Anesthesia, Dental; Anesthesia, General; Antiemetics; Chi-Square Distribution; Cleft Pa | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1996 |
A comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after tympanoplasty.
Topics: Adolescent; Adult; Antiemetics; Child; Double-Blind Method; Female; Humans; Male; Middle Aged; Nause | 1996 |
A comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after tympanoplasty.
Topics: Adolescent; Adult; Antiemetics; Child; Double-Blind Method; Female; Humans; Male; Middle Aged; Nause | 1996 |
A comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after tympanoplasty.
Topics: Adolescent; Adult; Antiemetics; Child; Double-Blind Method; Female; Humans; Male; Middle Aged; Nause | 1996 |
A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.
Topics: Abdomen; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; N | 1996 |
A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.
Topics: Abdomen; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; N | 1996 |
A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.
Topics: Abdomen; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; N | 1996 |
Antiemetic efficacy of ondansetron with patient-controlled analgesia.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Double-Blind Method; Female; Humans; Hysterectomy | 1996 |
Antiemetic efficacy of ondansetron with patient-controlled analgesia.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Double-Blind Method; Female; Humans; Hysterectomy | 1996 |
Antiemetic efficacy of ondansetron with patient-controlled analgesia.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Double-Blind Method; Female; Humans; Hysterectomy | 1996 |
Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery.
Topics: Adolescent; Adult; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans; Hysterectom | 1996 |
Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery.
Topics: Adolescent; Adult; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans; Hysterectom | 1996 |
Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery.
Topics: Adolescent; Adult; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans; Hysterectom | 1996 |
Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Double-Blind Me | 1996 |
Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Double-Blind Me | 1996 |
Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Double-Blind Me | 1996 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Adrenergic Agonists; Adult; Antiemetics; Atropine; Chemoprevention; Cholecystectomy, Laparoscopic; C | 1996 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Adrenergic Agonists; Adult; Antiemetics; Atropine; Chemoprevention; Cholecystectomy, Laparoscopic; C | 1996 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Adrenergic Agonists; Adult; Antiemetics; Atropine; Chemoprevention; Cholecystectomy, Laparoscopic; C | 1996 |
[Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1996 |
[Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1996 |
[Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1996 |
The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Blood Pressure; Child; Double-Blind Method; Fem | 1996 |
The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Blood Pressure; Child; Double-Blind Method; Fem | 1996 |
The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Blood Pressure; Child; Double-Blind Method; Fem | 1996 |
A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, | 1996 |
A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, | 1996 |
A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, | 1996 |
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Dose-Response Relationship, D | 1996 |
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Dose-Response Relationship, D | 1996 |
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Dose-Response Relationship, D | 1996 |
Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting.
Topics: Adult; Breast; Double-Blind Method; Female; Humans; Metabolic Clearance Rate; Middle Aged; Nausea; O | 1996 |
Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting.
Topics: Adult; Breast; Double-Blind Method; Female; Humans; Metabolic Clearance Rate; Middle Aged; Nausea; O | 1996 |
Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting.
Topics: Adult; Breast; Double-Blind Method; Female; Humans; Metabolic Clearance Rate; Middle Aged; Nausea; O | 1996 |
[Prevention of postoperative nausea and vomiting with ondansetron: a prospective, randomized, double-blind study in 90 patients].
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Ondansetro | 1995 |
[Prevention of postoperative nausea and vomiting with ondansetron: a prospective, randomized, double-blind study in 90 patients].
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Ondansetro | 1995 |
[Prevention of postoperative nausea and vomiting with ondansetron: a prospective, randomized, double-blind study in 90 patients].
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Ondansetro | 1995 |
Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial.
Topics: Acute Disease; Antiemetics; Antineoplastic Agents; Cisplatin; Data Interpretation, Statistical; Gran | 1996 |
Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial.
Topics: Acute Disease; Antiemetics; Antineoplastic Agents; Cisplatin; Data Interpretation, Statistical; Gran | 1996 |
Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial.
Topics: Acute Disease; Antiemetics; Antineoplastic Agents; Cisplatin; Data Interpretation, Statistical; Gran | 1996 |
Droperidol/ondansetron combination controls nausea and vomiting after tubal banding.
Topics: Antiemetics; Dopamine Antagonists; Double-Blind Method; Droperidol; Drug Combinations; Female; Human | 1996 |
Droperidol/ondansetron combination controls nausea and vomiting after tubal banding.
Topics: Antiemetics; Dopamine Antagonists; Double-Blind Method; Droperidol; Drug Combinations; Female; Human | 1996 |
Droperidol/ondansetron combination controls nausea and vomiting after tubal banding.
Topics: Antiemetics; Dopamine Antagonists; Double-Blind Method; Droperidol; Drug Combinations; Female; Human | 1996 |
Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; | 1996 |
Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; | 1996 |
Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; | 1996 |
Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, General; Antiemetics; | 1996 |
Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, General; Antiemetics; | 1996 |
Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, General; Antiemetics; | 1996 |
An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, | 1996 |
An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, | 1996 |
An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, | 1996 |
Prophylactic administration of ondansetron in emergency intraabdominal operations.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Emergencies; Female; Humans; Mal | 1996 |
Prophylactic administration of ondansetron in emergency intraabdominal operations.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Emergencies; Female; Humans; Mal | 1996 |
Prophylactic administration of ondansetron in emergency intraabdominal operations.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Emergencies; Female; Humans; Mal | 1996 |
A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Drug Administration S | 1997 |
The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Drug Administration S | 1997 |
The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Drug Administration S | 1997 |
A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures.
Topics: Antiemetics; Double-Blind Method; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Neurosu | 1996 |
A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures.
Topics: Antiemetics; Double-Blind Method; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Neurosu | 1996 |
A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures.
Topics: Antiemetics; Double-Blind Method; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Neurosu | 1996 |
Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy.
Topics: Adenoidectomy; Anesthesia; Antiemetics; Child; Child, Preschool; Double-Blind Method; Humans; Infant | 1997 |
Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy.
Topics: Adenoidectomy; Anesthesia; Antiemetics; Child; Child, Preschool; Double-Blind Method; Humans; Infant | 1997 |
Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy.
Topics: Adenoidectomy; Anesthesia; Antiemetics; Child; Child, Preschool; Double-Blind Method; Humans; Infant | 1997 |
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
Topics: Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
Topics: Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
Topics: Adult; Aged; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
An investigation of the effect of ondansetron on time to induction of anaesthesia with thiopentone and propofol.
Topics: Adult; Anesthesia, General; Anesthetics, Intravenous; Antiemetics; Double-Blind Method; Female; Huma | 1997 |
An investigation of the effect of ondansetron on time to induction of anaesthesia with thiopentone and propofol.
Topics: Adult; Anesthesia, General; Anesthetics, Intravenous; Antiemetics; Double-Blind Method; Female; Huma | 1997 |
An investigation of the effect of ondansetron on time to induction of anaesthesia with thiopentone and propofol.
Topics: Adult; Anesthesia, General; Anesthetics, Intravenous; Antiemetics; Double-Blind Method; Female; Huma | 1997 |
Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Adolescent; Adult; Aged; Anesthesia, Intravenous; Anesthetics, Intravenous; Antiemetics; Dexamethaso | 1997 |
Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Adolescent; Adult; Aged; Anesthesia, Intravenous; Anesthetics, Intravenous; Antiemetics; Dexamethaso | 1997 |
Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Adolescent; Adult; Aged; Anesthesia, Intravenous; Anesthetics, Intravenous; Antiemetics; Dexamethaso | 1997 |
Prophylactic administration of ondansetron in emergency intraabdominal operations.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Emergency Medical Services; Fema | 1997 |
Prophylactic administration of ondansetron in emergency intraabdominal operations.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Emergency Medical Services; Fema | 1997 |
Prophylactic administration of ondansetron in emergency intraabdominal operations.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Emergency Medical Services; Fema | 1997 |
Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 1997 |
Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 1997 |
Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 1997 |
[Clinical evaluation of ondansetron suppository].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; | 1997 |
[Clinical evaluation of ondansetron suppository].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; | 1997 |
[Clinical evaluation of ondansetron suppository].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; | 1997 |
Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine.
Topics: Aged; Analgesics, Opioid; Antiemetics; Blood Pressure; Double-Blind Method; Female; Hip; Humans; Inj | 1997 |
Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine.
Topics: Aged; Analgesics, Opioid; Antiemetics; Blood Pressure; Double-Blind Method; Female; Hip; Humans; Inj | 1997 |
Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine.
Topics: Aged; Analgesics, Opioid; Antiemetics; Blood Pressure; Double-Blind Method; Female; Hip; Humans; Inj | 1997 |
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Antiemetics; Female; Humans; Indoles; Nausea; Ondansetron; Quinolizines; Serotonin Antagonists; Vomi | 1997 |
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Antiemetics; Female; Humans; Indoles; Nausea; Ondansetron; Quinolizines; Serotonin Antagonists; Vomi | 1997 |
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Antiemetics; Female; Humans; Indoles; Nausea; Ondansetron; Quinolizines; Serotonin Antagonists; Vomi | 1997 |
[Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy].
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Humans; Middle | 1997 |
[Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy].
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Humans; Middle | 1997 |
[Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy].
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Humans; Middle | 1997 |
Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children.
Topics: Age Distribution; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; | 1997 |
Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children.
Topics: Age Distribution; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; | 1997 |
Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children.
Topics: Age Distribution; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; | 1997 |
[Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?].
Topics: Administration, Oral; Adolescent; Antiemetics; Child; Female; Humans; Male; Metoclopramide; Nausea; | 1996 |
[Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?].
Topics: Administration, Oral; Adolescent; Antiemetics; Child; Female; Humans; Male; Metoclopramide; Nausea; | 1996 |
[Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?].
Topics: Administration, Oral; Adolescent; Antiemetics; Child; Female; Humans; Male; Metoclopramide; Nausea; | 1996 |
Anti-emetic drug effects on cognitive and psychomotor performance: granisetron vs. ondansetron.
Topics: Adolescent; Adult; Affect; Antiemetics; Cognition; Cross-Over Studies; Double-Blind Method; Drug Mon | 1997 |
Anti-emetic drug effects on cognitive and psychomotor performance: granisetron vs. ondansetron.
Topics: Adolescent; Adult; Affect; Antiemetics; Cognition; Cross-Over Studies; Double-Blind Method; Drug Mon | 1997 |
Anti-emetic drug effects on cognitive and psychomotor performance: granisetron vs. ondansetron.
Topics: Adolescent; Adult; Affect; Antiemetics; Cognition; Cross-Over Studies; Double-Blind Method; Drug Mon | 1997 |
Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Double-Blind Method; Drug T | 1997 |
Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Double-Blind Method; Drug T | 1997 |
Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Double-Blind Method; Drug T | 1997 |
Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Droperidol; Female; Genitalia, Female; Hu | 1997 |
Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Droperidol; Female; Genitalia, Female; Hu | 1997 |
Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Droperidol; Female; Genitalia, Female; Hu | 1997 |
[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administratio | 1997 |
[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administratio | 1997 |
[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administratio | 1997 |
Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Female; Humans; Male; | 1997 |
Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Female; Humans; Male; | 1997 |
Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Female; Humans; Male; | 1997 |
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 1997 |
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 1997 |
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 1997 |
Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthesia Recovery Period; Anesthetics, Intravenous; Antiemet | 1997 |
Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthesia Recovery Period; Anesthetics, Intravenous; Antiemet | 1997 |
Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthesia Recovery Period; Anesthetics, Intravenous; Antiemet | 1997 |
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Do | 1997 |
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Do | 1997 |
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Do | 1997 |
Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Mal | 1997 |
Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Mal | 1997 |
Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Mal | 1997 |
[Evaluation of the efficacy of anti-emetic therapy with ondansetron injected intravenously at a daily dose of 8mg (analysis of material)].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; H | 1996 |
[Evaluation of the efficacy of anti-emetic therapy with ondansetron injected intravenously at a daily dose of 8mg (analysis of material)].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; H | 1996 |
[Evaluation of the efficacy of anti-emetic therapy with ondansetron injected intravenously at a daily dose of 8mg (analysis of material)].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; H | 1996 |
Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Ear, Middle; Female; Humans; Male; Middle Aged; | 1997 |
Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Ear, Middle; Female; Humans; Male; Middle Aged; | 1997 |
Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Ear, Middle; Female; Humans; Male; Middle Aged; | 1997 |
Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Cataract Extraction; C | 1997 |
Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Cataract Extraction; C | 1997 |
Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Cataract Extraction; C | 1997 |
[Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients].
Topics: Adult; Anesthesia; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Onda | 1997 |
[Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients].
Topics: Adult; Anesthesia; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Onda | 1997 |
[Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients].
Topics: Adult; Anesthesia; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Onda | 1997 |
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
Topics: Acute Disease; Adult; Antiemetics; Diarrhea; Gastrointestinal Diseases; Humans; Lymphatic Metastasis | 1997 |
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
Topics: Acute Disease; Adult; Antiemetics; Diarrhea; Gastrointestinal Diseases; Humans; Lymphatic Metastasis | 1997 |
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
Topics: Acute Disease; Adult; Antiemetics; Diarrhea; Gastrointestinal Diseases; Humans; Lymphatic Metastasis | 1997 |
A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy.
Topics: Adolescent; Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Health Care Costs; Humans; | 1997 |
A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy.
Topics: Adolescent; Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Health Care Costs; Humans; | 1997 |
A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy.
Topics: Adolescent; Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Health Care Costs; Humans; | 1997 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
The anti-emetic efficacy of a combination of ondansetron and droperidol.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Droperidol; Drug Therapy, Combin | 1997 |
The anti-emetic efficacy of a combination of ondansetron and droperidol.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Droperidol; Drug Therapy, Combin | 1997 |
The anti-emetic efficacy of a combination of ondansetron and droperidol.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Droperidol; Drug Therapy, Combin | 1997 |
The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug Th | 1997 |
The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug Th | 1997 |
The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug Th | 1997 |
Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Mal | 1997 |
Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Mal | 1997 |
Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Mal | 1997 |
Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Double-Blind Method; F | 1997 |
Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Double-Blind Method; F | 1997 |
Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Double-Blind Method; F | 1997 |
A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Administration Schedule; | 1997 |
A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Administration Schedule; | 1997 |
A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Administration Schedule; | 1997 |
Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.
Topics: Adult; Antiemetics; Chlorpromazine; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; | 1997 |
Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.
Topics: Adult; Antiemetics; Chlorpromazine; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; | 1997 |
Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.
Topics: Adult; Antiemetics; Chlorpromazine; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; | 1997 |
Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Hu | 1997 |
Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Hu | 1997 |
Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Hu | 1997 |
Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Droperidol; Female; Hu | 1997 |
Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Droperidol; Female; Hu | 1997 |
Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Droperidol; Female; Hu | 1997 |
Ondansetron dose response curve in high-risk pediatric patients.
Topics: Adenoidectomy; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind | 1997 |
Ondansetron dose response curve in high-risk pediatric patients.
Topics: Adenoidectomy; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind | 1997 |
Ondansetron dose response curve in high-risk pediatric patients.
Topics: Adenoidectomy; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind | 1997 |
Progress in reducing anticipatory nausea and vomiting: a study of community practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; | 1998 |
Progress in reducing anticipatory nausea and vomiting: a study of community practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; | 1998 |
Progress in reducing anticipatory nausea and vomiting: a study of community practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; | 1998 |
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting.
Topics: Adult; Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Drug Administration Sched | 1998 |
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting.
Topics: Adult; Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Drug Administration Sched | 1998 |
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting.
Topics: Adult; Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Drug Administration Sched | 1998 |
Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea and vomiting after minor gynaecological surgery.
Topics: Adult; Antiemetics; Dilatation and Curettage; Double-Blind Method; Female; Gynecologic Surgical Proc | 1997 |
Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea and vomiting after minor gynaecological surgery.
Topics: Adult; Antiemetics; Dilatation and Curettage; Double-Blind Method; Female; Gynecologic Surgical Proc | 1997 |
Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea and vomiting after minor gynaecological surgery.
Topics: Adult; Antiemetics; Dilatation and Curettage; Double-Blind Method; Female; Gynecologic Surgical Proc | 1997 |
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1998 |
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1998 |
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1998 |
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1998 |
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1998 |
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1998 |
International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Gynecologic Surgic | 1998 |
International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Gynecologic Surgic | 1998 |
International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Gynecologic Surgic | 1998 |
Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1997 |
Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1997 |
Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1997 |
Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after total abdominal hysterectomy.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Drug Combinations; Female; Humans; Hysterectomy | 1998 |
Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after total abdominal hysterectomy.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Drug Combinations; Female; Humans; Hysterectomy | 1998 |
Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after total abdominal hysterectomy.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Drug Combinations; Female; Humans; Hysterectomy | 1998 |
Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy.
Topics: Ambulatory Surgical Procedures; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthetics, D | 1998 |
Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy.
Topics: Ambulatory Surgical Procedures; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthetics, D | 1998 |
Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy.
Topics: Ambulatory Surgical Procedures; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthetics, D | 1998 |
A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Anesthesia, Intravenous; Anesthetics, Inhal | 1998 |
A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Anesthesia, Intravenous; Anesthetics, Inhal | 1998 |
A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Anesthesia, Intravenous; Anesthetics, Inhal | 1998 |
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineop | 1998 |
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineop | 1998 |
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineop | 1998 |
Ondansetron versus droperidol or placebo to prevent nausea and vomiting after otologic surgery.
Topics: Adult; Antiemetics; Droperidol; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Otorhinolary | 1998 |
Ondansetron versus droperidol or placebo to prevent nausea and vomiting after otologic surgery.
Topics: Adult; Antiemetics; Droperidol; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Otorhinolary | 1998 |
Ondansetron versus droperidol or placebo to prevent nausea and vomiting after otologic surgery.
Topics: Adult; Antiemetics; Droperidol; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Otorhinolary | 1998 |
Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 1998 |
Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 1998 |
Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 1998 |
Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bre | 1998 |
Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bre | 1998 |
Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bre | 1998 |
Ondansetron prevents refractory and severe methotrexate-induced nausea in rheumatoid arthritis.
Topics: Antiemetics; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Nausea | 1998 |
Ondansetron prevents refractory and severe methotrexate-induced nausea in rheumatoid arthritis.
Topics: Antiemetics; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Nausea | 1998 |
Ondansetron prevents refractory and severe methotrexate-induced nausea in rheumatoid arthritis.
Topics: Antiemetics; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Nausea | 1998 |
A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Double-Bl | 1998 |
A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Double-Bl | 1998 |
A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Double-Bl | 1998 |
Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Granisetron; Humans; Male; Midd | 1998 |
Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Granisetron; Humans; Male; Midd | 1998 |
Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Granisetron; Humans; Male; Midd | 1998 |
Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-R | 1998 |
Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-R | 1998 |
Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-R | 1998 |
[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cross-Over Studies; C | 1998 |
[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cross-Over Studies; C | 1998 |
[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cross-Over Studies; C | 1998 |
Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Droperidol; Female; Hu | 1998 |
Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Droperidol; Female; Hu | 1998 |
Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Droperidol; Female; Hu | 1998 |
Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study.
Topics: Antiemetics; Antineoplastic Agents; Child; Diphenhydramine; Drug Therapy, Combination; Female; Human | 1998 |
Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study.
Topics: Antiemetics; Antineoplastic Agents; Child; Diphenhydramine; Drug Therapy, Combination; Female; Human | 1998 |
Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study.
Topics: Antiemetics; Antineoplastic Agents; Child; Diphenhydramine; Drug Therapy, Combination; Female; Human | 1998 |
[Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Fe | 1998 |
[Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Fe | 1998 |
[Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Fe | 1998 |
The effects of serotonin3 receptor blockade on the psychobiological response to intravenous clomipramine in healthy human subjects.
Topics: Adult; Clomipramine; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Nausea; Ond | 1999 |
The effects of serotonin3 receptor blockade on the psychobiological response to intravenous clomipramine in healthy human subjects.
Topics: Adult; Clomipramine; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Nausea; Ond | 1999 |
The effects of serotonin3 receptor blockade on the psychobiological response to intravenous clomipramine in healthy human subjects.
Topics: Adult; Clomipramine; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Nausea; Ond | 1999 |
[Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Female; Humans; Inj | 1999 |
[Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Female; Humans; Inj | 1999 |
[Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Female; Humans; Inj | 1999 |
The impact of the menstrual cycle and ondansetron on postoperative nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Female; Humans; Menstrual Cycle; Nausea; Ondansetron; Postoperative | 1998 |
The impact of the menstrual cycle and ondansetron on postoperative nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Female; Humans; Menstrual Cycle; Nausea; Ondansetron; Postoperative | 1998 |
The impact of the menstrual cycle and ondansetron on postoperative nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Female; Humans; Menstrual Cycle; Nausea; Ondansetron; Postoperative | 1998 |
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Drug Therapy, Combination; Female; | 1999 |
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Drug Therapy, Combination; Female; | 1999 |
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Drug Therapy, Combination; Female; | 1999 |
An alternative method to alleviate postoperative nausea and vomiting in children.
Topics: 2-Propanol; Administration, Inhalation; Adolescent; Antiemetics; Child; Double-Blind Method; Female; | 1999 |
An alternative method to alleviate postoperative nausea and vomiting in children.
Topics: 2-Propanol; Administration, Inhalation; Adolescent; Antiemetics; Child; Double-Blind Method; Female; | 1999 |
An alternative method to alleviate postoperative nausea and vomiting in children.
Topics: 2-Propanol; Administration, Inhalation; Adolescent; Antiemetics; Child; Double-Blind Method; Female; | 1999 |
Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Infusions | 1999 |
Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Infusions | 1999 |
Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Infusions | 1999 |
A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1999 |
A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1999 |
A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1999 |
[Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1999 |
[Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1999 |
[Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1999 |
Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Fe | 1999 |
Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Fe | 1999 |
Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Fe | 1999 |
The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind M | 1999 |
The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind M | 1999 |
The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind M | 1999 |
Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy-induced nausea.
Topics: Aged; Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Blood Pressure; Carboplatin; Cis | 1999 |
Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy-induced nausea.
Topics: Aged; Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Blood Pressure; Carboplatin; Cis | 1999 |
Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy-induced nausea.
Topics: Aged; Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Blood Pressure; Carboplatin; Cis | 1999 |
Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tab
Topics: Administration, Oral; Adult; Antiemetics; Dose Fractionation, Radiation; Double-Blind Method; Female | 1999 |
Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tab
Topics: Administration, Oral; Adult; Antiemetics; Dose Fractionation, Radiation; Double-Blind Method; Female | 1999 |
Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tab
Topics: Administration, Oral; Adult; Antiemetics; Dose Fractionation, Radiation; Double-Blind Method; Female | 1999 |
A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Bone Marrow Transplantation; Child; Child, Preschool; Dexameth | 1999 |
A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Bone Marrow Transplantation; Child; Child, Preschool; Dexameth | 1999 |
A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Bone Marrow Transplantation; Child; Child, Preschool; Dexameth | 1999 |
Efficacy of ondansetron for prevention of postoperative nausea and vomiting after outpatient ear surgery under local anesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, Local; Antiemetics; Double-Blind Method; Female; Humans; Inject | 2000 |
Efficacy of ondansetron for prevention of postoperative nausea and vomiting after outpatient ear surgery under local anesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, Local; Antiemetics; Double-Blind Method; Female; Humans; Inject | 2000 |
Efficacy of ondansetron for prevention of postoperative nausea and vomiting after outpatient ear surgery under local anesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, Local; Antiemetics; Double-Blind Method; Female; Humans; Inject | 2000 |
Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Cost-Benefit Analysis; Female; Granisetron; Hu | 2000 |
Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Cost-Benefit Analysis; Female; Granisetron; Hu | 2000 |
Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Cost-Benefit Analysis; Female; Granisetron; Hu | 2000 |
Topotecan lacks third space sequestration.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2000 |
Topotecan lacks third space sequestration.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2000 |
Topotecan lacks third space sequestration.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2000 |
[Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
Topics: Administration, Oral; Antiemetics; Benzimidazoles; Carboplatin; Cisplatin; Cyclophosphamide; Doxorub | 2000 |
[Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
Topics: Administration, Oral; Antiemetics; Benzimidazoles; Carboplatin; Cisplatin; Cyclophosphamide; Doxorub | 2000 |
[Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
Topics: Administration, Oral; Antiemetics; Benzimidazoles; Carboplatin; Cisplatin; Cyclophosphamide; Doxorub | 2000 |
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combinat | 2000 |
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combinat | 2000 |
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combinat | 2000 |
The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 2000 |
The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 2000 |
The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 2000 |
Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.
Topics: Adolescent; Adult; Antiemetics; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; | 2000 |
Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.
Topics: Adolescent; Adult; Antiemetics; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; | 2000 |
Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.
Topics: Adolescent; Adult; Antiemetics; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; | 2000 |
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Hemato | 2000 |
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Hemato | 2000 |
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Hemato | 2000 |
Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
Topics: Adult; Aged; Antiemetics; Bone Marrow Transplantation; Double-Blind Method; Drug Evaluation; Female; | 2000 |
Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
Topics: Adult; Aged; Antiemetics; Bone Marrow Transplantation; Double-Blind Method; Drug Evaluation; Female; | 2000 |
Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
Topics: Adult; Aged; Antiemetics; Bone Marrow Transplantation; Double-Blind Method; Drug Evaluation; Female; | 2000 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Child; Child, Prescho | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Child; Child, Prescho | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Child; Child, Prescho | 1997 |
[A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Female; Humans; | 1998 |
[A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Female; Humans; | 1998 |
[A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Female; Humans; | 1998 |
Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Cross-Over Studies; Drug Cos | 2000 |
Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Cross-Over Studies; Drug Cos | 2000 |
Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Cross-Over Studies; Drug Cos | 2000 |
A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dexam | 2000 |
A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dexam | 2000 |
A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dexam | 2000 |
Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combinatio | 2000 |
Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combinatio | 2000 |
Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combinatio | 2000 |
Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug The | 2000 |
Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug The | 2000 |
Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug The | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th | 2000 |
Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Femal | 2000 |
Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Femal | 2000 |
Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Femal | 2000 |
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Drug Therapy | 2001 |
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Drug Therapy | 2001 |
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Drug Therapy | 2001 |
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Topics: Acetals; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Double-Blind Method | 2001 |
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Topics: Acetals; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Double-Blind Method | 2001 |
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Topics: Acetals; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Double-Blind Method | 2001 |
Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy.
Topics: Adolescent; Adult; Aged; Analgesia; Anesthesia; Antiemetics; Brain Neoplasms; Craniotomy; Dexamethas | 2001 |
Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy.
Topics: Adolescent; Adult; Aged; Analgesia; Anesthesia; Antiemetics; Brain Neoplasms; Craniotomy; Dexamethas | 2001 |
Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy.
Topics: Adolescent; Adult; Aged; Analgesia; Anesthesia; Antiemetics; Brain Neoplasms; Craniotomy; Dexamethas | 2001 |
Gender discrepancy observed between chemotherapy-induced emesis and hiccups.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Chi-Square Distribut | 2001 |
Gender discrepancy observed between chemotherapy-induced emesis and hiccups.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Chi-Square Distribut | 2001 |
Gender discrepancy observed between chemotherapy-induced emesis and hiccups.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Chi-Square Distribut | 2001 |
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Gen | 2001 |
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Gen | 2001 |
[Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Gen | 2001 |
Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Topics: Administration, Oral; Antiemetics; Costs and Cost Analysis; Double-Blind Method; Female; Granisetron | 2001 |
Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Topics: Administration, Oral; Antiemetics; Costs and Cost Analysis; Double-Blind Method; Female; Granisetron | 2001 |
Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Topics: Administration, Oral; Antiemetics; Costs and Cost Analysis; Double-Blind Method; Female; Granisetron | 2001 |
[Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Sched | 2002 |
[Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Sched | 2002 |
[Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Sched | 2002 |
The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical | 2001 |
The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical | 2001 |
The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical | 2001 |
Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Metoclopram | 2002 |
Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Metoclopram | 2002 |
Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Metoclopram | 2002 |
[Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2002 |
[Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2002 |
[Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2002 |
Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 2001 |
Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 2001 |
Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 2001 |
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 2002 |
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 2002 |
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 2002 |
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2D6; Female; | 2002 |
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2D6; Female; | 2002 |
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2D6; Female; | 2002 |
Oral ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Constipation; Double | 1992 |
Oral ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Constipation; Double | 1992 |
Oral ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Constipation; Double | 1992 |
Ondansetron is effective in decreasing postoperative nausea and vomiting.
Topics: Abdomen; Adult; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Injections, Intravenou | 1992 |
Ondansetron is effective in decreasing postoperative nausea and vomiting.
Topics: Abdomen; Adult; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Injections, Intravenou | 1992 |
Ondansetron is effective in decreasing postoperative nausea and vomiting.
Topics: Abdomen; Adult; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Injections, Intravenou | 1992 |
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1992 |
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1992 |
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1992 |
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Topics: Administration, Oral; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Femal | 1992 |
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Topics: Administration, Oral; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Femal | 1992 |
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Topics: Administration, Oral; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Femal | 1992 |
Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anesthesia, Obstetrical; Antiemetics; Double-Blind Me | 1992 |
Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anesthesia, Obstetrical; Antiemetics; Double-Blind Me | 1992 |
Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anesthesia, Obstetrical; Antiemetics; Double-Blind Me | 1992 |
[Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
Topics: Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Gastrointestinal Neoplasm | 1992 |
[Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
Topics: Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Gastrointestinal Neoplasm | 1992 |
[Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
Topics: Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Gastrointestinal Neoplasm | 1992 |
[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1992 |
[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1992 |
[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1992 |
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1992 |
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1992 |
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1992 |
[Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
Topics: Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Gastrointestina | 1992 |
[Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
Topics: Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Gastrointestina | 1992 |
[Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
Topics: Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Gastrointestina | 1992 |
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazo | 1992 |
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazo | 1992 |
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazo | 1992 |
[Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Hum | 1992 |
[Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Hum | 1992 |
[Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Hum | 1992 |
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1992 |
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1992 |
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Hu | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Hu | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Hu | 1992 |
Advances in the control of chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1992 |
Advances in the control of chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1992 |
Advances in the control of chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1992 |
Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 1992 |
Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 1992 |
Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 1992 |
[Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Cisplatin; Female; Humans; Lung Neoplasms; Male; Melanom | 1992 |
[Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Cisplatin; Female; Humans; Lung Neoplasms; Male; Melanom | 1992 |
[Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Cisplatin; Female; Humans; Lung Neoplasms; Male; Melanom | 1992 |
[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Gastrointestinal Neoplasms; Humans; Injections, | 1992 |
[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Gastrointestinal Neoplasms; Humans; Injections, | 1992 |
[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Gastrointestinal Neoplasms; Humans; Injections, | 1992 |
[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
Topics: Administration, Oral; Adult; Aged; Cisplatin; Double-Blind Method; Female; Head and Neck Neoplasms; | 1992 |
[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
Topics: Administration, Oral; Adult; Aged; Cisplatin; Double-Blind Method; Female; Head and Neck Neoplasms; | 1992 |
[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
Topics: Administration, Oral; Adult; Aged; Cisplatin; Double-Blind Method; Female; Head and Neck Neoplasms; | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle A | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle A | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle A | 1992 |
Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Cisplatin; Double-Blind Method; Humans; Injections, Intravenous; Male; Metoclopra | 1992 |
Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Cisplatin; Double-Blind Method; Humans; Injections, Intravenous; Male; Metoclopra | 1992 |
Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Cisplatin; Double-Blind Method; Humans; Injections, Intravenous; Male; Metoclopra | 1992 |
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1992 |
Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study.
Topics: Adult; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1992 |
Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study.
Topics: Adult; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1992 |
Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study.
Topics: Adult; Ambulatory Surgical Procedures; Double-Blind Method; Female; Humans; Injections, Intravenous; | 1992 |
Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Child; Female; Headache; Humans; Injections | 1992 |
Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Child; Female; Headache; Humans; Injections | 1992 |
Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Child; Female; Headache; Humans; Injections | 1992 |
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Drug Administration Schedule; Female | 1992 |
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Drug Administration Schedule; Female | 1992 |
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Double-Blind Method; Drug Administration Schedule; Female | 1992 |
[Prevention of postoperative nausea and vomiting by ondansetron].
Topics: Administration, Oral; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Nause | 1992 |
[Prevention of postoperative nausea and vomiting by ondansetron].
Topics: Administration, Oral; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Nause | 1992 |
[Prevention of postoperative nausea and vomiting by ondansetron].
Topics: Administration, Oral; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Nause | 1992 |
The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Nausea | 1992 |
The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Nausea | 1992 |
The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Nausea | 1992 |
Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Topics: Cisplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Nausea; Neoplasm | 1992 |
Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Topics: Cisplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Nausea; Neoplasm | 1992 |
Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Topics: Cisplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Nausea; Neoplasm | 1992 |
Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Administration Sche | 1992 |
Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Administration Sche | 1992 |
Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Administration Sche | 1992 |
Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; | 1992 |
Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; | 1992 |
Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; | 1992 |
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Dexamethasone; Doubl | 1991 |
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Dexamethasone; Doubl | 1991 |
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Dexamethasone; Doubl | 1991 |
Ondansetron.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combin | 1991 |
Ondansetron.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combin | 1991 |
Ondansetron.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combin | 1991 |
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; | 1990 |
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; | 1990 |
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; | 1990 |
Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male | 1990 |
Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male | 1990 |
Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male | 1990 |
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 1991 |
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 1991 |
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 1991 |
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Injections, Intr | 1991 |
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Injections, Intr | 1991 |
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Injections, Intr | 1991 |
Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Drug Evaluation; Female; Humans; | 1991 |
Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Drug Evaluation; Female; Humans; | 1991 |
Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Drug Evaluation; Female; Humans; | 1991 |
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1991 |
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1991 |
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1991 |
Ondansetron--the first of a new class of antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Multicenter Studies as Topic; Nausea; Ondans | 1991 |
Ondansetron--the first of a new class of antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Multicenter Studies as Topic; Nausea; Ondans | 1991 |
Ondansetron--the first of a new class of antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Multicenter Studies as Topic; Nausea; Ondans | 1991 |
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
Topics: Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1991 |
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
Topics: Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1991 |
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
Topics: Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1991 |
Reduction of carboplatin induced emesis by ondansetron.
Topics: Antiemetics; Carboplatin; Dysgerminoma; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondan | 1991 |
Reduction of carboplatin induced emesis by ondansetron.
Topics: Antiemetics; Carboplatin; Dysgerminoma; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondan | 1991 |
Reduction of carboplatin induced emesis by ondansetron.
Topics: Antiemetics; Carboplatin; Dysgerminoma; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondan | 1991 |
Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle | 1991 |
Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle | 1991 |
Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo.
Topics: Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle | 1991 |
Antiemetic efficacy of ondansetron after outpatient laparoscopy.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Female; Humans; | 1991 |
Antiemetic efficacy of ondansetron after outpatient laparoscopy.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Female; Humans; | 1991 |
Antiemetic efficacy of ondansetron after outpatient laparoscopy.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Female; Humans; | 1991 |
Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1991 |
Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1991 |
Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Oral treatment with ondansetron in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Antineoplastic C | 1991 |
Oral treatment with ondansetron in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Antineoplastic C | 1991 |
Oral treatment with ondansetron in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Antineoplastic C | 1991 |
Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs.
Topics: Antiemetics; Antineoplastic Agents; Electric Stimulation Therapy; Humans; Imidazoles; Nausea; Ondans | 1991 |
Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs.
Topics: Antiemetics; Antineoplastic Agents; Electric Stimulation Therapy; Humans; Imidazoles; Nausea; Ondans | 1991 |
Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs.
Topics: Antiemetics; Antineoplastic Agents; Electric Stimulation Therapy; Humans; Imidazoles; Nausea; Ondans | 1991 |
The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdominal Neoplasms; Adult; Aged; Antiemetics; Double-Blind Method; Humans; Imidazoles; Metocloprami | 1991 |
The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdominal Neoplasms; Adult; Aged; Antiemetics; Double-Blind Method; Humans; Imidazoles; Metocloprami | 1991 |
The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdominal Neoplasms; Adult; Aged; Antiemetics; Double-Blind Method; Humans; Imidazoles; Metocloprami | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Im | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Im | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Im | 1991 |
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
Topics: Acute Disease; Adolescent; Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; | 1991 |
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
Topics: Acute Disease; Adolescent; Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; | 1991 |
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
Topics: Acute Disease; Adolescent; Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; | 1991 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group.
Topics: Adult; Aged; Carboplatin; Epithelium; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; | 1991 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group.
Topics: Adult; Aged; Carboplatin; Epithelium; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; | 1991 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group.
Topics: Adult; Aged; Carboplatin; Epithelium; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; | 1991 |
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Drug Tolerance; Female; Humans; Imidazoles | 1990 |
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Drug Tolerance; Female; Humans; Imidazoles | 1990 |
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Drug Tolerance; Female; Humans; Imidazoles | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; | 1990 |
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; | 1990 |
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; | 1990 |
Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dose-Response Relationship, Drug; Drug Admin | 1990 |
Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dose-Response Relationship, Drug; Drug Admin | 1990 |
Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dose-Response Relationship, Drug; Drug Admin | 1990 |
Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 1990 |
Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 1990 |
Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 1990 |
Ondansetron and cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Ethics, Medical; Humans; Imidazoles; Nausea; Ondansetron; Research Design; Vomiting | 1990 |
Ondansetron and cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Ethics, Medical; Humans; Imidazoles; Nausea; Ondansetron; Research Design; Vomiting | 1990 |
Ondansetron and cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Ethics, Medical; Humans; Imidazoles; Nausea; Ondansetron; Research Design; Vomiting | 1990 |
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazoles; Male; Metoclop | 1990 |
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazoles; Male; Metoclop | 1990 |
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazoles; Male; Metoclop | 1990 |
Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome.
Topics: Adult; Double-Blind Method; Female; Gastric Emptying; Humans; Imidazoles; Male; Middle Aged; Nausea; | 1990 |
Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome.
Topics: Adult; Double-Blind Method; Female; Gastric Emptying; Humans; Imidazoles; Male; Middle Aged; Nausea; | 1990 |
Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome.
Topics: Adult; Double-Blind Method; Female; Gastric Emptying; Humans; Imidazoles; Male; Middle Aged; Nausea; | 1990 |
[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; H | 1990 |
[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; H | 1990 |
[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; H | 1990 |
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Human | 1989 |
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Human | 1989 |
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Human | 1989 |
275 other studies available for ondansetron and Nausea
| Article | Year |
|---|---|
Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Cytochrome P-450 CYP | 2022 |
Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Cytochrome P-450 CYP | 2022 |
Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Cytochrome P-450 CYP | 2022 |
[Nausea and vomiting in pregnancy: A place for ondansetron?]
Topics: Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Vomiting | 2021 |
[Nausea and vomiting in pregnancy: A place for ondansetron?]
Topics: Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Vomiting | 2021 |
[Nausea and vomiting in pregnancy: A place for ondansetron?]
Topics: Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Vomiting | 2021 |
Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.
Topics: Antiemetics; Female; Humans; Nausea; Neoplasms; Ondansetron; Pharmacogenetics; Vomiting | 2022 |
Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.
Topics: Antiemetics; Female; Humans; Nausea; Neoplasms; Ondansetron; Pharmacogenetics; Vomiting | 2022 |
Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.
Topics: Antiemetics; Female; Humans; Nausea; Neoplasms; Ondansetron; Pharmacogenetics; Vomiting | 2022 |
A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women.
Topics: Antiemetics; Child; Female; Genome-Wide Association Study; Humans; Nausea; Ondansetron; Pregnancy; P | 2022 |
A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women.
Topics: Antiemetics; Child; Female; Genome-Wide Association Study; Humans; Nausea; Ondansetron; Pregnancy; P | 2022 |
A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women.
Topics: Antiemetics; Child; Female; Genome-Wide Association Study; Humans; Nausea; Ondansetron; Pregnancy; P | 2022 |
Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice.
Topics: Antiemetics; Female; Folic Acid; General Practice; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2022 |
Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice.
Topics: Antiemetics; Female; Folic Acid; General Practice; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2022 |
Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice.
Topics: Antiemetics; Female; Folic Acid; General Practice; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2022 |
Is Right Unilateral Transversus Abdominis Plane (TAP) Block Successful in Postoperative Analgesia in Laparoscopic Cholecystectomy?
Topics: Abdominal Muscles; Analgesia; Analgesics, Opioid; Cholecystectomy, Laparoscopic; Double-Blind Method | 2022 |
Is Right Unilateral Transversus Abdominis Plane (TAP) Block Successful in Postoperative Analgesia in Laparoscopic Cholecystectomy?
Topics: Abdominal Muscles; Analgesia; Analgesics, Opioid; Cholecystectomy, Laparoscopic; Double-Blind Method | 2022 |
Is Right Unilateral Transversus Abdominis Plane (TAP) Block Successful in Postoperative Analgesia in Laparoscopic Cholecystectomy?
Topics: Abdominal Muscles; Analgesia; Analgesics, Opioid; Cholecystectomy, Laparoscopic; Double-Blind Method | 2022 |
Area postrema syndrome caused by medullary infarction.
Topics: Area Postrema; Female; Humans; Infarction; Metoclopramide; Nausea; Ondansetron; Syndrome; Vomiting | 2022 |
Area postrema syndrome caused by medullary infarction.
Topics: Area Postrema; Female; Humans; Infarction; Metoclopramide; Nausea; Ondansetron; Syndrome; Vomiting | 2022 |
Area postrema syndrome caused by medullary infarction.
Topics: Area Postrema; Female; Humans; Infarction; Metoclopramide; Nausea; Ondansetron; Syndrome; Vomiting | 2022 |
Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats.
Topics: Amino Acids; Animals; Aspartic Acid; Female; Glutamic Acid; Headache; Kynurenic Acid; Male; Metoclop | 2022 |
Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats.
Topics: Amino Acids; Animals; Aspartic Acid; Female; Glutamic Acid; Headache; Kynurenic Acid; Male; Metoclop | 2022 |
Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats.
Topics: Amino Acids; Animals; Aspartic Acid; Female; Glutamic Acid; Headache; Kynurenic Acid; Male; Metoclop | 2022 |
Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with Inflammatory Arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Humans; Methotrexate; Nausea; Onda | 2022 |
Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with Inflammatory Arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Humans; Methotrexate; Nausea; Onda | 2022 |
Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with Inflammatory Arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Humans; Methotrexate; Nausea; Onda | 2022 |
Embryo-fetal safety evaluation of ondansetron in rats.
Topics: Animals; Antiemetics; Embryo, Mammalian; Female; Nausea; Ondansetron; Pregnancy; Rats; Vomiting | 2023 |
Embryo-fetal safety evaluation of ondansetron in rats.
Topics: Animals; Antiemetics; Embryo, Mammalian; Female; Nausea; Ondansetron; Pregnancy; Rats; Vomiting | 2023 |
Embryo-fetal safety evaluation of ondansetron in rats.
Topics: Animals; Antiemetics; Embryo, Mammalian; Female; Nausea; Ondansetron; Pregnancy; Rats; Vomiting | 2023 |
Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; Nausea; Ondansetron; Pregnancy | 2023 |
Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; Nausea; Ondansetron; Pregnancy | 2023 |
Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
Topics: Antiemetics; Female; Humans; Hyperemesis Gravidarum; Infant, Newborn; Nausea; Ondansetron; Pregnancy | 2023 |
Ondansetron Safety Regarding Prolong QTc for Children with Head Trauma.
Topics: Adult; Antiemetics; Child; Craniocerebral Trauma; Electrocardiography; Humans; Long QT Syndrome; Nau | 2023 |
Ondansetron Safety Regarding Prolong QTc for Children with Head Trauma.
Topics: Adult; Antiemetics; Child; Craniocerebral Trauma; Electrocardiography; Humans; Long QT Syndrome; Nau | 2023 |
Ondansetron Safety Regarding Prolong QTc for Children with Head Trauma.
Topics: Adult; Antiemetics; Child; Craniocerebral Trauma; Electrocardiography; Humans; Long QT Syndrome; Nau | 2023 |
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug | 2020 |
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug | 2020 |
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug | 2020 |
Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antiemetics; Cleft Lip; Cleft Palate; Fema | 2020 |
Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antiemetics; Cleft Lip; Cleft Palate; Fema | 2020 |
Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antiemetics; Cleft Lip; Cleft Palate; Fema | 2020 |
Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Case-Control Studies; Child; Child, Preschool; Feasi | 2019 |
Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Case-Control Studies; Child; Child, Preschool; Feasi | 2019 |
Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Case-Control Studies; Child; Child, Preschool; Feasi | 2019 |
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Child; C | 2020 |
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Child; C | 2020 |
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Child; C | 2020 |
Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cannabis; Chronic Disease; Comparative Effe | 2020 |
Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cannabis; Chronic Disease; Comparative Effe | 2020 |
Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cannabis; Chronic Disease; Comparative Effe | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Emergency procedural sedation in children.
Topics: Anesthetics, Dissociative; Antiemetics; Child; Contraindications, Drug; Emergency Service, Hospital; | 2020 |
Emergency procedural sedation in children.
Topics: Anesthetics, Dissociative; Antiemetics; Child; Contraindications, Drug; Emergency Service, Hospital; | 2020 |
Emergency procedural sedation in children.
Topics: Anesthetics, Dissociative; Antiemetics; Child; Contraindications, Drug; Emergency Service, Hospital; | 2020 |
Effect of paroxetine on intestinal motility in the presence of ondansetron.
Topics: Animals; Antiemetics; Drug Interactions; Female; Gastrointestinal Motility; Ileum; Male; Muscle, Smo | 2020 |
Effect of paroxetine on intestinal motility in the presence of ondansetron.
Topics: Animals; Antiemetics; Drug Interactions; Female; Gastrointestinal Motility; Ileum; Male; Muscle, Smo | 2020 |
Effect of paroxetine on intestinal motility in the presence of ondansetron.
Topics: Animals; Antiemetics; Drug Interactions; Female; Gastrointestinal Motility; Ileum; Male; Muscle, Smo | 2020 |
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC).
Topics: Antiemetics; Cleft Lip; Cleft Palate; Contraindications, Drug; Drug Labeling; European Union; Female | 2021 |
Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC).
Topics: Antiemetics; Cleft Lip; Cleft Palate; Contraindications, Drug; Drug Labeling; European Union; Female | 2021 |
Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC).
Topics: Antiemetics; Cleft Lip; Cleft Palate; Contraindications, Drug; Drug Labeling; European Union; Female | 2021 |
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QT
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Domperidone; Drug Co | 2021 |
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QT
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Domperidone; Drug Co | 2021 |
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QT
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Domperidone; Drug Co | 2021 |
Effects of 5-HT
Topics: Acute Kidney Injury; Aged; Animals; Benzimidazoles; Cisplatin; Disease Models, Animal; Female; Grani | 2021 |
Effects of 5-HT
Topics: Acute Kidney Injury; Aged; Animals; Benzimidazoles; Cisplatin; Disease Models, Animal; Female; Grani | 2021 |
Effects of 5-HT
Topics: Acute Kidney Injury; Aged; Animals; Benzimidazoles; Cisplatin; Disease Models, Animal; Female; Grani | 2021 |
The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome.
Topics: Administration, Intravenous; Animals; Antiemetics; Dogs; Nausea; Ondansetron; Vestibular Diseases; V | 2021 |
The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome.
Topics: Administration, Intravenous; Animals; Antiemetics; Dogs; Nausea; Ondansetron; Vestibular Diseases; V | 2021 |
The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome.
Topics: Administration, Intravenous; Animals; Antiemetics; Dogs; Nausea; Ondansetron; Vestibular Diseases; V | 2021 |
Electrocardiogram Challenge Syncope in a Woman With Nausea and Diarrhea.
Topics: Aged; Cholecalciferol; Clonazepam; Diarrhea; Esomeprazole; Female; Fluconazole; Humans; Nausea; Onda | 2017 |
Electrocardiogram Challenge Syncope in a Woman With Nausea and Diarrhea.
Topics: Aged; Cholecalciferol; Clonazepam; Diarrhea; Esomeprazole; Female; Fluconazole; Humans; Nausea; Onda | 2017 |
Electrocardiogram Challenge Syncope in a Woman With Nausea and Diarrhea.
Topics: Aged; Cholecalciferol; Clonazepam; Diarrhea; Esomeprazole; Female; Fluconazole; Humans; Nausea; Onda | 2017 |
Nausea and vomiting: Therapeutic orphans of pediatric oncology.
Topics: Antiemetics; Child; Child, Preschool; Granisetron; Humans; Methotrexate; Nausea; Ondansetron; Precur | 2017 |
Nausea and vomiting: Therapeutic orphans of pediatric oncology.
Topics: Antiemetics; Child; Child, Preschool; Granisetron; Humans; Methotrexate; Nausea; Ondansetron; Precur | 2017 |
Nausea and vomiting: Therapeutic orphans of pediatric oncology.
Topics: Antiemetics; Child; Child, Preschool; Granisetron; Humans; Methotrexate; Nausea; Ondansetron; Precur | 2017 |
Arrhythmic Side of Ondansetron Alongside Antiemetic Effect.
Topics: Antiemetics; Double-Blind Method; Humans; Nausea; Ondansetron; Vomiting | 2017 |
Arrhythmic Side of Ondansetron Alongside Antiemetic Effect.
Topics: Antiemetics; Double-Blind Method; Humans; Nausea; Ondansetron; Vomiting | 2017 |
Arrhythmic Side of Ondansetron Alongside Antiemetic Effect.
Topics: Antiemetics; Double-Blind Method; Humans; Nausea; Ondansetron; Vomiting | 2017 |
Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study.
Topics: Administration, Intravenous; Adult; Aged; Analgesics, Opioid; Antibiotic Prophylaxis; Antiemetics; D | 2017 |
Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study.
Topics: Administration, Intravenous; Adult; Aged; Analgesics, Opioid; Antibiotic Prophylaxis; Antiemetics; D | 2017 |
Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study.
Topics: Administration, Intravenous; Adult; Aged; Analgesics, Opioid; Antibiotic Prophylaxis; Antiemetics; D | 2017 |
Comparison of Dexamethasone-Dimenhydrinate and Dexamethasone-Ondansetron in Prevention of Nausea and Vomiting in Postoperative Patients.
Topics: Antiemetics; Dexamethasone; Dimenhydrinate; Double-Blind Method; Drug Therapy, Combination; Humans; | 2018 |
Comparison of Dexamethasone-Dimenhydrinate and Dexamethasone-Ondansetron in Prevention of Nausea and Vomiting in Postoperative Patients.
Topics: Antiemetics; Dexamethasone; Dimenhydrinate; Double-Blind Method; Drug Therapy, Combination; Humans; | 2018 |
Comparison of Dexamethasone-Dimenhydrinate and Dexamethasone-Ondansetron in Prevention of Nausea and Vomiting in Postoperative Patients.
Topics: Antiemetics; Dexamethasone; Dimenhydrinate; Double-Blind Method; Drug Therapy, Combination; Humans; | 2018 |
White-Lipped Tree Viper (Cryptelytrops albolabris) Envenomation in an American Viper Keeper.
Topics: Adult; Analgesics, Opioid; Animals; Antiemetics; Antivenins; Dyspnea; Emergency Service, Hospital; F | 2017 |
White-Lipped Tree Viper (Cryptelytrops albolabris) Envenomation in an American Viper Keeper.
Topics: Adult; Analgesics, Opioid; Animals; Antiemetics; Antivenins; Dyspnea; Emergency Service, Hospital; F | 2017 |
White-Lipped Tree Viper (Cryptelytrops albolabris) Envenomation in an American Viper Keeper.
Topics: Adult; Analgesics, Opioid; Animals; Antiemetics; Antivenins; Dyspnea; Emergency Service, Hospital; F | 2017 |
Aromatherapy Relieves Nausea in ED Patients.
Topics: Adult; Antiemetics; Aromatherapy; Emergency Service, Hospital; Humans; Nausea; Ondansetron | 2018 |
Aromatherapy Relieves Nausea in ED Patients.
Topics: Adult; Antiemetics; Aromatherapy; Emergency Service, Hospital; Humans; Nausea; Ondansetron | 2018 |
Aromatherapy Relieves Nausea in ED Patients.
Topics: Adult; Antiemetics; Aromatherapy; Emergency Service, Hospital; Humans; Nausea; Ondansetron | 2018 |
Association between ondansetron use and symptom persistence in children with concussions: A 5P substudy.
Topics: Adolescent; Antiemetics; Brain Concussion; Canada; Child; Child, Preschool; Cohort Studies; Emergenc | 2019 |
Association between ondansetron use and symptom persistence in children with concussions: A 5P substudy.
Topics: Adolescent; Antiemetics; Brain Concussion; Canada; Child; Child, Preschool; Cohort Studies; Emergenc | 2019 |
Association between ondansetron use and symptom persistence in children with concussions: A 5P substudy.
Topics: Adolescent; Antiemetics; Brain Concussion; Canada; Child; Child, Preschool; Cohort Studies; Emergenc | 2019 |
Inhaled isopropyl alcohol for nausea and vomiting in the emergency department.
Topics: 2-Propanol; Administration, Inhalation; Emergency Service, Hospital; Humans; Nausea; Ondansetron; Pa | 2018 |
Inhaled isopropyl alcohol for nausea and vomiting in the emergency department.
Topics: 2-Propanol; Administration, Inhalation; Emergency Service, Hospital; Humans; Nausea; Ondansetron; Pa | 2018 |
Inhaled isopropyl alcohol for nausea and vomiting in the emergency department.
Topics: 2-Propanol; Administration, Inhalation; Emergency Service, Hospital; Humans; Nausea; Ondansetron; Pa | 2018 |
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Anxiety; Benzodiazepines; Cisplatin; Depression; De | 2018 |
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Anxiety; Benzodiazepines; Cisplatin; Depression; De | 2018 |
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Anxiety; Benzodiazepines; Cisplatin; Depression; De | 2018 |
Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dexamethasone; | 2018 |
Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dexamethasone; | 2018 |
Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dexamethasone; | 2018 |
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therap | 2018 |
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therap | 2018 |
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therap | 2018 |
Nausea in the peri-traumatic period is associated with prospective risk for PTSD symptom development.
Topics: Adolescent; Adult; Antiemetics; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Ondans | 2019 |
Nausea in the peri-traumatic period is associated with prospective risk for PTSD symptom development.
Topics: Adolescent; Adult; Antiemetics; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Ondans | 2019 |
Nausea in the peri-traumatic period is associated with prospective risk for PTSD symptom development.
Topics: Adolescent; Adult; Antiemetics; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Ondans | 2019 |
Helping Pregnant Women and Clinicians Understand the Risk of Ondansetron for Nausea and Vomiting During Pregnancy.
Topics: Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Risk; Vomiting | 2018 |
Helping Pregnant Women and Clinicians Understand the Risk of Ondansetron for Nausea and Vomiting During Pregnancy.
Topics: Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Risk; Vomiting | 2018 |
Helping Pregnant Women and Clinicians Understand the Risk of Ondansetron for Nausea and Vomiting During Pregnancy.
Topics: Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Risk; Vomiting | 2018 |
Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cleft Lip; Cleft Palate; Female; Heart Defects, Con | 2018 |
Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cleft Lip; Cleft Palate; Female; Heart Defects, Con | 2018 |
Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cleft Lip; Cleft Palate; Female; Heart Defects, Con | 2018 |
Inhaling isopropyl alcohol from alcohol wipes was amore effective antiemetic than oral ondansetron in nauseated adults.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiem | 2020 |
Inhaling isopropyl alcohol from alcohol wipes was amore effective antiemetic than oral ondansetron in nauseated adults.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiem | 2020 |
Inhaling isopropyl alcohol from alcohol wipes was amore effective antiemetic than oral ondansetron in nauseated adults.
Topics: 2-Propanol; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiem | 2020 |
In adults in the emergency department with nausea, neither droperidol nor ondansetron improved symptoms.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Nausea; Ondansetron | 2019 |
In adults in the emergency department with nausea, neither droperidol nor ondansetron improved symptoms.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Nausea; Ondansetron | 2019 |
In adults in the emergency department with nausea, neither droperidol nor ondansetron improved symptoms.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Nausea; Ondansetron | 2019 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats.
Topics: Animals; Antiemetics; Antineoplastic Agents; Behavior, Animal; Cannabinoids; Conditioning, Psycholog | 2013 |
Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats.
Topics: Animals; Antiemetics; Antineoplastic Agents; Behavior, Animal; Cannabinoids; Conditioning, Psycholog | 2013 |
Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats.
Topics: Animals; Antiemetics; Antineoplastic Agents; Behavior, Animal; Cannabinoids; Conditioning, Psycholog | 2013 |
Comparative pharmacokinetic studies of fast dissolving film and oral solution of ondansetron in rats.
Topics: Administration, Oral; Animals; Antiemetics; Antineoplastic Agents; Area Under Curve; Chemistry, Phar | 2013 |
Comparative pharmacokinetic studies of fast dissolving film and oral solution of ondansetron in rats.
Topics: Administration, Oral; Animals; Antiemetics; Antineoplastic Agents; Area Under Curve; Chemistry, Phar | 2013 |
Comparative pharmacokinetic studies of fast dissolving film and oral solution of ondansetron in rats.
Topics: Administration, Oral; Animals; Antiemetics; Antineoplastic Agents; Area Under Curve; Chemistry, Phar | 2013 |
An audit of the use of ondansetron in general medical patients.
Topics: Antiemetics; Guideline Adherence; Humans; Medical Audit; Nausea; Ondansetron; Practice Guidelines as | 2013 |
An audit of the use of ondansetron in general medical patients.
Topics: Antiemetics; Guideline Adherence; Humans; Medical Audit; Nausea; Ondansetron; Practice Guidelines as | 2013 |
An audit of the use of ondansetron in general medical patients.
Topics: Antiemetics; Guideline Adherence; Humans; Medical Audit; Nausea; Ondansetron; Practice Guidelines as | 2013 |
A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.
Topics: Animals; Anticipation, Psychological; Antiemetics; Cannabinoids; Chlordiazepoxide; Conditioning, Psy | 2014 |
A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.
Topics: Animals; Anticipation, Psychological; Antiemetics; Cannabinoids; Chlordiazepoxide; Conditioning, Psy | 2014 |
A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.
Topics: Animals; Anticipation, Psychological; Antiemetics; Cannabinoids; Chlordiazepoxide; Conditioning, Psy | 2014 |
Thermoregulatory correlates of nausea in rats and musk shrews.
Topics: Animals; Body Temperature Regulation; Feeding Behavior; Hypothermia; Male; Motion Sickness; Nausea; | 2014 |
Thermoregulatory correlates of nausea in rats and musk shrews.
Topics: Animals; Body Temperature Regulation; Feeding Behavior; Hypothermia; Male; Motion Sickness; Nausea; | 2014 |
Thermoregulatory correlates of nausea in rats and musk shrews.
Topics: Animals; Body Temperature Regulation; Feeding Behavior; Hypothermia; Male; Motion Sickness; Nausea; | 2014 |
Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Alleles; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2014 |
Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Alleles; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2014 |
Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Alleles; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2014 |
Drug treatment of adults with nausea and vomiting in primary care.
Topics: Adult; Antiemetics; Domperidone; Droperidol; Female; Histamine Antagonists; Humans; Male; Metoclopra | 2014 |
Drug treatment of adults with nausea and vomiting in primary care.
Topics: Adult; Antiemetics; Domperidone; Droperidol; Female; Histamine Antagonists; Humans; Male; Metoclopra | 2014 |
Drug treatment of adults with nausea and vomiting in primary care.
Topics: Adult; Antiemetics; Domperidone; Droperidol; Female; Histamine Antagonists; Humans; Male; Metoclopra | 2014 |
The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cytochrome P-450 CYP2D6; Drug Interactions; | 2014 |
The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cytochrome P-450 CYP2D6; Drug Interactions; | 2014 |
The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cytochrome P-450 CYP2D6; Drug Interactions; | 2014 |
[Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease].
Topics: Adult; Antiemetics; Antirheumatic Agents; Bone Marrow Diseases; Chemical and Drug Induced Liver Inju | 2015 |
[Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease].
Topics: Adult; Antiemetics; Antirheumatic Agents; Bone Marrow Diseases; Chemical and Drug Induced Liver Inju | 2015 |
[Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease].
Topics: Adult; Antiemetics; Antirheumatic Agents; Bone Marrow Diseases; Chemical and Drug Induced Liver Inju | 2015 |
Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department.
Topics: Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Nausea; Ondansetron; | 2014 |
Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department.
Topics: Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Nausea; Ondansetron; | 2014 |
Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department.
Topics: Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Nausea; Ondansetron; | 2014 |
Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report.
Topics: Antiemetics; Aprepitant; Bone Neoplasms; Breast Neoplasms; Female; Granisetron; Humans; Middle Aged; | 2015 |
Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report.
Topics: Antiemetics; Aprepitant; Bone Neoplasms; Breast Neoplasms; Female; Granisetron; Humans; Middle Aged; | 2015 |
Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report.
Topics: Antiemetics; Aprepitant; Bone Neoplasms; Breast Neoplasms; Female; Granisetron; Humans; Middle Aged; | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2015 |
Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care.
Topics: Analgesics, Opioid; Antiemetics; Emergency Service, Hospital; Humans; Military Medicine; Nausea; Off | 2015 |
Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care.
Topics: Analgesics, Opioid; Antiemetics; Emergency Service, Hospital; Humans; Military Medicine; Nausea; Off | 2015 |
Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care.
Topics: Analgesics, Opioid; Antiemetics; Emergency Service, Hospital; Humans; Military Medicine; Nausea; Off | 2015 |
Fluctuating serum aspartate aminotransferase activity in a complicated pregnancy.
Topics: Adult; Alanine Transaminase; Antiemetics; Aspartate Aminotransferases; Clinical Enzyme Tests; Female | 2015 |
Fluctuating serum aspartate aminotransferase activity in a complicated pregnancy.
Topics: Adult; Alanine Transaminase; Antiemetics; Aspartate Aminotransferases; Clinical Enzyme Tests; Female | 2015 |
Fluctuating serum aspartate aminotransferase activity in a complicated pregnancy.
Topics: Adult; Alanine Transaminase; Antiemetics; Aspartate Aminotransferases; Clinical Enzyme Tests; Female | 2015 |
Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors.
Topics: Antiemetics; Dexamethasone; Female; Humans; Male; Morpholines; Nausea; Neurokinin-1 Receptor Antagon | 2016 |
Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors.
Topics: Antiemetics; Dexamethasone; Female; Humans; Male; Morpholines; Nausea; Neurokinin-1 Receptor Antagon | 2016 |
Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors.
Topics: Antiemetics; Dexamethasone; Female; Humans; Male; Morpholines; Nausea; Neurokinin-1 Receptor Antagon | 2016 |
Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study.
Topics: Ambulances; Antiemetics; Emergency Medical Services; Female; Humans; Male; Metoclopramide; Nausea; O | 2016 |
Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study.
Topics: Ambulances; Antiemetics; Emergency Medical Services; Female; Humans; Male; Metoclopramide; Nausea; O | 2016 |
Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study.
Topics: Ambulances; Antiemetics; Emergency Medical Services; Female; Humans; Male; Metoclopramide; Nausea; O | 2016 |
Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective.
Topics: Adult; Antiemetics; Emergency Service, Hospital; Female; Humans; Logistic Models; Male; Metocloprami | 2016 |
Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective.
Topics: Adult; Antiemetics; Emergency Service, Hospital; Female; Humans; Logistic Models; Male; Metocloprami | 2016 |
Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective.
Topics: Adult; Antiemetics; Emergency Service, Hospital; Female; Humans; Logistic Models; Male; Metocloprami | 2016 |
Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; Clinical Trials, Phase III as Topic; Cost-B | 2017 |
Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; Clinical Trials, Phase III as Topic; Cost-B | 2017 |
Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; Clinical Trials, Phase III as Topic; Cost-B | 2017 |
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Therapy, Combin | 2016 |
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Therapy, Combin | 2016 |
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Therapy, Combin | 2016 |
Ondansetron-Induced Life Threatening Hypokalemia.
Topics: Antiemetics; Fever; Humans; Hypokalemia; Male; Middle Aged; Muscle Hypotonia; Nausea; Ondansetron | 2016 |
Ondansetron-Induced Life Threatening Hypokalemia.
Topics: Antiemetics; Fever; Humans; Hypokalemia; Male; Middle Aged; Muscle Hypotonia; Nausea; Ondansetron | 2016 |
Ondansetron-Induced Life Threatening Hypokalemia.
Topics: Antiemetics; Fever; Humans; Hypokalemia; Male; Middle Aged; Muscle Hypotonia; Nausea; Ondansetron | 2016 |
Evaluation of Pentravan
Topics: Administration, Cutaneous; Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Chemistry, Pharm | 2016 |
Evaluation of Pentravan
Topics: Administration, Cutaneous; Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Chemistry, Pharm | 2016 |
Evaluation of Pentravan
Topics: Administration, Cutaneous; Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Chemistry, Pharm | 2016 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiemetics; Autoreceptors; Conditioning, Psycholog | 2009 |
Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiemetics; Autoreceptors; Conditioning, Psycholog | 2009 |
Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiemetics; Autoreceptors; Conditioning, Psycholog | 2009 |
Ondansetron for the treatment of nausea associated with altitude sickness.
Topics: Altitude Sickness; Antiemetics; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Treatment Ou | 2008 |
Ondansetron for the treatment of nausea associated with altitude sickness.
Topics: Altitude Sickness; Antiemetics; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Treatment Ou | 2008 |
Ondansetron for the treatment of nausea associated with altitude sickness.
Topics: Altitude Sickness; Antiemetics; Female; Humans; Male; Middle Aged; Nausea; Ondansetron; Treatment Ou | 2008 |
[Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Female; H | 2009 |
[Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Female; H | 2009 |
[Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Female; H | 2009 |
Ondansetron and seizures.
Topics: Adult; Electroencephalography; Epilepsy; Epilepsy, Tonic-Clonic; Female; Follow-Up Studies; Humans; | 2009 |
Ondansetron and seizures.
Topics: Adult; Electroencephalography; Epilepsy; Epilepsy, Tonic-Clonic; Female; Follow-Up Studies; Humans; | 2009 |
Ondansetron and seizures.
Topics: Adult; Electroencephalography; Epilepsy; Epilepsy, Tonic-Clonic; Female; Follow-Up Studies; Humans; | 2009 |
The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Incidence; | 2010 |
The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Incidence; | 2010 |
The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Incidence; | 2010 |
Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months.
Topics: Anesthesia, General; Antiemetics; Antineoplastic Agents; Child, Preschool; Computer Simulation; Fema | 2010 |
Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months.
Topics: Anesthesia, General; Antiemetics; Antineoplastic Agents; Child, Preschool; Computer Simulation; Fema | 2010 |
Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months.
Topics: Anesthesia, General; Antiemetics; Antineoplastic Agents; Child, Preschool; Computer Simulation; Fema | 2010 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma | 2009 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma | 2009 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma | 2009 |
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administra | 2011 |
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administra | 2011 |
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administra | 2011 |
Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Health Care Surveys; Humans | 2011 |
Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Health Care Surveys; Humans | 2011 |
Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Health Care Surveys; Humans | 2011 |
Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report.
Topics: Anaphylaxis; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Female; Granisetron; Humans; Infan | 2010 |
Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report.
Topics: Anaphylaxis; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Female; Granisetron; Humans; Infan | 2010 |
Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report.
Topics: Anaphylaxis; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Female; Granisetron; Humans; Infan | 2010 |
Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications.
Topics: Adolescent; Adult; Antiemetics; Female; Home Infusion Therapy; Humans; Infusions, Subcutaneous; Meto | 2011 |
Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications.
Topics: Adolescent; Adult; Antiemetics; Female; Home Infusion Therapy; Humans; Infusions, Subcutaneous; Meto | 2011 |
Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications.
Topics: Adolescent; Adult; Antiemetics; Female; Home Infusion Therapy; Humans; Infusions, Subcutaneous; Meto | 2011 |
Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease.
Topics: Adolescent; Case-Control Studies; Child; Crohn Disease; Dose-Response Relationship, Drug; Female; Hu | 2011 |
Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease.
Topics: Adolescent; Case-Control Studies; Child; Crohn Disease; Dose-Response Relationship, Drug; Female; Hu | 2011 |
Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease.
Topics: Adolescent; Case-Control Studies; Child; Crohn Disease; Dose-Response Relationship, Drug; Female; Hu | 2011 |
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Prot | 2012 |
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Prot | 2012 |
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Prot | 2012 |
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2011 |
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2011 |
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2011 |
Photocrosslinkable biodegradable responsive hydrogels as drug delivery systems.
Topics: Antiemetics; Biocompatible Materials; Dextrans; Drug Compounding; Drug Delivery Systems; Hydrogels; | 2011 |
Photocrosslinkable biodegradable responsive hydrogels as drug delivery systems.
Topics: Antiemetics; Biocompatible Materials; Dextrans; Drug Compounding; Drug Delivery Systems; Hydrogels; | 2011 |
Photocrosslinkable biodegradable responsive hydrogels as drug delivery systems.
Topics: Antiemetics; Biocompatible Materials; Dextrans; Drug Compounding; Drug Delivery Systems; Hydrogels; | 2011 |
Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Bone Neoplasms; Female; Humans; Male; Middle Aged; Naus | 2012 |
Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Bone Neoplasms; Female; Humans; Male; Middle Aged; Naus | 2012 |
Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Bone Neoplasms; Female; Humans; Male; Middle Aged; Naus | 2012 |
Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2012 |
Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2012 |
Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2012 |
Ondansetron interferes with unconditioned lying-on belly and acquisition of conditioned gaping induced by LiCl as models of nausea-induced behaviors in rats.
Topics: Analysis of Variance; Animals; Antiemetics; Avoidance Learning; Conditioning, Classical; Disease Mod | 2012 |
Ondansetron interferes with unconditioned lying-on belly and acquisition of conditioned gaping induced by LiCl as models of nausea-induced behaviors in rats.
Topics: Analysis of Variance; Animals; Antiemetics; Avoidance Learning; Conditioning, Classical; Disease Mod | 2012 |
Ondansetron interferes with unconditioned lying-on belly and acquisition of conditioned gaping induced by LiCl as models of nausea-induced behaviors in rats.
Topics: Analysis of Variance; Animals; Antiemetics; Avoidance Learning; Conditioning, Classical; Disease Mod | 2012 |
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Cleft Lip; Cleft Palate; Female; Humans; H | 2012 |
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Cleft Lip; Cleft Palate; Female; Humans; H | 2012 |
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Cleft Lip; Cleft Palate; Female; Humans; H | 2012 |
Leaves of Hippophae rhamnoides prevent taste aversion in gamma-irradiated rats.
Topics: Animals; Antiemetics; Antioxidants; Behavior, Animal; Conditioning, Classical; Corticosterone; Dieta | 2011 |
Leaves of Hippophae rhamnoides prevent taste aversion in gamma-irradiated rats.
Topics: Animals; Antiemetics; Antioxidants; Behavior, Animal; Conditioning, Classical; Corticosterone; Dieta | 2011 |
Leaves of Hippophae rhamnoides prevent taste aversion in gamma-irradiated rats.
Topics: Animals; Antiemetics; Antioxidants; Behavior, Animal; Conditioning, Classical; Corticosterone; Dieta | 2011 |
Enhanced gastric retention of solid resin beads as a marker for emetic potential of agents in rats.
Topics: Anesthesia; Animals; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Ci | 2012 |
Enhanced gastric retention of solid resin beads as a marker for emetic potential of agents in rats.
Topics: Anesthesia; Animals; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Ci | 2012 |
Enhanced gastric retention of solid resin beads as a marker for emetic potential of agents in rats.
Topics: Anesthesia; Animals; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Ci | 2012 |
Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting.
Topics: Administration, Cutaneous; Animals; Antiemetics; Area Under Curve; Centrifugation; Chemistry, Pharma | 2013 |
Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting.
Topics: Administration, Cutaneous; Animals; Antiemetics; Area Under Curve; Centrifugation; Chemistry, Pharma | 2013 |
Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting.
Topics: Administration, Cutaneous; Animals; Antiemetics; Area Under Curve; Centrifugation; Chemistry, Pharma | 2013 |
Can early post-spinal heart rate predict subsequent nausea during anaesthesia for caesarean section?
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Analgesics, Opioid; Anesthesia, Obstetrical; Anesthesia | 2012 |
Can early post-spinal heart rate predict subsequent nausea during anaesthesia for caesarean section?
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Analgesics, Opioid; Anesthesia, Obstetrical; Anesthesia | 2012 |
Can early post-spinal heart rate predict subsequent nausea during anaesthesia for caesarean section?
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Analgesics, Opioid; Anesthesia, Obstetrical; Anesthesia | 2012 |
The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED.
Topics: Antiemetics; Child; Craniocerebral Trauma; Cross-Sectional Studies; Emergency Service, Hospital; Fem | 2013 |
The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED.
Topics: Antiemetics; Child; Craniocerebral Trauma; Cross-Sectional Studies; Emergency Service, Hospital; Fem | 2013 |
The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED.
Topics: Antiemetics; Child; Craniocerebral Trauma; Cross-Sectional Studies; Emergency Service, Hospital; Fem | 2013 |
Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT(3) receptor in the posterior and anterior insular cortex.
Topics: 5,6-Dihydroxytryptamine; Animals; Avoidance Learning; Biguanides; Cerebral Cortex; Conditioning, Cla | 2012 |
Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT(3) receptor in the posterior and anterior insular cortex.
Topics: 5,6-Dihydroxytryptamine; Animals; Avoidance Learning; Biguanides; Cerebral Cortex; Conditioning, Cla | 2012 |
Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT(3) receptor in the posterior and anterior insular cortex.
Topics: 5,6-Dihydroxytryptamine; Animals; Avoidance Learning; Biguanides; Cerebral Cortex; Conditioning, Cla | 2012 |
Motherisk update. Is ondansetron safe for use during pregnancy?
Topics: Antiemetics; Canada; Cleft Palate; Female; Fetus; Humans; Long QT Syndrome; Morning Sickness; Nausea | 2012 |
Motherisk update. Is ondansetron safe for use during pregnancy?
Topics: Antiemetics; Canada; Cleft Palate; Female; Fetus; Humans; Long QT Syndrome; Morning Sickness; Nausea | 2012 |
Motherisk update. Is ondansetron safe for use during pregnancy?
Topics: Antiemetics; Canada; Cleft Palate; Female; Fetus; Humans; Long QT Syndrome; Morning Sickness; Nausea | 2012 |
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Guideline Adhere | 2013 |
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Guideline Adhere | 2013 |
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Guideline Adhere | 2013 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
In brief: intravenous ondanstron (Zofran) 32 mg withdrawn.
Topics: Antiemetics; Antineoplastic Agents; Humans; Long QT Syndrome; Nausea; Ondansetron; Product Recalls a | 2012 |
In brief: intravenous ondanstron (Zofran) 32 mg withdrawn.
Topics: Antiemetics; Antineoplastic Agents; Humans; Long QT Syndrome; Nausea; Ondansetron; Product Recalls a | 2012 |
In brief: intravenous ondanstron (Zofran) 32 mg withdrawn.
Topics: Antiemetics; Antineoplastic Agents; Humans; Long QT Syndrome; Nausea; Ondansetron; Product Recalls a | 2012 |
Migraine-type headaches in children receiving chemotherapy and ondansetron.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Female; Humans; Male; Migraine Disorders; Nau | 2002 |
Migraine-type headaches in children receiving chemotherapy and ondansetron.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Female; Humans; Male; Migraine Disorders; Nau | 2002 |
Migraine-type headaches in children receiving chemotherapy and ondansetron.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Female; Humans; Male; Migraine Disorders; Nau | 2002 |
[Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
Topics: Administration, Sublingual; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2003 |
[Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
Topics: Administration, Sublingual; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2003 |
[Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
Topics: Administration, Sublingual; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2003 |
The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.
Topics: Adult; Analysis of Variance; Antiemetics; Female; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2004 |
The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.
Topics: Adult; Analysis of Variance; Antiemetics; Female; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2004 |
The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.
Topics: Adult; Analysis of Variance; Antiemetics; Female; Humans; Nausea; Ondansetron; Pregnancy; Pregnancy | 2004 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indo | 2005 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indo | 2005 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indo | 2005 |
Pretreatment with ondansetron blunts plasma vasopressin increases associated with morphine administration in ferrets.
Topics: Animals; Antiemetics; Arginine Vasopressin; Ferrets; Male; Morphine; Nausea; Ondansetron; Postoperat | 2005 |
Pretreatment with ondansetron blunts plasma vasopressin increases associated with morphine administration in ferrets.
Topics: Animals; Antiemetics; Arginine Vasopressin; Ferrets; Male; Morphine; Nausea; Ondansetron; Postoperat | 2005 |
Pretreatment with ondansetron blunts plasma vasopressin increases associated with morphine administration in ferrets.
Topics: Animals; Antiemetics; Arginine Vasopressin; Ferrets; Male; Morphine; Nausea; Ondansetron; Postoperat | 2005 |
Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting.
Topics: Analysis of Variance; Animals; Antiemetics; Association Learning; Cannabidiol; Cannabinoids; Conditi | 2006 |
Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting.
Topics: Analysis of Variance; Animals; Antiemetics; Association Learning; Cannabidiol; Cannabinoids; Conditi | 2006 |
Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting.
Topics: Analysis of Variance; Animals; Antiemetics; Association Learning; Cannabidiol; Cannabinoids; Conditi | 2006 |
Re: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Electrocardiography; Granisetron | 2005 |
Re: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Electrocardiography; Granisetron | 2005 |
Re: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Electrocardiography; Granisetron | 2005 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; | 2005 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; | 2005 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; | 2005 |
Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea.
Topics: Animals; Antiemetics; Conditioning, Operant; Disease Models, Animal; Dronabinol; Infusions, Intraven | 2006 |
Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea.
Topics: Animals; Antiemetics; Conditioning, Operant; Disease Models, Animal; Dronabinol; Infusions, Intraven | 2006 |
Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea.
Topics: Animals; Antiemetics; Conditioning, Operant; Disease Models, Animal; Dronabinol; Infusions, Intraven | 2006 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compou | 2006 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compou | 2006 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compou | 2006 |
Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Eating; Gastric Emptying; Mal | 2007 |
Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Eating; Gastric Emptying; Mal | 2007 |
Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Eating; Gastric Emptying; Mal | 2007 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinucli | 2007 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinucli | 2007 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinucli | 2007 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2007 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2007 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2007 |
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Cachexia; Humans; Mianserin; Mirtazapine; Nause | 2007 |
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Cachexia; Humans; Mianserin; Mirtazapine; Nause | 2007 |
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Cachexia; Humans; Mianserin; Mirtazapine; Nause | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chem | 2007 |
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chem | 2007 |
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chem | 2007 |
Safety of ondansetron loading doses in children with cancer.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; | 2008 |
Safety of ondansetron loading doses in children with cancer.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; | 2008 |
Safety of ondansetron loading doses in children with cancer.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; | 2008 |
Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cytarab | 2008 |
Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cytarab | 2008 |
Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cytarab | 2008 |
The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.
Topics: Anti-Dyskinesia Agents; Antiemetics; Antineoplastic Agents; Biperiden; Brain; Child; Dose-Response R | 2008 |
The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.
Topics: Anti-Dyskinesia Agents; Antiemetics; Antineoplastic Agents; Biperiden; Brain; Child; Dose-Response R | 2008 |
The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.
Topics: Anti-Dyskinesia Agents; Antiemetics; Antineoplastic Agents; Biperiden; Brain; Child; Dose-Response R | 2008 |
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Epirubicin | 2008 |
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Epirubicin | 2008 |
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Epirubicin | 2008 |
Ondansetron and minor oral surgery.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Placebos; Postoperative Complications; Serotonin Antagonis | 1995 |
Ondansetron and minor oral surgery.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Placebos; Postoperative Complications; Serotonin Antagonis | 1995 |
Ondansetron and minor oral surgery.
Topics: Antiemetics; Humans; Nausea; Ondansetron; Placebos; Postoperative Complications; Serotonin Antagonis | 1995 |
Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Haloperidol; Humans | 1994 |
Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Haloperidol; Humans | 1994 |
Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Haloperidol; Humans | 1994 |
Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Costs and Cost Analysis; Droperi | 1995 |
Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Costs and Cost Analysis; Droperi | 1995 |
Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Costs and Cost Analysis; Droperi | 1995 |
Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials.
Topics: Anesthesia Department, Hospital; Controlled Clinical Trials as Topic; Data Collection; England; Heal | 1995 |
Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials.
Topics: Anesthesia Department, Hospital; Controlled Clinical Trials as Topic; Data Collection; England; Heal | 1995 |
Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials.
Topics: Anesthesia Department, Hospital; Controlled Clinical Trials as Topic; Data Collection; England; Heal | 1995 |
Effectiveness and economy of low-dose ondansetron.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Nausea; Ondansetron; Practice Guidelines as To | 1995 |
Effectiveness and economy of low-dose ondansetron.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Nausea; Ondansetron; Practice Guidelines as To | 1995 |
Effectiveness and economy of low-dose ondansetron.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Nausea; Ondansetron; Practice Guidelines as To | 1995 |
The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
Topics: Animals; Cisplatin; Disease Models, Animal; Female; Granisetron; Male; Nausea; Ondansetron; Swine; T | 1995 |
The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
Topics: Animals; Cisplatin; Disease Models, Animal; Female; Granisetron; Male; Nausea; Ondansetron; Swine; T | 1995 |
The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
Topics: Animals; Cisplatin; Disease Models, Animal; Female; Granisetron; Male; Nausea; Ondansetron; Swine; T | 1995 |
[Quality of life in oncology. Importance of optimal control of nausea/vomiting induced by antineoplastic agents].
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Quality of Life; Vomiting | 1994 |
[Quality of life in oncology. Importance of optimal control of nausea/vomiting induced by antineoplastic agents].
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Quality of Life; Vomiting | 1994 |
[Quality of life in oncology. Importance of optimal control of nausea/vomiting induced by antineoplastic agents].
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Quality of Life; Vomiting | 1994 |
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Hydroxyindoleacetic | 1993 |
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Hydroxyindoleacetic | 1993 |
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Hydroxyindoleacetic | 1993 |
Reports from the University Hospital Consortium (UHC) Technology Advancement Center.
Topics: Academic Medical Centers; Drug-Related Side Effects and Adverse Reactions; Multicenter Studies as To | 1995 |
Reports from the University Hospital Consortium (UHC) Technology Advancement Center.
Topics: Academic Medical Centers; Drug-Related Side Effects and Adverse Reactions; Multicenter Studies as To | 1995 |
Reports from the University Hospital Consortium (UHC) Technology Advancement Center.
Topics: Academic Medical Centers; Drug-Related Side Effects and Adverse Reactions; Multicenter Studies as To | 1995 |
Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Eto | 1995 |
Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Eto | 1995 |
Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Eto | 1995 |
Right, wrong, and surrogate endpoints.
Topics: Anesthesiology; Clinical Trials as Topic; Costs and Cost Analysis; Humans; Nausea; Ondansetron; Vomi | 1995 |
Right, wrong, and surrogate endpoints.
Topics: Anesthesiology; Clinical Trials as Topic; Costs and Cost Analysis; Humans; Nausea; Ondansetron; Vomi | 1995 |
Right, wrong, and surrogate endpoints.
Topics: Anesthesiology; Clinical Trials as Topic; Costs and Cost Analysis; Humans; Nausea; Ondansetron; Vomi | 1995 |
Right, wrong, and surrogate endpoints.
Topics: Anesthesiology; Humans; Nausea; Ondansetron; Vomiting | 1995 |
Right, wrong, and surrogate endpoints.
Topics: Anesthesiology; Humans; Nausea; Ondansetron; Vomiting | 1995 |
Right, wrong, and surrogate endpoints.
Topics: Anesthesiology; Humans; Nausea; Ondansetron; Vomiting | 1995 |
Ondansetron for symptomatic relief in terminal uraemia.
Topics: Administration, Oral; Aged; Female; Humans; Male; Nausea; Ondansetron; Uremia; Vomiting | 1995 |
Ondansetron for symptomatic relief in terminal uraemia.
Topics: Administration, Oral; Aged; Female; Humans; Male; Nausea; Ondansetron; Uremia; Vomiting | 1995 |
Ondansetron for symptomatic relief in terminal uraemia.
Topics: Administration, Oral; Aged; Female; Humans; Male; Nausea; Ondansetron; Uremia; Vomiting | 1995 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
Pharmacist development and use of antiemetic protocols.
Topics: Antiemetics; Antineoplastic Agents; Clinical Protocols; France; Humans; Nausea; Ondansetron; Pharmac | 1995 |
Pharmacist development and use of antiemetic protocols.
Topics: Antiemetics; Antineoplastic Agents; Clinical Protocols; France; Humans; Nausea; Ondansetron; Pharmac | 1995 |
Pharmacist development and use of antiemetic protocols.
Topics: Antiemetics; Antineoplastic Agents; Clinical Protocols; France; Humans; Nausea; Ondansetron; Pharmac | 1995 |
Ondansetron for the prevention of nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1995 |
Ondansetron for the prevention of nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1995 |
Ondansetron for the prevention of nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1995 |
Dysphoria after treatment with ondansetron.
Topics: Adult; Antineoplastic Agents; Depressive Disorder; Female; Humans; Nausea; Ondansetron | 1995 |
Dysphoria after treatment with ondansetron.
Topics: Adult; Antineoplastic Agents; Depressive Disorder; Female; Humans; Nausea; Ondansetron | 1995 |
Dysphoria after treatment with ondansetron.
Topics: Adult; Antineoplastic Agents; Depressive Disorder; Female; Humans; Nausea; Ondansetron | 1995 |
Practical points in the use of ondansetron.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Practical points in the use of ondansetron.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Practical points in the use of ondansetron.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Anaphylactoid reactions associated with ondansetron.
Topics: Adult; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cis | 1994 |
Anaphylactoid reactions associated with ondansetron.
Topics: Adult; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cis | 1994 |
Anaphylactoid reactions associated with ondansetron.
Topics: Adult; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cis | 1994 |
Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Appetite; Breast Neoplasms; Consc | 1994 |
Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Appetite; Breast Neoplasms; Consc | 1994 |
Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Appetite; Breast Neoplasms; Consc | 1994 |
[The management of vomiting and nausea with zofran during the chemotherapy of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Feeding an | 1994 |
[The management of vomiting and nausea with zofran during the chemotherapy of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Feeding an | 1994 |
[The management of vomiting and nausea with zofran during the chemotherapy of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Feeding an | 1994 |
Comment: Ondansetron for treating nausea and vomiting in the poisoned patient.
Topics: Humans; Ipecac; Nausea; Ondansetron; Poisoning; Vomiting | 1994 |
Comment: Ondansetron for treating nausea and vomiting in the poisoned patient.
Topics: Humans; Ipecac; Nausea; Ondansetron; Poisoning; Vomiting | 1994 |
Comment: Ondansetron for treating nausea and vomiting in the poisoned patient.
Topics: Humans; Ipecac; Nausea; Ondansetron; Poisoning; Vomiting | 1994 |
[Ondansetron on postoperative nausea and vomiting].
Topics: Abdomen; Adult; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Pos | 1994 |
[Ondansetron on postoperative nausea and vomiting].
Topics: Abdomen; Adult; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Pos | 1994 |
[Ondansetron on postoperative nausea and vomiting].
Topics: Abdomen; Adult; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Pos | 1994 |
Loss of efficacy of ondansetron-dexamethasone during successive courses in female patients receiving high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1994 |
Loss of efficacy of ondansetron-dexamethasone during successive courses in female patients receiving high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1994 |
Loss of efficacy of ondansetron-dexamethasone during successive courses in female patients receiving high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1994 |
Surrogate end points. Are they meaningful?
Topics: Antiemetics; Child; Humans; Incidence; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Surrogate end points. Are they meaningful?
Topics: Antiemetics; Child; Humans; Incidence; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Surrogate end points. Are they meaningful?
Topics: Antiemetics; Child; Humans; Incidence; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
When regulatory requirements conflict with ethical study design: the case of oral ondansetron.
Topics: Antineoplastic Agents; Control Groups; Double-Blind Method; Drug and Narcotic Control; Ethics, Medic | 1994 |
When regulatory requirements conflict with ethical study design: the case of oral ondansetron.
Topics: Antineoplastic Agents; Control Groups; Double-Blind Method; Drug and Narcotic Control; Ethics, Medic | 1994 |
When regulatory requirements conflict with ethical study design: the case of oral ondansetron.
Topics: Antineoplastic Agents; Control Groups; Double-Blind Method; Drug and Narcotic Control; Ethics, Medic | 1994 |
Ondansetron for postoperative nausea and vomiting: decisions in the absence of comparative trials.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Postoperative Complications; United States; U | 1994 |
Ondansetron for postoperative nausea and vomiting: decisions in the absence of comparative trials.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Postoperative Complications; United States; U | 1994 |
Ondansetron for postoperative nausea and vomiting: decisions in the absence of comparative trials.
Topics: Clinical Trials as Topic; Humans; Nausea; Ondansetron; Postoperative Complications; United States; U | 1994 |
On the relationship between nausea and vomiting in patients undergoing chemotherapy. Italian Group for Antiemetic Research.
Topics: Antiemetics; Cisplatin; Confounding Factors, Epidemiologic; Dexamethasone; Diphenhydramine; Factor A | 1994 |
On the relationship between nausea and vomiting in patients undergoing chemotherapy. Italian Group for Antiemetic Research.
Topics: Antiemetics; Cisplatin; Confounding Factors, Epidemiologic; Dexamethasone; Diphenhydramine; Factor A | 1994 |
On the relationship between nausea and vomiting in patients undergoing chemotherapy. Italian Group for Antiemetic Research.
Topics: Antiemetics; Cisplatin; Confounding Factors, Epidemiologic; Dexamethasone; Diphenhydramine; Factor A | 1994 |
Zofran: first of a new class of antiemetics.
Topics: Humans; Nausea; Ondansetron; Vomiting | 1994 |
Zofran: first of a new class of antiemetics.
Topics: Humans; Nausea; Ondansetron; Vomiting | 1994 |
Zofran: first of a new class of antiemetics.
Topics: Humans; Nausea; Ondansetron; Vomiting | 1994 |
Pharmacoeconomic analyses: whose perspective counts and costs the most?
Topics: Adult; Cisplatin; Cost-Benefit Analysis; Decision Trees; Drug Evaluation; Humans; Metoclopramide; Na | 1994 |
Pharmacoeconomic analyses: whose perspective counts and costs the most?
Topics: Adult; Cisplatin; Cost-Benefit Analysis; Decision Trees; Drug Evaluation; Humans; Metoclopramide; Na | 1994 |
Pharmacoeconomic analyses: whose perspective counts and costs the most?
Topics: Adult; Cisplatin; Cost-Benefit Analysis; Decision Trees; Drug Evaluation; Humans; Metoclopramide; Na | 1994 |
Cost-effectiveness, not cost containment.
Topics: Cisplatin; Cost Control; Cost-Benefit Analysis; Drug Evaluation; Humans; Metoclopramide; Nausea; Ond | 1994 |
Cost-effectiveness, not cost containment.
Topics: Cisplatin; Cost Control; Cost-Benefit Analysis; Drug Evaluation; Humans; Metoclopramide; Nausea; Ond | 1994 |
Cost-effectiveness, not cost containment.
Topics: Cisplatin; Cost Control; Cost-Benefit Analysis; Drug Evaluation; Humans; Metoclopramide; Nausea; Ond | 1994 |
Zofran (Ondansetron hydrochloride) injection.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Zofran (Ondansetron hydrochloride) injection.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Zofran (Ondansetron hydrochloride) injection.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1994 |
Oral ondansetron: a useful addition to the supportive care armamentarium?
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1994 |
Oral ondansetron: a useful addition to the supportive care armamentarium?
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1994 |
Oral ondansetron: a useful addition to the supportive care armamentarium?
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1994 |
Ondansetron for treating nausea and vomiting in the poisoned patient.
Topics: Acetaminophen; Adolescent; Charcoal; Colchicine; Drug Overdose; Female; Humans; Nausea; Ondansetron; | 1994 |
Ondansetron for treating nausea and vomiting in the poisoned patient.
Topics: Acetaminophen; Adolescent; Charcoal; Colchicine; Drug Overdose; Female; Humans; Nausea; Ondansetron; | 1994 |
Ondansetron for treating nausea and vomiting in the poisoned patient.
Topics: Acetaminophen; Adolescent; Charcoal; Colchicine; Drug Overdose; Female; Humans; Nausea; Ondansetron; | 1994 |
Seizure associated with ondansetron.
Topics: Adult; Gram-Negative Bacterial Infections; Humans; Male; Nausea; Ondansetron; Seizures; Shock, Septi | 1993 |
Seizure associated with ondansetron.
Topics: Adult; Gram-Negative Bacterial Infections; Humans; Male; Nausea; Ondansetron; Seizures; Shock, Septi | 1993 |
Seizure associated with ondansetron.
Topics: Adult; Gram-Negative Bacterial Infections; Humans; Male; Nausea; Ondansetron; Seizures; Shock, Septi | 1993 |
[Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combina | 1993 |
[Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combina | 1993 |
[Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combina | 1993 |
Ondansetron and the prevention of postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Research Design; Vomiting | 1993 |
Ondansetron and the prevention of postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Research Design; Vomiting | 1993 |
Ondansetron and the prevention of postoperative nausea and vomiting.
Topics: Humans; Nausea; Ondansetron; Postoperative Complications; Research Design; Vomiting | 1993 |
Ondansetron versus metoclopramide and droperidol: an unfair comparison.
Topics: Anesthesiology; Droperidol; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications | 1993 |
Ondansetron versus metoclopramide and droperidol: an unfair comparison.
Topics: Anesthesiology; Droperidol; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications | 1993 |
Ondansetron versus metoclopramide and droperidol: an unfair comparison.
Topics: Anesthesiology; Droperidol; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications | 1993 |
Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron.
Topics: Abdominal Pain; Adult; Diarrhea; Female; Humans; Nausea; Ondansetron; Prospective Studies | 1993 |
Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron.
Topics: Abdominal Pain; Adult; Diarrhea; Female; Humans; Nausea; Ondansetron; Prospective Studies | 1993 |
Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron.
Topics: Abdominal Pain; Adult; Diarrhea; Female; Humans; Nausea; Ondansetron; Prospective Studies | 1993 |
Ondansetron by subcutaneous infusion.
Topics: Female; Humans; Infusion Pumps; Middle Aged; Nausea; Ondansetron; Vomiting | 1993 |
Ondansetron by subcutaneous infusion.
Topics: Female; Humans; Infusion Pumps; Middle Aged; Nausea; Ondansetron; Vomiting | 1993 |
Ondansetron by subcutaneous infusion.
Topics: Female; Humans; Infusion Pumps; Middle Aged; Nausea; Ondansetron; Vomiting | 1993 |
Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Protocols; Female; Humans; Nause | 1993 |
Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Protocols; Female; Humans; Nause | 1993 |
Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Protocols; Female; Humans; Nause | 1993 |
Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports.
Topics: Accidental Falls; Adult; Craniocerebral Trauma; Epilepsy, Generalized; Humans; Intensive Care Units; | 1993 |
Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports.
Topics: Accidental Falls; Adult; Craniocerebral Trauma; Epilepsy, Generalized; Humans; Intensive Care Units; | 1993 |
Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports.
Topics: Accidental Falls; Adult; Craniocerebral Trauma; Epilepsy, Generalized; Humans; Intensive Care Units; | 1993 |
Ondansetron in the treatment of intractable nausea associated with theophylline toxicity.
Topics: Adult; Delayed-Action Preparations; Humans; Male; Nausea; Ondansetron; Poisoning; Theophylline; Vomi | 1993 |
Ondansetron in the treatment of intractable nausea associated with theophylline toxicity.
Topics: Adult; Delayed-Action Preparations; Humans; Male; Nausea; Ondansetron; Poisoning; Theophylline; Vomi | 1993 |
Ondansetron in the treatment of intractable nausea associated with theophylline toxicity.
Topics: Adult; Delayed-Action Preparations; Humans; Male; Nausea; Ondansetron; Poisoning; Theophylline; Vomi | 1993 |
[On what indication should serotonin antagonists be used? A retrospective study of the use of ondansetron at an oncologic unit].
Topics: Administration, Oral; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Male; Nausea; No | 1993 |
[On what indication should serotonin antagonists be used? A retrospective study of the use of ondansetron at an oncologic unit].
Topics: Administration, Oral; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Male; Nausea; No | 1993 |
[On what indication should serotonin antagonists be used? A retrospective study of the use of ondansetron at an oncologic unit].
Topics: Administration, Oral; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Male; Nausea; No | 1993 |
Zofran makes chemo bearable.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Lung Neoplasms; Nausea; Ondansetron | 1993 |
Zofran makes chemo bearable.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Lung Neoplasms; Nausea; Ondansetron | 1993 |
Zofran makes chemo bearable.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Lung Neoplasms; Nausea; Ondansetron | 1993 |
Ondansetron and VIPoma.
Topics: Adult; Humans; Male; Nausea; Ondansetron; Pancreatic Neoplasms; Vipoma | 1993 |
Ondansetron and VIPoma.
Topics: Adult; Humans; Male; Nausea; Ondansetron; Pancreatic Neoplasms; Vipoma | 1993 |
Ondansetron and VIPoma.
Topics: Adult; Humans; Male; Nausea; Ondansetron; Pancreatic Neoplasms; Vipoma | 1993 |
Antiemetic effects of ondansetron and metopimazine.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Isonipecotic Acids; Nausea; Ondansetron; Vomiting | 1993 |
Antiemetic effects of ondansetron and metopimazine.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Isonipecotic Acids; Nausea; Ondansetron; Vomiting | 1993 |
Antiemetic effects of ondansetron and metopimazine.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Isonipecotic Acids; Nausea; Ondansetron; Vomiting | 1993 |
Ondansetron leads antiemetic research.
Topics: Antineoplastic Agents; Costs and Cost Analysis; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1993 |
Ondansetron leads antiemetic research.
Topics: Antineoplastic Agents; Costs and Cost Analysis; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1993 |
Ondansetron leads antiemetic research.
Topics: Antineoplastic Agents; Costs and Cost Analysis; Humans; Nausea; Ondansetron; Serotonin; Vomiting | 1993 |
Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia | 1993 |
Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia | 1993 |
Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia | 1993 |
Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Nausea; Ondansetr | 1993 |
Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Nausea; Ondansetr | 1993 |
Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Nausea; Ondansetr | 1993 |
Placebos and principles: a trial of ondansetron.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Control Groups; Ethics, Medical; Humans; Nausea; No | 1993 |
Placebos and principles: a trial of ondansetron.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Control Groups; Ethics, Medical; Humans; Nausea; No | 1993 |
Placebos and principles: a trial of ondansetron.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Control Groups; Ethics, Medical; Humans; Nausea; No | 1993 |
Ondansetron plus dexamethasone in the control of high dose cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Evaluation; Female; Humans; Male; Middle Aged; Nausea; O | 1993 |
Ondansetron plus dexamethasone in the control of high dose cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Evaluation; Female; Humans; Male; Middle Aged; Nausea; O | 1993 |
Ondansetron plus dexamethasone in the control of high dose cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Evaluation; Female; Humans; Male; Middle Aged; Nausea; O | 1993 |
Ondansetron use in a major university teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Drug Utilization; Female; Hospital Bed Capacity, 500 and over; Hospi | 1993 |
Ondansetron use in a major university teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Drug Utilization; Female; Hospital Bed Capacity, 500 and over; Hospi | 1993 |
Ondansetron use in a major university teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Drug Utilization; Female; Hospital Bed Capacity, 500 and over; Hospi | 1993 |
Use of ondansetron (Zofran)
Topics: Adult; Female; Humans; Middle Aged; Nausea; Ondansetron; Terminal Care; Vomiting | 1993 |
Use of ondansetron (Zofran)
Topics: Adult; Female; Humans; Middle Aged; Nausea; Ondansetron; Terminal Care; Vomiting | 1993 |
Use of ondansetron (Zofran)
Topics: Adult; Female; Humans; Middle Aged; Nausea; Ondansetron; Terminal Care; Vomiting | 1993 |
Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting.
Topics: Adult; Algorithms; Antiemetics; Antineoplastic Agents; Cost Savings; Humans; Nausea; Ondansetron; Pr | 1995 |
Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting.
Topics: Adult; Algorithms; Antiemetics; Antineoplastic Agents; Cost Savings; Humans; Nausea; Ondansetron; Pr | 1995 |
Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting.
Topics: Adult; Algorithms; Antiemetics; Antineoplastic Agents; Cost Savings; Humans; Nausea; Ondansetron; Pr | 1995 |
Nurses' perceptions of antiemetic effectiveness.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug | 1995 |
Nurses' perceptions of antiemetic effectiveness.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug | 1995 |
Nurses' perceptions of antiemetic effectiveness.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug | 1995 |
Placebo controlled trials of ondansetron for postoperative nausea and vomiting.
Topics: Antiemetics; Controlled Clinical Trials as Topic; Humans; Nausea; Ondansetron; Placebos; Postoperati | 1996 |
Placebo controlled trials of ondansetron for postoperative nausea and vomiting.
Topics: Antiemetics; Controlled Clinical Trials as Topic; Humans; Nausea; Ondansetron; Placebos; Postoperati | 1996 |
Placebo controlled trials of ondansetron for postoperative nausea and vomiting.
Topics: Antiemetics; Controlled Clinical Trials as Topic; Humans; Nausea; Ondansetron; Placebos; Postoperati | 1996 |
Improved outcome with chronic subcutaneous infusion of odansetron for intractable nausea and vomiting.
Topics: Administration, Cutaneous; Adult; Antiemetics; Female; Humans; Nausea; Ondansetron; Vomiting | 1996 |
Improved outcome with chronic subcutaneous infusion of odansetron for intractable nausea and vomiting.
Topics: Administration, Cutaneous; Adult; Antiemetics; Female; Humans; Nausea; Ondansetron; Vomiting | 1996 |
Improved outcome with chronic subcutaneous infusion of odansetron for intractable nausea and vomiting.
Topics: Administration, Cutaneous; Adult; Antiemetics; Female; Humans; Nausea; Ondansetron; Vomiting | 1996 |
Successful management of intractable nausea with ondansetron: a case study.
Topics: Aged; Antiemetics; Drug Administration Schedule; Female; Humans; Nausea; Ondansetron; Palliative Car | 1996 |
Successful management of intractable nausea with ondansetron: a case study.
Topics: Aged; Antiemetics; Drug Administration Schedule; Female; Humans; Nausea; Ondansetron; Palliative Car | 1996 |
Successful management of intractable nausea with ondansetron: a case study.
Topics: Aged; Antiemetics; Drug Administration Schedule; Female; Humans; Nausea; Ondansetron; Palliative Car | 1996 |
Re: 'Cost-effectiveness of 5-hydroxytryptamin3 receptor antagonists: a retrospective comparison of ondansetron and granisetron'.
Topics: Cost-Benefit Analysis; Granisetron; Nausea; Ondansetron; Salvage Therapy; Serotonin Antagonists; Vom | 1996 |
Re: 'Cost-effectiveness of 5-hydroxytryptamin3 receptor antagonists: a retrospective comparison of ondansetron and granisetron'.
Topics: Cost-Benefit Analysis; Granisetron; Nausea; Ondansetron; Salvage Therapy; Serotonin Antagonists; Vom | 1996 |
Re: 'Cost-effectiveness of 5-hydroxytryptamin3 receptor antagonists: a retrospective comparison of ondansetron and granisetron'.
Topics: Cost-Benefit Analysis; Granisetron; Nausea; Ondansetron; Salvage Therapy; Serotonin Antagonists; Vom | 1996 |
[Future trends in chemotherapy and impact on the management of emesis].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chronobiology Phenomena; Drug Administr | 1995 |
[Future trends in chemotherapy and impact on the management of emesis].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chronobiology Phenomena; Drug Administr | 1995 |
[Future trends in chemotherapy and impact on the management of emesis].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chronobiology Phenomena; Drug Administr | 1995 |
[The 5HT3-receptor antagonist Zofran (ondansetron) as an agent for preventing nausea and vomiting during the cytostatic treatment of cancer patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Humans; In | 1996 |
[The 5HT3-receptor antagonist Zofran (ondansetron) as an agent for preventing nausea and vomiting during the cytostatic treatment of cancer patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Humans; In | 1996 |
[The 5HT3-receptor antagonist Zofran (ondansetron) as an agent for preventing nausea and vomiting during the cytostatic treatment of cancer patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Humans; In | 1996 |
[Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery].
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Child; Female; Humans; Male; M | 1996 |
[Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery].
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Child; Female; Humans; Male; M | 1996 |
[Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery].
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Child; Female; Humans; Male; M | 1996 |
Extrapyramidal reaction caused by ondansetron.
Topics: Aged; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Humans; Male; Multiple Myeloma; Na | 1996 |
Extrapyramidal reaction caused by ondansetron.
Topics: Aged; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Humans; Male; Multiple Myeloma; Na | 1996 |
Extrapyramidal reaction caused by ondansetron.
Topics: Aged; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Humans; Male; Multiple Myeloma; Na | 1996 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
Tardive dyskinesia as a result of long-term prochlorperazine use.
Topics: Antiemetics; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatal Outcome; Female; Granisetron; Hum | 1996 |
Tardive dyskinesia as a result of long-term prochlorperazine use.
Topics: Antiemetics; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatal Outcome; Female; Granisetron; Hum | 1996 |
Tardive dyskinesia as a result of long-term prochlorperazine use.
Topics: Antiemetics; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatal Outcome; Female; Granisetron; Hum | 1996 |
Radiotherapy and drugs: 'setrons' once again.
Topics: Abdomen; Abdominal Neoplasms; Antiemetics; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1996 |
Radiotherapy and drugs: 'setrons' once again.
Topics: Abdomen; Abdominal Neoplasms; Antiemetics; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1996 |
Radiotherapy and drugs: 'setrons' once again.
Topics: Abdomen; Abdominal Neoplasms; Antiemetics; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1996 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
[Acute tolerance in hyperfractionated accelerated whole-body irradiation].
Topics: Adult; Antiemetics; Bone Marrow Transplantation; Drug Evaluation; Female; Humans; Male; Nausea; Onda | 1996 |
[Acute tolerance in hyperfractionated accelerated whole-body irradiation].
Topics: Adult; Antiemetics; Bone Marrow Transplantation; Drug Evaluation; Female; Humans; Male; Nausea; Onda | 1996 |
[Acute tolerance in hyperfractionated accelerated whole-body irradiation].
Topics: Adult; Antiemetics; Bone Marrow Transplantation; Drug Evaluation; Female; Humans; Male; Nausea; Onda | 1996 |
Always more "setrons": how many do we need?
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indoles; Nausea; Ondansetron; S | 1997 |
Always more "setrons": how many do we need?
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indoles; Nausea; Ondansetron; S | 1997 |
Always more "setrons": how many do we need?
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indoles; Nausea; Ondansetron; S | 1997 |
[Use of ondansetron for prevention of postoperative nausea and vomiting in major ambulatory surgery].
Topics: Ambulatory Surgical Procedures; Antiemetics; Humans; Nausea; Ondansetron; Postoperative Complication | 1996 |
[Use of ondansetron for prevention of postoperative nausea and vomiting in major ambulatory surgery].
Topics: Ambulatory Surgical Procedures; Antiemetics; Humans; Nausea; Ondansetron; Postoperative Complication | 1996 |
[Use of ondansetron for prevention of postoperative nausea and vomiting in major ambulatory surgery].
Topics: Ambulatory Surgical Procedures; Antiemetics; Humans; Nausea; Ondansetron; Postoperative Complication | 1996 |
Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy.
Topics: Adolescent; Antiemetics; Case-Control Studies; Child; Conditioning, Classical; Female; Humans; Male; | 1997 |
Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy.
Topics: Adolescent; Antiemetics; Case-Control Studies; Child; Conditioning, Classical; Female; Humans; Male; | 1997 |
Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy.
Topics: Adolescent; Antiemetics; Case-Control Studies; Child; Conditioning, Classical; Female; Humans; Male; | 1997 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Antiemetics; Cholecystectomy, Laparoscopic; Droperidol; Drug Therapy, Combination; Humans; Metoclopr | 1997 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Antiemetics; Cholecystectomy, Laparoscopic; Droperidol; Drug Therapy, Combination; Humans; Metoclopr | 1997 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Antiemetics; Cholecystectomy, Laparoscopic; Droperidol; Drug Therapy, Combination; Humans; Metoclopr | 1997 |
Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
Topics: Adult; Antiemetics; Antihypertensive Agents; Epoprostenol; Female; Humans; Hypertension, Pulmonary; | 1997 |
Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
Topics: Adult; Antiemetics; Antihypertensive Agents; Epoprostenol; Female; Humans; Hypertension, Pulmonary; | 1997 |
Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
Topics: Adult; Antiemetics; Antihypertensive Agents; Epoprostenol; Female; Humans; Hypertension, Pulmonary; | 1997 |
Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Female; Fever; HIV Infections; Humans; | 1997 |
Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Female; Fever; HIV Infections; Humans; | 1997 |
Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Female; Fever; HIV Infections; Humans; | 1997 |
Fighting nausea in the '90s: more and better anti-emetics can help.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Synergism; Drug Therapy, Combination; Granis | 1997 |
Fighting nausea in the '90s: more and better anti-emetics can help.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Synergism; Drug Therapy, Combination; Granis | 1997 |
Fighting nausea in the '90s: more and better anti-emetics can help.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Synergism; Drug Therapy, Combination; Granis | 1997 |
Acute severe depression following peri-operative ondansetron.
Topics: Adult; Depressive Disorder; Female; Humans; Nausea; Ondansetron; Premedication; Serotonin Antagonist | 1997 |
Acute severe depression following peri-operative ondansetron.
Topics: Adult; Depressive Disorder; Female; Humans; Nausea; Ondansetron; Premedication; Serotonin Antagonist | 1997 |
Acute severe depression following peri-operative ondansetron.
Topics: Adult; Depressive Disorder; Female; Humans; Nausea; Ondansetron; Premedication; Serotonin Antagonist | 1997 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
Correct choice of anti-emetic.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1997 |
Correct choice of anti-emetic.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1997 |
Correct choice of anti-emetic.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1997 |
The "big little problem" of postoperative nausea and vomiting: do we know the answer yet?
Topics: Antiemetics; Humans; Meta-Analysis as Topic; Nausea; Ondansetron; Outcome Assessment, Health Care; P | 1997 |
The "big little problem" of postoperative nausea and vomiting: do we know the answer yet?
Topics: Antiemetics; Humans; Meta-Analysis as Topic; Nausea; Ondansetron; Outcome Assessment, Health Care; P | 1997 |
The "big little problem" of postoperative nausea and vomiting: do we know the answer yet?
Topics: Antiemetics; Humans; Meta-Analysis as Topic; Nausea; Ondansetron; Outcome Assessment, Health Care; P | 1997 |
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Utilization; Female; Granisetron; Guideline | 1998 |
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Utilization; Female; Granisetron; Guideline | 1998 |
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Utilization; Female; Granisetron; Guideline | 1998 |
[Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Ad | 1998 |
[Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Ad | 1998 |
[Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Ad | 1998 |
Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Fe | 1998 |
Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Fe | 1998 |
Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Fe | 1998 |
Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
Topics: Animals; Antiemetics; Gamma Rays; Granisetron; Macaca fascicularis; Male; Nausea; Neutrons; Ondanset | 1998 |
Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
Topics: Animals; Antiemetics; Gamma Rays; Granisetron; Macaca fascicularis; Male; Nausea; Neutrons; Ondanset | 1998 |
Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
Topics: Animals; Antiemetics; Gamma Rays; Granisetron; Macaca fascicularis; Male; Nausea; Neutrons; Ondanset | 1998 |
The anti-emetic efficacy of a combination of ondansetron and droperidol.
Topics: Antiemetics; Droperidol; Drug Therapy, Combination; Humans; Nausea; Ondansetron; Postoperative Compl | 1998 |
The anti-emetic efficacy of a combination of ondansetron and droperidol.
Topics: Antiemetics; Droperidol; Drug Therapy, Combination; Humans; Nausea; Ondansetron; Postoperative Compl | 1998 |
The anti-emetic efficacy of a combination of ondansetron and droperidol.
Topics: Antiemetics; Droperidol; Drug Therapy, Combination; Humans; Nausea; Ondansetron; Postoperative Compl | 1998 |
Ondansetron compared with metoclopramide in the treatment of PONV.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative C | 1998 |
Ondansetron compared with metoclopramide in the treatment of PONV.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative C | 1998 |
Ondansetron compared with metoclopramide in the treatment of PONV.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative C | 1998 |
Desflurane and nausea following ondansetron premedication.
Topics: Anesthetics, Inhalation; Antiemetics; Desflurane; Humans; Isoflurane; Nausea; Ondansetron; Postopera | 1998 |
Desflurane and nausea following ondansetron premedication.
Topics: Anesthetics, Inhalation; Antiemetics; Desflurane; Humans; Isoflurane; Nausea; Ondansetron; Postopera | 1998 |
Desflurane and nausea following ondansetron premedication.
Topics: Anesthetics, Inhalation; Antiemetics; Desflurane; Humans; Isoflurane; Nausea; Ondansetron; Postopera | 1998 |
Ondansetron in nausea and vomiting induced by spinal morphine.
Topics: Analgesics, Opioid; Antiemetics; Female; Humans; Injections, Spinal; Middle Aged; Morphine; Nausea; | 1998 |
Ondansetron in nausea and vomiting induced by spinal morphine.
Topics: Analgesics, Opioid; Antiemetics; Female; Humans; Injections, Spinal; Middle Aged; Morphine; Nausea; | 1998 |
Ondansetron in nausea and vomiting induced by spinal morphine.
Topics: Analgesics, Opioid; Antiemetics; Female; Humans; Injections, Spinal; Middle Aged; Morphine; Nausea; | 1998 |
Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.
Topics: Adult; Aged; Diarrhea; Flushing; Gastric Emptying; Humans; Malignant Carcinoid Syndrome; Middle Aged | 1998 |
Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.
Topics: Adult; Aged; Diarrhea; Flushing; Gastric Emptying; Humans; Malignant Carcinoid Syndrome; Middle Aged | 1998 |
Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.
Topics: Adult; Aged; Diarrhea; Flushing; Gastric Emptying; Humans; Malignant Carcinoid Syndrome; Middle Aged | 1998 |
Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribut | 1998 |
Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribut | 1998 |
Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribut | 1998 |
Inhibition of anaesthetic-induced emesis by a NK1 or 5-HT3 receptor antagonist in the house musk shrew, Suncus murinus.
Topics: Anesthesia; Animals; Halothane; Humans; Male; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron | 1998 |
Inhibition of anaesthetic-induced emesis by a NK1 or 5-HT3 receptor antagonist in the house musk shrew, Suncus murinus.
Topics: Anesthesia; Animals; Halothane; Humans; Male; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron | 1998 |
Inhibition of anaesthetic-induced emesis by a NK1 or 5-HT3 receptor antagonist in the house musk shrew, Suncus murinus.
Topics: Anesthesia; Animals; Halothane; Humans; Male; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron | 1998 |
Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Car | 1999 |
Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Car | 1999 |
Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Car | 1999 |
Cost accounting supports clinical evaluations.
Topics: Academic Medical Centers; Accounting; Cost Allocation; Drug Costs; Drug Utilization Review; Financia | 1994 |
Cost accounting supports clinical evaluations.
Topics: Academic Medical Centers; Accounting; Cost Allocation; Drug Costs; Drug Utilization Review; Financia | 1994 |
Cost accounting supports clinical evaluations.
Topics: Academic Medical Centers; Accounting; Cost Allocation; Drug Costs; Drug Utilization Review; Financia | 1994 |
Ondansetron: costs and resource utilisation in a US teaching hospital setting.
Topics: Costs and Cost Analysis; Hospitals, Teaching; Humans; Length of Stay; Middle Aged; Nausea; Ondansetr | 1993 |
Ondansetron: costs and resource utilisation in a US teaching hospital setting.
Topics: Costs and Cost Analysis; Hospitals, Teaching; Humans; Length of Stay; Middle Aged; Nausea; Ondansetr | 1993 |
Ondansetron: costs and resource utilisation in a US teaching hospital setting.
Topics: Costs and Cost Analysis; Hospitals, Teaching; Humans; Length of Stay; Middle Aged; Nausea; Ondansetr | 1993 |
Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Topics: Chemotherapy, Adjuvant; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Dose-Res | 1994 |
Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Topics: Chemotherapy, Adjuvant; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Dose-Res | 1994 |
Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Topics: Chemotherapy, Adjuvant; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Dose-Res | 1994 |
Is ondansetron cost effective?
Topics: Antiemetics; Cost-Benefit Analysis; Humans; Length of Stay; Nausea; Ondansetron; Retrospective Studi | 1994 |
Is ondansetron cost effective?
Topics: Antiemetics; Cost-Benefit Analysis; Humans; Length of Stay; Nausea; Ondansetron; Retrospective Studi | 1994 |
Is ondansetron cost effective?
Topics: Antiemetics; Cost-Benefit Analysis; Humans; Length of Stay; Nausea; Ondansetron; Retrospective Studi | 1994 |
Developing and implementing oral 5-HT3 receptor antagonist guidelines: a multidisciplinary process.
Topics: Administration, Oral; Antiemetics; Cancer Care Facilities; Female; Hospital Bed Capacity, 300 to 499 | 1998 |
Developing and implementing oral 5-HT3 receptor antagonist guidelines: a multidisciplinary process.
Topics: Administration, Oral; Antiemetics; Cancer Care Facilities; Female; Hospital Bed Capacity, 300 to 499 | 1998 |
Developing and implementing oral 5-HT3 receptor antagonist guidelines: a multidisciplinary process.
Topics: Administration, Oral; Antiemetics; Cancer Care Facilities; Female; Hospital Bed Capacity, 300 to 499 | 1998 |
Cost effectiveness ratio: an often misunderstood term.
Topics: Cost-Benefit Analysis; Droperidol; Health Care Costs; Humans; Nausea; Ondansetron; Postoperative Com | 1999 |
Cost effectiveness ratio: an often misunderstood term.
Topics: Cost-Benefit Analysis; Droperidol; Health Care Costs; Humans; Nausea; Ondansetron; Postoperative Com | 1999 |
Cost effectiveness ratio: an often misunderstood term.
Topics: Cost-Benefit Analysis; Droperidol; Health Care Costs; Humans; Nausea; Ondansetron; Postoperative Com | 1999 |
5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Ferrets; Gamma | 1999 |
5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Ferrets; Gamma | 1999 |
5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Ferrets; Gamma | 1999 |
Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.
Topics: Adult; Antiemetics; Domperidone; Drug Administration Schedule; Female; Humans; Incidence; Indoles; M | 1999 |
Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.
Topics: Adult; Antiemetics; Domperidone; Drug Administration Schedule; Female; Humans; Incidence; Indoles; M | 1999 |
Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.
Topics: Adult; Antiemetics; Domperidone; Drug Administration Schedule; Female; Humans; Incidence; Indoles; M | 1999 |
Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Ana | 1999 |
Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Ana | 1999 |
Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Ana | 1999 |
Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Canada; Drug Costs; Female; Health Care Costs; Humans; Male; Mid | 1999 |
Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Canada; Drug Costs; Female; Health Care Costs; Humans; Male; Mid | 1999 |
Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Canada; Drug Costs; Female; Health Care Costs; Humans; Male; Mid | 1999 |
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Canada; Cost-Benefit Analysis; Humans; Metoclo | 1999 |
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Canada; Cost-Benefit Analysis; Humans; Metoclo | 1999 |
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Canada; Cost-Benefit Analysis; Humans; Metoclo | 1999 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
5-HT3 receptors, nausea, and serotonin reuptake inhibition.
Topics: Antiemetics; Fluvoxamine; Humans; Nausea; Ondansetron; Receptors, Serotonin; Receptors, Serotonin, 5 | 1997 |
5-HT3 receptors, nausea, and serotonin reuptake inhibition.
Topics: Antiemetics; Fluvoxamine; Humans; Nausea; Ondansetron; Receptors, Serotonin; Receptors, Serotonin, 5 | 1997 |
5-HT3 receptors, nausea, and serotonin reuptake inhibition.
Topics: Antiemetics; Fluvoxamine; Humans; Nausea; Ondansetron; Receptors, Serotonin; Receptors, Serotonin, 5 | 1997 |
Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combinati | 2000 |
Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combinati | 2000 |
Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combinati | 2000 |
Prevention of delayed emesis caused by chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Confounding Factors, Epidemiologic; Dexamethasone; Drug Therapy, | 2000 |
Prevention of delayed emesis caused by chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Confounding Factors, Epidemiologic; Dexamethasone; Drug Therapy, | 2000 |
Prevention of delayed emesis caused by chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Confounding Factors, Epidemiologic; Dexamethasone; Drug Therapy, | 2000 |
Computerized system for outcomes-based antiemetic therapy in children.
Topics: Antiemetics; Child; Cost-Benefit Analysis; Female; Humans; Male; Nausea; Odds Ratio; Ondansetron; Ti | 2000 |
Computerized system for outcomes-based antiemetic therapy in children.
Topics: Antiemetics; Child; Cost-Benefit Analysis; Female; Humans; Male; Nausea; Odds Ratio; Ondansetron; Ti | 2000 |
Computerized system for outcomes-based antiemetic therapy in children.
Topics: Antiemetics; Child; Cost-Benefit Analysis; Female; Humans; Male; Nausea; Odds Ratio; Ondansetron; Ti | 2000 |
Ondansetron in multiple sclerosis.
Topics: Adult; Female; Humans; Multiple Sclerosis; Nausea; Ondansetron; Palliative Care; Serotonin Antagonis | 2000 |
Ondansetron in multiple sclerosis.
Topics: Adult; Female; Humans; Multiple Sclerosis; Nausea; Ondansetron; Palliative Care; Serotonin Antagonis | 2000 |
Ondansetron in multiple sclerosis.
Topics: Adult; Female; Humans; Multiple Sclerosis; Nausea; Ondansetron; Palliative Care; Serotonin Antagonis | 2000 |
Ondansetron rather than metoclopramide for bupropion-induced nausea.
Topics: Adult; Antiemetics; Bupropion; Depressive Disorder; Drug Interactions; Female; Humans; Metoclopramid | 2001 |
Ondansetron rather than metoclopramide for bupropion-induced nausea.
Topics: Adult; Antiemetics; Bupropion; Depressive Disorder; Drug Interactions; Female; Humans; Metoclopramid | 2001 |
Ondansetron rather than metoclopramide for bupropion-induced nausea.
Topics: Adult; Antiemetics; Bupropion; Depressive Disorder; Drug Interactions; Female; Humans; Metoclopramid | 2001 |
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions.
Topics: Aged; Antiemetics; Humans; Iloprost; Infusions, Intravenous; Male; Metoclopramide; Nausea; Ondansetr | 2001 |
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions.
Topics: Aged; Antiemetics; Humans; Iloprost; Infusions, Intravenous; Male; Metoclopramide; Nausea; Ondansetr | 2001 |
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions.
Topics: Aged; Antiemetics; Humans; Iloprost; Infusions, Intravenous; Male; Metoclopramide; Nausea; Ondansetr | 2001 |
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2002 |
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2002 |
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2002 |
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2002 |
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2002 |
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2002 |
Pharmacokinetics of ondansetron in patients receiving cisplatin therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Male; Middle Aged; Nausea; | 1992 |
Pharmacokinetics of ondansetron in patients receiving cisplatin therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Male; Middle Aged; Nausea; | 1992 |
Pharmacokinetics of ondansetron in patients receiving cisplatin therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Male; Middle Aged; Nausea; | 1992 |
The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indazoles; Models, Theoretical; | 1992 |
The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indazoles; Models, Theoretical; | 1992 |
The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indazoles; Models, Theoretical; | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Postoperative pain and nausea after laparoscopic cholecystectomy.
Topics: Adult; Aged; Analgesia; Cholecystectomy, Laparoscopic; Female; Humans; Male; Middle Aged; Nausea; On | 1992 |
Ondansetron for patients given abdominal radiotherapy.
Topics: Abdominal Neoplasms; Aged; Antiemetics; Child; Female; Humans; Imidazoles; Nausea; Ondansetron; Radi | 1992 |
Ondansetron for patients given abdominal radiotherapy.
Topics: Abdominal Neoplasms; Aged; Antiemetics; Child; Female; Humans; Imidazoles; Nausea; Ondansetron; Radi | 1992 |
Ondansetron for patients given abdominal radiotherapy.
Topics: Abdominal Neoplasms; Aged; Antiemetics; Child; Female; Humans; Imidazoles; Nausea; Ondansetron; Radi | 1992 |
Ondansetron in intractable nausea and vomiting.
Topics: Adult; Antiemetics; Bone Neoplasms; Breast Neoplasms; Female; Humans; Imidazoles; Nausea; Ondansetro | 1992 |
Ondansetron in intractable nausea and vomiting.
Topics: Adult; Antiemetics; Bone Neoplasms; Breast Neoplasms; Female; Humans; Imidazoles; Nausea; Ondansetro | 1992 |
Ondansetron in intractable nausea and vomiting.
Topics: Adult; Antiemetics; Bone Neoplasms; Breast Neoplasms; Female; Humans; Imidazoles; Nausea; Ondansetro | 1992 |
Subcutaneous ondansetron.
Topics: Antiemetics; Humans; Imidazoles; Injections, Subcutaneous; Male; Middle Aged; Nausea; Ondansetron | 1992 |
Subcutaneous ondansetron.
Topics: Antiemetics; Humans; Imidazoles; Injections, Subcutaneous; Male; Middle Aged; Nausea; Ondansetron | 1992 |
Subcutaneous ondansetron.
Topics: Antiemetics; Humans; Imidazoles; Injections, Subcutaneous; Male; Middle Aged; Nausea; Ondansetron | 1992 |
Who should receive a 5-HT3 antagonist?
Topics: Acute Disease; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin | 1992 |
Who should receive a 5-HT3 antagonist?
Topics: Acute Disease; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin | 1992 |
Who should receive a 5-HT3 antagonist?
Topics: Acute Disease; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin | 1992 |
Ondansetron in postoperative nausea and vomiting. Proceedings of a symposium. London, 28 February 1992.
Topics: Humans; Nausea; Ondansetron; Postoperative Care; Surgical Procedures, Operative; Vomiting | 1992 |
Ondansetron in postoperative nausea and vomiting. Proceedings of a symposium. London, 28 February 1992.
Topics: Humans; Nausea; Ondansetron; Postoperative Care; Surgical Procedures, Operative; Vomiting | 1992 |
Ondansetron in postoperative nausea and vomiting. Proceedings of a symposium. London, 28 February 1992.
Topics: Humans; Nausea; Ondansetron; Postoperative Care; Surgical Procedures, Operative; Vomiting | 1992 |
Serotonin-Mediated Emesis: The Role of Ondansetron. Proceedings of a symposium. Fort Lauderdale, Florida, April 24-26, 1992.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1992 |
Serotonin-Mediated Emesis: The Role of Ondansetron. Proceedings of a symposium. Fort Lauderdale, Florida, April 24-26, 1992.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1992 |
Serotonin-Mediated Emesis: The Role of Ondansetron. Proceedings of a symposium. Fort Lauderdale, Florida, April 24-26, 1992.
Topics: Antineoplastic Agents; Humans; Nausea; Ondansetron; Radiotherapy; Vomiting | 1992 |
Ondansetron: A new concept in the management of emesis. Proceedings from an investigators meeting. Seattle, Washington, September 1990.
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1992 |
Ondansetron: A new concept in the management of emesis. Proceedings from an investigators meeting. Seattle, Washington, September 1990.
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1992 |
Ondansetron: A new concept in the management of emesis. Proceedings from an investigators meeting. Seattle, Washington, September 1990.
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1992 |
Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dac | 1992 |
Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dac | 1992 |
Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dac | 1992 |
Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children.
Topics: Child; Child, Preschool; Humans; Lymphoma, T-Cell; Nausea; Ondansetron; Precursor Cell Lymphoblastic | 1992 |
Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children.
Topics: Child; Child, Preschool; Humans; Lymphoma, T-Cell; Nausea; Ondansetron; Precursor Cell Lymphoblastic | 1992 |
Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children.
Topics: Child; Child, Preschool; Humans; Lymphoma, T-Cell; Nausea; Ondansetron; Precursor Cell Lymphoblastic | 1992 |
Relationships between ondansetron systemic exposure and antiemetic efficacy and safety in cancer patients receiving cisplatin.
Topics: Cisplatin; Humans; Injections, Intravenous; Male; Nausea; Neoplasms; Ondansetron; Safety | 1992 |
Relationships between ondansetron systemic exposure and antiemetic efficacy and safety in cancer patients receiving cisplatin.
Topics: Cisplatin; Humans; Injections, Intravenous; Male; Nausea; Neoplasms; Ondansetron; Safety | 1992 |
Relationships between ondansetron systemic exposure and antiemetic efficacy and safety in cancer patients receiving cisplatin.
Topics: Cisplatin; Humans; Injections, Intravenous; Male; Nausea; Neoplasms; Ondansetron; Safety | 1992 |
Serotonin antagonist antiemetics: progress and concerns.
Topics: Antineoplastic Agents; Child; Humans; Nausea; Ondansetron | 1992 |
Serotonin antagonist antiemetics: progress and concerns.
Topics: Antineoplastic Agents; Child; Humans; Nausea; Ondansetron | 1992 |
Serotonin antagonist antiemetics: progress and concerns.
Topics: Antineoplastic Agents; Child; Humans; Nausea; Ondansetron | 1992 |
Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Female; Humans; Kid | 1992 |
Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Female; Humans; Kid | 1992 |
Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Female; Humans; Kid | 1992 |
Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
Topics: Acute Kidney Injury; Cisplatin; Humans; Metoclopramide; Nausea; Neoplasms; Ondansetron; Thrombocytop | 1992 |
Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
Topics: Acute Kidney Injury; Cisplatin; Humans; Metoclopramide; Nausea; Neoplasms; Ondansetron; Thrombocytop | 1992 |
Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
Topics: Acute Kidney Injury; Cisplatin; Humans; Metoclopramide; Nausea; Neoplasms; Ondansetron; Thrombocytop | 1992 |
Ondansetron: indications and applications in the paediatric intensive care unit.
Topics: Adolescent; Child; Child, Preschool; Critical Care; Female; Humans; Male; Nausea; Ondansetron; Vomit | 1992 |
Ondansetron: indications and applications in the paediatric intensive care unit.
Topics: Adolescent; Child; Child, Preschool; Critical Care; Female; Humans; Male; Nausea; Ondansetron; Vomit | 1992 |
Ondansetron: indications and applications in the paediatric intensive care unit.
Topics: Adolescent; Child; Child, Preschool; Critical Care; Female; Humans; Male; Nausea; Ondansetron; Vomit | 1992 |
Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Female; Humans; Injections, Intravenous; Male | 1992 |
Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Female; Humans; Injections, Intravenous; Male | 1992 |
Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Female; Humans; Injections, Intravenous; Male | 1992 |
Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cost-Benefit Analysis; Dexamethasone; Female | 1992 |
Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cost-Benefit Analysis; Dexamethasone; Female | 1992 |
Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cost-Benefit Analysis; Dexamethasone; Female | 1992 |
Ondansetron in the control of refractory emesis following radiotherapy.
Topics: Adult; Antiemetics; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Radiotherapy; Seroto | 1992 |
Ondansetron in the control of refractory emesis following radiotherapy.
Topics: Adult; Antiemetics; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Radiotherapy; Seroto | 1992 |
Ondansetron in the control of refractory emesis following radiotherapy.
Topics: Adult; Antiemetics; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Radiotherapy; Seroto | 1992 |
Antiemetic or antinauseant effect of ondansetron?
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1992 |
Antiemetic or antinauseant effect of ondansetron?
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1992 |
Antiemetic or antinauseant effect of ondansetron?
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1992 |
Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1992 |
Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1992 |
Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1992 |
Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?
Topics: Antiemetics; Antineoplastic Agents; Female; Humans; Imidazoles; Male; Nausea; Ondansetron; Severity | 1992 |
Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?
Topics: Antiemetics; Antineoplastic Agents; Female; Humans; Imidazoles; Male; Nausea; Ondansetron; Severity | 1992 |
Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?
Topics: Antiemetics; Antineoplastic Agents; Female; Humans; Imidazoles; Male; Nausea; Ondansetron; Severity | 1992 |
High-dose and long-term use of ondansetron.
Topics: Antiemetics; Dexamethasone; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; Time Facto | 1992 |
High-dose and long-term use of ondansetron.
Topics: Antiemetics; Dexamethasone; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; Time Facto | 1992 |
High-dose and long-term use of ondansetron.
Topics: Antiemetics; Dexamethasone; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; Time Facto | 1992 |
Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Ondansetron versus dexamethasone.
Topics: Antiemetics; Dexamethasone; Humans; Imidazoles; Nausea; Ondansetron; Research Design | 1991 |
Ondansetron versus dexamethasone.
Topics: Antiemetics; Dexamethasone; Humans; Imidazoles; Nausea; Ondansetron; Research Design | 1991 |
Ondansetron versus dexamethasone.
Topics: Antiemetics; Dexamethasone; Humans; Imidazoles; Nausea; Ondansetron; Research Design | 1991 |
Ondansetron vs dexamethasone for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dexamethasone; Hu | 1991 |
Ondansetron vs dexamethasone for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dexamethasone; Hu | 1991 |
Ondansetron vs dexamethasone for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dexamethasone; Hu | 1991 |
[Ondansetron--a 5HT 3 receptor antagonist for the treatment of nausea and vomiting induced by cytostatics and radiotherapy].
Topics: Antiemetics; Antineoplastic Agents; Combined Modality Therapy; Humans; Imidazoles; Nausea; Neoplasms | 1991 |
[Ondansetron--a 5HT 3 receptor antagonist for the treatment of nausea and vomiting induced by cytostatics and radiotherapy].
Topics: Antiemetics; Antineoplastic Agents; Combined Modality Therapy; Humans; Imidazoles; Nausea; Neoplasms | 1991 |
[Ondansetron--a 5HT 3 receptor antagonist for the treatment of nausea and vomiting induced by cytostatics and radiotherapy].
Topics: Antiemetics; Antineoplastic Agents; Combined Modality Therapy; Humans; Imidazoles; Nausea; Neoplasms | 1991 |
Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Imida | 1991 |
Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Imida | 1991 |
Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Imida | 1991 |
The big "little problem".
Topics: Anesthetics; Antiemetics; Causality; Humans; Imidazoles; Nausea; Ondansetron; Postoperative Complica | 1991 |
The big "little problem".
Topics: Anesthetics; Antiemetics; Causality; Humans; Imidazoles; Nausea; Ondansetron; Postoperative Complica | 1991 |
The big "little problem".
Topics: Anesthetics; Antiemetics; Causality; Humans; Imidazoles; Nausea; Ondansetron; Postoperative Complica | 1991 |
Introduction: the clinical challenge.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1991 |
Introduction: the clinical challenge.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1991 |
Introduction: the clinical challenge.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1991 |
Odansetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1991 |
Odansetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1991 |
Odansetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1991 |
Making chemotherapy easier.
Topics: Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; | 1990 |
Making chemotherapy easier.
Topics: Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; | 1990 |
Making chemotherapy easier.
Topics: Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; | 1990 |
Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1990 |
Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1990 |
Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1990 |
Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
Topics: Administration, Oral; Antiemetics; Drug Administration Schedule; Drug Evaluation; Female; Humans; Im | 1990 |
Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
Topics: Administration, Oral; Antiemetics; Drug Administration Schedule; Drug Evaluation; Female; Humans; Im | 1990 |
Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
Topics: Administration, Oral; Antiemetics; Drug Administration Schedule; Drug Evaluation; Female; Humans; Im | 1990 |
[Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Female; Humans; Imidazoles; Male; Middle | 1990 |
[Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Female; Humans; Imidazoles; Male; Middle | 1990 |
[Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Female; Humans; Imidazoles; Male; Middle | 1990 |
Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin.
Topics: Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1990 |
Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin.
Topics: Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1990 |
Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin.
Topics: Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1990 |
5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imidazoles; | 1990 |
5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imidazoles; | 1990 |
5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imidazoles; | 1990 |
Correlation of anti-emetic efficacy and plasma levels of ondansetron.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Serotoni | 1990 |
Correlation of anti-emetic efficacy and plasma levels of ondansetron.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Serotoni | 1990 |
Correlation of anti-emetic efficacy and plasma levels of ondansetron.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Serotoni | 1990 |
Ondansetron: a new entity in emesis control.
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1990 |
Ondansetron: a new entity in emesis control.
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1990 |
Ondansetron: a new entity in emesis control.
Topics: Antiemetics; Humans; Imidazoles; Nausea; Ondansetron; Vomiting | 1990 |
GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Neoplasms; Ondansetro | 1989 |
GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Neoplasms; Ondansetro | 1989 |
GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Neoplasms; Ondansetro | 1989 |
The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; Imidazoles; M | 1989 |
The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; Imidazoles; M | 1989 |
The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; Imidazoles; M | 1989 |
Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1989 |
Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1989 |
Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1989 |
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Imidazoles; Injections, Intravenous; Lympho | 1987 |
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Imidazoles; Injections, Intravenous; Lympho | 1987 |
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Imidazoles; Injections, Intravenous; Lympho | 1987 |
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.
Topics: Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1988 |
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.
Topics: Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1988 |
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.
Topics: Cisplatin; Humans; Imidazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1988 |